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A B S T R A C T
Background
Melanoma is one of the most aggressive forms of skin cancer, with the potential to metastasise to other parts of the body via the
lymphatic system and the bloodstream. Melanoma accounts for a small percentage of skin cancer cases but is responsible for the
majority of skin cancer deaths. Various imaging tests can be used with the aim of detecting metastatic spread of disease following a
primary diagnosis of melanoma (primary staging) or on clinical suspicion of disease recurrence (re-staging). Accurate staging is crucial
to ensuring that patients are directed to the most appropriate and effective treatment at different points on the clinical pathway.
Establishing the comparative accuracy of ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and positron
emission tomography (PET)-CT imaging for detection of nodal or distant metastases, or both, is critical to understanding if, how, and
where on the pathway these tests might be used.
Objectives
Primary objectives
We estimated accuracy separately according to the point in the clinical pathway at which imaging tests were used. Our objectives were:
• to determine the diagnostic accuracy of ultrasound or PET-CT for detection of nodal metastases before sentinel lymph node biopsy
in adults with confirmed cutaneous invasive melanoma; and
• to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for whole body imaging in adults with cutaneous invasive
melanoma:
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© for detection of any metastasis in adults with a primary diagnosis of melanoma (i.e. primary staging at presentation); and
© for detection of any metastasis in adults undergoing staging of recurrence of melanoma (i.e. re-staging prompted by findings on
routine follow-up).
We undertook separate analyses according to whether accuracy data were reported per patient or per lesion.
Secondary objectives
We sought to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for whole body imaging (detection of any
metastasis) in mixed or not clearly described populations of adults with cutaneous invasive melanoma.
For study participants undergoing primary staging or re-staging (for possible recurrence), and for mixed or unclear populations, our
objectives were:
• to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for detection of nodal metastases;
• to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for detection of distant metastases; and
• to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for detection of distant metastases according to metastatic
site.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists as well as published systematic review articles.
Selection criteria
We included studies of any design that evaluated ultrasound (with or without the use of fine needle aspiration cytology (FNAC)), CT,
MRI, or PET-CT for staging of cutaneous melanoma in adults, compared with a reference standard of histological confirmation or
imaging with clinical follow-up of at least three months’ duration. We excluded studies reporting multiple applications of the same test
in more than 10% of study participants.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on the
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2)). We estimated accuracy using the bivariate hierarchical method to
produce summary sensitivities and specificities with 95% confidence and prediction regions. We undertook analysis of studies allowing
direct and indirect comparison between tests. We examined heterogeneity between studies by visually inspecting the forest plots of
sensitivity and specificity and summary receiver operating characteristic (ROC) plots. Numbers of identified studies were insufficient
to allow formal investigation of potential sources of heterogeneity.
Main results
We included a total of 39 publications reporting on 5204 study participants; 34 studies reporting data per patient included 4980 study
participants with 1265 cases of metastatic disease, and seven studies reporting data per lesion included 417 study participants with 1846
potentially metastatic lesions, 1061 of which were confirmed metastases. The risk of bias was low or unclear for all domains apart from
participant flow. Concerns regarding applicability of the evidence were high or unclear for almost all domains. Participant selection
from mixed or not clearly defined populations and poorly described application and interpretation of index tests were particularly
problematic.
The accuracy of imaging for detection of regional nodal metastases before sentinel lymph node biopsy (SLNB) was evaluated in 18
studies. In 11 studies (2614 participants; 542 cases), the summary sensitivity of ultrasound alone was 35.4% (95% confidence interval
(CI) 17.0% to 59.4%) and specificity was 93.9% (95% CI 86.1% to 97.5%). Combining pre-SLNB ultrasound with FNAC revealed
summary sensitivity of 18.0% (95% CI 3.58% to 56.5%) and specificity of 99.8% (95% CI 99.1% to 99.9%) (1164 participants;
259 cases). Four studies demonstrated lower sensitivity (10.2%, 95% CI 4.31% to 22.3%) and specificity (96.5%,95% CI 87.1% to
99.1%) for PET-CT before SLNB (170 participants, 49 cases). When these data are translated to a hypothetical cohort of 1000 people
eligible for SLNB, 237 of whom have nodal metastases (median prevalence), the combination of ultrasound with FNAC potentially
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allows 43 people with nodal metastases to be triaged directly to adjuvant therapy rather than having SLNB first, at a cost of two people
with false positive results (who are incorrectly managed). Those with a false negative ultrasound will be identified on subsequent SLNB.
Limited test accuracy data were available for whole body imaging via PET-CT for primary staging or re-staging for disease recurrence,
and none evaluated MRI. Twenty-four studies evaluated whole body imaging. Six of these studies explored primary staging following
a confirmed diagnosis of melanoma (492 participants), three evaluated re-staging of disease following some clinical indication of
recurrence (589 participants), and 15 included mixed or not clearly described population groups comprising participants at a number
of different points on the clinical pathway and at varying stages of disease (1265 participants). Results for whole body imaging could
not be translated to a hypothetical cohort of people due to paucity of data.
Most of the studies (6/9) of primary disease or re-staging of disease considered PET-CT, two in comparison to CT alone, and three
studies examined the use of ultrasound. No eligible evaluations of MRI in these groups were identified. All studies used histological
reference standards combined with follow-up, and two included FNAC for some participants. Observed accuracy for detection of any
metastases for PET-CT was higher for re-staging of disease (summary sensitivity from two studies: 92.6%, 95% CI 85.3% to 96.4%;
specificity: 89.7%, 95% CI 78.8% to 95.3%; 153 participants; 95 cases) compared to primary staging (sensitivities from individual
studies ranged from 30% to 47% and specificities from 73% to 88%), and was more sensitive than CT alone in both population
groups, but participant numbers were very small.
No conclusions can be drawn regarding routine imaging of the brain via MRI or CT.
Authors’ conclusions
Review authors found a disappointing lack of evidence on the accuracy of imaging in people with a diagnosis of melanoma at different
points on the clinical pathway. Studies were small and often reported data according to the number of lesions rather than the number
of study participants. Imaging with ultrasound combined with FNAC before SLNB may identify around one-fifth of those with nodal
disease, but confidence intervals are wide and further work is needed to establish cost-effectiveness. Much of the evidence for whole body
imaging for primary staging or re-staging of disease is focused on PET-CT, and comparative data with CT or MRI are lacking. Future
studies should go beyond diagnostic accuracy and consider the effects of different imaging tests on disease management. The increasing
availability of adjuvant therapies for people with melanoma at high risk of disease spread at presentation will have a considerable impact
on imaging services, yet evidence for the relative diagnostic accuracy of available tests is limited.
P L A I N L A N G U A G E S U M M A R Y
How good are ultrasound, CT, MRI, and PET-CT for identifying spread of disease in the body among people with melanoma?
What is the aim of the review?
We wanted to find out which imaging tests are better for identifying spread of disease among people with a first diagnosis of melanoma
(primary staging) and among people with possible recurrence of melanoma (re-staging). We looked at the evidence for ultrasound, CT,
MRI, and PET-CT and included 39 studies to answer these questions.
Why are imaging tests for melanoma important?
Melanoma is one of the most aggressive forms of skin cancer, with potential for metastases (cancer cells) to spread to the lymph nodes
and other organs of the body. To make sure that people with melanoma receive the most appropriate and effective treatment, it is
important to identify whether the disease has spread and to which parts of the body it has spread. This is called ’staging of disease’.
Staging is done to find out if a melanoma has spread to regional lymph nodes or to lymph nodes close to the original melanoma, and to
determine if the melanoma has spread to lymph nodes in other parts of the body or to organs of the body such as the liver or the brain
(distant metastases). Imaging tests are tools that can be used to help find out how much the disease has spread. Several new treatments
are now available for reducing the risk of spread of melanoma and for treating melanoma when it has spread.
What was studied in the review?
The review includes four imaging tests that create images of the body in different ways. Ultrasound uses high-frequency sound waves
to create images, CT scans use ionising radiation in the form of X-rays (a very low dose of radiation), and MRI uses large magnets and
non-ionising radiation in the form of radio waves (which are not harmful) to generate images of the body. PET-CT requires injection
of a weakly radioactive substance (FDG). The PET part of the scan identifies areas of the body that take up a lot of FDG (indicating
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possibly cancerous cells), and the CT part of the scan helps to improve image quality and to more accurately pinpoint areas using more
FDG. Ultrasound can also be performed along with a fairly simple procedure called ’fine needle aspiration cytology’ (FNAC), by which
a very fine needle is used to take a small sample of cells from a lymph node that looks suspicious on ultrasound. A microscope is then
used to identify whether or not the cells are malignant.
Imaging can be used at different time points after diagnosis of melanoma. Healthcare providers can use imaging to look at the regional
lymph nodes closest to the melanoma before a type of surgery called sentinel lymph node biopsy is performed. Sentinel lymph node
biopsy takes out the lymph nodes that are most likely to have metastases inside them so they can be tested in a laboratory. Imaging can
also be used after sentinel lymph node biopsy or in people with higher-risk melanoma to look for any spread of disease. Imaging can
be used in people who were treated for melanoma at an earlier point and who might be having a recurrence of their disease.
What are the main results of the review?
Ultrasound of regional lymph nodes before sentinel lymph node biopsy
We found 11 relevant studies including 2614 people. Three of these studies compared ultrasound on its own to ultrasound combined
with FNAC. Results suggest that the combined procedure correctly identifies around one-fifth of people with metastases in the lymph
nodes with very few false positive results (people with incorrect diagnosis of metastasis). These results can be illustrated by imagining a
group of 1000 people with melanoma who are going to have sentinel lymph node biopsy, of whom 237 (24%) have metastases in the
lymph nodes. The combination of ultrasound with FNAC potentially allows 43 people with lymph node metastases to be identified
and avoid a sentinel lymph node biopsy, at a cost of two people with false positive results who might go on to have the wrong treatment.
Those with metastases in the lymph nodes that are missed on ultrasound (false negatives) will be identified on subsequent SLNB.
Whole body imaging (detection of any metastases)
We found 24 studies, but only nine were clear about the point in the time course of disease that imaging was carried out. Six studies
including 492 people looked at imaging for primary staging following a confirmed diagnosis of melanoma, and three studies in 589
people evaluated re-staging of disease in people with possible recurrence of disease.
Most of the studies (6/9) considered PET-CT, two in comparison to CT alone, and three studies examined the use of ultrasound. We
did not find any suitable studies of MRI in these groups.
Overall results suggest that PET-CT is better for correctly identifying people with metastatic spread of disease who might be having
a recurrence of disease (re-staging) than people who have a new diagnosis of melanoma (primary staging). PET-CT also seems to be
better than CT for identifying spread of disease in both groups of people, but studies were very small and results might not be reliable.
How reliable are the results of the studies included in this review?
In most of our studies, a reliable diagnosis of spread of disease (or reference standard) was made by performing biopsy and by following
up with people over time using clinical assessment and imaging. There was often a lack of detail on how patients were followed up and
which tests were used. Lots of studies did not include people at clearly defined time points in the disease process, making it difficult to
assess the relevance of their results. Reporting of application and interpretation of tests was poor.
To whom do the results of this review apply?
Thirty-three studies were done in Europe (85%), and the rest in North America (n = 4), Asia (n = 1), or Oceania (n = 1). The average
age of people in the studies was between 50 and 67 years, and around half were men. Studies mostly included people with melanoma
on any part of the body, but two included only people with melanoma on the head or neck. Studies often included people at different
stages of disease, and we were not able to look at the accuracy of tests for people at any particular disease stage. Studies were small, and
their results might not match what happens in real life.
What are the implications of this review?
Reviewers found some evidence to support the use of imaging with ultrasound combined with FNAC before sentinel lymph node
biopsy, but further work is needed to establish cost-effectiveness. Limited evidence is available for whole body imaging for primary
staging or re-staging of disease. Available evidence is focused on PET-CT; there are few comparisons with CT and no comparisons with
MRI. Future research needs to look at more than test accuracy and must consider the effects of different imaging tests on treatment
decisions for patients.
How up-to-date is this review?
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The reviewers searched for and included studies published up to August 2016.*
*In these studies, biopsy and clinical or imaging follow-up were the reference standards (methods of establishing the final diagnosis).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question How accurate is ultrasound, CT, MRI, or PET-CT for staging or re-staging of cutaneous invasive melanoma in adults?
Population: Adults with a conf irmed diagnosis of melanoma undergoing imaging for staging purposes:
• Before sent inel lymph node biopsy (SLNB) to ident if y nodal metastases
• For full body staging following removal of the primary melanoma
• For full body staging due to suspected recurrence of disease
Index test(s): Ultrasound with or without f ine needle aspirat ion cytology (FNAC)
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Positron emission tomography-computed tomography (PET-CT)
Comparator test: All of the index tests may be used in comparison to each other
Target condition: For pre-SLNB imaging: detect ion of nodal metastases
For all other imaging: detect ion of any metastases
Reference standard: Histology plus clinical or imaging follow-up
Action: If accurate, posit ive results of imaging before SLNB in some circumstances could allow patients with nodal metastases to proceed
direct ly to commence adjuvant therapy and avoid an addit ional invasive procedure (SLNB). Accurate whole body imaging will allow
appropriate locoregional and systemic therapies to be init iated in a t imely manner
Quantity of evidence (n = 39 stud-
ies)
Number of studies Number of participants Number of cases
Per patient data: 34 4980 1265
Per lesion data: 7 417 (1846 lesions) 1061 metastases
Limitations
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Risk of bias: Some concerns due to poor report ing across almost all domains. Unclear risk for part icipant select ion method (11/ 39) or exclusions
not clearly described (3/ 39). High risk f rom exclusions on the basis of index test results (4/ 39). Low risk for the index test for pre-
SLNB ultrasound (6/ 11), other ultrasound evaluat ion (3/ 5), CT (7/ 10), and MRI (4/ 4). For PET-CT, unclear risk f rom lack of descript ion of
blinded case note review to ascertain imaging results for retrospect ive studies (13/ 23) and high risk f rom data driven select ion of test
threshold (1/ 23). Unclear risk for reference standard f rom lack of detail on part icipant follow-up schedules (12/ 39). Lack of blinding of
the histological diagnosis (2/ 39) or data collect ion on follow-up (3/ 39) to the index result . High risk f rom dif ferent ial verif icat ion (20/ 39)
and part icipant exclusions (13/ 39). Low risk for comparisons between tests (6/ 9)
Applicability of evidence to ques-
tion:
High or unclear concern for applicability for almost all domains. High concern for part icipant select ion f rom mixed populat ions (11/ 39) or
data presented per lesion (5/ 39). Unclear concern f rom lack of clarity regarding study populat ion. High concern for index tests f rom poor
descript ion of test thresholds (pre-SLNB ultrasound (1/ 11), other ultrasound (1/ 5), CT (5/ 10), MRI (3/ 4), PET-CT (4/ 23)) or consensus
test interpretat ion (CT (6/ 10), MRI (2/ 4), PET-CT (11/ 23)). Unclear concern for applicat ion and interpretat ion of the index test (pre-SLNB
US (10/ 11), CT (3/ 10), MRI (2/ 4), PET-CT (6/ 23)) or unclear observer expert ise (pre-SLNB ultrasound (6/ 11), CT (3), MRI (2/ 4), PET-CT
(6/ 23)). Unclear concern for applicability of the reference standard f rom lack of descript ion of the target condit ion or no breakdown of
cases according to nodal or distant metastases. Expert ise of the histopathologist poorly described (6/ 39)
Findings
Thirty-nine studies report ing accuracy data for pre-SLNB imaging (n = 18) or for whole body imaging (n = 24) were included. The 24 studies of whole body imaging were of
primary staging (n = 6) or staging for potent ial recurrence of disease (n = 3), or were conducted in mixed or not clearly described populat ions (n = 15). As we are unable to
make clear statements regarding the expected accuracy of imaging at any part icular point on the clinical pathway for the mixed populat ion group, the f indings presented are
based on results for pre-SLNB imaging, and for primary staging and re-staging of melanoma only
Test: pre-SLNB imaging
Test Studies:
patients
(cases)
Sensitivity
(95% CI)
Specificity
(95% CI)
Numbers in a cohort of 1000 lesions at a median prevalence of 23.7%a
TP
(95% CI)
FN
(95% CI)
FP
(95% CI)
TN
(95% CI)
US 11:
2614 (542)
35.4
(17.0 to 59.4)
93.9
(86.1 to 97.5)
84
(40 to 141)
153
(197 to 96)
47
(106 to 19)
716
(657 to 744)
US + FNAC 3:
1164 (259)
18.0
(3.58 to 56.5)
99.8
(99.1 to 99.9)
43
(8 to 134)
194
(229 to 103)
2
(7 to 1)
761
(756 to 762)7
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PET-CT 4:
170 (49)
10.2
(4.31 to 22.3)
96.5
(87.1 to 99.1)
24
(10 to 53)
213
(227 to 184)
27
(98 to 7)
736
(665 to 756)
Whole bodyimaging for primary staging of melanoma
Quantity of evidence
(n = 6 studies)
Number of studies Number of participants Number of cases
Any metastases 3 81 51
Nodal metastases 3 373 68
Distant metastases 2 112 17
Findings
Four of the six studies evaluated PET-CT, one in comparison to CT
• In part icipants with primary melanomas > 4 mm thick (two studies), sensit ivit ies for the detect ion of any metastases were 30% (95%CI 7% to 65%) to 47% (95%CI 29% to
65%), and specif icit ies 73% (95%CI 45% to 92%) to 88% (95% CI 68% to 97%).
• One study of any part icipant referred for PET-CT demonstrated no false posit ive results for either CT or PET-CT for the detect ion of nodal metastases (specif icity 100%,
95%CI 92% to 100%); however, sensit ivity was higher for PET-CT (38%, 95%CI 14% to 68%) compared to CT (23%, 95%CI 5% to 54%). For the detect ion of distant metastases,
two addit ional cases were detected with PET-CT (sensit ivity 42%, 95%CI 15% to 72%) in comparison to CT (25%, 95%CI 5% to 57%) with no dif ference in specif icity (93%, 95%
CI 81% to 99%).
• One study of PET-CT suggested an SUVmax threshold ≥ 2.2 at baseline and predicted later recurrence with a sensit ivity of 89% (95%Cl 52% to 100%) and specif icity 61%
(95%CI 41% to 78%).
No data for MRI were ident if ied. Results for ultrasound for the detect ion of nodal metastases (2 studies) were highly variable and likely subject to bias
Whole bodyimaging for re-staging of melanoma
Quantity of evidence (n = 3 studies) Number of studies Number of participants (lesions) Number of cases (metastases)
Any metastases: 2 (1) 153 (139) 95 (87)
Nodal metastases: 1 460 37
Distant metastases: 0 N/ A N/ A
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Findings:
• Two studies of PET-CT for re-staging were pooled; summary sensit ivity for the detect ion of any metastasis was 92.6% (95% CI 85.3% to 96.4%) and specif icity 89.7%
(95%CI 78.8% to 95.3%) (153 pat ients, 95 cases).
• In one of the two studies, PET-CT was more sensit ive (89%, 95% CI 78% to 96%) than CT alone (increase of 21%). With sim ilar specif icity (88%, 95%CI 76% to 95%), PET-
CT was more sensit ive in the subgroup with stage Illc to IV disease (100%, 95% CI 81% to 100%) than in those with less advanced disease (84%, 95%Cl 69% to 94%). One
study of ultrasound in clinically node negat ive pat ients undergoing follow-up demonstrated 100% sensit ivity (95%CI 91% to 100%) for ’common signs of malignancy’ or focal
hypoechoic cort ical thickening (considered test posit ive) with a specif icity of 93% (95%CI 90% to 95%).
No data for MRI were ident if ied.
aMedian prevalence observed across 11 studies of pre-SLNB ultrasound (interquart ile range: 25th percent ile 20.5%, 75th
percent ile 25.4%).
CT: computed tomography; FN: false negat ive; FNAC: f ine needle aspirat ion cytology; FP: false posit ive; MRI: magnetic
resonance imaging; PET: positron emission tomography; SLNB: sent inel lymph node biopsy; TN: true negat ive; TP: true
posit ive.
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Ac-
curacy (DTA) reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Appendix 2 provides a glossary of terms used, and
Appendix 3 presents a table of acronyms used.
Target condition being diagnosed
Melanoma is one of the most aggressive forms of skin cancer, with
the potential to metastasise to other parts of the body via the lym-
phatic systemand the bloodstream.Melanoma accounts for a small
percentage of skin cancer cases but is responsible for up to 75%
of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
Melanoma arises from uncontrolled proliferation of melanocytes -
the epidermal cells that produce pigment ormelanin. It most com-
monly arises in the skin but can occur in any organ that contains
melanocytes, including mucosal surfaces, the back of the eye, and
the lining around the spinal cord andbrain. ’Cutaneousmelanoma’
refers to a skin lesion with malignant melanocytes present in
the dermis, and includes superficial spreading and nodular, acral
lentiginous, and lentigo maligna melanoma variants (Figure 1).
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Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr. Rubeta Matin: reproduced with permission.
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The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia, with 11,405 new cases of melanoma of the
skin (ACIM 2014), and in New Zealand, with 2341 registered
cases in 2010 (Cancer Society of New Zealand 2013). In the USA
for 2014, the predicted incidence was 73,870 per annum, and the
predicted number of deaths 9940 (Siegel 2015). The highest rates
in Europe are seen in northwestern Europe and the Scandinavian
countries, with highest incidence reported in Switzerland of 25.8
per 100,000 in 2012. Rates in the UK trebled from 4.6 and 6.0
per 100,000 in men and women, respectively, in England in 1990,
to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). In the
UK, melanoma has one of the fastest rising incidence rates of any
cancer, and it shows the biggest projected increase in incidence
between2007 and2030 (Mistry 2011). In the decade leadingup to
2013, age standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2459 deaths in 2014 (Cancer Research
UK 2017a). Although overall incidence rates are higher in women
than in men, the rate of incidence in men is increasing faster than
in women (Arnold 2014).
The rising incidence of melanoma is thought to be primarily re-
lated to rising recreational sun exposure and tanning bed use,
along with an increasingly ageing population with higher life-
time recreational ultraviolet (UV) exposure (Boniol 2012;Gandini
2005), in conjunction with possible earlier detection (Belbasis
2016; Linos 2009). Putative risk factors are reviewed in detail else-
where (Belbasis 2016), but they can be broadly divided into host
and environmental factors. Host factors include fair skin and light
hair or eye colour; older age (Geller 2002); male sex (Geller 2002);
previous skin cancer history (Tucker 1985); predisposing skin le-
sions (e.g. high melanocytic naevus counts) (Gandini 2005), clin-
ically atypical naevi (Gandini 2005), and large congenital naevi
(Swerdlow 1995)); genetically inherited skin disorders (e.g. xero-
derma pigmentosum) (Lehmann 2011); and a family history of
melanoma (Gandini 2005). Environmental factors include recre-
ational and occupational exposure to sunlight (both cumulative
and episodic burning) (Armstrong 1977; Gandini 2005); artificial
tanning (Boniol 2012); and immunosuppression (e.g. in organ
transplant recipients or human immunodeficiency virus (HIV)-
positive individuals) (DePry 2011). Lower socioeconomic class
may be associated with delayed presentation and thus more ad-
vanced disease at diagnosis (Reyes-Ortiz 2006).
The main prognostic indicators following diagnosis of cutaneous
melanoma can be divided into histological and clinical factors.
Histologically, Breslow thickness is the single most important pre-
dictor of survival, as it is a quantitative measure of tumour inva-
sion or volume, and thus propensity to metastasise (Balch 2001).
Other factors associated with poorer prognosis histologically in-
clude microscopic ulceration, mitotic rate, microscopic satellites,
regression, lymphovascular invasion, and nodular (rapidly grow-
ing) or amelanotic (lacking inmelanin pigment) subtypes (Moreau
2013; Shaikh 2012). Independent of tumour thickness, prognosis
is worse in older people, males, and those with locally recurrent
lesions, regional lymph node involvement, or primary lesion loca-
tion on the scalp or neck (Zemelman 2014).
Following histological confirmation of diagnosis, the lesion is
staged according to the American Joint Committee on Can-
cer (AJCC) Staging System to inform treatment strategy (the
eighth version of the Staging System - AJCC 8 - is outlined in
Gershenwald 2017). Stage 0 refers to melanoma in situ; stages I to
II localised melanoma; stage III regional metastasis (spread to the
lymph nodes, usually but not always those nearest to the primary
tumour); and stage IV distant metastasis. A preliminary stage is
assigned based on histological evaluation (thickness of primary le-
sion and presence of ulceration) and clinical (and sometimes radi-
ological) assessment of regional lymph nodes. A pathological stage
is then confirmed based on histology of the primary lesion and
of the regional lymph nodes (if the patient has sentinel lymph
node biopsy (SLNB) or completion lymphadenectomy (CLND)
for those with clinically palpable lymph nodes) and imaging to
confirm the presence or absence of disseminated disease, where
indicated.
An American database of over 40,000 patients from 1998 on-
wards, which assisted the development of AJCC 8, indicated five-
year survival of 99% for very early-stage melanoma, dropping to
anything between 32% and 93% in stage III disease, depending
on tumour thickness, the presence of ulceration, and the number
of involved nodes (Gershenwald 2017). Before the advent of tar-
geted therapy and immunotherapies, disseminated melanoma (to
distant sites/visceral organs) was associated with median survival
of six to nine months, one-year survival of 25%, and three-year
survival of 15% (Balch 2009; Korn 2008).
Between 1975 and 2010, five-year relative survival for melanoma
(i.e. not including death from other causes) in the United States
increased from 80% to 94%, with survival for localised, regional,
and distant disease estimated at 99%, 70%, and 18%, respec-
tively, in 2010 (Cho 2014). However, mortality rates showed little
change, at 2.1 per 100,000 deaths in 1975, and 2.7 per 100,000
in 2010 (Cho 2014). Increasing incidence of localised disease over
the same period (from 5.7 to 21 per 100,000) suggests that much
of the observed improvement in survival may be due to earlier de-
tection and heightened vigilance (Cho 2014). New targeted ther-
apies for advanced (stage IV) melanoma (e.g. BRAF inhibitors)
have improved survival, and immunotherapies are evolving such
that long-term survival is being documented (Rozeman 2018). No
new data regarding survival prospects for patients with stage IV
disease were analysed for the AJCC 8 staging guidelines because
of lack of contemporary data (Gershenwald 2017).
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Treatment of melanoma
Treatment of melanoma varies to some extent, according to the
stage of disease upon diagnosis. For primary melanoma, the main-
stay of treatment is complete lesion excision, with a safety margin
some distance from the borders of the primary tumour to remove
both the tumour and any malignant cells that might have spread
into the surrounding skin (Garbe 2016; Marsden 2010; NICE
2015a; SIGN 2017; Sladden 2009). Recommended surgical mar-
gins vary according to tumour thickness - Garbe 2016 - and stage
of disease at presentation -NICE 2015a. Evidence for further local
or regional interventions such as wider surgical margins is limited
(Sladden 2009; Wheatley 2016), although further trials in this
area are planned.
Sentinel lymph node biopsy has been offered to those without
clinically palpable lymph nodes as a means of providing prog-
nostic information for several years, with the option of CLND
in the event of a positive result (metastases identified on SLNB).
Recent data (MLST II - Kyrgidis 2015 and Morton 2014 - and
DeCOG - Leiter 2016 and Leiter 2018 - trials) show no sur-
vival benefit from CLND for this patient group, and the proce-
dure is no longer a standard of care for most patients. Recent ad-
vances demonstrating longer recurrence-free survival for patients
with stage III melanoma receiving BRAF-directed therapy or im-
munotherapies have resulted in use of SLNB as a test to identify
patients who should be offered adjuvant treatment (Eggermont
2016; Eggermont 2018; Long 2017; Weber 2017). Currently
available guidelines do not, as yet, reflect this recent change in
practice (Garbe 2016; NICE 2015a). In the UK, the National
Institute for Health and Care Excellence (NICE) has already ap-
proved dabrafenib and trametinib for adjuvant treatment of re-
sected BRAF V600 mutation positive melanoma (NICE 2018a),
with further appraisals of pembrolizumab for adjuvant treatment
of melanoma with high risk of recurrence (NICE 2018b), as well
as ongoing appraisals of nivolumab for adjuvant treatment of re-
sected stage III and IV melanoma (NICE 2019a).
For stage IV melanoma, dacarbazine was the only drug approved
worldwide for many years, with fotemustine used in some Euro-
pean countries (Avril 2004), and interleukin (IL)-2 given in the
USA (Atkins 1999). Temozolomide has also been used, especially
for peoplewith brainmetastases, because of its strong ability to pass
the blood-brain barrier (Lukas 2014; Zhu 2014). This landscape
has changeddramatically, with twodistinct therapeutic approaches
suggesting survival benefit in metastatic melanoma: (1) targeting
mutations in tumour cells, and (2) providing immunomodulation
(Chapman 2011; Chapman 2012; Dummer 2014; Hamid 2013;
Hodi 2010; Larkin 2014; Robert 2015; Villanueva 2010). Sev-
eral different therapies have now shown high response rates and,
most important, have demonstrated for the first time in the treat-
ment of melanoma the potential for a durable clinical response
(Chapman 2011; Hamid 2013; Hodi 2010; Hodi 2016; Larkin
2015; Maio 2015; Sznol 2013). Several therapies are now recom-
mended for use alone or in combination for particular subgroups
of patients with metastatic melanoma, both in the UK - NICE
2018a - and beyond - Garbe 2016 - and have recently been the
topic of a Cochrane Review (Pasquali 2018). An appraisal of en-
corafenib with binimetinib for advanced BRAF V600 mutation
positive melanoma is under way (NICE 2019b), and several other
treatments are currently suspended pending marketing authorisa-
tion applications from the companies concerned (NICE 2018c).
Psychosocial interventions to improve quality of life and general
psychological distress after diagnosis for patients with cancer are
also available. However, a Cochrane Review found considerable
variation in the evidence to support such interventions (Galway
2012).
Index test(s)
Accurate staging of melanoma is more important than ever, in
part to avoid unnecessary treatment and associated morbidity in
those with early-stage disease, and in part to ensure that potentially
effective therapies are initiated in a timely manner for those with
nodal or distant metastatic disease.
Imaging techniques such as ultrasound, computed tomography
(CT), or magnetic resonance imaging (MRI) scans can be under-
taken at several points along the clinical pathway, including on
initial presentation of disease (primary staging), on development
of recurrence (re-staging), and on follow-up after previous treat-
ment for those who are asymptomatic for recurrence. The use of
imaging during follow-up with no specific clinical indication for
imaging (i.e. as amonitoring test for disease surveillance) is not the
focus of our reviews. Historically,most staging in terms of imaging
has been undertaken in people with clinical stage III and IV dis-
ease (see Clinical pathway). However, this landscape is changing
as more adjuvant systemic therapies for melanoma are becoming
available.
Imaging tests are typically undertaken and interpreted by radiolo-
gists, with decisions about patient management following imaging
or SLNB made at multi-disciplinary team meetings that include
oncologists, dermatologists, and surgeons (Clinical pathway).
Ultrasound
Ultrasound uses high-frequency sound waves to create images of
the body. Ultrasound can be used to assist in detection of diseased
lymph nodes with clinically node negative melanoma; in treat-
ment of patients who have a positive imaging result, proceeding
to fine needle aspiration cytology (FNAC) or core biopsy; and in
treatment of patients who are negative on ultrasound alone or on
ultrasound combined with FNAC proceeding to SLNB. A 2011
systematic review identified 21 studies of ultrasound for primary
lymph node staging or surveillance; for primary staging, sensitivity
was 60% for detection of diseased lymph nodes, with specificity of
97% (the number of studies that considered staging vs surveillance
is unclear) (Xing 2011).
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Computed tomography (CT) (non-contrast-enhanced
or contrast-enhanced)
Computed tomography scans use ionising radiation in the form of
X-rays to take cross-sectional images of the body (Bluemm 1983;
van Waes 1983). This procedure involves varying amounts of ra-
diation according to the area of the body to be scanned (Mahesh
2017), and it can be conducted with an intravenous contrast agent
(contrast-enhanced) to increase the sensitivity of metastasis detec-
tion in solid organs.
Mohr 2009 describes contrast-enhanced CT as the best method
of identifying intrathoracic metastases and as superior to X-ray
for detection of mediastinal and hilar adenopathy associated with
lymphatic spread and for assessment of lesions in the bone. Com-
puted tomography can also be used for assessment of metastatic
spread to the brain, but magnetic resonance imaging (MRI) is
considered more sensitive (Goulart 2011). Overall specificity is
reportedly high for detection of regional nodal and distant disease,
but sensitivity varies from 23% to 85% for detection of lymph
node metastases, and from 25% to 74% for assessment of distant
spread (Xing 2011).
Magnetic resonance imaging (MRI) (non-contrast-
enhanced or contrast-enhanced)
Magnetic resonance imaging scans use large magnets and non-
ionising radiation in the form of radio waves to generate images
of the body (Ai 2012). These scans are more expensive and take
longer to carry out compared to CT scans (Whaley 2016b).
We did not identify any systematic reviews of MRI for melanoma
staging through our scoping searches; however, several studies have
considered whole body MRI (Jouvet 2014; Mosavi 2013), as well
as MRI for detection of brain or hepatic metastases (Aukema
2010a; Sofue 2012). Because melanoma is one of the top three
cancers responsible for brain metastases (Cagney 2017), the body
of evidence for the incremental accuracy of MRI compared with
other imaging tests must be considered.
PET-CT (positron emission tomography-computed
tomography)
Positron emission tomography-computed tomography is a hybrid
imaging technique that provides both functional and anatom-
ical information. It involves injection of a weakly radioactive
positron-emitting radiopharmaceutical, which is usually 2-deoxy-
2-[18F]fluoro-D-glucose (FDG), for the purposes of oncological
imaging. The distribution of FDG throughout the body is rep-
resented on images, with malignant tissue usually demonstrating
greater levels of FDG uptake than normal tissue (Lammertsma
2017). The low-dose CT component of the study generates atten-
uation factors that improve the quality of PET images and allows
accurate anatomical localisation of areas of FDG uptake (IAEA
2016). Although initially, PET scanners were stand-alone devices,
since 2004, all modern scanners have been integrated PET-CT
scanners (Jones 2017). A systematic review of the added value of
integrated PET-CT compared to PET alone across a range of can-
cers suggested a 10% increase in sensitivity of PET-CT compared
to PET alone from a meta-analysis of 10 comparative studies (Gao
2013). For these reasons, PET alone has not been considered as
an index test for this review.
In comparison to CT alone, PET-CT is generally considered to be
a more sensitive test (Xing 2011); however, increases in sensitivity
must be linked to any patient benefit in terms of changes in man-
agement and ultimately in patient outcomes (Schroer-Gunther
2012; Subesinghe 2013). It may be that PET-CT has the greatest
added value for metastases in areas that are difficult to image with
CT or other imaging modalities (Tan 2012), or for indeterminate
metastases in areas such as the lung. Whether these assumptions
are supported by current evidence has yet to be established. The
evidence report for theNICE guideline in 2015 found no evidence
“to suggest that earlier treatment of metastatic disease improves
survival and therefore increased sensitivity was viewed currently
as not an important issue” (NICE 2015d). With adjuvant therapy
now an increasing option for melanoma, this conclusion seems
likely to be revised in a future guideline update.
Clinical pathway
Staging of confirmed melanoma takes place in secondary and ter-
tiary care settings only (NICE 2015a). Recommendations on the
management of melanoma following diagnosis, published in the
2015 NICE Guideline (NICE 2015a), as well as in other UK
guideline documents (Burkill 2014; Marsden 2010; Melanoma
Taskforce 2011), are summarised in Figure 2 and are outlined be-
low; however, practice varies across the UK. It is important to note
that clinical practice is changing as more adjuvant therapies are
licensed for the treatment of melanoma, and this is not adequately
reflected by current guidelines. However, a consensus statement
reflecting changes in decision thresholds for the use of SLNB for
staging of melanoma has been published (Melanoma Focus 2018).
Any key variations in practice recommended in European or US
guidelines (ESMO 2019; Swetter 2019), or under consideration
in a current Australian guideline update (Cancer Council Australia
2019; Gyorki 2018; Millward 2018; Morton 2018; Saw 2018),
are also reflected below.
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Figure 2. Summary of 2015 NICE guideline recommendations for the management of cutaneous
melanoma following primary diagnosis (NICE 2015a); not necessarily reflective of current practice.
Following complete excision of the primary lesion, all patients
should undergo preliminary staging. This involves a detailed clin-
ical history to determine if there are any symptoms such as weight
loss suggesting metastatic spread of disease, followed by a thor-
ough clinical examination, including whole body skin examina-
tion, palpation of the lymph nodes, and full abdominal and chest
examination (Figure 2). A preliminary stage is assigned on the ba-
sis of histopathology results for the primary lesion(s). Those with
palpable lymph nodes are automatically assigned to clinical stage
III or IV, and those with no palpable lymph nodes are assigned a
stage between 0 and IIC, according to the thickness of the tumour
(Breslow) and the presence of ulceration (Gershenwald 2017).
The results of all investigations carried out during the process
of diagnosis are discussed at a multi-disciplinary team meeting
(Melanoma Taskforce 2011), where decisions regarding further
staging procedures are made. This could be a local skin multi-
disciplinary team or, for those with stage IIB disease and above,
a specialist skin multi-disciplinary team (Marsden 2010). Teams
should include dermatologists, surgeons (including plastic sur-
geons), medical and clinical oncologists, radiologists, histopathol-
ogists, skin cancer nurse specialists, physiotherapists, psycholo-
gists, lymphoedema service providers, occupational therapists, and
cosmetic camouflage advisors (Melanoma Taskforce 2011).
On currentUK guidance (based onAJCCversion 7 (Balch 2009)),
no further staging investigations beyond a full clinical examina-
tion are recommended for people with thin melanomas (≤ 1 mm)
without ulceration ormitoses, and SLNB is reserved for those with
stage IB or stage II disease (NICE 2015a). Current practice is now
based on staging according to AJCC version 8, for example, with
‘thin’ melanomas now defined as < 0.8 mm in thickness without
evidence of ulceration (Gershenwald 2017). Furthermore, with
the advent of new adjuvant therapies, SLNB is now considered
essential in determining eligibility for systemic adjuvant therapy
(Gyorki 2018; Melanoma Focus 2018; Swetter 2019), and imag-
ing is used in sentinel node positive patients to confirm absence
of further disease spread (ESMO 2019; Swetter 2019). SLNB
is recommended for those with primary melanoma greater than
1.0 mm and should be considered for some patients with thin-
ner melanomas (i.e. melanomas < 0.8 mm with ulceration, and
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melanomas 0.8 to 1.0 mm with or without ulceration), especially
in the presence of lymphovascular invasion or a mitotic rate of at
least 2 per mm² (Melanoma Focus 2018). Those with clinically
palpable lymph nodes or with significant nodal disease identified
on imaging are likely to undergo CLND, with the option of ad-
juvant therapy for those with no evidence of distant metastases.
Available recommendations on the optimal choice of imaging tests
vary to some extent, even within theUK (Burkill 2014;Melanoma
Focus 2014; NICE 2015a). Computed tomography is generally
the imaging test of choice; however, some centres additionally of-
fer high-resolution ultrasound, MRI, or PET-CT scans. The Na-
tional Institute for Health and Care Excellence recommends CT
staging to identify those who may benefit from systemic therapy
among those with stage IIC, stage III, or suspected stage IV disease
(NICE 2015a), as well as imaging of the brain (with CT for adults
and MRI for children and young adults) only if metastatic disease
outside the central nervous system is suspected (NICE 2015a).
However, the Melanoma Focus position paper recommends that
all ‘high-risk’ patients should undergo CT of the chest, abdomen,
and pelvis (or whole body PET-CT), plus MRI of the head, as
standard treatment (Melanoma Focus 2014). In current clinical
practice, eligibility for imaging is likely to diverge from both of
these target groups; however, the emergence of new treatment op-
tions is not likely to impact the choice of imaging tests performed
nor body sites imaged.
European guidelines recommend pre-SLNB baseline lymph node
(LN) ultrasound for stage IB to IIA disease, and CT or PET for
stage IIB and upwards (ESMO 2019). Australian guidelines in
Morton 2018 and US guidelines in Swetter 2019 recommend
against baseline imaging for all asymptomatic and clinically node
negative patients. In the United States, CT or PET-CT may be
considered for sentinel lymph node (SLN) positive disease but
otherwise should be reserved for investigation of specific signs
or symptoms or nodal or distant metastases (Swetter 2019). In
Australia, US and FNAC are recommended to identify the extent
of regional LN involvement in clinically node positive melanoma
(Saw 2018), as well as whole body PET-CT with CT or MRI of
the brain for clinical stage III or IV disease (Saw 2018; Millward
2018).
The Royal College of Radiologists guideline recommends that
scans should be tailored according to the site of the primary lesion
and most likely the regional lymph node basin. In general, CT
imaging of the head, chest, abdomen, and pelvis should be em-
ployed for lower limb and lower body wall lesions, with CT of the
neck added for upper limb, scalp, neck, and upper torso primary
tumours (Burkill 2014).Magnetic resonance imagingmay bemore
appropriate for imaging the central nervous system (Burkill 2014).
Although PET-CT has been suggested to have a role in imaging
the lower limbs, further evidence is required (Burkill 2014).
Genotyping is also now offered to identify BRAFmutations to al-
low further planning of systemic treatment (Melanoma Taskforce
2011; NICE 2018a; NICE 2019b).
Prior test(s)
Consideration of the degree of prior testing that study participants
have undergone is key to interpretation of resulting test accuracy
indices, which are known to vary according to the spectrum or case
mix of included participants (Lachs 1992; Leeflang 2013; Moons
1997; Usher-Smith 2016). Prior testing can be considered in two
ways. First, the results of any tests undertaken around the time
of application of the index test may contribute to the decision to
undertake the index test in any particular study participant. For
example, PET-CT may be undertaken because of the presence of
high-risk primary melanoma characteristics or because of abnor-
mal findings on abdominal ultrasound or chest X-ray; the likeli-
hood of abnormal findings on PET-CT, and therefore sensitivity
or specificity, may be influenced by the results of any tests previ-
ously undergone.
Second, prior testing can be considered in terms of the place on
the clinical pathway or the time course of disease that patients
have reached. People undergoing imaging for staging following a
primary diagnosis of melanoma are less likely to have metastatic
spread of disease compared to those forwhom imaging is prompted
by signs of recurrence, and the nature of any disease spread is
likely to vary between a primary staging population and patients
undergoing follow-up, who may have already undergone previous
treatment such as complete lymphadenectomy. Reinhardt 2006
evaluated the accuracy of CT, PET, and PET-CT in 250 partic-
ipants with melanoma “at different time points in the course of
disease”, including primary staging after sentinel node biopsy (n
= 75); therapy control after chemotherapy for metastatic disease
(n = 42); staging of clinically suspected recurrent disease (n = 65);
and assessment during follow-upwithin five years of primary treat-
ment (n = 68). For both nodal and distant staging, the overall sen-
sitivity and specificity of each test masked likely variations in accu-
racy between subgroups. For example, the overall sensitivity and
specificity of CT for detection of nodal metastases were 85% and
87%, but when estimated for each subgroup of participants, the
sensitivity of CT ranged from 67% for those undergoing follow-
up to 93% for those having imaging for treatment evaluation, and
specificities ranged from 73% for the treatment evaluation group
to 93% for those having primary staging (Reinhardt 2006). The
overall pooled analysis suggested statistically significant differences
in sensitivities (CT 73% vs PET-CT 99%; P < 0.0001) and in
specificities (CT 88% vs PET-CT 98%; P < 0.0001) for detection
of distant metastases, but for the primary staging subgroup, no
difference in sensitivities was observed (93.8% for both tests) and
the difference in specificities was non-significant (CT 94.9% vs
PET-CT 98.3%) (Reinhardt 2006). For the re-staging subgroup,
differences in both sensitivities (CT 85% vs PET-CT 100%) and
specificities (CT 79% vs PET-CT 96%) between tests were ob-
served (Reinhardt 2006). Although subgroup numbers were rela-
tively small, these findings lend support to the hypothesis that the
clinical pathway does affect test accuracy in this context, although
as for other tests and diseases, the mechanisms of action can be
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complex and difficult to identify (Leeflang 2013).
Role of index test(s)
Ultrasound with FNAC as a triage test before SLNBwas originally
promoted as having a role in fast-tracking those with positive cy-
tology results (micro-metastases identified) to CLND, while those
with negative cytology may proceed to SLNB, as required (Voit
2014). With the changing clinical pathway and lack of evidence
for survival benefit from CLND (Leiter 2018; Morton 2014), the
only potential role for ultrasound and FNAC in the UK is consid-
ered to be seen at centres where SLNB is not immediately available
(with a positive cytology result indicating that adjuvant therapy
should be initiated); however this approach is still recommended
for use following primary melanoma diagnosis in Europe (ESMO
2019), as well as for clinically node positive melanoma in Australia
(Saw 2018).
No role has been recommended for imaging tests in early-stage
disease. The need to rule out distant metastases among those who
are otherwise eligible for adjuvant therapy suggests that imaging
might now be used in a much more broadly defined patient group
than previously. To date, CT has been recommended as the imag-
ing approach of choice for detection of nodal and distant spread
for those with stage III or IV disease (and for those with stage
IIC if no SLNB has been performed) (NICE 2015a). Positron
emission tomography-computed tomography is increasingly used;
however, practice varies across the country, primarily according to
availability. The advantages of disease management derived from
PET-CT are not yet known. Themost appropriate role forMRI in
staging melanoma in adults, other than for central nervous system
disease, remains unclear.
Alternative test(s)
Several other tests may be used to inform disease management
following a diagnosis of melanoma.
Sentinel lymph node biopsy, which allows detection of metastatic
spread to the regional lymph node basins, is the topic of another
review in this series of reviews (Ferrante di Ruffano 2019).
Core needle biopsy of the lymph nodes, as in Whaley 2016a, or
FNAC, as in Hall 2013, to confirm the presence of macro-metas-
tases can be guided by simple palpation or, for more deep-seated
lesions, via image-based guidance to identify micro-metastases (re-
quiring use of a microscope for visualisation) (Bohelay 2015). Al-
though the accuracy of core needle biopsy compared to fine needle
aspiration has been identified as a key clinical question for investi-
gation, this topic is beyond the scope of these reviews, which focus
primarily on detection of non-palpable metastatic disease.
Genetic testing of primary melanoma specimens, for BRAF mu-
tations for example, is used increasingly (NICE 2015a), particu-
larly with the emergence of systemic treatments for BRAF V600
mutation positive melanoma (Chapman 2011; Chapman 2012;
Larkin 2014; Larkin 2015). However, its purpose is to inform sys-
temic treatment decisions rather than to serve as an integral part of
the staging procedure itself. Biomarkers, such as S100, are used in
countries such as Germany as a marker of prognosis (Gray 2014),
or of early disease relapse (Peric 2011), rather than for staging pur-
poses per se (Egberts 2010; Pirpiris 2010), and lactate dehydroge-
nase (LDH) is part of AJCC staging for stage IV (Pirpiris 2010);
however, these approaches are beyond the scope of our reviews.
Rationale
Appropriate staging of melanoma is crucial for ensuring that pa-
tients are directed to the most appropriate and effective treatment.
Several tests are available to assist in the staging ofmelanoma; how-
ever, their comparative accuracy for detection of nodal or distant
metastases, or both, according to histological stage at presentation
is unclear.
The NICE guideline recommendations for staging (see Clinical
pathway) were based on available systematic reviews of both SLNB
and imaging tests (Hall 2013; Jimenez-Requena 2010; Krug 2008;
Rodriguez 2014; Valsecchi 2011; Xing 2011), with some sup-
plementary data derived from primary studies (NICE 2015d).
Most reviews are limited in terms of currency (de Rosa 2011;
Jimenez-Requena 2010; Krug 2008; Valsecchi 2011; Warycha
2009; Xing 2011), with literature searches in most cases extend-
ing only as recently as 2009 (Jimenez-Requena 2010; Krug 2008;
Valsecchi 2011; Xing 2011). Furthermore, the only review that
compared accuracy across imaging tests did not consider histolog-
ical stage (Xing 2011). Two reviews provide a more recent evalu-
ation of PET and PET-CT (search dates up to 2012 and 2011,
respectively) (Rodriguez 2014; Schroer-Gunther 2012); however,
the Schroer-Gunther 2012 review also relied on previously pub-
lished reviews (Jimenez-Requena 2010; Krug 2008), with supple-
mentary searching for more recently published studies, and the
Rodriguez 2014 review included only stage III melanoma. The
Schroer-Gunther 2012 review relied on quality assessment that
was carried out for the original systematic reviews, and only a
small number of studies were eventually included; the review au-
thors themselves recommend that future reviews should include a
broader range of study designs (Schroer-Gunther 2012).
The comparative accuracy of imaging tests according to stage of
disease therefore remains to be determined. Furthermore, any ev-
idence for or against the routine use of brain scanning in stage
III melanoma with either CT or MRI remains to be identified.
Positron emission tomography-computed tomography is increas-
ingly used, but any additional role of this test comparedwithCTor
MRI needs to be examined according to particular patient groups.
This review follows a generic Cochrane DTA protocol for stag-
ing of melanoma (Dinnes 2017). The Background and Methods
sections of this review therefore include some text that was orig-
inally published in the protocol (Dinnes 2017), along with text
that overlaps some of our other reviews for the diagnosis or staging
of melanoma (e.g. Dinnes 2018; Ferrante di Ruffano 2019).
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O B J E C T I V E S
Primary objectives
We estimated accuracy separately according to the point in the
clinical pathway at which imaging tests were used. Our objectives
were:
• to determine the diagnostic accuracy of ultrasound or PET-
CT for detection of nodal metastases before sentinel lymph node
biopsy in adults with confirmed cutaneous invasive melanoma;
and
• to determine the diagnostic accuracy of ultrasound, CT,
MRI, or PET-CT for whole body imaging in adults with
cutaneous invasive melanoma:
◦ for detection of any metastasis in adults with a primary
diagnosis of melanoma (i.e. primary staging at presentation); and
◦ for detection of any metastasis in adults undergoing
staging of recurrence of melanoma (i.e. re-staging prompted by
findings on routine follow-up).
We undertook separate analyses according to whether accuracy
data were reported per patient or per lesion.
Secondary objectives
We sought to determine the diagnostic accuracy of ultrasound,
CT, MRI, or PET-CT for whole body imaging (detection of any
metastasis) in mixed or not clearly described populations of adults
with cutaneous invasive melanoma.
For study participants undergoing primary staging or re-staging
(for possible recurrence), and for mixed or unclear populations,
our objectives were:
• to determine the diagnostic accuracy of ultrasound, CT,
MRI, or PET-CT for detection of nodal metastases;
• to determine the diagnostic accuracy of ultrasound, CT,
MRI, or PET-CT for detection of distant metastases; and
• to determine the diagnostic accuracy of ultrasound, CT,
MRI, or PET-CT for detection of distant metastases according
to metastatic site.
Investigation of sources of heterogeneity
We aimed to consider a range of potential sources of heterogeneity
for investigation, as outlined in our generic protocol and described
in Appendix 4, but insufficient data were identified to allow any
heterogeneity investigations to be undertaken.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of results
of the index test versus a reference standard, including:
• prospective and retrospective studies;
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test(s) (concurrently) and a reference standard;
• studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests and all
receive a reference standard (between-person comparative
studies);
• studies that recruit a series of participants unselected by
true disease status; and
• diagnostic case-control studies that separately recruit
diseased and non-diseased groups (Rutjes 2005).
We excluded follow-up and surveillance studies using repeated
imaging tests to detect disease recurrence, as defining the most
appropriate follow-up schedule for melanoma patients is not the
primary objective of these reviews.
We excluded studies if it was not possible to derive the numbers
of true positives, false positives, false negatives, and true negatives
from data provided in the paper, and we excluded small studies
with fewer than five disease positive or fewer than five disease
negative participants or lesions identified on imaging. Although
the size threshold of five is arbitrary, such small studies are likely
to yield unreliable estimates of sensitivity or specificity, and are
unlikely to add precision to estimates of accuracy.
We included studies reporting either lesion-based or participant-
based analyses; however, we accorded more weight to those re-
porting data on a per participant basis as detection of multiple
metastatic sites in an individual patient may have a disproportion-
ate effect on estimates of test accuracy based on per lesion data.
Furthermore, treatment following staging is generally directed to
the patient rather than to the individual metastatic lesion, making
the patient the more appropriate unit of analysis.
We excluded studies available only as conference abstracts.
Participants
We included studies in adults with cutaneous melanoma at any
primary site who were undergoing staging, either following pri-
mary presentation of disease or following recurrence of disease.
We included for completeness studies that included mixed pop-
ulations of patients, or where the clinical pathway could not be
determined, but we undertook no statistical pooling. We included
studies if up to 10% of participants had other forms of melanoma
such as ocular or mucosal melanoma. We included studies with
greater proportions of participants with non-cutaneous melanoma
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and studies including participants with other forms of cancer only
if test results for participants with cutaneous melanoma could be
differentiated.
Index tests
Studies reporting accuracy data for a single application of one or
more of the following tests were eligible for inclusion.
• Ultrasound (with or without subsequent FNAC or core
biopsy).
• CT (non-contrast-enhanced or contrast-enhanced).
• PET-CT (¹ FDG only).
• MRI (non-contrast-enhanced or contrast-enhanced).
We included any threshold for deciding test positivity, either qual-
itative or quantitative.
We excluded studies reporting multiple applications of the same test
in more than 10% of study participants because of anticipated
effects on test accuracy (multiple tests increasing the chance of de-
tection of metastases, thereby increasing test sensitivity and reduc-
ing specificity). The threshold of 10% is arbitrary but allows for
inclusion of studies primarily focused on evaluating the accuracy
of a single test application for staging of disease.We excluded stud-
ies of surveillance imaging following initial definitive treatment.
Target conditions
Primary target conditions were defined as detection of:
• nodal metastases in participants scheduled for SLNB (to
identify those who should proceed directly to CLND); and
• any metastases for all other staging.
Two additional definitions of the target condition were considered
in secondary analyses, namely, detection of:
• any nodal metastases; and
• any distant metastases (combined or by metastatic site).
Reference standards
Acceptable reference standards include:
• histology of lymph node or distant specimens, with samples
obtained by core biopsy, SLNB, or lymph node dissection;
• cytology of lymph node specimens, with samples obtained
by core biopsy or fine needle aspiration;
• clinical or radiological follow-up to identify nodal or
distant recurrence of at least three months; and
• any combination of the above.
We excluded studies using cross-sectional imaging-based reference
standards (i.e. direct comparison of the index test vs an alternative
reference standard imaging test).
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed screening of search results for po-
tentially relevant papers for all reviews at the same time. A search
combining disease-related terms with terms related to test names,
using both text words and subject headings, was formulated. The
search strategy was designed to capture studies evaluating tests for
the diagnosis or staging of skin cancer. As a majority of records
were related to searches for tests for staging of disease, a filter using
terms related to cancer staging and to accuracy indices was applied
to the staging test search to try to eliminate irrelevant studies, for
example, those using imaging tests to assess treatment effective-
ness. A sample of 300 records that would be missed by applying
this filter was screened and the filter adjusted to include potentially
relevant studies. When piloted onMEDLINE, inclusion of the fil-
ter for staging tests reduced the overall numbers by around 6000.
The final search strategy, incorporating the filter, was subsequently
applied to all bibliographic databases as listed below (Appendix 5).
The final search result was cross-checked against the list of studies
included in five systematic reviews; our search identified all but
one of these studies, and this study was not indexed on MED-
LINE. The Information Specialist devised the search strategy, with
input from the Information Specialist from Cochrane Skin. No
additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies.
• MEDLINE via OVID (from 1946).
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID.
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7), in the Cochrane Library.
• Cochrane Database of Systematic Reviews (CDSR; 2016,
Issue 8), in the Cochrane Library.
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2).
• CRD HTA (Health Technology Assessment) database
(2016, Issue 3).
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) via EBSCO from 1960.
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search.
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• Conference Proceedings Citation Index (CPCI), via Web of
Science™ (from 1990; searched 28 August 2016).
• Science Citation Index (SCI) Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’, and ’skin cancer’ com-
bined with ’diagnosis’.
• Zetoc (from 1993; searched 28 August 2016).
• US National Institutes of Health Ongoing Trials Register (
www.clinicaltrials.gov; searched 29 August 2016).
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/; searched 29 August 2016).
• World Health Organization International Clinical Trials
Registry Platform ( apps.who.int/trialsearch/; searched 29
August 2016).
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress), but because of time constraints, we were unable to fol-
low up on potentially relevant studies identified from conference
abstracts. We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies, and we included any missed by
our searches. We checked the reference lists of all included papers,
and subject experts within the author team reviewed the final list of
included studies. We conducted no electronic citation searching.
Data collection and analysis
Selection of studies
At least one review author (JDi or NC) screened titles and ab-
stracts and discussed and resolved any queries by consensus. A pi-
lot screen of 539 MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. Primary test ac-
curacy studies and test accuracy reviews (for scanning of reference
lists) of any test used to investigate suspected melanoma, basal cell
carcinoma (BCC), or cutaneous squamous cell carcinoma (cSCC)
were included at initial screening. Inclusion criteria were applied
independently by both a clinical review author (from one of a
team of 12 clinician reviewers) and a methodologist review author
(JDi, NC, or LFR) to all full-text articles, and disagreements were
resolved by consensus or by a third party (JDe, CD, HW, RM)
(Appendix 6). No study authors were contacted in regard to study
eligibility because of the volume of data retrieved. Authors of eli-
gible studies were contacted when insufficient data were presented
to allow for construction of 2×2 contingency tables.
The study selection process is described in a PRISMA-DTA
flowchart (McInnes 2018).
Data extraction and management
One clinical (SAC, AD, AG, LP) and at least one methodologist
review author (LFR, JDi) extracted data concerningdetails of study
design, participants, index test(s) or test combinations, criteria
for index test positivity, reference standards, and data required to
populate a 2×2 diagnostic contingency table for each index test
using a piloted data extraction form. Disagreements were resolved
through discussion or by a third party (JDe, CD, HW, RM).
Dealing with multiple publications and companion papers
In the event of multiple reports of a primary study, the most
complete and up-to-date data source available was used to con-
tribute 2×2 contingency table data to eliminate double-counting
of datasets. When possible, yield of information regarding study
methods and participants was maximised by extracting relevant
data from multiple publications.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies us-
ing the Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) checklist (Whiting 2011), which had been tai-
lored to the review topic (Appendix 7). We piloted the modified
QUADAS-2 tool on a small number of included full-text articles.
One clinical (as detailed above) and at least one methodologist re-
view author (LFR, JDi, BH, or SB) independently assessed quality
for the remaining studies; any disagreement was resolved by con-
sensus or by a third party when necessary (JDe, CD, HW, RM).
Statistical analysis and data synthesis
We conducted separate analyses first according to whether study
participants were recruited on primary presentation of melanoma
or with a disease recurrence, and second according to our primary
and secondary objectives (i.e. detection of any metastasis (which
must include both nodal and distant recurrence) and detection of
nodal metastasis alone or detection of any distant metastasis, as
defined under Target condition being diagnosed).
Studies may report test accuracy per lesion or per patient. Our
unit of analysis for primary analyses was the patient, as study
participants may have multiple metastatic sites at any one time,
such that a per lesion analysis may overestimate test accuracy.
We initially explored the data by plotting estimates of sensitiv-
ity and specificity on coupled forest plots and in receiver operat-
ing characteristic (ROC) space for each index test. We performed
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meta-analyses using the bivariatemethod to produce summary op-
erating points (summary sensitivities and specificities) with 95%
confidence and prediction regions (Chu 2006; Macaskill 2010;
Reitsma 2005). When few studies were available for a meta-anal-
ysis, we simplified the bivariate model to univariate fixed-effect or
random-effects logistical regression models depending on whether
or not heterogeneity was observed on forest plots and in ROC
space (Takwoingi 2015). If there were only two or three studies
and we observed heterogeneity on the plots, we did not pool the
data, as a fixed-effect approach would be inappropriate and the
number of studies too small to reliably estimate random effects.
To compare the accuracy of the index tests, we performed both di-
rect and indirect test comparisons, as comparative studies are scarce
(Takwoingi 2013). To formally compare index tests, we added a
co-variate for test type to a bivariate model (i.e. bivariate meta-re-
gression). We used likelihood ratio tests to assess the statistical sig-
nificance of differences in sensitivity and specificity by comparing
models without the co-variate terms versus models containing the
co-variate terms. Using parameter estimates from bivariate meta-
regression models, we calculated absolute differences in sensitivity
and specificity. We obtained 95% confidence intervals and P val-
ues for these differences using the delta method and theWald test,
respectively. When the number of studies in a direct comparison
was insufficient for meta-regression, we examined individual study
results and computed absolute differences in sensitivity and speci-
ficity for each comparative study. We calculated 95% confidence
intervals (CIs) for these differences using the Newcombe-Wilson
method without continuity correction (Newcombe 1998).
We conducted analyses using ReviewManager 5 (ReviewManager
2014), alongwith themeqrlogit command in the statistical software
STATA version 15 (STATA 2017).
Investigations of heterogeneity
We initially examined heterogeneity between studies by visually
inspecting forest plots of sensitivity and specificity and summary
ROC plots. We identified insufficient numbers of studies to allow
meta-regression to formally investigate potential sources of het-
erogeneity.
Sensitivity analyses
We performed no sensitivity analyses because limited data were
available.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for
detecting funnel plot asymmetry (Deeks 2005), we did not assess
publication bias.
R E S U L T S
Results of the search
We identified and screened for inclusion a total of 34,507 unique
references. Of these, we reviewed 1035 full-text papers for eligi-
bility for any one of the reviews of tests for staging of melanoma
or cSCC. Of the 1035 full-text papers assessed, we excluded 829
from all reviews in our series (see Figure 3 PRISMA flow diagram
of search and eligibility results).
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Figure 3. PRISMA flow diagram.
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Of the 390 studies tagged as potentially eligible for this review of
imaging tests for staging of melanoma, we included 39 publica-
tions. Exclusions were due to publication as a conference abstract
(n = 202), not a primary study (n = 103), not a test accuracy study
(no index test and or reference standard reported) (n = 11), wrong
index test (n = 125; including 17 studies with more than one scan
reported per participant), inadequate reference standard (n = 90),
wrong study population (n = 47), inadequate sample size (n = 55),
wrong target condition (n = 125), missing data to complete 2×2
contingency table (n = 46), and duplicate or related publication
(n = 86). We have provided a list of the 351 publications excluded
from this review with reasons for exclusion in Characteristics of
excluded studies. We contacted the authors of four included stud-
ies for further details of study methods (Chai 2012; Reinhardt
2006; Stoffels 2012; Voit 2014). We received a response in regard
to one study (Reinhardt 2006), but study authors did not provide
the additional data requested.
The 39 included study publications provide 195 contingency table
datasets for a total of 5204 study participants. Thirty-four studies
reported data on a per patient basis, including two that also re-
ported data per lesion identified on imaging (Cachin 2014; Iagaru
2007), and five reported data only on a per lesion basis (Dellestable
2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007; Pfluger
2011). The 34 studies that reported data per patient included
4980 study participants, 1265 of whom had confirmed metastatic
disease. The seven studies that reported data per lesion included
417 study participants with 1846 potentially metastatic lesions
identified on imaging, 1061 of which were confirmed metastases.
Table 1 cross-tabulates the index tests evaluated and the popula-
tion groups and target conditions considered in the 39 included
studies. Eighteen studies considered the use of imaging for nodal
metastases before SLNB; 11 of these studies considered the use
of ultrasound, and eight evaluated PET-CT. Twenty-four studies
evaluated the use of imaging as a staging tool in study participants
undergoing primary staging on diagnosis of melanoma (n = 6) or
re-staging for recurrence of disease (n = 3), or inclusion of mixed
(n = 11) or not clearly described populations (n = 4). The imaging
tests evaluated included ultrasound (n = 5), CT (n = 10), MRI (n
= 4), and PET-CT (n = 15) for detection of any metastases (n =
14), nodal metastases (n = 14), or distant metastases (n = 9). Five
studies also reported data separately by metastatic site.
Methodological quality of included studies
The overall methodological quality of all included study cohorts
is summarised in Figure 4 and Figure 5. Studies were generally at
low or unclear risk of bias and of high or unclear concern regarding
applicability of the evidence.
Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Over half of studies (23; 59%) were at low risk of bias for partici-
pant selection.High risk of bias was observed in four studies (10%)
because of inappropriate participant exclusions; all excluded study
participants on the basis of findings on the index test (ultrasound
in all cases) (Hinz 2011; Hinz 2013; Radzhabova 2009; Rubaltelli
2011). Those at unclear risk of bias (n = 12) did not clearly de-
scribe participant recruitment as random or consecutive (n = 11)
(all except Iagaru 2007) (Abbott 2011; Aukema 2010b; Cachin
2014;Hocevar 2004; Iagaru 2007; Jouvet 2014; Kang 2011; Klebl
2003; Pfluger 2011; Prayer 1990; Sanki 2009; Singh 2008), or
did not clearly report participant exclusions (n = 3) (Iagaru 2007;
Kang 2011; Pfluger 2011).
Over half of evaluations were considered at low risk of bias for the
index test (55% (6/11) for pre-SLNB ultrasound; 60% (3/5) for
other uses of ultrasound; 70% (7/10) for CT; 100% (4/4) forMRI;
and 43% (10/23) for PET-CT). Across the 11 evaluations of pre-
SLNB ultrasound, five (45%) studies were retrospective or unclear
in the nature of their design and did not describe blinded case
note review to ascertain imaging test results (Hinz 2013; Hocevar
2004; Radzhabova 2009; Sanki 2009; van Rijk 2006). The same
rationale for unclear risk of bias was made for two of the five (40%)
other evaluations of ultrasound (Prayer 1990; Rubaltelli 2011),
three evaluations of CT (30%) (Iagaru 2007; Pfluger 2011; van
den Brekel 1998), and 13 (57%) evaluations of PET-CT (Abbott
2011; Arrangoiz 2012; Aukema 2010a; Hinz 2013; Iagaru 2007;
Kang 2011; Klode 2010; Pfluger 2011; Revel 2010; Singh 2008;
Strobel 2007a; van Wissen 2016; Wagner 2012). One evaluation
of pre-SLNB ultrasound - Radzhabova 2009 - and one of PET-
CT - Iagaru 2007 - did not clearly prespecify the index test thresh-
old. One study of PET-CT - Kang 2011 - retrospectively selected
the maximum standardised uptake value (SUVmax) threshold for
PET-CT using ROC analysis and therefore scored high risk of bias
for this domain.
Most studies (27/39) were judged at low risk of bias for the
reference standard; the 12 studies at unclear risk of bias pro-
vided no information on the follow-up schedule used to deter-
mine final disease status (Arrangoiz 2012; Aukema2010a; Aukema
2010b; Bastiaannet 2009; Cachin 2014; Dellestable 2011; Iagaru
2007; Jouvet 2014; Pfluger 2011; Rubaltelli 2011; Strobel 2007b;
Veit-Haibach 2009). Although blinding of the reference stan-
dard diagnosis did not contribute to overall risk of bias, two
studies clearly reported blinding of the histological diagnosis
(Pfannenberg 2007; Sibon 2007), and three reported blinding
of data collection on follow-up (Hausmann 2011; Pfannenberg
2007; Reinhardt 2006). Two studies reported no blinding of his-
tological diagnosis (Cachin 2014; Singh 2008), and three re-
ported no blinding to the original imaging result during follow-
up (Abbott 2011; Cachin 2014; Jouvet 2014).
Two-thirds of studies were at high risk of bias for participant flow
and timing (26/39), and one was judged as having unclear risk.
High risk of bias was considered in one study because of per-
formance of the imaging test (PET-CT) up to four months af-
ter the reference standard (SLNB) (Maubec 2007); in 19 studies
(49%) because of differential verification (Abbott 2011; Arrangoiz
2012; Aukema 2010a; Aukema 2010b; Bastiaannet 2009; Cachin
2014; Dellestable 2011; Hausmann 2011; Iagaru 2007; Jouvet
2014; Kang 2011; Klebl 2003; Pfannenberg 2007; Pfluger 2011;
Prayer 1990; Reinhardt 2006; Strobel 2007a; Strobel 2007b;
Veit-Haibach 2009); and in 13 studies (33%) because of exclusion
of participants from the analysis (Bastiaannet 2009; Cachin 2014;
Chai 2012; Dellestable 2011; Hafner 2004; Hausmann 2011;
Klebl 2003; Pfannenberg 2007; Pfluger 2011; Radzhabova 2009;
Rubaltelli 2011; van Wissen 2016; Wagner 2012).
Among the nine studies providing direct comparisons of index
tests, sixwere judged at low risk of bias for the comparative domain.
Pfluger 2011 was considered at high risk of bias, as PET-CT and
CT images were interpreted side by side, and in Hinz 2013, only
a subgroup of those with US also underwent PET-CT. In two
studies, blinding between tests was not clearly described (Hinz
2013; Iagaru 2007).
In terms of applicability of evidence to the review question, 40% (n
= 16) of studies were of high or unclear concern due to participant
selection (Figure 4). High concern was primarily due to inclusion
of participants from mixed population groups (including primary
staging, re-staging, or patient follow-up) (Abbott 2011; Aukema
2010a; Bastiaannet 2009; Cachin 2014; Dellestable 2011; Klebl
2003; Pfannenberg 2007; Pfluger 2011; Reinhardt 2006; van den
Brekel 1998; van Wissen 2016), or it was due to the presentation
of only per lesion rather than per patient data (Dellestable 2011;
Hausmann 2011; Jouvet 2014; Pfannenberg 2007; Pfluger 2011).
Three studies were of unclear concern due to lack of clear descrip-
tion of the indication for imaging (Aukema 2010b; Iagaru 2007;
Strobel 2007b).
Almost all test evaluations were considered at high or unclear con-
cern around applicability of the index test. For pre-SLNB ultra-
sound, there was high concern from lack of detail regarding the
threshold used (n=1) (Hafner 2004), andunclear concern resulted
from lack of information on application and interpretation of the
index test (n = 9) (Chai 2012; Hafner 2004; Hinz 2011; Hocevar
2004; Kunte 2009; Radzhabova 2009; Sibon 2007; van Rijk 2006;
Voit 2014), or regarding the expertise of the observer performing
the ultrasound examination (n = 6) (Chai 2012;Hinz 2011; Kunte
2009; Radzhabova 2009; Sanki 2009; van Rijk 2006).
For CT, six evaluations were of high concern due to use of con-
sensus test interpretation (Iagaru 2007; Jouvet 2014; Pfannenberg
2007; Pfluger 2011; Reinhardt 2006; Veit-Haibach 2009), two
for MRI (Jouvet 2014; Pfannenberg 2007), and 11 for PET-CT
(Aukema 2010a; Aukema 2010b; Iagaru 2007; Jouvet 2014; Kang
2011; Pfannenberg 2007; Pfluger 2011; Reinhardt 2006; Revel
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2010; Strobel 2007a; Strobel 2007b). Only five CT evaluations
described the provision of usual clinical information to test inter-
preters (Jouvet 2014; Pfannenberg 2007; Pfluger 2011; Reinhardt
2006; Veit-Haibach 2009), one evaluation of MRI (Pfannenberg
2007), and four for PET-CT (Pfannenberg 2007; Pfluger 2011;
Reinhardt 2006; Revel 2010). Three CT evaluations were un-
clear on the information provided to assist test interpretation
(Bastiaannet 2009; Dellestable 2011; van den Brekel 1998), two
for MRI (Dellestable 2011; Hausmann 2011), and six for PET-
CT (Dellestable 2011; Kell 2007; Klode 2010; Maubec 2007;
Singh 2008; Veit-Haibach 2009).
Inadequate details of test threshold were provided in five evalu-
ations of CT (Bastiaannet 2009; Dellestable 2011; Iagaru 2007;
Jouvet 2014; Reinhardt 2006), three for MRI (Dellestable 2011;
Hausmann 2011; Jouvet 2014), and four for PET-CT (Abbott
2011; Hinz 2013; Jouvet 2014; Reinhardt 2006). Threshold
details were unclear for one study for both CT and MRI
(Pfannenberg 2007), as were six for PET-CT (Aukema 2010a;
Aukema 2010b; Dellestable 2011; Klode 2010; Maubec 2007;
Wagner 2012). Two CT evaluations were unclear with regard to
observer expertise (Dellestable 2011; vandenBrekel 1998), one for
MRI (Dellestable 2011), and seven for PET-CT (Arrangoiz 2012;
Dellestable 2011; Hinz 2013; Kell 2007; Klode 2010; Maubec
2007; Revel 2010).
For applicability of the reference standard, five studies were consid-
ered of low concern (Hafner 2004; Hinz 2011; Hinz 2013; Kang
2011; van Wissen 2016), and one was rated of high concern be-
cause it did not present data for the primary target condition of any
metastasis (nodal plus distant metastases) (Veit-Haibach 2009).
The remaining 33 studies were considered at unclear concern for
applicability because they did not clearly define the target condi-
tion or provide a breakdown according to nodal or distant metas-
tases. Only five studies described the expertise of the histopatholo-
gist (Hafner 2004;Hinz 2011;Hinz 2013;Kang 2011; vanWissen
2016); the remaining studies were rated of unclear concern.
Findings
1. Imaging for detection of nodal metastases before
SLNB
Imaging before SLNB can be used to identify patients with nodal
metastatic disease that is not detectable clinically such that they can
bypass the SLNB procedure and undergo complete lymph node
dissection. Eighteen studies were included, 10 of which considered
the use of pre-SLNB ultrasound (Chai 2012; Hafner 2004; Hinz
2011;Hocevar 2004; Kunte 2009; Radzhabova 2009; Sanki 2009;
Sibon 2007; van Rijk 2006; Voit 2014); seven evaluated PET-CT
(Arrangoiz 2012; Kell 2007; Klode 2010; Maubec 2007; Revel
2010; Singh 2008; Wagner 2012), and one evaluated both tests
(Hinz 2013). Three studies of ultrasound also presented accuracy
data for ultrasound combined with FNAC (i.e. complete lymph
node dissection recommended only if both ultrasound and FNAC
were positive for metastases) (Hocevar 2004; van Rijk 2006; Voit
2014).
Forest plots of study data are provided in Figure 6. Summary
estimates for indirect and direct comparisons of tests are presented
in Table 2 and Figure 7. Summary details of all studies in this
section are presented alphabetically in Appendix 8.
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Figure 6. Forest plot of all data for pre-SLNB ultrasound, ultrasound plus FNAC, or PET-CT for the
detection of nodal metastasis.
(HN MM - head and neck only malignant melanoma.)
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Figure 7. Summary ROC plot comparing pre-SLNB ultrasound vs ultrasound plus FNAC vs PET-CT.
Description of studies
Study design and setting. Four of the 18 studies (22%)were prospec-
tive case series (Hafner 2004; Hinz 2011; Kunte 2009; Maubec
2007), nine (50%)were retrospective (Arrangoiz 2012;Chai 2012;
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Hinz 2013; Kell 2007; Klode 2010; Revel 2010; Sibon 2007; van
Rijk 2006; Wagner 2012), and five (28%) did not clearly report
the design (Hocevar 2004; Radzhabova 2009; Sanki 2009; Singh
2008; Voit 2014). Studies were conducted in Europe (n = 14),
Australia (n = 1; Sanki 2009), and the USA (n = 3; Arrangoiz
2012; Chai 2012; Kell 2007).
Participants. Thirteen of the 18 studies (72%) were considered
to have been conducted in ‘standard’ SLNB populations, either
reporting the inclusion of participants with primary melanomas
with Breslow thickness of at least 0.76 mm or 1 mm unless other
adverse prognostic factors were present such as Clark level of at
least IV, ulceration, or regression (Chai 2012; Hafner 2004; Hinz
2011; Kell 2007; Klode 2010; Kunte 2009; Sanki 2009; Sibon
2007; Singh 2008; van Rijk 2006; Voit 2014), or reporting in-
cluding ‘candidates for SLNB’ with no further detail (Hocevar
2004; Radzhabova 2009). One study restricted inclusion to par-
ticipants with head and neck melanoma only (Revel 2010), and
the remaining four studies included only higher-risk participants,
with Breslow thickness of at least 2 mm (Hinz 2013), or 4 mm
(Arrangoiz 2012; Maubec 2007; Wagner 2012).
A total of 2894 participants were included, with 640 nodal metas-
tases identified (prevalence 22%, ranging from 10% inHinz 2011
to 60% in Hinz 2013). Sample sizes ranged from 20 participants
in Hinz 2013 and Maubec 2007 to 1000 in Voit 2014. When
reported (n = 11), the ages of included participants ranged from
one year in Hocevar 2004 to 94 years in Voit 2014. The mean
age of included participants was reported in 11 studies (the me-
dian of reported means was 57.5 years, range 50 to 67 years),
and the median age was reported in five studies (the median of
reported means was 58 years, range 55 to 62 years); five stud-
ies reported neither the mean nor median age of included study
participants (Hinz 2013; Hocevar 2004; Radzhabova 2009; Sanki
2009; Wagner 2012). When reported (n = 15), 48% of included
participants were male. Of 11 studies reporting the site of the
primary melanoma lesion (excluding Revel 2010, which included
head and neck melanomas only), the percentage of participants
with head and neck melanoma ranged from 0% in Hinz 2013
to 36% in Maubec 2007 (median 14%), and melanoma of the
extremities, including the hands or feet where documented, from
32% in Maubec 2007 to 56% in Kunte 2009 (median 50%).
Ultrasound. The 11 studies of pre-SLNB ultrasound were all con-
ducted in standard SLNB populations, although Hinz 2013 re-
stricted inclusion to participants with melanomas at least 2 mm
thick or with risk factors such as ulceration or regression. The two
studies by Hinz and colleagues excluded participants with clas-
sic sonographic signs of lymphatic metastasis (Hinz 2011; Hinz
2013), whereas Radzhabova 2009 included only those who were
positive on US or in whom metastases could not be excluded.
Studies employed mainly B-mode ultrasound, with two stud-
ies also employing Doppler ultrasound in all participants (Hinz
2011; Voit 2014). B-mode ultrasound frequencies were variable,
mainly ranging from 5 or 6 MHz to 10 or 12 MHz in each
study, apart fromVoit 2014, which used three transducers ranging
from 1 to 18 MHz in frequency. Ultrasound was performed be-
fore lymphoscintigraphy in five studies (Chai 2012; Hafner 2004;
Hinz 2011; Hinz 2013; Sibon 2007), after lymphoscintigraphy in
two studies (Sanki 2009; Voit 2014), and both before and after
lymphoscintigraphy in four studies (Hocevar 2004; Kunte 2009;
Radzhabova 2009; van Rijk 2006). Lymph node basins were im-
aged according to the site of the primary melanoma (Chai 2012;
Hafner 2004; Hinz 2011; Hinz 2013; Sibon 2007; Voit 2014),
according to the site marked following lymphoscintigraphy (Sanki
2009; Voit 2014), or this information was not reported (Hocevar
2004; Kunte 2009; Radzhabova 2009; van Rijk 2006). Criteria for
detection of nodal metastases were clearly described in all studies
apart fromHafner 2004 (Appendix 8). Ultrasoundwas reported to
be performed by dermatologists (Kunte 2009), sonographers (Voit
2014), radiologists (Hafner 2004; Hocevar 2004; Sibon 2007),
or nuclear medicine physicians (Sanki 2009), or this was not re-
ported.
PET-CT.Of the eight studies of PET-CT before SLNB, four were
conducted in any participant eligible for SLNB (Hinz 2013; Kell
2007; Klode 2010; Singh 2008); one in those with head and neck
melanoma (Revel 2010); and three in higher-risk melanoma pop-
ulations (Arrangoiz 2012; Maubec 2007; Wagner 2012). Singh
2008 also reported data for the subgroup of participants with
higher-riskmelanoma (Breslow thickness > 4mm).When reported
(n = 3), studies employed two-dimensional (2D) PET (Wagner
2012), three-dimensional (3D) PET (Maubec 2007), or either 2D
or 3D PET (Arrangoiz 2012). PET was combined with unen-
hanced - in Arrangoiz 2012, Kell 2007, and Maubec 2007 - or
contrast-enhanced - in Hinz 2013, Klode 2010, and Singh 2008 -
CT scans (use of contrast not reported in Revel 2010 and Wagner
2012). When reported, CT was used for attenuation correction
(Arrangoiz 2012; Hinz 2013; Revel 2010; Singh 2008; Wagner
2012), as well as for anatomical localisation (Revel 2010; Wagner
2012).
Criteria for the detection of nodal metastases were not reported
in Hinz 2013, were based on a qualitative assessment of increased
18FDG uptake in six studies (Kell 2007; Klode 2010; Maubec
2007;Revel 2010; Singh 2008;Wagner 2012), andwere based on a
quantitative assessment of focal uptake in Arrangoiz 2012 (SUV≥
2.5) (see Appendix 8). Performance and interpretation of PET-CT
were not clearly described. For example, Wagner 2012 reported
interpretation by a nuclear medicine specialist, while two others
mentioned an in-house medical physicist - Singh 2008 - and a
teamof radiologists and nuclear physicians - Arrangoiz 2012.Only
Revel 2010 andWagner 2012 reported the provision of clinical or
other radiological findings to assist PET-CT interpretation.
Reference standard. Ten studies (56%) evaluated the accuracy of
imaging in comparison to histology fromSLNBalone (Hinz 2011;
Hinz 2013; Kell 2007; Klode 2010; Kunte 2009; Radzhabova
2009; Revel 2010; Sanki 2009; Sibon 2007; Singh 2008), seven
studies (39%) included histology results from participants pro-
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ceeding directly to CLND as well as SLNB results as a reference
standard (Chai 2012; Hafner 2004; Hocevar 2004;Maubec 2007;
van Rijk 2006; Voit 2014; Wagner 2012), and one study reported
only data for histology based on CLND or SLNB combined with
follow-up to determine any false negative results on PET-CT as
the reference standard (Arrangoiz 2012).
Participant exclusions. Five studies reported the exclusion of be-
tween two and eight participants primarily due to technical failure
of SLNB (sentinel node not identified or SLNB not performed)
(Chai 2012; Hafner 2004; Maubec 2007; Revel 2010; Wagner
2012), and in one study (Radzhabova 2009), 100 participants did
not undergo SLNB on the basis of a negative ultrasound finding.
Results: ultrasound for detection of nodal metastases
Across the 11 ultrasound evaluations, sensitivity for detection of
nodal metastasis in comparison to a histological reference standard
(SLNB or LCND) ranged from 0% in Hafner 2004 to 33% in
Chai 2012 and Kunte 2009 in eight studies, and from 71% in
Hocevar 2004 and Voit 2014 to 100% in Radzhabova 2009 in
three. Specificity ranged from73% inVoit 2014 to 100% inKunte
2009, Hinz 2011, Hinz 2013, and Radzhabova 2009) (Figure 6).
Radzhabova 2009 included a highly selected group of study par-
ticipants, which likely explains the perfect sensitivity and speci-
ficity observed. The particularly low sensitivity in Hafner 2004
(0%) may be related to the use of only a 5-MHz ultrasound trans-
ducer, but this study was poorly reported and other explanations
may be possible. The relatively high sensitivities (both 71%) in
Hocevar 2004 and Voit 2014 are also difficult to explain based
on the information reported. In terms of specificity, Kunte 2009,
Hinz 2011, and Hinz 2013 all applied ultrasound before and after
the use of lymphoscintigraphy, which is likely to have contributed
to the 100% specificity observed.
The summary sensitivity of ultrasound across the 11 studies was
35.4% (95% CI 17.0% to 59.4%) and summary specificity was
93.9% (86.1% to 97.5%) for 2614 participants and 542 con-
firmed cases of nodal metastasis (Table 2; Figure 7).
The three studies that reported the accuracy of ultrasound com-
bined with FNAC reported decreased sensitivity but increased
specificity in comparison to ultrasound alone. Sensitivities ranged
from 3% (95% CI 0% to 14%) in van Rijk 2006 to 51% (95%
CI 44% to 58%) in Voit 2014, and specificities ranged from 99%
(95% CI 92% to 100%) in van Rijk 2006 to 100% (95% CI 99%
to 100%) in Voit 2014 (Figure 6). The summary sensitivity was
18.0% (95% CI 3.58% to 56.5%), and summary specificity was
99.8% (95% CI 99.1% to 99.9%), based on 1164 participants
and 259 cases (Table 2; Figure 7).
Results: PET-CT for detection of nodal metastases
The four studies comparing PET-CT to histology based on SLNB
in standard SLNB populations reported sensitivities ranging from
0% (95% CI 0% to 26%) in Hinz 2013 to 22% (95% CI 3% to
60%) in Kell 2007, and specificities from 89% (95% CI 72% to
98%) inKell 2007 to 100% (95%CI 63% to 100%) inHinz 2013
and 100% (95% CI 92% to 100%) in Klode 2010 (Figure 6).
The summary sensitivity was 10.2% (95% CI 4.31% to 22.3%)
and summary specificity was 96.5% (95% CI 87.1% to 99.1%)
for 170 participants and 49 confirmed cases of nodal metastasis
(Table 2; Figure 7).
Data from the three studies in higher-risk melanoma populations
(75 participants with 28 cases) that compared PET-CT to histol-
ogy based on SLNB alone could not be pooled because of substan-
tial heterogeneity likely resulting from small sample sizes (Maubec
2007; Singh 2008; Wagner 2012). Sensitivities ranged from 0%
(95% CI 0% to 41%) in Maubec 2007 to 43% (95% CI 18% to
71%) in Wagner 2012, and specificities from 92% (95% CI 64%
to 100%) in Maubec 2007 to 100% (95% CI 48% to 100%) in
Singh 2008 and 100% (95% CI 88% to 100%) in Wagner 2012
(Figure 6).
One of these studies -Maubec 2007 - andArrangoiz 2012 reported
data for PET-CT compared to histology based on SLNB plus
follow-up to identify false negatives. Maubec 2007 identified one
additional false negative result on follow-up, but sensitivity (0%)
and specificity (92%) remained the same with marginal changes
to CIs (95% CI 0% to 37% for sensitivity and 62% to 100%
for specificity). Arrangoiz 2012 reported sensitivity of PET-CT as
41% (95%CI 24% to 61%) and specificity as 89% (95% CI 71%
to 98%) (Figure 6).
Revel 2010 reported the sensitivity of PET-CT as 20% (95% CI
3%to56%) and100%(95%CI 69%to100%) for 20 participants
with head and neckmelanoma when compared to SLNB alone as a
reference standard. Adding data for a follow-up reference standard
identified two additional nodal metastases missed on PET-CT for
sensitivity of 17% (95% CI 2% to 48%) and specificity of 100%
(95% CI 69% to 100%) (Figure 6).
Results: comparison between tests
Upon comparison of ultrasound alone, ultrasound plus FNAC,
and PET-CT, summary sensitivities were not statistically signifi-
cantly different (P = 0.07), and summary specificities were signif-
icantly higher for ultrasound plus FNAC compared to the other
two modalities (P < 0.001) (Table 2; Figure 7).
The direct comparison of ultrasound alone versus ultrasound plus
FNAC suggested higher sensitivity (58.7%, 95% CI 36.5% to
77.9%) but lower specificity (79.4%, 95% CI 70.0% to 86.4%)
(3 studies; 1164 participants; 259 cases of nodal metastases) for
ultrasound alone compared to the overall pooled result. Requiring
both ultrasound and FNAC to be positive for nodal metastases
(as an indicator for CLND instead of SLNB) reduced sensitivity
by 40.7% (95% CI 6.50% to 75.0%; P = 0.02) but increased
specificity by 20.4% (95% CI 12.2% to 28.6%; P < 0.001) (Table
2).
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2. Whole body imaging for detection of any
metastases, nodal metastases, and distant metastases
Twenty-four studies evaluated whole body imaging. Summary
characteristics of all studies are tabulated alphabetically in
Appendix 9, and a narrative description is provided in Appendix
10. Results are presented below according to the population group
studied, the target condition and imaging test, and the presenta-
tion of data per patient and per lesion.
Primary staging
Six studies recruited participants undergoing primary staging fol-
lowing a confirmed diagnosis of melanoma (Arrangoiz 2012;
Hafner 2004; Kang 2011; Maubec 2007; Prayer 1990; Veit-
Haibach 2009). Two studies included any participant follow-
ing diagnosis of melanoma (Kang 2011; Veit-Haibach 2009);
two excluded those with distant metastases on diagnosis (Hafner
2004; Maubec 2007). Maubec 2007 restricted data to those with
melanomas at least 4 mm in thickness; one study included clin-
ically node positive participants but did not report exclusion of
those with distantmetastases (Prayer 1990), and one included only
clinically node negative participants with melanomas of at least
4 mm Breslow thickness (Arrangoiz 2012). Three studies also re-
ported data for pre-SLNB imaging (Arrangoiz 2012;Hafner 2004;
Maubec 2007), two of which reported subgroup data for clinically
node negative participants who underwent SLNB (Hafner 2004;
Maubec 2007). All six studies reported accuracy data on a per pa-
tient basis; no per lesion data were identified.
Forest plots of all available study data are presented in Figure
8. Summary details of all studies in this section are presented
alphabetically in Appendix 9. Sensitivities and specificities from
studies evaluating more than one target condition (any metastasis,
nodal metastasis, or distant metastasis) are tabulated in Appendix
11.
Figure 8. Forest plot of imaging for primary staging, for the detection of any metastases, nodal metastases,
and distant metastases (per patient and per lesion data).
Results: detection of any metastases
Three studies presented data for detection of any metastasis in 118
study participants with 51 cases of metastatic disease (Figure 8)
(Arrangoiz 2012; Kang 2011; Maubec 2007); the prevalence of
metastases ranged from 24% in Kang 2011 to 57% in Arrangoiz
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CT. No data on CT were identified for participants undergoing
primary staging of melanoma.
MRI.No data onMRI were identified for participants undergoing
primary staging of melanoma.
PET-CT.Three studies presented per patient data for PET-CT for
detection of any metastasis; no per lesion data were identified.
Two studies evaluated PET-CT in participants with melanomas≥
4 mm in thickness: one reported sensitivity and specificity for de-
tection of any metastases of 47% (95% CI 29% to 65%) and 88%
(95% CI 68% to 97%) (56 participants; 32 cases of metastatic
disease) (Arrangoiz 2012); and in the other (Maubec 2007), sen-
sitivity was 30% (95% CI 7% to 65%) and specificity 73% (95%
CI 45% to 92%) (25 participants; 10 cases of metastatic disease)
(Figure 8). Arrangoiz 2012 identified four patients with distant
metastases whose disease would have been missed without PET-
CT imaging (prevalence of distant metastases 4/56; 7%). In the
other study (Maubec 2007), no distant metastases were identified,
but all three false positive results suggested possible distant metas-
tases.
The third study evaluated PET-CT for the prediction of sub-
sequent recurrence in any participant following diagnosis of
melanoma (Kang 2011). Stage of disease on presentation was re-
ported as stage 0 (n = 7), stage I or II (n = 23), stage III (n = 6),
and stage IV (n = 1); all patients underwent curative surgery for
primary and metastatic lesions. The sensitivity of PET-CT for the
prediction of later recurrence at an SUVmax≥ 2.2 at baseline was
89% (95% CI 52% to 100%) and specificity 61% (95% CI 41%
to 78%) (37 participants; nine cases of metastatic disease) (Figure
8). The accuracy of PET-CT for initial staging was not reported.
Three of the nine patients who developed recurrence during fol-
low-up were stage III or greater at presentation.
Results: detection of nodal metastases
Three studies presented data for the detection of nodal metastases
in 373 participants with 68 cases of nodal metastases (Hafner
2004; Prayer 1990; Veit-Haibach 2009) (Figure 8); the prevalence
of nodal metastases ranged from 13% in Prayer 1990 to 26% in
Hafner 2004.
Ultrasound. Two studies evaluated the use of ultrasound in any
participant following the diagnosis of melanoma, including those
who were clinically node positive (Hafner 2004; Prayer 1990).
Hafner 2004 restricted inclusion to those with melanomas ≥ 1
mm in thickness, and all underwent SLNB including three with
clinically detectable nodal metastases (data for clinically node neg-
ative are reported in the pre-SLNB imaging section above). The
sensitivity of ultrasound was 8% (95% CI 1% to 25%) and speci-
ficity 88% (95%CI 78% to 94%) (100 participants, 26with nodal
metastases) (Figure 8); the only true positive results were both
detected on physical examination. In Prayer 1990, the sensitivity
of ultrasound was 100% (95% CI 88% to 100%) and specificity
97% (95% CI 93% to 99%) (217 participants, 29 with nodal
metastases) (Figure 8). These results are likely to be influenced
by incorporation bias and inadequate follow-up to identify false
negatives on ultrasound. Of 217 included participants, 15% (35/
217) had suspicious findings on palpation; however, among these,
only those who were also found to have suspicious nodes on ul-
trasound had histological verification (n = 15). This left 17 who
were positive on palpation but negative on ultrasound, along with
165 who were negative on both palpation and ultrasound, with a
six-month follow-up reference standard.
Other imaging tests. One study presented data comparing CT
with PET-CT for the detection of nodal metastases in all par-
ticipants referred for PET-CT after primary melanoma resection
(Veit-Haibach 2009). No false positive results were obtained with
either test (specificity 100%, 95% CI 92% to 100%), but sensi-
tivity was higher for PET-CT (38%, 95% CI 14% to 68%) com-
pared to CT (23%, 95% CI 5% to 54%) (56 participants, 13 with
nodal metastases) (Figure 8). Initial staging procedures including
histology of the primary lesion, SLNB, and all imaging procedures
apart from PET-CT identified four of the 13 participants with
nodal metastases, two of whom were identified only on SLNB
and were missed by all imaging tests (Veit-Haibach 2009). Both
CT and PET-CT correctly identified additional participants with
nodal metastases (one and three, respectively) that were not picked
up by other staging procedures at the time of melanoma diagnosis.
No data on MRI to detect nodal disease were identified for par-
ticipants undergoing primary staging of melanoma.
Results: detection of distant metastases
Two studies presented data for the detection of distant metastases
in 112 participants with 17 cases of distant metastases (Arrangoiz
2012; Veit-Haibach 2009) (Figure 8); the prevalence of distant
metastases was 9% in Arrangoiz 2012 and 21% in Veit-Haibach
2009.
CT.One study presented data for CT: sensitivity for the detection
of 12 distant metastases was 25% (95% CI 5% to 57%) and
specificity 93% (95% CI 81% to 99%) (56 participants) (Veit-
Haibach 2009).
MRI.No per patient data on MRI were identified for participants
undergoing primary staging of melanoma.
PET-CT. Veit-Haibach 2009 provided a direct comparison of CT
with PET-CT; two additional cases of distant metastases were
detected in comparison to CT (sensitivity 42%, 95% CI 15% to
72%), with no difference in specificity (93%, 95% CI 81% to
99%) (Figure 8).
Arrangoiz 2012 evaluated the use of PET-CT in clinically node
negative participants with primary melanoma greater than 4 mm
in thickness and no indications for distant metastases; all five dis-
tant metastases were detected by PET-CT (sensitivity 100%, 95%
CI 48% to 100%), with three false positive results (specificity
94%, 95% CI 84% to 99%) (56 participants).
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Results: detection of distant metastases by metastatic site
No data were identified for the detection of metastatic disease
according to metastatic site in participants undergoing imaging
for primary staging of melanoma.
In three of six studies, scan coverage was reported to include the
skull (Arrangoiz 2012; Kang 2011; Maubec 2007), but the detec-
tion of brain metastases was not separately documented.
Re-staging
Three studies recruited participants undergoing imaging for re-
staging of disease following a clinical indication of recurrence
(Iagaru 2007;Rubaltelli 2011; Strobel 2007a).One study included
any participant having imaging for re-staging purposes (Iagaru
2007), and two included clinically node negative participants ei-
ther undergoing ultrasound of the regional lymph nodes as part of
a follow-up program (Rubaltelli 2011), or with raised serum S100
(> 0.2 µg/L) during follow-up (Strobel 2007a).
Forest plots of all available study data are presented in Figure 9.
Summary estimates of sensitivity and specificity are presented in
Table 2. Summary details of all studies in this section are presented
alphabetically in Appendix 9.
Figure 9. Forest plot of imaging for re-staging of melanoma, for the detection of any metastases or nodal
metastases (per patient and per lesion data).
Results: detection of any metastases
Two studies provided per patient data for the detection of any
metastasis in 153 participants with 95 cases of metastatic disease
(Figure 9); the prevalence of any metastasis was 53% in Iagaru
2007 and 83% in Strobel 2007a.
CT. In one study, the sensitivity of CT for detection of any metas-
tasis on a per patient basis was 68% (95% CI 54% to 80%) and
specificity 94% (95% CI 83% to 99%) (106 participants; 56 cases
of metastatic disease) (Iagaru 2007).
MRI.No data onMRI were identified for participants undergoing
re-staging of melanoma.
PET-CT. Two studies evaluated PET-CT on a per-patient ba-
sis in 153 participants, 95 of whom had confirmed metastases
(Iagaru 2007; Strobel 2007a); summary sensitivity was 92.6%
(95%CI 85.3% to 96.4%) and specificity 89.7% (95%CI 78.8%
to 95.3%) (Table 2).
Comparison of PET-CT with CT in Iagaru 2007 demonstrated
PET-CT to be more sensitive (89%, 95% CI 78% to 96%) than
CT alone (increase of 21%), with similar specificity (88%, 95%
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CI 76% to 95%). Similar results were observed on a per lesion ba-
sis (Figure 9). Although numbers were small, PET-CT was more
sensitive in the subgroup with stage IIIc to IV disease who under-
went PET-CT for re-staging after therapy (100%, 95% CI 81%
to 100%) (n = 32; 18 with metastatic disease) than in those with
less advanced disease (84%, 95% CI 69% to 94%).
Results: detection of nodal metastases
One study presented per patient data for the detection of nodal re-
currence after primary treatment in 460 participants with 37 cases
of nodal metastases (prevalence 8%) (Rubaltelli 2011) (Figure 9).
Ultrasound. Considering participants with ’common signs of ma-
lignancy’ or with focal hypoechoic cortical thickening as positive
for metastases detected all participants with nodal metastases (sen-
sitivity 100%, 95% CI 91% to 100%) with a specificity of 93%
(95% CI 90% to 95%) (460 participants, 37 with nodal metas-
tases) (Rubaltelli 2011). The combination of contrast-enhanced
ultrasound with B-mode ultrasound for participants with focal
cortical thickening (presence of perfusion defects corresponding
to the cortical focal thickening required for a positive test result)
increased specificity to 100% (95% CI 98% to 100%).
Other imaging tests. No data on CT, MRI, or PET-CT for the
detection of nodal metastases were identified for participants un-
dergoing re-staging for recurrence of melanoma.
Results: detection of distant metastases
No data were identified for the detection of distant metastases in
participants undergoing re-staging for disease recurrence.
Results: detection of distant metastases by metastatic site
Two of three studies conducted in participants undergoing imag-
ing for re-staging of melanoma included imaging of the brain and
documented some results for the detection of brain metastases.
In Iagaru 2007, one of the nine lesions classified as a false negative
on PET-CT was a brain lesion that was identified by MRI during
follow-up; the total number of brain metastases identified in the
study was not reported.
In Strobel 2007a, two brain metastases were identified on PET-
CT, both ofwhichwere confirmed tobemalignant on the reference
standard.
3. Staging in mixed or not clearly described
populations
Studies in mixed and not clearly described populations have been
considered together on the basis that we would be unable to make
clear statements regarding the expected accuracy of imaging at
any particular point on the clinical pathway for either subset of
studies. Table 3 describes variability in the clinical pathway and
indications for imaging, inclusion criteria, and stage of disease of
participants included in these studies.
Fifteen studies were conducted in mixed population groups (n =
11), including participants undergoing primary staging, re-stag-
ing, and follow-up imaging (i.e. at more than one point in the clin-
ical pathway) (Abbott 2011; Aukema 2010a; Bastiaannet 2009;
Cachin 2014; Dellestable 2011; Klebl 2003; Pfannenberg 2007;
Pfluger 2011; Reinhardt 2006; van den Brekel 1998; van Wissen
2016), or did not clearly describe the clinical pathway in included
participants (n = 4) (Aukema 2010b; Hausmann 2011; Jouvet
2014; Strobel 2007b).
Stage of disease on recruitment was not reported in four stud-
ies (Aukema 2010a; Cachin 2014; Klebl 2003; Strobel 2007b),
two studies included any stage of disease (with 56% (Reinhardt
2006) and 73% (Dellestable 2011) at stage III or stage IV), six
included only stage III melanoma (Abbott 2011; Aukema 2010b;
Bastiaannet 2009; Pfluger 2011; van den Brekel 1998; vanWissen
2016), one included stage IV only (Jouvet 2014), and two in-
cluded either stage III or IV melanoma (both with just under 40%
with stage III disease) (Hausmann 2011; Pfannenberg 2007).
Nine of the fifteen studies reported accuracy data only on a
per patient basis (Abbott 2011; Aukema 2010a; Aukema 2010b;
Bastiaannet 2009; Klebl 2003; Reinhardt 2006; Strobel 2007b;
van den Brekel 1998; van Wissen 2016), five reported data
per lesion (Dellestable 2011; Hausmann 2011; Jouvet 2014;
Pfannenberg 2007; Pfluger 2011), and one reported both per pa-
tient and per lesion data (Cachin 2014). Of those reporting per
lesion data, two studies reported accuracy data only for those
imaging abnormalities identified by each test (Dellestable 2011;
Jouvet 2014), such that comparative studies reported different
numbers of lesions and confirmed metastases per index test eval-
uated (Dellestable 2011; Jouvet 2014). Three studies included
all lesions detected by any index test so that the number of le-
sions included in each 2×2 contingency table was the same for
every test (Hausmann 2011; Pfannenberg 2007; Pfluger 2011);
two included all lesions considered suspicious by any one index
test (Hausmann 2011; Pfannenberg 2007); and one reported in-
cluding only lesions considered positive for melanoma on at least
one index test (Pfluger 2011). Variation in lesion inclusion has the
potential to reduce sensitivity in studies that included all lesions
detected by any index test, as any metastases missed by any one test
would count as false negative results in the contingency table; any
missed benign lesions would be considered true negative results,
but a large number of lesions would need to be missed to have any
detectable effect on specificity.
The considerable clinical heterogeneity between studies in terms
of population groups, stages of disease, lesion selection, differences
between tests, anddefinitions of target conditions (either including
or excluding imaging of the brain) means that no conclusions
can be drawn from studies in mixed and not clearly described
populations (Table 3; Appendix 9). Study results are therefore
described narratively in Appendix 12.
34Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D I S C U S S I O N
Summary of main results
There is a considerable volume of literature evaluating the accu-
racy of imaging tests for staging of melanoma, but other than the
specific use of imaging to identify nodal metastases before sentinel
lymph node biopsy (SLNB), only a small number of identified
studies were eligible for our review and were conducted in well-
defined populations of participants undergoing primary staging
or re-staging for disease recurrence. In terms of methodological
quality, studies were generally at low or unclear risk of bias, with
methods of participant selection and blinded case note review par-
ticularly poorly reported. Studies were of high or unclear concern
regarding the applicability of evidence due to participant selection
from mixed or not clearly defined populations, poorly described
application and interpretation of the index test or observer exper-
tise, and lack of definition of the target condition (e.g. including
or excluding the detection of metastases of the brain, no break-
down of cases according to nodal or distant metastases). Because
few studies compared eligible tests and because available data for
magnetic resonance imaging (MRI) were limited and information
regarding the stage of disease at diagnosis was lacking, we could
not fully answer the review question.
Four main findings can be drawn from our review.
1. Pre-SLNB ultrasound combined with fine needle aspiration
cytology (FNAC) allows around a fifth of patients with nodal
metastases to be identified with few false positive results.
Half of all included studies (18/39) considered the use of imag-
ing before SLNB to identify people with nodal metastases, par-
ticularly the use of ultrasound with or without FNAC (n = 11).
Study populations were well defined and included people likely to
be considered eligible for SLNB in routine practice. Studies pri-
marily used B-mode ultrasound, although two also used Doppler
ultrasound in all participants, and the use of ultrasound before or
after lymphoscintigraphy to identify sentinel nodes varied.
Summary of findings presents key results and translates summary
estimates to a hypothetical cohort of 1000 lesions. Given that com-
pletion lymphadenectomy (CLND) is no longer a standard of care
for patients who are eligible for SLNB, the previously postulated
benefit from ultrasound and FNAC of triaging those with nodal
metastases on cytology directly to CLND is no longer relevant.
We have therefore framed the potential benefit from ultrasound
and FNAC in terms of access to adjuvant therapy, but any benefit
would be incurred only if a result from imaging and cytology could
be obtained significantly more quickly than an SLNB result, or, if
SLNB was not available or was contraindicated.
All imaging tests had poor sensitivity, detecting at best a third of
people with nodal metastases that were not clinically detectable
(sensitivity of 35.4% for ultrasound alone); however, all summary
specificities were higher than 90%.
With use of the median prevalence of nodal metastases observed
across the 11 studies of ultrasound, a test sensitivity of 35.4%
would correctly identify 84 of 237 people with nodal metastases
but with 47 false positive results, or people who would be in-
correctly considered for adjuvant therapy. Combining ultrasound
with FNAC, such that only those positive on both ultrasound and
subsequent FNAC would be considered to have nodal disease (i.e.
a more narrowly defined threshold for test positivity), reduces by
41 the number of people with nodal metastases who are correctly
identified (from 84 to 43) but also reduces to two the number with
false positive results. In other words, for every 1000 people eligi-
ble for SLNB, ultrasound with FNAC has the potential to allow
around a fifth of those with nodal metastases to be considered for
adjuvant therapy without the need for a more invasive procedure
(SLNB), at a cost of two people being inappropriately managed
(false negatives).
However, considerable between-study differences were observed,
such that the number of people with false positive results could
range between one and seven, and the number of people with false
negative results could range between 8 and 134. Results were also
dominated by a single large study of 1000 participants from an
expert group (Voit 2014), and it is difficult to determine whether
these results could be replicated.
2. Limited test accuracy datawere available forwhole body imaging
via positron emission tomography-computed tomography (PET-
CT) for primary staging or re-staging for disease recurrence and
none evaluated MRI.
Of 24 studies meeting the inclusion criteria for this review, only
six clearly recruited participants who were undergoing primary
staging following a confirmed diagnosis of melanoma and three
recruited participants undergoing imaging for re-staging of disease
following some clinical indication of recurrence. Most of the stud-
ies (6/9) considered PET-CT, two in comparison to CT alone, and
three studies examined the use of ultrasound. None of the stud-
ies included in these groups evaluated MRI. Observed sensitivi-
ties and specificities for the detection of any metastases for PET-
CT appeared to be higher for those having re-staging of disease
(summary sensitivity from two studies was 92.6% and specificity
89.7%) compared to primary staging (sensitivities ranged from
30% to 47% and specificities from 73% to 88%) and were more
sensitive than CT alone in both population groups, but partici-
pant numbers were very small.
3. No conclusions can be drawn regarding routine imaging of the
brain with either MRI or CT.
We excluded from this review a number of studies that reported
data for ‘conventional imaging’ including CT or MRI because
they did not have clearly defined imaging protocols whereby all
included participants underwent both tests (Finkelstein 2004;
Fuster 2004; Gulec 2003; Oehr 1999; Paquet 2000; Rinne 1998).
Furthermore we identified no eligible studies reporting data for
MRI in primary or re-staging populations.
Of the studies conducted inmixed populations, scan coverage vari-
ably included the brain such that the definition of the target con-
dition of any metastasis could either include or specifically exclude
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the detection of brain metastases. Generally speaking, studies were
too small to include significant numbers of brain lesions. Only two
studies in mixed population groups identified a sufficient number
of brain metastases to allow sensitivities to be estimated. Jouvet
2014 showed CT with intravenous (IV) contrast and MRI with
ultrafast gradient echo sequences to have sensitivities of 95% (CT)
or more (100% for MRI) compared to 65% sensitivity for MRI
without ultrafast gradient echo sequences. In Cachin 2014, PET-
CT detected one of seven confirmed metastases of the brain (sen-
sitivity 14%, 95% CI 0% to 58%).
4. There are high concerns regarding the applicability of the evi-
dence, although risk of bias is generally low.
Study quality was moderate in terms of risk of bias, and there are
real concerns regarding the applicability of the evidence to the
review question. Much of this concern is due to the inclusion of
mixed and not clearly defined participant groups. There was a ten-
dency to include participants based on the availability of results
for a particular test, but more careful consideration of the indica-
tion for imaging is needed before the comparative accuracy of tests
at different points on the clinical pathway can be established. Al-
though there is an understandable temptation to translate results
frommixed populations to a primary staging or re-staging setting,
there is at least some evidence that accuracy varies by pathway and
in different ways for different tests (Reinhardt 2006), and this is
supported by work in other fields (Leeflang 2013).
Further concerns around applicability relate to reporting of data
per lesion as opposed to per patient, not only potentially impact-
ing estimates of test sensitivity and specificity but making it more
difficult to consider the implications of testing for patient man-
agement unless further information is provided in the papers. Al-
though one might expect sensitivity to be inflated by per lesion
data, effects on accuracy are not always clear cut. Cachin 2014
was one of the few studies reporting data both per patient and per
lesion; both the sensitivity and specificity of PET-CT were higher
for data reported per patient (87% and 71%) compared to those
reported per lesion (80% and 54%). The detection of additional
metastatic lesions by any one test is of limited benefit if there is
no resulting change in stage of disease classification or in patient
management options. For example, in Pfluger 2011, the five le-
sions found to be false negative on unenhanced PET-CT were
all identified in patients with multiple metastases, such that there
would have been no impact on TNM stage; on the other hand,
all six false positive lesions were identified in otherwise metastasis-
free patients who were falsely upstaged from M0 to M1.
We also noted variations in the scan coverage between studies,
which will impact the definition of the target condition, and lim-
ited information was provided on the thresholds used to identify
the presence of metastases.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and method-
ologists, and attempts to contact study authors to clarify data. A
detailed and replicable analysis of methodological quality was un-
dertaken and a clear analysis structure was adopted.
In comparison to other available systematic reviews of imaging
tests (e.g. Catalano 2011; Danielsen 2014; El-Maraghi 2008;
Rodriguez 2014; Sadigh 2014; Schroer-Gunther 2012; Xing
2011), our review covers a more recent search period and a broader
review question, including both primary staging and re-staging
of melanoma, as opposed to one or the other (Danielsen 2014;
Schroer-Gunther 2012), and this review considers the compara-
tive accuracy of different tests as opposed to reviewing a single
test (as in all other reviews apart from Xing 2011). We have also
separately considered data according to reporting of study data per
patient as opposed to per lesion - an approach not taken by any of
the other identified systematic reviews.
Our stringent application of review inclusion criteria means that
we excluded a considerable proportion of studies included in pre-
vious reviews. For example, across a selection of four reviews con-
sidering PET, we included only 3 of 12 (El-Maraghi 2008), 7 of 12
(Xing 2011), 3 of 9 (Rodriguez 2014), and 1 of 7 studies included
in those reviews (Danielsen 2014). We excluded studies on the
basis of having evaluated PET alone rather than PET-CT (Acland
2000; Acland 2001; Belhocine 2002; Fink 2004; Havenga 2003;
Koskivuo 2007; Longo 2003; Nguyen 1999; Steinert 1998; Tyler
2000; Vereecken 2005; Wagner 1999; Wagner 2005), a combina-
tion of PET and PET-CT, which could not be differentiated from
each other (Horn 2006; Wagner 2011), use of PET for treatment
response (Beasley 2012; Raymond 2011), use of an inadequate
reference standard (e.g. minimum follow-up period was not re-
ported) (Peric 2011), inadequate sample size (Libberecht 2005), or
inability to estimate the 2×2 data (Mottaghy 2007). We included
all five PET-CT studies included by Schroer-Gunther and col-
leagues for primary staging ofmelanoma (Schroer-Gunther 2012),
but we considered two of the five to have been conducted inmixed
rather than primary staging populations (Aukema 2010b; Strobel
2007b).
A similar picture was observed for other tests. We included only 7
of 22 studies of ultrasound and 4 of 13 studies of CT alone that
were included by Xing 2011, 6 of 24 studies of ultrasound from
Catalano 2011, and 2 of 8 studies of CT in Sadigh 2014. The
most common reason for exclusion of studies of ultrasound from
this review was the reporting of more than one ultrasound scan
per patient (e.g. Binder 1997; Brountzos 2003; Schmid-Wendtner
2003; Tregnaghi 1997; Voit 2001). For CT, it was the report-
ing of accuracy data for CT combined with other imaging tests
such as MRI in Finkelstein 2004 and Fuster 2004 or reporting of
more than one CT scan per patient in Sawyer 2009 and Swetter
2002, inadequate reference standards (Buzaid 1993; Buzaid 1995;
Chomyn 1992; Holder 1998), or the inclusion of more than 10%
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of participants with non-cutaneous melanoma (Brady 2006; Sofue
2012).
The main concerns for this review result from the poor reporting
of primary studies, in particular, limiting assessment of studies
according to clinical pathway, by stage of disease on diagnosis, and
by varying definitions of the target condition. This review is also
somewhat limited by the date of the last search (2016); however,
imaging of melanoma has not been a particularly fast-moving field
(with only 7 of 39 included studies published in the five years
before the search); furthermore, we are not aware of publication
of any landmark studies in the interim period.
Applicability of findings to the review question
Varying definitions of eligible study populations and lack of clarity
regarding the patient pathway and any prior testing restrict the
extent to which our findings can be applied in the clinical setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We identified a disappointing lack of evidence for imaging in pop-
ulations of participants that were clearly defined according to the
clinical pathway. Studies were generally small and reported data
according to the number of lesions identified as opposed to the
number of study participants included. We identified some ev-
idence to suggest that imaging with ultrasound combined with
fine needle aspiration cytology (FNAC) before sentinel lymph
node biopsy (SLNB) may have a limited role, but further work
is needed to identify whether the suggested benefit in terms of
avoiding SLNB is cost-effective. Much of the evidence for whole
body imaging for primary staging or re-staging of disease is focused
on positron emission tomography-computed tomography (PET-
CT), and comparative data with CT or magnetic resonance imag-
ing (MRI) are lacking. Increasing availability of adjuvant therapies
for melanoma is bound to have a considerable impact on imaging
services, but the evidence base to support any increase in imaging
for primary staging of disease is limited.
Implications for research
Although there are challenges in designing studies that will remain
relevant at the point of publication of findings in such a rapidly
changing landscape, and despite potential limitations in service
provision in terms of access to different imaging modalities, key
questions remain around themost appropriate use of imaging tests
for melanoma. In particular, studies need to go beyond diagnostic
accuracy and must consider the effects of different imaging tests
on patient management.
First, the role of ultrasound of the regional lymph nodes following
a primary diagnosis of melanoma is unclear.When combined with
FNAC, ultrasound has the potential to avoid SLNB in around a
quarter of people with lymph node metastases, allowing them to
proceed directly to adjuvant therapy; however, whether this ap-
proach would actually be implemented in clinical practice, and
for which patients or at which centres of care, needs to be deter-
mined. An economic model using currently available data, poten-
tially incorporating downstream consequences as more adjuvant
therapies become available, would determine the circumstances
under which this pathway saves resources and is worthwhile.
For whole body staging, comparative accuracy studies that incor-
porate changes to patient management as a result of imaging are
needed both for those undergoing primary staging following a
confirmed diagnosis of melanoma and for those undergoing re-
staging of disease on clinical suspicion of recurrence. For primary
staging in particular, more clarity is needed regarding who should
undergo whole body staging in terms of whether this should be re-
stricted to those with confirmed stage III or IV disease (identified
clinically or following SLNB), or whether there is a role for more
widespread imaging in high-risk groups, for example. A survey
of current practice in the UK would be useful, to identify which
imaging tests are being used in which patient groups across the
country and why.
Studies should carry out blinded comparisons of routine imag-
ing using contrast-enhanced CT of the neck, chest, abdomen,
and pelvis and contrast-enhanced CT of the head, with full body
18FDG PET-CT, and with post-contrast whole body MRI, or
MRI of the head alone, in all participants. The final diagnosis
should be established by histology and with the implementation
of a clearly defined imaging follow-up schedule in all study partic-
ipants. Study results in terms of accuracy should be reported per
lesion and per patient and should be reported by metastatic site to
allow an assessment of the success and failure of contrast-enhanced
CT and 18FDG PET-CT in different areas of the body. Imaging
of the brain with contrast-enhanced CT versus MRI could also be
performed.
It is essential that future research studies be clear about the diag-
nostic pathway followed by study participants, and they should
conform to the updated Standards for Reporting of Diagnostic
Accuracy (STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abbott 2011
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prosp. database: yes)
Country: UK
Data collection: NR; up to May 08
Inclusion criteria: stage III: micro-metastases on SLNB or clinically detectable nodal metastases
on diagnosis or FU
Patient characteristics and set-
ting
Presentation: mixed (either undergoing FU after prior SLNB/LND for micro-metastases or pre-
senting with clinically detectable nodal disease at or subsequent to initial diagnosis (primary/FU))
Number patients: 34 (microscopic group 20; macroscopic group 14)
Number primary lesions: 34
Number LNBs/metastases: NR
Stage of disease: IIIA 18, 53%; IIIB 10, 29%; IIIC 6, 18%
Median age: microscopic group 50 y - macroscopic group 63 y
Range: microscopic group 19 74 y; macroscopic group 48 79 y
Male: microscopic group 14, 70%; macroscopic group 6, 43%
Primary lesion site: HN 1, 3%; upper extremity 3, 9%; trunk 20, 59%; lower extremity 10, 29%
Breslow/Clark:microscopic group mean BT 2.27 mm (1.2 to 9.7 mm)
Macroscopic group:mean BT 2.01 mm (1.0 to 13 mm)
Ulceration: NR
Other: NR
Index tests PET-CT: 2D; CT (NR)
Machine: General Electric ST, Wisconsin, USA
Scan coverage: skull base to upper thigh
Contrast:NR
CT parameters: NR
FDG: 400 MBq
Breath hold: NR
CT used for: attenuation correction and lesion localisation
Reconstruction: iterative technique using an ordered subset expectation-maximisation algorithm
Threshold: clearly indicative/highly suspicious for malignancy considered positive
Number observers: NR
Qualification (experience): nuclear medicine consultants (experienced)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical NR; other tests NR
Target condition and reference
standard(s)
Histology/Imaging FU
Histological detail (n, %): NR, mixture of excisions and LND (5, 15%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): clinical and/or radiological FU (incl PET-CT) (34, 100%)
FU schedule: every 3 months for clinical examination; annual PET (second annual PET reported
for 15/34 (44%) and third annual for 4/34 (12%)). All FU clinically ≥ 6 months following each
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Abbott 2011 (Continued)
surveillance PET-CT
FU duration:microscopic mean 38 months (21 to 54 months); macroscopic mean 34 months (15
to 52 months)
Reference blinding: aware of prior PET-CT results during FU
#
Target condition
Data: per pt
Definition: any (excl brain; including local, ITM)
Prevalence: 7/34 = 21%; 4 local or ITM, 2 nodal, 1 distant metastasis
Flow and timing Index to histology interval: NR
Index to FU interval: 3 months
Exclusions: n = 0
Comparative
Notes Other results: 3 recurrences occurred in microscopic group (1 ITM and 1 pulmonary detected by
PET-CT plus 1 local recurrencemissed on first annual PET-CT); 4 clinically undetected recurrences
occurred in macroscopic group (2 LN, 1 local detected by PET-CT, and 1 ITM missed by staging
PET-CT)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear High
DOMAIN 2: Index Test PET-CT
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Abbott 2011 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
No
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
Unclear
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Abbott 2011 (Continued)
by a dermatopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Arrangoiz 2012
Study characteristics
Patient sampling Design: non-comparative; retrospective (medical record review)
Country: USA
Data collection: Jan 03 to Jan 09
Inclusion criteria: node negative; BT > 4 mm
Patient characteristics and set-
ting
Presentation: primary
Number patients: 56
Number primary lesions: 56
Number LNBs/metastases: NR
Stage of disease: all T4, clinically node negative, and negative for distant metastases
Mean age: 67 years;Median age: NR; Range: 26 to 89 years
Male: 32 (57%)
Primary lesion site: trunk 16, 29%; extremities 28, 50%; head and neck 12, 21%
Breslow/Clark: BT median 6 mm; mean 9 mm; range 4.1 to 40 mm
Ulceration: 34, 61%
Other: satellitosis: 25, 45%
Index tests PET-CT: 2D or 3D; CT (U, helical, low dose)
Machine: GE Discovery LS PET/CT Scanner (from 2003 to 10/2010) or a Siemens Biograph 16
PET/CT Scanner (from 10/2010 onwards)
SUV values reportedly comparable with cross-calibration by manufacturer-trained field engineers
and in-house medical physicist
Scan coverage: WB; vertex of the head down to feet for all patients
Contrast: U
CT parameters: Discovery LS - 140 kVp, 90 mA; Siemens Biograph - 130 kVp, 100 mA; 5 mm
FDG: 15 mCi (IV)
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Arrangoiz 2012 (Continued)
Breath hold: normal breathing
CT used for: attenuation correction; co-registered images
Reconstruction:Discovery LS - ordered subsets expectation maximisation (OSEM) algorithm with
28 subsets and 2 iterations. Siemens Biograph - rueX algorithm with 21 subsets and 2 iterations
Threshold: SUV 2.5
Number observers: NR; ’in-house medical physicist’ mentioned
Qualification (experience): NR; ’in-house medical physicist’ mentioned (NR)
Diagnosis (single, consensus, etc.): unclear
Info provided during test interpretation: clinical NR; other tests NR
Target condition and reference
standard(s)
Histology (SLNB, CLND, biopsy); FU
Histological detail (n, %): NR (54, 96% (48 SNB and 6 LND)). Histopathologist: NR
FNAC (n, %): NR (NR)
Follow-up (n, %):NR; 2/56 had no SLNB or LND reported so must have had some follow-up to
confirm absence of disease. Also the number D+ reported by authors in Table 4 does not add up to
combined SLNB/CLND numbers D+; presume that 4 of SLNB negative must have recurred with
regional disease at some point (NR)
FU schedule: NR
FU duration: NR
Reference blinding: NR
Target condition
Data: per pt
Definition: any mets (NR; scan incl head); Prevalence: 32/56 = 57%
Definition: nodal mets; Prevalence: 29/56 = 52%
Definition: distant mets (not documented; scan incl head); Prevalence: 5/56 = 9%
Flow and timing Index to histology interval: NR; states that 6 “proceeded directly to therapeutic lymph node
dissection” after PET
Index to FU interval: NR
Exclusions: n = 0; N/A
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
Unclear
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of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Aukema 2010a
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prosp. database: NR)
Country:Netherlands
Data collection: Aug 2006 to Mar 2009
Inclusion criteria: raised S100 during FU after resection of nodal or distant metastases or with
high-risk primary tumour
Patient characteristics and set-
ting
Presentation: mixed (15 treated for locoregional recurrence and 5 for distant mets; remaining 26
followed up after primary melanoma treatment)
Number patients: 46
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR; unfavorable primary tumour (n = 6); primary melanoma with simultaneous
nodal metastases (n = 18); unknown primary melanoma with nodal metastasis (n = 2); locoregional
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recurrence (n = 15); distant recurrence (n = 5)
Mean age: 59 years; Range: 25 to 93 years
Male: NR
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests PET-CT: NR; CT (U)
Machine: Gemini II, Philips, Eindhoven, The Netherlands
Scan coverage: whole body; not described
Contrast: U
CT parameters: kV NR; 40 mAs; 5 mm
FDG: 180 to 240 MBq (4.9 to 6.5 mCi)
Breath hold: no breath hold instructions reported
CT used for: attenuation correction; PET fused to low-dose CT
Reconstruction: NR
Threshold: NR; “hypermetabolic lesions”
#
MRI: patients underwent MRI of the brain; insufficient data to include separate 2×2
Machine: Achieva, Philips, Eindhoven, The Netherlands
Scan coverage: brain
Contrast: yes, not documented
MRI parameters: transversal T2-weighted; axial fluid attenuated inversion recovery (FLAIR) imag-
ing, diffusion-weighted imaging and pre- and post-contrast coronal T1-weighted 3D-FFE imaging
Tesla: 3.0
Number observers: 3
Qualification (experience): nuclear medicine physicians (experienced’)
Diagnosis (single, consensus,etc.): consensus of 3
Info provided during test interpretation: clinical NR; other tests NR; MRI brain also conducted
Target condition and reference
standard(s)
FNAC/histology/imaging FU
Histological detail (n, %): NR (13, 28.3%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): clinical exam; CT (33, 71.7%)
FU schedule: NR
FU duration: for disease negative only (n = 19): median 12 months (4 to 32 months); NR for full
sample
Reference blinding: NR
Target condition
Data: per pt
Definition: any (not documented; brain NR)
Prevalence: 23/46 = 50%
Flow and timing Index to histology interval: NR
Index to FU interval:
Exclusions: n = NR
Comparative
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Notes Other result: “MRI revealed 2 brain metastases of 2 and 4 mm in 1 patient (2%). This patient also
had other distant metastases that were detected by PET-CT”
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
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Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Unclear
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
75Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aukema 2010a (Continued)
High
Aukema 2010b
Study characteristics
Patient sampling Design: non-comparative; prospective
Country:Netherlands
Data collection: Oct 06 to Mar 09
Inclusion criteria: clinically node positive with no sign of distant metastases; primary/re-staging
NR
Patient characteristics and set-
ting
Presentation: unclear (NR; all have palpable and proven LN metastases)
Number patients: 70
Number primary lesions: 70
Number LNBs/metastases: 73
Stage of disease: ≥ stage IIIb (all with clinically palpable nodes)
Mean age: 58 y;Median age: NR; Range: NR
Male: 37 (54%)
Primary lesion site: upper extremity 4, 6%; lower extremity 37, 53%; trunk 19, 27%; head/neck
9, 13%; unknown primary 1, 1%
Breslow/Clark: Breslow: median 3 mm
Ulceration: NR
Other: NR
Index tests PET-CT: 2D; CT (U)
Machine: Gemini II, Philips, Eindhoven, The Netherlands
Scan coverage: WB according to primary lesion site (i.e. with regard to inclusion of cranium or
lower extremities)
Contrast: U
CT parameters: kV NR; 40 mAs; 5 mm
FDG: 180 to 240 MBq
Breath hold: no breath hold instructions reported
CT used for: attenuation correction; PET fused to low-dose CT
Reconstruction: PET was fused with low-dose CT after correction for attenuation
Threshold: NR; “metabolically active”
#
MRI: patients underwent MRI of the brain; insufficient data to include separate 2×2
Machine: Achieva, Philips, Eindhoven, The Netherlands
Scan coverage: brain
Contrast: yes, not documented
MRI parameters: transversal T2-weighted; axial fluid attenuated inversion recovery (FLAIR) imag-
ing, diffusion-weighted imaging and pre- and post-contrast coronal T1-weighted 3D-FFE imaging
Tesla: 3.0
#
Number observers: 3
Qualification (experience): nuclear medicine physicians (NR)
Diagnosis (single, consensus,etc.): consensus of 3
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Info provided during test interpretation: clinical NR; other tests NR; MRI brain also conducted
Target condition and reference
standard(s)
FNAC/histology/imaging FU
Histological detail (n, %): NR (NR; 11 with histology or cytology). Histopathologist: NR
FNAC (n, %): NR (NR; 11 with histology or cytology)
Follow-up (n, %): CT, ultrasound, or clinical follow-up for TP cases (59; 84%)
FU schedule: NR
FU duration: ≥ 6 months
Reference blinding: NR
#
Target condition
Data: per pt
Definition: any mets (incl in transit mets and skull according to primary lesion site); Prevalence:
30/70 = 43%
Metastases: PET-CT detected additional involved LNBs (3) and ’distant’ metastases (20); false
negative results included ITM (2), liver metastases (1), extensive metastases 3 months post PET-
CT (1)
Flow and timing Index to histology interval: N/A
Index to FU interval: NR
Exclusions: n = 0; N/A
Comparative
Notes Other result:MRI: detected brain mets in 5 pts, 4 with multiple other metastases detected by PET-
CT and 1 with solitary brain metastases. Outcome: 2 received dexamethasone and radiotherapy of
the brain, 1 was treated with temozolomide, and 1 received supportive care; solitary brain metastasis
removed surgically and underwent adjuvant whole brain radiotherapy; no signs of recurrent disease
at 15 months
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
Unclear
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normal practice?
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Unclear
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
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Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Bastiaannet 2009
Study characteristics
Patient sampling Design: within-person comparison; prospective
Country:Netherlands
Data collection: Jul 2003 to Dec 2007
Inclusion criteria: node positive (clinical or histology/cytology proven) candidates for CLND
Patient characteristics and set-
ting
Presentation: mixed (primary (LN mets diagnosed at time of primary diagnosis) 39, 15.5%; re-
currence (LN mets identified ≤ 3 years since primary dx) 145, 57.8%; recurrence (> 3 years since
primary dx) 67, 26.7%)
Number patients: 251
Number primary lesions: 251
Number LNBs/metastases: NR
Stage of disease: III (100%)
Mean age: reported in Bastiannet 2012 as 56.9 years (n = 253); Range: 19 to 93 years - 76 (30.
3%) < 50 years; 99 (39.4%) 50 to 65 years; 76 (30.3%) > 65 years
Male: 152 (61%)
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Primary lesion site:HN 29, 11.6%; upper extremities 26, 10.4%; trunk 93, 37.0%; lower extrem-
ities 88, 35.0%; unknown primary 15, 6.0%
Breslow/Clark: Breslow: ≤ 1 mm 32, 12.8%; 1.0 to 2.0 mm 73, 29.1%; ≥ 2.0 129, 51.4%;
unknown primary 15, 5.9%; missing 2, 0.8%
Clark level: I/II/III (n = 84; 33.5%), IV/V (n = 144; 57.4%), unknown primary (n = 15; 5.9%),
missing (n = 8; 3.2%)
Ulceration: yes 53, 21.1%; unknown 15, 6%
Other: localisation of SLN: neck 43, 17.1%; axilla 94, 37.5%; inguinal 114, 45.4%
Index tests CT: CE, spiral, multi-slice
Machine: NR
Scan coverage: chest, abdomen plus neck for those with LN in the neck
Contrast: oral and IV
CT parameters: NR; ’multi-slice’
Breath hold: no breath hold instructions reported
Threshold: NR (presence/absence of mets)
Number observers: NR
Qualification (experience): attending staff nuclear medicine physicians (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical NR; other tests blinded to PET
Target condition and reference
standard(s)
Histology/FU
Histological detail (n, %): cytopathology, histopathology (NR). Histopathologist: NR
FNAC (n, %): NR (NR)
Follow-up (n, %): bone scan, MRI, ’follow-up’ (251, 100%)
FU schedule: NR
FU duration:median 13.7 months; minimum 6months stated for index test positive, NR for index
test negative
Reference blinding: NR
Target condition
Data: per pt
Definition: distant mets (including lymph nodes beyond regional LNs)
Prevalence: 78/251 = 31%
Metastases: 120 TP metastatic sites identified by CT included liver (20), lung (41), abdomen (13)
, bone (10), subcutaneous (5), other (11); 16 patients FN on CT had metastases in the bone (5),
lung (5), multiple sites (2), liver (2), sternal (1), leg (1)
Presenting LN metastases were correctly identified by CT in 231/151 patients and by PET alone
in 229/251
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 8; excluded due to follicular structure (n = 1), > 13 years between primary and
lymph nodes (n = 3), incidence abroad (n = 1), mucosal melanoma (n = 2), primary melanoma
treated as benign lesion (n = 1)
Comparative
Notes Other result: (1) accuracy of PET alone, (2) change in treatment resulting from PET and/or CT
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
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Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Design: non-comparative; prospective
Country: France
Data collection: Aug 2008 to Sep 2010
Inclusion criteria: prior history of cutaneous or ocular MM undergoing staging or re-staging
including (a) newly diagnosed at any TNM stage, (b) known visceral or cutaneous MMmetastases
with unknown primary tumour, or (c) MM without metastases (included to assess test specificity)
Patient characteristics and set-
ting
Presentation: mixed (melanoma status at inclusion was one of the following: “newly diagnosed
cutaneous or ocular melanoma at any TNM stage, presence of known visceral melanoma metastases,
or cutaneousmelanomametastaseswith unknownprimary tumour. Patientswithmelanomawithout
metastases were also included, principally to assess the specificity of the imaging. Also states imaging
was for staging or for re-staging”)
Number patients: 87
Number primary lesions: NR
Number LNBs/metastases: 85
Stage of disease: NR; 45 (51% were diagnosed with melanoma mets on study Inclusion)
Mean age: NR;Median age: NR; Range: NR
Male: 42 (48.3%)
Primary lesion site: NR
Breslow/Clark: Breslow thickness (mm): < 1.0: 12, 13.8%; 1.0 to 2.0: 34, 39.1%; ≥ 2.0, 41, 47.
1%
Clark level: I 3, 3.4%; II 2, 2.3%; III 20, 23.0%; IV 46, 52.9%; V 3, 3.4%; not known 13, 14.9%
Ulceration: NR
Other: cutaneous melanoma pigmentation: pigmented 51, 58.6%; achromic 7, 8.0%; not known
29, 33.3%
Index tests PET-CT: NR; SPECT used in 4 of 8 centres
Machine: Discovery ST2, GE; Biograph 6, Siemens; Biograph HIREZ True Point, Siemens; Dis-
covery ST4, GE; Gemini Dual, Philips; Gemini, Philips
Scan coverage: WB (not further described)
Contrast:NR
CT parameters: SPECT; N/A
FDG: 3 to 5 MBq/kg
Breath hold: NR
CT used for: PET ’correlated’ with CT abnormalities
Reconstruction: iterative in 6 of 8 centres; filtered back-projection in 2 of 8 centres
Threshold: PET positive if there was focal uptake greater thanmediastinal or liver uptake that could
not clearly be related to physiological processes; negative when a normal distribution of tracer was
observed, even if the CT scan showed abnormalities. Bone accumulations were considered positive
when the uptake was higher than in normal bone marrow. Any instance of equivocal PET uptake
was considered positive
Number observers: NR
Qualification (experience): nuclear physician (experienced)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical NR; other tests NR; PET interpretation inde-
pendent of CT and then correlated with CT
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Target condition and reference
standard(s)
Histology/Imaging FU/FU
Histological detail (n, %): NR; “a total of 25 biopsies (1 per patient) were performed.” (25; 28.
7%). Histopathologist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): could include CT scan, biopsy, pathology, clinical follow-up (87, 100%)
FU schedule: NR
FU duration: ≥ 6 months
Reference blinding: NR
Target condition
Data: per pt
Definition: any (incl brain, subcutaneous mets); Prevalence: 39/67 = 58%
Data: per lesion
Definition: any (incl brain, subcutaneous); Prevalence: 85/176 = 48%
Definition: nodal; Prevalence: 20/39 = 51%
Definition: distant (incl brain and skin); Prevalence: 65/137 = 47%
Definition: bone; Prevalence: 14/34 = 41%
Definition: lung; Prevalence: 10/27 = 37%
Definition: soft tissue; Prevalence: 16/25 = 64%
Definition: skin; Prevalence: 7/9 = 78%
Definition: brain; Prevalence: 7/9 = 78%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 20; 12 did not undergo FDG PET due to imaging cancellation; 8 are unaccounted
for (text describes 75 having PET but reports results for only 67)
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
No
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normal practice?
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
No
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Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Chai 2012
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prosp. database: yes)
Country: USA
Data collection: Jun 2005 to Sep 2009
Inclusion criteria: node negative, BT > 0.76 mm or < 0.76 mm with high-risk features such as
ulceration, high mitotic rate, or positive deep margin
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 325
Number primary lesions: 325
Number LNBs/metastases: 347 LNBs
Stage of disease: NR
Mean age: NR;Median age: 58 years; Range: 18 to 86 years
Male: 189 (58%)
Primary lesion site: head and neck 34 (10.5%), trunk 129 (39.7%), upper extremity 101 (31.1%)
, lower extremity 61 (18.8%)
86Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chai 2012 (Continued)
Breslow/Clark: BT median (range) 1.78 (0.42 to 14.4); BT ≤ 1.00 56 (17.2%), 1.01 to 2.00 136
(41.8%), 2.01 to 4.00 88 (27.1%), 4.00 44 (13.5%), unknown 1 (0.3%)
Clark level: III 24 (7.4%), IV 275 (84.6%), V 20 (6.2%), unknown 6 (1.8%)
Ulceration: 97, 29.8%; unknown 16, 4.9%
Other: regression present 26 (8.0%), unknown 15 (4.6%).
Growth phase: radial 20 (6.2%), vertical 283 (87.1%), unknown 22 (6.7%)
Angiolymphatic invasion: present 15 (4.6%), unknown 20 (6.2%)
Mitotic rate: 0 9 (2.8%), C1 303 (93.2%), unknown 23 (7.1%)
Index tests US: B mode; linear array
Machine: NR
Scan coverage: acc to primary MM site and discretion of attending surgeon (extremity melanomas
- ipsilateral groin or axilla, MM of hand or forearm also had epitrochlear US and of lower leg had
popliteal US; HNMM - ipsilateral neck, parotid, and supraclavicular US; MM on trunk according
to Sappey’s line - at or above the beltline included axillary ultrasound, at or below included groin
ultrasound, lesions close to the midline had bilateral US)
Contrast:N/A
FNAC: If US performed the day before SLNB,US-guided FNACwas offered; FNAC+ve proceeded
to CLND, FNAC- to SLNB as planned
Threshold: US - classed as “abnormal,” “suspicious,” or “indeterminate - recommending a short-
term follow-up” were considered positive (criteria described in detail)
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical NR; other tests NR
Target condition and reference
standard(s)
Histology (CLND/SLNB)
Histological detail (n, %):H&E (serial section); IHC (NR) (325, 100%). Histopathologist:NR
FNAC (n, %): NR; all positive on CLND (6, 1.8%)
Follow-up (n, %): NR (NR; presume 100%)
FU schedule: NR
FU duration: NR; FU for SLNB negatives mentioned but no description given
Reference blinding: NR
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 64/317 = 20%
Flow and timing Index to histology interval: US performed either immediately or several days before LS
Index to FU interval: NR
Exclusions: n = 8; 1 patient had ultrasound of a non-draining nodal basin, while the actual draining
basin identified by lymphoscintigraphy was not examined with ultrasound; this patient was not
included in further analysis for comparison between ultrasound and SLNB. Plus 7 SLN positive
who did not get US
Comparative
Notes
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: France
Data collection: Aug 2006 to May 2007
Inclusion criteria: PET-CT for primary staging or follow-up of MM, regardless of AJCC stage or
indication for examination
Excluded if contraindications to MRI or iodine injection
Patient characteristics and set-
ting
Presentation:mixed (both primary staging and FU; breakdown reported but not legible on scanned
pdf )
Number patients: 40
Number primary lesions: 40
Number LNBs/metastases: NR; 72 lesions
Stage of disease: AJCC I to II 11, 27.5%; AJCC III to IV 29, 72.5%
Mean age: 57 years; Range: 27 to 85 years
Male: 20 (50%)
Primary lesion site: NR
Breslow/Clark: BT mean 3.2 mm, median 2.7 mm, range 0.6 to 11 mm
Ulceration: NR
Other: NR
Index tests CT
Machine: VCT (General Electric Healthcare, Wisconsin, USA)
Scan coverage: skull, neck, thorax, abdomen, pelvis
Contrast: iodised injection was administered by the same venous route as for previous examinations
CT parameters: NR
Breath hold: no breath hold instructions reported
Threshold: NR
MRI:WB, DW, T2STIR, CE 3D gradient echo
Machine: Signa Excite HD MRI (General Electric Healthcare, Milwaukee, United States)
Scan coverage: WB; head to lower limbs
MRI parameters: T2STIR, T1, diffusion, 3D gradient echo T1 after gadolinium injection
Magnet: 1.5 T
Threshold: NR
#
PET-CT: NR; CT (CE)
Machine: Biograph “coupled to an X-ray scanner for attenuation correction and anatomical regis-
tration”
Scan coverage: WB; top of the skull to the feet
Contrast: unclear; contrast is reported for CT; however CT component of PET-CT is not clear
CT parameters: NR
FDG: 5.5 MBq/kg
Breath hold: no breath hold instructions reported
CT used for: attenuation correction and anatomical registration
Reconstruction: NR
Threshold: focal uptake; unusual location or visual or quantitative intensity (SUV measurement)
Number observers: 3
Qualification (experience): NR (NR)
90Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dellestable 2011 (Continued)
Diagnosis (single, consensus, etc.): single with consensus if results of any modality disagree
Info provided during test interpretation: clinical NR; other tests - each of the 3 exams was
interpreted by a different reader, who had no knowledge of results of the other 2
Target condition and reference
standard(s)
Histology/Imaging or clin FU
Histological detail (n, %): NR (36 lesions, 28% of 128). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): clinical or radiological (72, 56%)
FU schedule: NR
FU duration: > 4 months
Reference blinding: N/A
Target condition
Data: per lesion
Definition: any (incl brain); Prevalence: CT 72/119 = 61%; MRI 70/117 = 60%; PET-CT 72/
119 = 61%
Definition: nodal; Prevalence: CT 31/39 = 79%; MRI 31/40 = 78%; PET-CT 31/38 = 82%
Definition: site specific (bone); Prevalence: CT 14/17 = 82%; MRI 14/16 = 88%; PET-CT 14/
17 = 82%
Definition: site specific (liver); Prevalence: CT 4/21 = 19%; MRI 4/26 = 15%; PET-CT 4/25 =
16%
Definition: site specific (lung); Prevalence: CT 13/16 = 81%; MRI 13/14 = 93%; PET-CT 13/
15 = 87%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions:CT n = 20 lesions; 4 lesions with indeterminate reference and 16 not picked up by CT;
MRI n = 9 lesions; 4 lesions with indeterminate reference and 7 not picked up by MRI; PET-CT
n = 9 lesions; 4 lesions with indeterminate reference and 5 not picked up by PET
Comparative (1) Each of the three exams was interpreted by a different reader, who had no knowledge of results
of the other 2
(2) Tests were consecutively applied, same day
(3) Prospective study included all patients scheduled for PET-CT
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
No
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Unclear
Low High
DOMAIN 2: Index Test MRI
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Unclear
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
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Low
Hafner 2004
Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: Switzerland
Data collection: Aug 1999 to Mar 2002
Inclusion criteria: any cutaneous MM with BT ≥ 1 mm without evidence of detectable distant
metastasis (includes clinically palpable)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB/any primary)
Number patients: 101
Number primary lesions: 101
Number LNBs/metastases: 105 LNBs; 136 SLNs
Stage of disease: NR; stage IV (evidence of distant mets) excluded
Median age: 55 years; Range: 18 to 79 years
Male: 55 (55%)
Primary lesion site: limbs 49, 49%; trunk 35, 35%; H&N 16, 16%
Breslow/Clark: Breslow: 1.01 to 2 mm 38; 2.01 to 4 mm 43; > 4.0 mm 19
Ulceration: NR
Other: NR
Index tests US: B-mode
Machine: Acuson Sequoia 512 or General Electric Logiq 700 Experty, with dedicated 5-MHz
curved array probes
Scan coverage: regional lymph nodes of the groins, axillae, and neck (abdominal US also performed)
Contrast:N/A
FNAC: clinically or radiologically suspect LN mets underwent FNAC; FNAC+ underwent SLNB
and CLND in same procedure
Threshold: NR; ’radiologically suspect’
Number observers: 1
Qualification (experience): radiologist (NR)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical unclear; clinical exam by dermatologist and US
by radiologist; other tests NR
Target condition and reference
standard(s)
Histology (CLND/SLNB)
Histological detail (n, %): SLN id - hot or blue node; SLN positive based on EORTC and UICC
recommendations (100; 100%).Histopathologist: all specimens were examined by an experienced
pathologist
FNAC (n, %): appears that some had FNAC before SLNB but not clearly reported: “In the presence
of a clinically or radiologically suspect lymph node metastasis, fine-needle aspiration was performed.
If the lymph node proved to be cytologically positive for melanoma metastasis, SN biopsy was
performed” (nNR; abstract reports 3 LNmets identified on physical exam, 2 of which were detected
by US)
Follow-up (n, %): NR; implies CT but could include any of study tests (chest X-ray, US, PET,
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CT) (NR)
FU schedule: NR
FU duration: 20 months (8 to 39)
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets
Prevalence: 23/97 = 24%, including 3 clinically node positive 26/100 = 26%
Flow and timing Index to histology interval: 2 weeks
Index to FU interval: 6 months
Exclusions: n = 4; 1 sentinel node was not found intraoperatively; 3 clinically node positive were
excluded by Bham team for pre-SLNB analysis
Comparative
Notes Other result: no confirmed distant mets detected at time of imaging; 9 patients with suspicious
findings on imaging were negative for progression/recurrence at 12 months; PET (2), abdominal
US (3), chest X-ray (4)
5/26 SLNB positive and 4/74 SLNB negative patients had recurrence OR progression (no break-
down by US result was given). Recurrences in the SLN positive group were 1 nodal and 4 distant,
and in the SLN negative group were 4 nodal plus 1 ITM and 1 distant mets in 2 patients with nodal
recurrences
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
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Low Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test Ultrasound
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
98Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hausmann 2011
Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: Germany
Data collection: NR; 18-month period
Inclusion criteria: AJCC stage III or IV MM; clinical indication for imaging was positive sentinel
node biopsy or suspicious lesions on ultrasound or X-ray studies
Excluded if second tumours
Patient characteristics and set-
ting
Presentation: unclear (pts described as having undergone previous assessment of tumour spread
based on ADO (German) guidelines but staging/re-staging not described; indication for imaging
was SLN+ or suspicious lesions were identified on ultrasound or X-ray)
Number patients: 50 eligible; 33 included
Number primary lesions: 50
Number LNBs/metastases: NR
Stage of disease: full sample only: stage III (19); stage IV (31)
Mean age: full sample only: 59.6 years; Range: full sample only: 26 to 86 years
Male: full sample only: 32 (64%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests CT: U + CE, multi-detector
Machine: multi-detector CT (Somatom Volume Zoom, Siemens Healthcare Sector, Erlangen)
Scan coverage: skull base to pelvis; CT andMR compared for “neck to the pelvis” only; sites imaged
included lungs, liver, spleen, kidneys, adrenal glands, subcutaneous tissue, lymph nodes, muscle,
bone marrow, and “other”
Contrast: U + CE
CT parameters: NR
Breath hold: no breath hold instructions reported
Threshold: NR (presence/absence of mets)
#
MRI: U + CE; ’standard sequences’
Machine: Magnetom Avanto, Siemens Healthcare Sector, Erlangen
Scan coverage:WB;NR. CT andMR compared for “neck to the pelvis” only; sites imaged included
lungs, liver, spleen, kidneys, adrenal glands, subcutaneous tissue, lymphnodes,muscle, bonemarrow,
and “other”
MRI parameters: standard sequences with parallel imaging techniques
Magnet: 1.5 T
Threshold: NR (presence/absence of mets)
#
Number observers: 4 (results for 2 included)
Qualification (experience): radiologist (high)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical diagnosis/age/sex; other tests blinded to MRI/
CT
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Target condition and reference
standard(s)
Histology or Imaging FU
Histological detail (n, %): NR (NR). Histopathologist:
FNAC (n, %): (0)
Follow-up (n, %): physical examination, blood tests, ultrasound studies, X-rays, CT scans of the
body from the neck to the pelvis (WB-CT) as well as MRI of the head (MRI-CR) (33, 100%)
FU schedule: 3 to 12 months
FU duration: ≥ 3 months
Reference blinding: FU by an independent radiologist
Target condition
Data: per lesion
Definition: any mets (excl brain); Prevalence: 455/824 = 55%
Definition: nodal: 192/379 = 51%
Definition: site specific (liver): 33/67 = 49%
Definition: site specific (lung): 145/197 = 74%a
Definition: site specific (subcutaneous): 33/46 = 72%
Definition: site specific (other): 51/118 = 43% (estimated by adding individual 2×2s for originally
reported ’Other’ category plus adrenal, kidney, muscle, and spleen sites)
Flow and timing Index to histology interval: N/A
Index to FU interval: minimum 3 months
Exclusions: n = 17; no WB-CT follow-up undertaken
Comparative (1) Test interpretation blinded
(2) Within 14 days
(3) Prospective study; indication for testing was positive SLNB or findings on US or X-ray
Notes Other result: results presented by region and for less experienced observers, 3 and 4; also presented
number of mets detected by cranial MR but no 2×2 extractable
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Unclear
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Did the study report data on a
per patient rather than per le-
sion basis?
No
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test MRI
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
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Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Yes
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
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High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
Low
Hinz 2011
Study characteristics
Patient sampling Design: non-comparative; prospective
Country: Germany
Data collection: Oct 2007 to Feb 2009
Inclusion criteria: clinically node negative, BT ≥ 1 mm or < 1 mm with risk factors such as
ulceration or regression
Excluded if sono-morphological criteria for lymph node metastases
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB but includes a secondary nodular SSM)
Number patients: 81
Number primary lesions: 81
Number LNBs/metastases: NR; 170 SLNs
Stage of disease: NR
Mean age: 52.8 years; Median age: NR; Range: SD 15.4 years; range reported for node positive
only (36 to 62 years)
Male: 48 (59%)
Primary lesion site: head 2, 2.5%; trunk 36, 44.4%; upper ext 14, 17.2%; lower ext 23, 28.4%;
acral 6, 7.4%
Breslow/Clark:median BT 1.68 mm (0.76 to 6.00 mm); 0.75 to 1.00 mm 20, 25%; 1.01 to 1.50
mm 24, 30%; 1.51 to 2.00 mm 12, 15%; 2.01 to 4.00 mm 18, 22%; > 4 mm 7, 9%
Clark levels: II 1, 1%; III 26, 32%; IV 47, 58%; V 7, 9%
Ulceration: 14, 17.3%
Other: NR
Index tests US: B-mode (linear array); Doppler
Machine: Nemio SSA-550A; Toshiba Diagnostic Ultrasound System, Neuss, Germany
Scan coverage: LN areas predicted by sites of melanoma
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Contrast: N/A
FNAC: N/A
Threshold: positive radiological findings according to published criteria plus PD signs of accessory
peripheral vessels or displacement of intranodal vessels or asymmetrical avascular areas or aberrant
course of central vessels
Number observers: 1 of 4 clinicians trained in USS imaging
Qualification (experience): NR; broad experience in dermato-oncology and special ultrasound
skills (NR)
Diagnosis (single, consensus, etc.): unclear; appears as though single observer
Info provided during test interpretation: clinical NR; likely full info available; other tests NR
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (serial section); IHC (S-100, HMB 45, and Melan A); mets
categorised as macro or micro mets or as cluster of cells (10 to 30 grouped cells) in the subcapsular
space or interfollicular zone, or isolated melanoma cells (1 to≤ 20 individual cells) (ref Starz 2001)
(1). Histopathologist: 2 experienced dermatopathologists
FNAC (n, %): NR (NR)
Follow-up (n, %): not stated (N/A)
FU schedule: NR
FU duration: not stated
Reference blinding: NR
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 8/81 = 10%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 0
Comparative
Notes Other result: of 7 FN LNBs, 3 were classified as reactive on US and 4 were not visualised; the 2
TPs were both correctly classified pre-LS and post-LS. Of 8 SLN positive, all described in text as
micro-mets, but Table 2 describes 5 as > 2 mm and 3 as ≤ 2 mm; both TPs were > 2 mm
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
High Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
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of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hinz 2013
Study characteristics
Patient sampling Design: within-person comparison; retrospective (retrospective computer-aided search of preoper-
atively performed staging procedures)
Country: Germany
Data collection: Jan 2009 to Jan 2011
Inclusion criteria: high risk cutaneous MM; implies BT ≥ 2.0 mm or RF such as ulceration or
regression
Excluded if classic sonographic signs of lymphatic metastasis
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 20
Number primary lesions: 20
Number LNBs/metastases: 59 SLN
Stage of disease: NR
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Mean age: full sample 55.2 years;Median age: NR; Range: full sample SD 13.3 years
Male: 9 (45%)
Primary lesion site: trunk n = 10 (50%); upper extremity n = 3 (15%); lower extremity n = 4
(20%); acral n = 3 (15%)
Breslow/Clark: BT 1.01 to 2 mm n = 3 (15%), 2.10 to 4 mm n = 9 (45%), > 4 mm n = 8 (40%)
Clark level: III n = 1 (5%); IV n = 16 (80%); V n = 3 (15%)
Ulceration: 7, 35%
Other:
Index tests US: B-mode
Machine: Nemio SSA-550A; Toshiba Diagnostic Ultrasound System, Neuss, Germany
Scan coverage: all relevant regional LN basins depending on localisation of the primary melanoma
Contrast:N/A
FNAC:N/A
Threshold: morphology criteria of Solbiati 1988, Vassalo 1992, and Voit 2010; suspicious LNs
were re-examined with US after LS
PET-CT: 2D/3D NR; CE-CT, helical. Reinhardt 2006 states helical, dual detector
Machine: Biograph; Siemens Medical Solutions Inc., Erlangen, Germany
Scan coverage: WB; Reinhardt 2006: “base of the skull to the apex of the lungs, ... from the
shoulders to upper thighs, ... from the proximal femura to the tip of the toes”
Contrast:Reinhardt 2006: iodinated oral contrast agent (Peritrast-oral-GI; Köhler Chemie GmbH,
Alsbach, Germany)
CT parameters: 130 kV, 40 mAs (Reinhardt 2006); 5 mm (Reinhardt 2006)
FDG: 371 ± 41 MBq (Reinhardt 2006)
Breath hold: limited breath hold technique for CT and shallow breathing for PET
CT used for: Reinhardt 2006: attenuation correction based on re-scaling of the CT image
Reconstruction: iterative reconstruction with attenuation correction based on re-scaling of the CT
image as described elsewhere (Kinahan 2003)
Threshold: NR
Number observers: unclear
Qualification (experience): US by physicians with broad experience in dermato-oncology (NR);
NR for PET-CT
Diagnosis (single, consensus, etc.): unclear; appears as though single observer for US, NR for
PET-CT
Info provided during test interpretation: clinical: clinical exam/US performed by same clinician;
other tests: before PET-CT
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (Serial); IHC (S-100, HMB 45, and Melan A). Mets were
classified according to Carlson et al (2003) - macro-metastasis (> 2 mm), micro-metastasis (≤ 2
mm), cluster of cells (10 to 30 grouped cells) in the subcapsular space or interfollicular zone, or
isolated melanoma cells (1 to ≤ 20 individual cells) in subcapsular sinuses. Histopathologist: 2
experienced
FNAC (n, %): - (0)
Follow-up (n, %): - (0)
FU schedule: N/A
FU duration: N/A
Reference blinding: NR
Target condition
Data: per pt
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Definition: nodal mets; Prevalence: 12/20 = 60% (17/59 SLN = 29%)
Flow and timing Index to histology interval: before lymphoscintigraphy
Index to FU interval: N/A
Exclusions: n = 0
Comparative (1) Blinding unclear; US undertaken before CT
(2) Tests undertaken consecutively
(3) Only subgroup of those with US had PET-CT; reason NR
Notes Other result: no FU for FNs reported; all 17 disease positive were micro-metastases
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
High Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
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Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
No
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High
Hocevar 2004
Study characteristics
Patient sampling Design: within-person comparison; unclear design
Data collection: Jun 2002 to Aug 2003
Inclusion criteria: MM candidates for SLNB (SLNB eligibility NR)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 57
Number primary lesions: 57
Number LNBs/metastases: 61
Stage of disease: NR
Mean age: NR;Median age: NR; Range: 1 to 93 years
Male: 21 (37%)
Primary lesion site: 14, 25% head; 19, 38% trunk; 24, 42% extremity
Breslow/Clark: BT < 1 mm 2, 4%; BT 1 to 2 mm 23, 40%; BT 2.01 to 4 mm 20, 35%; BT > 4
mm 12, 21%
Clark level: unknown 2, 4%; III 23, 42%; IV 26, 44%; V 6, 10%
Ulceration: 21, 37%; unknown 3, 5%
Index tests US: B-mode; linear array transducer with small parts probe
Machine: Power Vision 800, Toshiba Corporation, Ottawa, Japan
Scan coverage: NR
Contrast:N/A
FNAC:US + ve; Giemsma stained according to Papanicolaou method, and if necessary, immunocy-
tochemical reaction with monoclonal antibody HMB45 and S100 on an automatic immunostainer
Threshold: rounded appearance of the LN, Ioss of the hilar echogenic reflex, and deformed radial
nodal vascularity
Number observers: 1
Qualification (experience): oncological radiologist (NR)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical NR; other tests NR
Target condition and reference
standard(s)
Histology (CLND or SLNB)
Histological detail (n, %): H&E (step sectioned); IHC (S100). If negative, additional sections
stained with S100 and HMB45 (CLND; SLNB). Histopathologist: NR
FNAC (n, %):melanoma cells in lymph node sample from FNA (14/17 US + ve underwent FNAC)
Follow-up (n, %): NR (NR)
FU schedule: NR
FU duration: NR
Reference blinding: NR
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 14/57 = 25%
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Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 0
Comparative
Notes Other result: no FU to identify FNs; 10/14 disease positive were macro-metastases; US alone
correctly picked up 2/4 micro-metastases
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Unclear
Iagaru 2007
Study characteristics
Patient sampling Design: within-person comparison; retrospective (Prosp. database: NR)
Country: USA
Data collection: Jan 2003 to Jun 2005
Inclusion criteria: PET-CT for MM re-staging
Patient characteristics and set-
ting
Presentation: re-staging (all patients had the study requested for disease re-staging)
Number patients: 106
Number primary lesions: NR
Number LNBs/metastases: 139 metastatic lesions
Stage of disease: 76 stage I to IIIc; 30 stage IIIb to IV
Mean age: 56.8 years ± 15.9 years;Median age: NR; Range: 20 to 87 years
Male: 68 (64.1%)
Primary lesion site: NR
Breslow/Clark: BT at initial diagnosis (n = 76): mean 3.56 mm, 0.4 to 25 mm; < 1 mm in 6 (8%)
, 1 to 4.0 mm in 58 (76%), > 4 mm in 12 (16%)
Clark level (n = 70): 3 (4%), level II; 13 (19%), level III; 43 (61%), level IV; 11 (16%), level V
Ulceration: NR
Other: NR
Index tests CT: U, multi-slice helical
Machine: Discovery LS PET/CT unit (GE Medical Systems, Milwaukee, WI)
Scan coverage: WB; top of the head to the ankles
Contrast:N/A
CT parameters: 140 kV, 40 mA; 5 mm
Breath hold: no breath hold instructions reported
Threshold: NR
#
PET-CT: 2D; CT (U, multi-slice helical)
Machine: Discovery LS PET/CT unit (GE Medical Systems, Milwaukee, WI)
Scan coverage: WB; top of the head to the ankles
Contrast: U
CT parameters: 140 kV, 40 mA; 5 mm
FDG: 15 mCi
Breath hold: no breath hold instructions reported
CT used for: attenuation correction and anatomical localisation
Reconstruction: standard iterative algorithm (OSEM, 2 iterative steps, 28 subsets) using GE soft-
ware release 5.0
Threshold: SUVmax ≥ 2.5
#
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Number observers: NR
Qualification (experience): nuclear medicine physicians and radiologists (board certified)
Diagnosis (single, consensus, etc.): consensus
Info provided during test interpretation: clinical - NR for original interpretation or for re-inter-
pretation; other tests - NR for original interpretation or for re-interpretation
Target condition and reference
standard(s)
Histology/FU
Histological detail (n, %): NR (97, 91.5%). Histopathologist: NR
FNAC (n, %): N/A
Follow-up (n, %): NR (9, 8.5%)
FU schedule: NR
FU duration: NR
Reference blinding: PET-CT and pathology reported were ’reviewed’; no blinding described
Target condition
Data: per pt
Definition: any mets (incl skin and brain)
Prevalence per patient: 56/106 = 53% (stage I to IIIc 38/76 = 50%; stage IIIb to IV 18/30 = 60%)
Prevalence per lesion: 87/139 = 63%
Metastases: of the 50 patients TP on PET-CT: 7 were residual MM, 34 ’metastases’, and 9
’widespread metastases’. FN on PET-CT documented only per lesion: 6 recurrences at the resection
site, 2 sub-centimetre soft tissue nodules, and 1 brain lesion (identified by MRI presumably during
follow-up)
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 0; N/A
Comparative (1) Blinding between tests unclear
(2) Test interval consecutive; same scanner
(3) Retrospective; all had PET-CT with separate interpretation of CT alone
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Unclear
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Unclear
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
116Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Iagaru 2007 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Unclear
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
No
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
Unclear
Jouvet 2014
Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: France
Data collection: Mar 2009 to Jan 2012
Inclusion criteria: AJCC stage IV cutaneous MM referred for simultaneous staging by PET-CT,
CT, superficial lymph node US, and MRI
Patient characteristics and set-
ting
Presentation: unclear (no details; referred for simultaneous staging)
Number patients: 37
Number primary lesions: NR
Number LNBs/metastases: 209 lesions (n varies per test)
Stage of disease: stage IV: 37 (100%)
Mean age: NR;Median age: NR; Range: NR
Male: NR (0%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests US: B-mode
Machine: NR; 12.5-MHz surface probe
Scan coverage: putative lymphatic drainage area of the primary melanoma
Contrast:N/A
FNAC:N/A
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Threshold: circular/ovoid hypoechoic lymph node and no hyperechoic hilum
#
CT: CE; helical; 16 row
Machine: CT Philips Scanner (Philips Medical System, Eindhoven, The Netherlands)
Scan coverage: neck/chest/abdomen/pelvis; “cervico-thoraco-abdomino-pelvic helicoidal acquisi-
tion”; then skull
Contrast: iodinated IV injection
CT parameters: 120 kV, 250 mAs (neck to pelvis); 140 kV, 120 mAs (skull); 1.25 mm (neck to
pelvis); 2.5 mm (skull)
Breath hold: no breath hold instructions reported
Threshold: NR (presence/absence of mets)
#
MRI (DW) and MRI (DW + VIBE): DW, VIBE - 3D echo gradient CE, T1 - skull
Machine: AVANTO (33 mT, 120 mT/m, Siemns, Erlangen, Germany)
Scan coverage: WB; top of skull to feet
MRI parameters: echo-planar DW; axial with coronal reconstruction; VIBE (3D gradient echo w
CE); T1 axial on skull
Magnet: 1.5 T
Threshold: NR (presence/absence of mets)
#
PET-CT: 3D GSO; CT (CE, helical; 2 row)
Machine: Gemini PET-CT (Philips Medical System, Eindhoven, The Netherlands)
Scan coverage: skull base to the feet (lower limb MM); skull to thighs (MM head, upper limbs,
and trunk)
Contrast: CE
CT parameters: 120 to 140 kV, 100 mAs; 6.5 mm
FDG: 5.2 MBq/kg 1 hour before scanning
Breath hold: no breath hold instructions reported
CT used for: unclear; PET was attenuation corrected but does not state using CT, PET images
superimposed with CT data
Reconstruction: attenuation corrected PET data were iteratively reconstructed and superimposed
with CT data
Threshold: NR (presence/absence of mets)
#
US, CT, MRI:
Number observers: 1
Qualification (experience): radiologist (experienced).
Diagnosis (single, consensus, etc.): consensus of 2 (all images interpreted independently by 2
examiners; discordant results resolved by consensus) Presume ultrasound also undertaken by radi-
ologist
Info provided during test interpretation: clinical - NR; other tests - blinded
PET-CT:
Number observers: 2
Qualification (experience): nuclear medicine specialist (experienced)
Diagnosis (single, consensus, etc.): consensus of 2 (all images interpreted independently by 2
examiners; discordant results resolved by consensus)
Info provided during test interpretation: clinical - NR; other tests - blinded
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Target condition and reference
standard(s)
FNAC, FU:
Histological detail (n, %): N/A (0). Histopathologist: NR
FNAC (n, %): no details; FNAC was performed in 5 cases, and all other positive cases have been
diagnosed on the basis of progression of the target (5, 13.5%)
Follow-up (n, %): ’sequential imaging’; not further described (32; 86.5%)
FU schedule: NR
FU duration: > 9 months
Reference blinding: N/A
Target condition
Data: per lesion
Definition: any mets (incl brain, subcut); Prevalence: CT 115/209 = 55%; MRI 125/218 = 57%
Definition: any (excl brain mets); Prevalence: CT 95/186 = 51%; MRI 105/195 = 54%; PET-CT
104/191 = 54%
Definition: nodal; Prevalence: all tests 23/53 = 43%
Definition: nodal (superficial); Prevalence: all tests 13/33 = 39% (per LNB)
Definition: site specific (bone); Prevalence: CT 15/33 = 45%; MRI 16/35 = 46%; PET-CT 16/
35 = 46%
Definition: site specific (liver); Prevalence: all tests 12/27 = 44%
Definition: site specific (lung); Prevalence: all tests 31/45 = 69%
Definition: site specific (local); Prevalence: MRI, PET-CT only 10/22 = 45%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 0; N/A
Comparative (1) “All the examiners were unaware to the results of the other imaging techniques”
(2) “All examinations were performed within a mean interval of 7 days”
(3) Prospective; “referred for simultaneous staging”
Notes Other result: provides K values for inter- and intra-observer agreements, but not the 2×2 tables for
each observer
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Unclear
Did the study report data on a
per patient rather than per le-
sion basis?
No
Unclear High
DOMAIN 2: Index Test Ultrasound
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test MRI
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
No
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detail to allow replication?
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
No
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
Yes
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
Low
Kang 2011
Study characteristics
Patient sampling Design: non-comparative; retrospective (medical record review)
Country: S Korea
Data collection: Mar 2005 to Sep 2009
Inclusion criteria: newly diagnosed cutaneous MM undergoing staging work-up with PET-CT
(any stage, including clinically node positive)
Patient characteristics and set-
ting
Presentation: primary (any)
Number patients: 37
Number primary lesions: 37
Number LNBs/metastases: NR
Stage of disease: stage 0: 7 (18.9%); stage I: 6 (16.2%); stage II: 17 (45.9%); stage III: 6 (16.2%);
stage IV: 1 (2.7%)
Mean age: 61.7y ± 13.6 years;Median age: NR; Range: 48.1 to 75.3 years
Male: 17 (45.9%)
Primary lesion site: hand/foot 23 (62.1%), trunk 6 (16.2), head/neck 4 (10.8%), extremity 4 (10.
8%)
Breslow/Clark: BT < 1.0 mm 8, 22%; ≥ 1 mm 15, 41%; NR 14, 38%
Ulceration: present 7, 19%; absent 30, 81%
Other: mean SUVmax 2.8 ± 2.3
Index tests PET-CT: CT (U, 6 slice or 16 slice)
Machine: Reveal RT-HiRez CTIMI (Knoxville, TN, USA), a 6-slice CT; or Discovery ST (GE
Health Systems, Milwaukee, Wl, USA), a 16-slice CT
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Scan coverage: vertex of skull to knees; plus lower limbs if with lower leg MM
Contrast: U
CT parameters: Reveal RT-HiRez 130 kV, 95 mA; Discovery ST 140 kV, 160 mA; Reveal RT-
HiRez 2.5 mm; Discovery ST 3.75 mm
FDG: 350 to 400 MBq
Breath hold: NR; ’standard protocol’
CT used for: unclear; combined PET-CT unit; mentions identification of anatomical location on
fused PET-CT image
Reconstruction: ordered subset expectation-maximisation
Threshold: SUVmax ≥ 2.2 (set using ROC analysis)
#
Number observers: 2
Qualification (experience): nuclear physicians (experienced)
Diagnosis (single, consensus, etc.): consensus of 2
Info provided during test interpretation: clinical - NR; other tests - N/A
Target condition and reference
standard(s)
Histology/Imaging FU
Histological detail (n, %): reported for only 6 of disease positive group (6 (16.2%)).Histopathol-
ogist: experienced dermatopathologist and pathologist
FNAC (n, %): N/A (0)
Follow-up (n, %): clinical, CT, PET-CT (37 (100%))
FU schedule: physical examination every 3 months for 1 to 2 years, then every 6 months; imaging
every 6 to 12 months and/or when clinically indicated
FU duration: median followup 24.3 ± l l.7 months (range 8 to 55 months)
Reference blinding: NR
#
Target condition
Data: per pt
Definition: any mets (incl brain, local/skin); Prevalence: 9/37 = 24%
Flow and timing Index to histology interval: NR
Index to FU interval: 3 months
Exclusions: n = 0
Comparative
Notes Other result: sites of recurrence were LN (3); distant (5; lung or liver); ’local’ (2); skin (1); 3 patients
died related to CMM
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
High High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Kell 2007
Study characteristics
Patient sampling Design: non-comparative; retrospective (prospective database)
Country: USA
Data collection: NR; 12-month period
Inclusion criteria: MM, BT ≥ 0.76 mm, candidates for SLNB who underwent PET-CT (46/83
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with SLNB)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 37
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: 61.4 years;Median age: NR; Range: NR
Male: NR (0%)
Primary lesion site: NR
Breslow/Clark:mean BT 2.4 mm
Ulceration: NR
Other: NR
Index tests PET-CT: CT (U)
Machine: NR
Scan coverage: base of skull to feet
Contrast: U
CT parameters: NR
FDG: NR
Breath hold: NR; standard protocols
CT used for: NR
Reconstruction: NR; combined PET-CT images
Threshold: quantitative for areas of abnormally increased 18-FDG uptake relative to surrounding
normal tissues and areas of increased physiological uptake
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): NR (37, 100%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): NR (NR)
FU schedule: NR
FU duration: NR
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 9/37 = 24%
Flow and timing Index to histology interval: NR
Index to FU interval: N/A
Exclusions: n = 0; 46 with SLNB but no PET-CT could not be included
Comparative
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Notes Other result: PET-CT revealed no unheralded metastatic disease but did identify a second occult
malignancy in 4 (10.8%) patients undergoing therapy for melanoma
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Low
Klebl 2003
Study characteristics
Patient sampling Design: within-person comparison (US vs palpation)
Country: Germany
Data collection: Aug 1997 to Dec 1998
Inclusion criteria: MM Clark level IV or V undergoing FU after primary surgery
Patient characteristics and set-
ting
Presentation: mixed (primary (n = 8), follow-up (n = 75))
Number patients: 83
Number primary lesions: 83
Number LNBs/metastases: NR; 653 LNs examined
Stage of disease: NR
Mean age: NR;Median age: NR; Range: NR
Male: 46 (55%)
Primary lesion site: NR
Breslow/Clark: Clark level IV 68, 82%; level V 15, 18%
Ulceration: NR
Index tests US: B-mode US; high-resolution linear array
Machine: HDI Ultramark 9 using a high-resolution 5- to 10-MHz linear sonicator
Scan coverage: cervical, axillary, and inguinal LNBs
Contrast:N/A
FNAC: no
Threshold: suspicious/indeterminate/benign based on diameter, shape, echogenicity, and vascular-
isation pattern
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - unclear; could be same examiner as for LN
palpation; other tests - NR
Target condition and reference
standard(s)
Histology (NR), FU
Histological detail (n, %): NR (17, 20%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): NR (62, 75%)
FU schedule: suspicious, but not clearly malignant findings were reviewed at intervals of 6 to 8
weeks. For unremarkable findings, a check was carried out after 6 to 12months as part of the tumour
follow-up
FU duration: minimum 1 year; mean time since primary surgery 2.6 ± 2.3 years
Reference blinding: NR
#
Target condition
Data: per pt
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Definition: nodal mets; Prevalence: 17/79 = 22%
Flow and timing Index to histology interval: NR
Index to FU interval: 6 to 8 weeks for control visit, 6 to 12 months for FU visit
Exclusions: n = 4; 4 were indeterminate on follow-up so that a final diagnosis could not be made
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear High
DOMAIN 2: Index Test Ultrasound
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
Unclear
132Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Klebl 2003 (Continued)
applicable manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Klode 2010
Study characteristics
Patient sampling Design: non-comparative; retrospective (prospective database NR)
Country: Germany
Data collection: Jan 2004 to Dec 2006
Inclusion criteria: primary MM AJCC stage I or II (BT > 1 mm)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 61
Number primary lesions: NR
Number LNBs/metastases: 174 SLNs
Stage of disease: NR (I or II)
Mean age: 58.8; Median age: 61; Range: 31 to 82
Male: 36 (0.5901%)
Primary lesion site: trunk and lower limbs 26, 42.6%; upper extremities 9, 14.8%; NR for re-
maining 27 lesions
Breslow/Clark: BT mean 2.62 mm, median 2.0 mm, range 1 to 8 mm
Ulceration: 15, 24.6%
Other: NR
Index tests PET-CT: 2D/3D NR; CE-CT
Machine: Siemens Biograph Duo PET-CT scanner (Siemens, Erlangen)
Scan coverage: cranial base to mid-femur; additional views according to melanoma localisation
Contrast: iodine-containing contrast agent
CT parameters: NR
FDG: 349 mBq
Breath hold: breath hold instructions NR
CT used for: NR
Reconstruction: NR
Threshold: NR; hypermetabolic tumour focus
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - NR; other tests - NR
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Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (serial); IHC (S100, MElanA, HMB45). Tumour focus < 2.0
mm defined as micro-metastasis; ≥ 2.0 mm macro-metastasis (61, 100%) Histopathologist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): NR (61, 100%)
FU schedule: NR
FU duration: median 38 months, 13 to 55 months
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 14/61 = 23% (17/174 SLNs = 10%)
Flow and timing Index to histology interval: median 14 days PET to SLNB
Index to FU interval: NR
Exclusions: n = 0; 60 patients with SLNB did not agree to preop PET
Comparative
Notes Other result: 174 SLNs removed from 68 lymphatic drainage areas. The TP result was a macro-
mets > 10 mm; of the 16 FNs on PET-CT, 2 were macro-mets (5.5 mm and 10 mm) and 14 were
micro-mets. On FU, disease progression observed in 6 patients (3 of whom died), 3 of whom were
SLN positive (PET-CT result NR)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
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Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
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Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kunte 2009
Study characteristics
Patient sampling Design: non-comparative; prospective
Data collection: Dec 2002 to Mar 2003
Inclusion criteria: cutaneous MM SLNB candidates; reported as ’mainly’ ≥ 1.0 mm BT or risk
factors (ulceration or regression or Clark level IV and V)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 25
Number primary lesions: 25
Number LNBs/metastases: 68 LNBs; 35 SLNs
Stage of disease: NR
Mean age: 54 years;Median age: NR; Range: NR
Male: 15 (60%)
Primary lesion site: limbs 14, 56%; head and neck 2, 8%; trunk 9, 36%
Breslow/Clark: Breslow ≤ 1 mm 8, 32%; 1.01 to 2 mm 11, 44%; 2.01 to 4 mm 5, 20%; > 4.0
mm 1, 4%
Ulceration: 6, 24%
Other: regression 0, 0%
Index tests US: B-mode; linear transducer
Machine: SSA-340 A; Toshiba Medical Systems, Neuss, Germany
Scan coverage: regional lymphatic basins
Contrast:N/A
FNAC: no
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Threshold: qualitative presence of morphological features (described)
#
Number observers: 2
Qualification (experience): dermatologists (experienced)
Diagnosis (single, consensus, etc.): unclear
Info provided during test interpretation: clinical - unclear; may be same dermatologists as for
clinical exam; other tests - pre and post lymphoscintigraphy ultrasound
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (serial section); IHC (S-100, HMB 45, NKiC3, Melan A).
LNs with histologically proven tumour deposits were considered metastatic except when fewer
than 4 isolated tumour cells were present. The metastatic deposit was documented for each SLN
concerning location within the LN and size (micro-metastasis and macro-metastasis) (25, 100%).
Histopathologist: NR
FNAC (n, %): - (0)
Follow-up (n, %): - (0)
FU schedule: N/A
FU duration: N/A
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 6/25 = 24% (6/35 SLN; 17%)
Flow and timing Index to histology interval: < 24 hours
Index to FU interval: N/A
Exclusions: n = NR; NR
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
Yes
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in the clinical pathway and who
would be eligible for imaging in
normal practice?
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
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Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Maubec 2007
Study characteristics
Patient sampling Design: non-comparative; prospective
Country: France
Data collection: Jan 2004 to Jun 2005
Inclusion criteria: any MM BT > 4 mm; SLNB planned if clinically node negative
Excluded if presence of distant mets (those with clinically palpable nodes were included but no
SLNB was given and no 2×2 can be estimated)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB) and primary (any)
Number patients: 25
Number primary lesions: 26
Number LNBs/metastases: 20 from 19 pts
Stage of disease: all T4; 3 clinically node positive; post surgery: AJCC stage IIB 10, 40%; IIC 4,
16%; IIIA 4, 16%; IIIB 6, 24%; IIIC in 1, 4%
Mean age: 60 years; Range: 14 to 87 years
Male: 15 (0.6%)
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Primary lesion site: trunk 8, 32%; limbs 8; 32%; head and neck 9, 36%
Breslow/Clark:mean BT 6.6 mm, range 4.8 to 12.5 mm
Ulceration: 9, 36%
Index tests PET-CT: 3D; CT (U)
Machine:Biograph, LSOSystem, SiemensMedical Systems,Germany; full-ring tomograph (ECAT
ACCEL, CPS Innovation, Knoxville, Tennesee), single-slice spiral CT (Somatom Emotion, Siemens
Medical Solutions)
Scan coverage: WB; “top of the head to the mid-thigh and included if necessary, the lower limbs”
Contrast: U
CT parameters: 110 kV; 80 mA; 5 mm
FDG: 5 MBq/kg
Breath hold: normal breathing; “no breath hold instructions”
CT used for: NR; integrated system
Reconstruction: iterative algorithm (FORE and AWOSEM) with 2 iterations, 8 subsets, and a 5-
mm full-width half maximum (FWHM) Gaussian post filter
Threshold: uptake site suspicious for malignancy or not clearly explained by a benign aetiology
(SUV estimated but does not appear to formally contribute to diagnosis)
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histology (SLNB, CLND)
Histological detail (n, %): H&E (serial); IHC (S100, HMB45, Melan A). Processed according
to EORTC melanoma group (22, 88%; 3 node positive underwent CLND; 19 had SLNB; 3 no
surgery). Histopathologist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): NR (25, 100%)
FU schedule: mean 11 months (2 to 19 months)
Reference blinding: NR
#
Target condition
Data: per pt (data per LNB but counted as per patient as 20 LNBs examined in 19 patients)
Definition: nodal mets (pre-SLNB population); Prevalence: 7/20 = 35%; 1 FN identified on FU
Definition: any mets (full population); Prevalence: 7/25 = 28% (no distant metastases identified)
Flow and timing Index to histology interval: NR; some PET performed up to 4 months after SLNB
Index to FU interval: NR
Exclusions: n = 6; 3 clinically node positive underwent CLND (all PET+ and N+); 3 did not
undergo any surgery
Comparative
Notes Other result: 3 PET +ve for distant mets; all found to to be FP
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
High
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Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: Germany
Data collection: Sep 2004 to Sep 2005
Inclusion criteria: stage III or IV cutaneous MM undergoing imaging for exclusion of widespread
disease; confirmation of local disease before surgical resection; further characterisation of abnor-
mal radiological, clinical, and laboratory (S100 protein, lactic dehydrogenase) findings; routine
melanoma surveillance of high-risk MM
Patient characteristics and set-
ting
Presentation: mixed (included exclusion of widespread disease and confirmation of local disease
before surgical resection (n = 9); characterisation of abnormal radiological, clinical, and laboratory
findings (n = 48); routine melanoma surveillance in high-risk patients (n = 7))
Number patients: 64
Number primary lesions: NR
Number LNBs/metastases: 420
Stage of disease: stage III (25, 39%); stage IV (39, 61%)
Mean age: 57.8 years; Range: 23.3 to 79.1 years
Male: 41 (64%)
Primary lesion site: NR
Breslow/Clark:mean BT 2.69 mm (0.6, 12 mm)
Ulceration: NR
Other: NaR
Index tests CT: CT (CE, 16 row multi-slice)
Machine: Hi-Rez Biograph 16 (Siemens Medical Solutions, Knoxville, TN)
Scan coverage: base of the skull to the lower legs
Contrast:Ultravist 370, ScheringGmbH,Berlin,Germany, plus 1000mlMannitol 2%as a negative
oral contrast agent before CT
CT parameters: 120 kV, 120 to 160 mAs; 5 mm (axial, with an increment of 5 mm) and 3 mm
(coronal with an increment of 2 mm)
Breath hold: CT: patients were asked to stop breathing in normal expiration during contrast-
enhanced CT scans for optimal co-registration
Threshold: based on morphological characteristics and enhancement pattern; region-specific nodal
size criteria based on measurement of the small axis diameter
#
MRI: CE; multiple phased-array; axial and coronal
Machine: Avanto, Siemens AG, Erlangen, Germany
Scan coverage: head to toe
MRI parameters: N/A
Magnet: N/A
Threshold: based onmorphological characteristics and enhancement pattern; detected lymph nodes
smaller than 10 mm but with brighter signal on T1 sequences due to the paramagnetic effect of
melanin; also were rated as suspicious
#
PET-CT: 3D; CT (CE, 16 row multi-slice)
Machine: Hi-Rez Biograph 16 (Siemens Medical Solutions, Knoxville, TN)
Scan coverage: base of the skull to the lower legs
Contrast: Ultravist 370, Schering GmbH, Berlin, Germany, plus 1000 mL Mannitol 2% as a
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negative oral contrast agent before CT
CT parameters: 120 kV, 120 to 160 mAs; 5 mm (axial, with an increment of 5 mm) and 3 mm
(coronal with an increment of 2 mm)
FDG: 370 MBq F-FDG IV 55 to 65 minutes before scanning
Breath hold: CT: patients were asked to stop breathing in normal expiration during contrast-
enhanced CT scans for optimal co-registration
CT used for: attenuation corrected and co-registered
Reconstruction: iteratively reconstructed using commercial software (eSoft; Siemens, Erlangen,
Germany)
Threshold: for PET: any focal tracer uptake exceeding normal regional tracer accumulation was
assessed as a malignant lesion. Lesions rated malignant or probably malignant were considered to
be malignant
#
Number observers: 6
Qualification (experience): 2 dermato-oncologists; 2 radiologists (2 specialists in nuclear medicine,
2 CT radiologists, and 2 MRI radiologists)
Diagnosis (single, consensus, etc.): consensus of 2 or 4
Info provided during test interpretation: clinical - aware of clinical status; other tests - blinded
to results of other imaging studies and previous tests
Target condition and reference
standard(s)
Histology/Imaging/FU
Histological detail (n, %): NR; confirmed by histology after resection; 65 (15%). Histopatholo-
gist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): PET-CT, CT, dedicated MRI, ultrasound, bone scan or radiography, tumour
markers (S100, lactic dehydrogenase), other laboratory and clinical tests (267 (64%) lesions by
imaging follow-up, 88 (21%) lesions by clinical follow-up)
FU schedule: regular 3-month interval follow-up schedule
FU duration: mean 252.5 days (range 99 to 474 days)
Reference blinding: N/A
#
Target condition
Data: per lesion
Definition: any metastases (excl brain); Prevalence: 297/420 = 71%
Definition: nodal; Prevalence: 102/158 = 65%
Definition: distant (excl local); Prevalence: 136/182 = 75%
Definition: site specific (bone); Prevalence: 35/50 = 70%
Definition: site specific (lung); Prevalence: 53/70 = 76%
Definition: site specific (local); Prevalence: 59/80 = 74%
Definition: site specific (other); Prevalence: 13/25 = 52%
Flow and timing Index to histology interval: NR
Index to FU interval: every 3 months
Exclusions: n = 36; no wbMRI (n = 25; due to metallic implants or claustrophobia (5 patients)
; refusal of a second whole body examination on the same day (17 patients) or abortion of the
examination (3 patients); no evidence of tumour spread (3 patients); lack of follow-up data for
lesion characterisation (8 patients))
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Comparative (1) Blinded to the results of other imaging studies and previous tests
(2) 24-hour to 72-hour interval
(3) prospective; consecutively referred for staging
Notes Other result: when changes in the treatment schedule were analysed for the influence of different
imaging procedures, PET/ CT performed best; 90.2% of the changes could be motivated by PET-
CT alone, 87.8% by wbMRI alone (cerebral metastases excluded), 75.6% by PET alone, and 73.
2% by CT alone
#
Text states that MRI sensitivity increased from 79.8% to 86.9% on retrospective review of images
not blinded to the other imaging tests (i.e. FNs reduced from 60 to 39)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
No
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test MRI
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
No
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applicable manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Yes
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
Low
Pfluger 2011
Study characteristics
Patient sampling Design: within-person comparison; retrospective (Prosp. database NR)
Country: Germany
Data collection: NR; 3.5-year period
Inclusion criteria: MM with regional LN metastases (NR if clinically detectable or micro-metas-
tases) undergoing PET-CT for primary staging or during follow-up. Included only lesions consid-
ered malignant by at least 1 of the 3 modalities
Patient characteristics and set-
ting
Presentation: mixed (PET-CT was done for primary staging and for follow-up)
Number patients: 50
Number primary lesions: NR
Number LNBs/metastases: 232 lesions
Stage of disease: NR
Mean age: 57 years; Range: 29 to 85 years
Male: 36 (72%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
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Index tests CT: U & CE, dual-slice, helical
Machine: Philips Gemini PET/CT System (Philips, Hamburg, Germany), consisting of a dedicated
GSO full-ring PET scanner and a dual-slice helical CT scanner
Scan coverage: WB; from the skull including the legs
Contrast: reports for unenhanced and CE using 120 mL (2.5 mL/s) of iodine-containing contrast
medium
CT parameters: U - 140 kV, 20 mAs, 5 mm; CE - 120 kV, 145 mAs, 2.5 mm
Breath hold: CT expiration protocols for shallow free breathing during the emission scan for CE
only
Threshold: unenhanced - abnormal soft tissue masses and/or enlarged LNs (diameter > 1.0 cm);
contrast enhanced - same plus degree of contrast enhancement
#
PET-CT: 3D; CT (U and CE, dual-slice, helical)
Machine: Philips Gemini PET/CT System (Philips, Hamburg, Germany), consisting of a dedicated
GSO full-ring PET scanner and a dual-slice helical CT scanner
Scan coverage: WB; from the skull including the legs
Contrast: 120 mL (2.5 mL/s) of iodine-containing contrast medium
CT parameters: 120 kV, 145 mAs, 2.5 mm
FDG: 200 MBq
Breath hold: CT expiration protocols for shallow free breathing during the emission scan
CT used for: unclear; reports side-by-side PET-CT display with spatially synchronised images
Reconstruction: NR
Threshold: non-physiologically increased uptake of FDGwith SUVmax > 2.5. CT (U and CE) and
PET alone first analysed separately, followed by combined PET-CT analysis using a side-by-side
display with spatially synchronised images to ensure the same lesion was assessed on both modalities.
For lesions with discrepant results on CT and PET, the finding of the modality with the higher
diagnostic confidence score was accepted. If results from both modalities were discrepant and had
the same diagnostic confidence score value, the lesion was judged positive.Confidence scores were
assigned as follows: (1) both observers uncertain about positive or negative findings, (2) one observer
uncertain and one observer certain and (3) both observers certain. If there were no signs of an active
tumour lesion or physiological changes in one modality, the diagnostic confidence score “3” was
assigned to this “lesion” that was suspicious for melanoma involvement in another modality
#
Number observers: 2
Qualification (experience): NR (experienced); consensus
Info provided during test interpretation: clinical - knowledge of clinical data but blinded to any
imaging. Other tests - PET-CT viewed side by side
Target condition and reference
standard(s)
Histology/FU
Histological detail (n, %): NR (41, 17.7%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): used an imaging method ’appropriate to the respective lesion (38 PET-CT scans,
8 CT scans, 4 ultrasound examinations)’ (191, 82.3%)
FU schedule: NR
FU duration: ≥ 6 months; no further detail
Reference blinding: NR
#
Target condition
Data: per pt
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Definition: any (incl subcutaneous, brain); Prevalence: 151/232 = 65%
Metastases: only FP and FN results were documented by anatomical site. FNs on CE CT included
subcutaneous (6), bone or bone marrow (5), muscular (4), LN (4), liver (3). FNs on unenhanced
PET-CT included 3 liver, 1 LN, 1 spleen (no FNs on CE, PET-CT)
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = NR; in cases of new tumour lesions during the follow-up period, these lesions were
not included in the study. The reason for not including these lesions was the fact that non-detectable
lesions in CT or 18F-FDG PET cannot be distinguished from non-existent lesions in the case of a
newly detected tumour lesion during follow-up
Comparative (1) Combined PET-CT analysis using a side-by-side display with spatially synchronised images to
ensure the same lesion was assessed on both modalities
(2) Same scanner
(3) Retrospective; all with PET-CT
Notes Other result: all 6 FPs on PET-CT would have affected TNM classification as they would have
been single metastatic lesions in otherwise metastasis-free patients. The 5 FNs on unenhanced PET-
CT did not affect TNM classification as all were identified in patients with multiple metastases
(stage M1c)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
No
Unclear High
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DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Unclear
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
No
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or testing strategies?
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
High
Prayer 1990
Study characteristics
Patient sampling Design: within-person comparison (US vs palpation); unclear
Country: Austria
Data collection: NR; 18-month period
Inclusion criteria: primary MM investigated before or after removal of the primary melanoma in
postoperative follow-up
Patient characteristics and set-
ting
Presentation: primary (LNs investigated before or after removal of the primary melanoma in post-
operative follow-up)
Number patients: 217
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: 56 years;Median age: NR; Range: 25 to 82 years
Male: 104 (48%)
Primary lesion site: HN 42, 19%; arm 61, 28%; shoulder 23, 11%; leg 91, 42%
Breslow/Clark: BT < 0.75 mm 25, 12%; 0.75 to 1.5 mm 96, 44%; 1.5 to 3.00 mm 79, 36%; > 3
mm 17, 8%
Clark level: II 93; III 89; IV 33
Ulceration: NR
Other: NR
Index tests US: B-mode
Machine: ATL ‘Ultramark 8’ with an anular array and detachable elastomere
Scan coverage: primary LNs depending on tumour localisation. Cervical (42); axillary (84); inguinal
(91)
Contrast:N/A
FNAC:N/A
Threshold: suspicious - circular and oval masses with poor echo; longitudinally configurated LNs
with echogenic eccentric hilum regarded as “enlarged reactively”
#
Number observers: 1
Qualification (experience): radiologist (NR)
Diagnosis (single, consensus, etc.): single
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Info provided during test interpretation: clinical - unclear; different clinicians for palpation
(dermatologist) and for US (radiologist); other tests - NR
Target condition and reference
standard(s)
Histology (presume LND), FU for US negative
Histological detail (n, %): NR (29, 13%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): NR (188, 87%)
FU schedule: every 2 months
FU duration: 6 months
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 29/217 = 13%
Flow and timing Index to histology interval: NR
Index to FU interval: 2 months
Exclusions: n = 0
Comparative
Notes Other result: there were no false-negative US results (i.e. melanomametastases did not occur within
the following 6 months in any of the patients classified as having no suspect regional lymph nodes)
. The smallest metastasis detected by ultrasound was 11 mm in diameter
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
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Unclear Low
DOMAIN 2: Index Test Ultrasound
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
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Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
Radzhabova 2009
Study characteristics
Patient sampling Design: non-comparative; unclear
Country: Russia
Data collection: NR
Inclusion criteria: clinically node negative MM and SLNB (based on US result)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 152
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: NR;Median age: NR; Range: NR
Male: NR (0%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests US: B-mode; sectoral and linear
Machine: NR
Scan coverage: NR
Contrast:N/A
FNAC:N/A
Threshold: test positive considered as high PSV, EDV, S/D, and PI < 1000. Mets could not be
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excluded if PSV and PI were high but EDV = 0, S/D was undetectable (PI - pulse index, PSV -
peak systolic volume, EDV - end-diastolic volume, Stuart index)
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histo (SLNB); FU
Histological detail (n, %): NR (52, 100%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): NR (0)
FU schedule: NR
FU duration: NR
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 11/52 = 21%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 100; benign on US did not get SLNB
Comparative
Notes 2 FN on SLNB identified during FU; all 100 with no SLNB reportedly disease free on FU
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
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Did the study report data on a
per patient rather than per le-
sion basis?
Yes
High Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
Yes
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e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Reinhardt 2006
Study characteristics
Patient sampling Design: within-person comparison; retrospective (Prosp. database NR)
Country: Germany
Data collection: Nov 2002 to Jun 2004
Inclusion criteria: cutaneous MM referred for PET-CT for primary staging after sentinel node
biopsy, for therapy control after chemotherapy ofmetastatic disease, for staging of clinically suspected
recurrent disease, and during follow-up within 5 years of primary treatment
Excluded if inadequate reference standard (no histology or FU < 1 year)
Patient characteristics and set-
ting
Presentation: mixed (primary staging after sentinel node biopsy (n = 75); therapy control after
chemotherapy of metastatic disease (n = 42), staging of clinically suspected recurrent disease (n =
65), during follow-up within 5 years of primary treatment (n = 68))
Number patients: 250
Number primary lesions: 250
Number LNBs/metastases: NR; 670 lesions identified
Stage of disease: initial pathology: stage I 22, 9%; stage II 88, 35%; stage III 108, 43%; stage IV
32, 13%
Mean age: 58 years ± 16 years
Male: 145 (58%)
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Primary lesion site: NR
Breslow/Clark: tumour depth ≤ 1.0 mm 29, 12%; 1.01 to 2.0 mm 68, 27%; 2.01 to 4.0 mm 66,
26%; > 4.0 mm 64, 26%
Ulceration: NR
Other: NR
Index tests CT: CE, helical, dual detector
Machine: Biograph; Siemens Medical Solutions Inc., Hoffman Estates, Illinois, USA
Scan coverage: WB; base of skull to tip of toes in 3 parts
Contrast: Peritrast-oral-GI; Kohler Chemie GmbH, Alsbach, Germany
CT parameters: 130 kV, 40 mAs, 5 mm
Breath hold: limited breath hold for CT and shallow breathing for PET
Threshold: NR; states only that accuracy was assessed according to current AJCC staging classifi-
cation
#
PET-CT: CT (CE), helical, dual detector
Machine: Biograph; Siemens Medical Solutions Inc., Hoffman Estates, Illinois, USA
Scan coverage: WB; base of skull to tip of toes in 3 parts
Contrast: Peritrast-oral-GI; Kohler Chemie GmbH, Alsbach, Germany
CT parameters: 130 kV, 40 mAs, 5 mm
FDG: 371 ± 40 MBq FDG through an anterior cubital vein
Breath hold: limited breath hold for CT and shallow breathing for PET
CT used for: attenuation correction based on re-scaling of the CT image
Reconstruction: iteratively reconstructed with attenuation correction on the basis of re-scaling of
the CT image as described elsewhere (Kinahan 2003)
#
Threshold: NR; states only that accuracy was assessed according to current AJCC staging classifi-
cation
Number observers: NR
Qualification (experience): NR; consensus by each of 2 experienced investigators
Diagnosis (single, consensus, etc.): consensus (of 2)
Info provided during test interpretation: clinical - routine clinical fashion - same clinical clinical
information about each patient; other tests - blinded to competitive imaging procedure
Target condition and reference
standard(s)
Histology (SLNB or other biopsy), FU
Histological detail (n, %): no details; 100, 40% for N-staging (including 15 with SLNB); 20, 8%
for M-staging. Histopathologist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): all available clinical information, laboratory tests, radiologic and nuclear
medicine imaging studies such as MRI, contrast-enhanced CT, ultrasound, and bone scans (250,
100%)
FU schedule: every 3 months
FU duration: ≥ 1 year
Reference blinding: blinded to standard of reference; data collection for the reference standard was
done by a physician unaware of the results of PET-CT imaging
#
Target condition
Data: per pt
Definition: any (excl brain); Prevalence: 116/250 = 46%
161Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reinhardt 2006 (Continued)
Definition: nodal; Prevalence: 78/250 = 31%
Definition: distant; Prevalence: 84/250 = 34%
Metastases: distant metastases included distant LN, lungs, and other organs (numbers per group
NR and not further differentiated by anatomical site)
Flow and timing Index to histology interval: NR
Index to FU interval: 3 months
Exclusions: n = 0
Comparative (1) Blinded to competitive imaging procedure
(2) Same scanner; CT performed 1 minute before PET
(3) All undergoing PET-CT
Notes Other result: data reported by clinical setting, for differentiation by metastatic sites (M1A toM1C)
, and for detection of visceral and non-visceral metastases, but number diseased per group is not
given such that 2×2 cannot be estimated
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Yes
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
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2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
Low
Revel 2010
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prosp. database NR)
Country: France
Data collection: Jan 2005 to Sep 2008
Inclusion criteria: clinically node negative HN MM qithpre-SLNB PET-CT
Excluded if or > 1 month between PET-CT and SLNB
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 22
Number primary lesions: 22
Number LNBs/metastases: 21
Stage of disease: stage I or II
Mean age: 60 years; Range: 18 to 88 years
Male: 16 (73%)
Primary lesion site: scalp 5, 23%; cheek 3, 14%; cervical or neck 3, 14%; atrial region (ear,mastoid,
temples) 6, 27%; palpebral or periorbital 4, 18%; frontal 1, 5%
Breslow/Clark: 4.5 mm (0.26 to 10 mm)
Ulceration: unknown
Index tests PET-CT:
Machine: Biograph 2 (Siemens1 Germany) (2003 to 2007); Biograph 6 True V imager (Siemens1)
(2007 onwards)
Scan coverage: WB; vertex to the toes
Contrast:NR
CT parameters: Biograph 2: 130 kV, 80 mAs; Biograph 6: 130 kV, 4D Care Dose; Biograph 2: 5
mm Biograph 6: 4 mm
FDG: 5.5 MBq/kg for Biograph 2; 4 MBq/kg for Biograph 6 True V; Flucis1, Schering, Cisbio
International
Breath hold: no breath hold instructions reported
CT used for: appears to be used for attenuation correction; also describes anatomical localisation
on fused images
Reconstruction: iterative reconstruction algorithms using Osem 3D, with correction of scatter and
attenuation
Threshold: any hypermetabolic focus more intense than the surrounding background, including
equivocal foci, was systematically compared with the corresponding anatomical structure on the
coupled CT, after accuracy of registration on merged PET-CT images was verified. An FN was
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considered present if a patient was SLN positive and PET-CT for the same basin was negative,
regardless of whether PET was positive for a different LNB
#
Number observers: 2
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): consensus of 2
Info provided during test interpretation: clinical - localisation of the initial tumor and standard
clinical and radiological assessment were known during image interpretation; other tests - standard
radiological assessment - known but blinded to review of PET alone
Target condition and reference
standard(s)
Histology (SLNB); FU
Histological detail (n, %): H&E; IHC (S100, HMB45, melanA antibodies) (22, 100%).
Histopathologist: NR
FNAC (n, %): N/A (N/A)
Follow-up (n, %): NR (22/22, 100%)
FU schedule: NR
FU duration: mean 17 months (range 1 to 44)
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 10/20 = 50% (excluding 2 SLNB failures (histo only reference
standard)); 12/22 = 55% (including 2 SLNB failures (histo + FU reference standard))
Flow and timing Index to histology interval: 12 days; PET undergone in month before surgery
Index to FU interval: NR
Exclusions: n = 2; 2 test fails (no SN detected; however data can be extracted excluding these)
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
167Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Revel 2010 (Continued)
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Rubaltelli 2011
Study characteristics
Patient sampling Design: NC; unclear
Country: Italy
Data collection: Jun 2008 to Dec 2009
Inclusion criteria: cutaneous MM with US of regional LNs as part of follow-up
Excluded if or malignant on B-mode US as assessed by usual US features
Patient characteristics and set-
ting
Presentation: re-staging (all undergoing postoperative follow-up designed to ensure early identifi-
cation of lymph node metastases)
Number patients: 436
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: 54 years;Median age: 58 years; Range: 27 to 81 years
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Male: full sample: 240 (52%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests US: B-mode plus contrast-enhanced US for subgroup; linear array transducers
Machine: Sonoline Elegra Scanner (Siemens Healthcare)
Scan coverage: variable: axillary lymph nodes for MM of the upper limbs, inguinal lymph nodes
for MM of the lower limbs, both axillary and inguinal lymph nodes for MM of the trunk, and
cervical and supraclavicular lymph nodes for MM of the head and neck (72 neck, 248 axillary, and
354 inguinal LNBs were examined). LNBs identified on B-mode US were examined with CE US
Contrast: sulfur hexafluoride microbubbles (SonoVue, Bracco)
FNAC: yes as ref standard
Threshold: B-mode - focal hypoechoic cortical thickening - focal area of cortex at least twice as
thick as the cortex in the remainder of the same lymph node. CE - perfusion defects corresponding
to cortical focal thickening; homogeneous intense enhancement of the cortex considered benign
#
Number observers: 1 of 3
Qualification (experience): sonologist (high)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
FNAC; histo in FNAC+, FU in some FNAC-
FNAC (n, %): no details (436, 100%)
Histological detail (n, %): no details (13, 3%). Histopathologist: NR
Follow-up (n, %): US, clinical exam (31/44 negative on CE-US, 70%)
FU schedule: NR
FU duration: 6 to 16 months (median, 10 months)
Reference blinding: NR
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 13/436 = 3%
Flow and timing Index to histology interval: US and FNAC consecutive
Index to FU interval: NR
Exclusions: n = 24; definite signs of malignancy on B-mode US
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
High Low
DOMAIN 2: Index Test Ultrasound
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Sanki 2009
Study characteristics
Patient sampling Design: non-comparative; unclear (cites ethics approval for MSLT-I and MSLT-II trials, so likely
prospective database at a minimum; text states that US findings were extracted from original reports,
however, which implies retrospective)
Country: Australia
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Data collection: Jan 2001 to Aug 2005
Inclusion criteria: SLNB; BT > 1 mm or < 1 mm with adverse histological features, such as Clark
level IV to V invasion, ulceration, or high mitotic rate
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 716
Number primary lesions: NR
Number LNBs/metastases: 871 LNBs
Stage of disease: NR
Mean age: NR;Median age: NR; Range: NR
Male: NR (0%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests US: B-mode US; linear array transducer with high-resolution small-parts probe
Machine: ATL Ultramark-9 HDI with a linear array L10-5 transducer (Advanced Technology
Laboratories Australia Pty Ltd, New South Wales, Australia); Toshiba Aplio US System (Toshiba,
Otawara-Shi, Japan) with PLT-1204AT probe (Toshiba)
Scan coverage: sites marked by nuclear medicine physician during LS
Contrast:N/A
FNAC:N/A
Threshold: reclassification of original report as suspicious, or highly probable (e.g. increased vascular
signature, rounding of the normal ovoid shape of the nodes, loss of normal hilar echoes, presence
of focal low-level subcapsular space echoes)
#
Number observers: NR
Qualification (experience): nuclear medicine physician (NR)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical - NR; other tests - result of lymphoscintigraphy
known
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (serial section); IHC (S100, HMB45); (716, 100%).
Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): NR (100% (not ref standard for US)
FU schedule: NR
FU duration: 13.5 months (mean, 18.4 months)
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 125/716 = 17% (144/871 LNBs = 17%)
Flow and timing Index to histology interval: SLN performed within 24 hours of LS and US
Index to FU interval: NR
Exclusions: n = 0
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Comparative
Notes Other result: 24 FNs on SLNB were reported; not broken down by US result
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
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Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Low
Sibon 2007
Study characteristics
Patient sampling Design: non-comparative; retrospective (prospective database with prospective re-interpretation of
US images)
Country: France
Data collection: Jan 1999 to May 2005
Inclusion criteria: SLNB; BT > 1 mm or < 1 mm with adverse histological features, such as Clark
level IV to V invasion, ulceration, or high mitotic rate
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 131
Number primary lesions: 132
Number LNBs/metastases: NR; 189 SLNs
Stage of disease: NR
Mean age: 56 years; Range: 17 to 92 years
Male: 70 (53%)
Primary lesion site: arms 18, 13.6%; legs 43, 33%; trunk 48, 32%; hands/feet 10, 8%; HN 18,
14%
Breslow/Clark:mean BT 2.60 ± 2.91 mm; ≤ 1 mm 12, 9%; 1.01 to 2.00 mm 67, 51%; 2.01 to
4.00 mm 16, 27%; unknown 1, 1%
Clark level: II 8, 6%; III 30, 23%; IV 88, 66%, V 7, 5%; unknown 1, 1%
Ulceration: 37, 28%
Other: regression 13, 10%
Index tests US: B-mode; linear transducer
Machine: Power Vision 6000 (Toshiba Medical France SA, Puteaux, France)
Scan coverage: site of the excised primary melanoma scar and followed paths of the lymphatic
vessels to lymph node area(s)
Contrast:N/A
FNAC:N/A
Threshold: stringent criteria: circular/oval hypoechoic lymph node with Solbiati index < 1.5 and
no hyperechoic hilum; non-stringent criteria included presence of 1 or 2 of stringent criteria and/
or 1 or 2 minor criteria (nodular hypoechoic focus within a lymph node with an irregular lymph
node margin)
#
Number observers: unclear how many undertook the original examination but 1 radiologist re-
viewed all images
Qualification (experience): radiologist (high)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical - NR for original interpretation or for re-inter-
pretation; other tests - radiologist reviewed original radiology reports and images
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Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): H&E (serial section); IHC (S-100 and HMB45) for H&E negative
only. Any size of tumour deposit was considered metastatic unless < 5 isolated tumour cells present
(131, 100%). Histopathologist: NR
FNAC (n, %): N/A (-)
Follow-up (n, %): NR (NR)
FU schedule: NR
FU duration: NR
Reference blinding: re-interpretaion blinded to patient outcomes
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 35/133 = 26%
Flow and timing Index to histology interval: US 24 hours before LS
Index to FU interval: NR
Exclusions: n = 0
Comparative
Notes Other result: US detected 1/24 micro-metastases < 2 mm and 2/11 macro-metastases ≥ 2 mm
(both > 5 mm) identified on SLNB
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
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DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
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Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Singh 2008
Study characteristics
Patient sampling Design: non-comparative; unclear
Country: Germany
Data collection: NR
Inclusion criteria: primary MM undergoing SLNB (all > 1 mm)
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 52
Number primary lesions: NR
Number LNBs/metastases: 67 LNBs; 111 SLNs
Stage of disease: all stage I or II
Mean age: 55 years;Median age: 61 years; Range: 17 to 76 years
Male: 36 (69%)
Primary lesion site: extremities 23, 44%; trunk 16, 31%; HN 13, 25%
Breslow/Clark:mean 3.46 mm, range 1.0 to 12.0 mm
Ulceration: NR
Other: NR
Index tests PET-CT: helical, CT (CE, dual detector)
Machine: Biograph; Siemens Medical Solutions Inc., Hoffman Estates, Illinois, USA
Scan coverage: WB; base of skull to tip of toes in 3 parts
Contrast: Peritrast-oral-GI; Kohler Chemie GmbH, Alsbach, Germany
CT parameters: 130 kV, 40 mAs, 5 mm
FDG: 370 ± 40 MBq FDG through an anterior cubital vein
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Breath hold: limited breath hold for CT and shallow breathing for PET
CT used for: attenuation correction based on re-scaling of CT image; image fusion
Reconstruction: iterative (not further detailed)
Threshold: any focal uptake more than background unless it was found to be a false positive focus
(physiological accumulation or brown fat tissue) in fusion imaging
#
Number observers: 2
Qualification (experience): 2 experienced observers assessed FDG PET-CT fusion imaging inde-
pendently; also refers to team of radiologists and nuclear physicians (experienced)
Diagnosis (single, consensus, etc.): consensus
Info provided during test interpretation: clinical - NR; other tests - PET before LS
Target condition and reference
standard(s)
Histology (SLNB)
Histological detail (n, %): “the surgeons knew the FDG-PET findings”; H&E with IHC only in
H&E negative (52, 100%). Histopathologist: NR
FNAC (n, %): N/A
Follow-up (n, %): N/A
FU schedule: N/A
FU duration: N/A
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 14/52 = 27% (BT > 4 mm 7/12 = 58%; BT ≤ 4 mm 7/40 =
17%)
Flow and timing Index to histology interval: PET before LS before SLNB
Index to FU interval: NR
Exclusions: n = 0
Comparative
Notes Other result: 2 TPs; both BT ≥ 4 mm; FPs < 4 mm
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Unclear Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
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of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Strobel 2007a
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prosp. database NR)
Country: Switzerland
Data collection: Jan 2005 to Jan 2006
Inclusion criteria: high-risk melanoma (BT > 4 mm, or Clark level III or IV, or known resected
metastases) and raised S-100 (> 0.2 µg/L) undergoing follow-up after primary treatment
Excluded if FDG PET/ CT and S-100B measurement > 2 weeks apart; treatment initiated between
PET-CT and tumour marker measurement; or systemic therapy before PET-CT investigation
Patient characteristics and set-
ting
Presentation: re-staging (all patients followed up according to updated Swiss melanoma guidelines)
Number patients: 47
Number primary lesions: 47
Number LNBs/metastases: NR
Stage of disease: NR
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Mean age: 58.4 years; Range: 20 to 83 years
Male: 20 (43%)
Primary lesion site: NR
Breslow/Clark: BT 1.02 to 15 mm; unknown in 9
Ulceration: NR
Other: NR
Index tests PET-CT: 2D PET, CT (CE, multi-slice, helical)
Machine: Discovery LS or Discovery ST (GE Health Systems, Milwaukee, WI); integrated PET
scanner (GE Advance Nxi, GE Health Systems, Milwaukee, WI) with a multi-slice helical CT
(LightSpeed Plus or Lightspeed 16; GE Health Systems, Milwaukee, WI)
Scan coverage: head to knees with scanning of lower legs for patients with primary tumours of the
lower extremities
Contrast: oral CT contrast agent given 15 minutes before injection of 18F-FDG
CT parameters: 140 kV, 40 mAs, 4.25 mm
FDG: 370 to 400 MBq
Breath hold: CT: breath holding in the normal expiratory position
CT used for: attenuation correction, fused
Reconstruction: standard iterative algorithm (OSEM)
Threshold:FDGuptake clearly greater than background and establishedmorphological CT criteria;
if a focal FDG-active lesion was detected, the exact anatomical localisation was determined on
fused PET-CT images. Lesions with 18F-FDG uptake in physiological sites or benign variants (e.
g. muscles, brown fatty tissue, pulmonary infiltrations) were determined as benign
#
Number observers: 2
Qualification (experience): nuclear radiology physicians (experienced)
Diagnosis (single, consensus, etc.): consensus of 2
Info provided during test interpretation: clinical - blinded to serum S-100B; other tests - blinded
Target condition and reference
standard(s)
Histology/cytology/imaging/FU
Histological detail (n,%):no details (29, 62%; 20 distantmets and 9 LNmets).Histopathologist:
NR
FNAC (n, %): no details (4, 8.5%)
Follow-up (n, %): MRI, PET-CT follow-up, clinical follow-up (47, 100%)
FU schedule: follow-up PET-CT examinations 3 or 6 months later; no clinical suspicion of metas-
tases arose > 6 months after the scan
FU duration: minimum 6 months (range 6 to 18 months in all patients)
Reference blinding: NR
Target condition
Data: per pt
Definition: any (incl brain, subcut); Prevalence: 39/47 = 83%; included 9 regional LN metastases
and 30 distant metastases, including 12 with lung metastases and 2 with brain metastases (not
further documented)
Flow and timing Index to histology interval: NR
Index to FU interval: 3 months
Exclusions: n = 0
Comparative
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Notes Other result: reports characteristics of those with elevated S-100 but no mets detected on imaging
Two brain metastases detected on PET-CT - elevated FDG uptake compared with normal brain
tissue or additional bleeding. Both confirmed on reference standard; method not documented;
however both showed perifocal vasogenic oedema on CT
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
183Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Strobel 2007a (Continued)
Was the test interpreted by an
experienced examiner?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
184Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Strobel 2007a (Continued)
High
Strobel 2007b
Study characteristics
Patient sampling Design: non-comparative; prospective
Country: Switzerland
Data collection: Aug 2004 to Apr 2005
Inclusion criteria: high-risk melanoma (BT > 4 mm, or Clark level III or IV, or known resected
metastases) and raised S-100 (> 0.2 µg/L) undergoing follow-up after primary treatment
Excluded if systemic therapy before PET-CT investigation
Patient characteristics and set-
ting
Presentation: unclear (NR; PET-CT for depiction or exclusion of metastases)
Number patients: 124
Number primary lesions: NR
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: 54.4 years; Range: 15 to 82 years
Male: 59 (48%)
Primary lesion site: NR
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests PET-CT: CT (CE, multi-slice, helical)
Machine: Discovery LS or Discovery ST (GE Health Systems, Milwaukee, WI)
Scan coverage: head to knees with scanning of lower legs for patients with primary tumours of
lower extremities
Contrast: oral CT contrast agent given 15 minutes before injection of 18F-FDG
CT parameters: 140 kV, 40 mAs, 4.25 mm
FDG: 350 to 400 MBq
Breath hold: CT: breath holding in normal expiratory position
CT used for: attenuation correction, fused
Reconstruction: standard iterative algorithm (OSEM)
Threshold: results presented based on co-registered PET-CT alone and on PET-CT with separate
interpretation of CT component. Mets present if detected by 1 or both readers. FDG uptake clearly
greater than background (plus establishedmorphological CT criteria for separate CT interpretation)
; if a focal FDG-active lesion was detected, the exact anatomical localisation was determined on
fused PET-CT images. Lesions with 18F-FDG uptake in physiological sites or benign variants (e.g.
muscles, brown fatty tissue, pulmonary infiltrations) were determined as benign. Semi-quantitative
analysis of FDG uptake in terms of SUVmax also conducted
#
Number observers: 2
Qualification (experience): nuclear radiology physicians (experienced (13 years and 7 years))
Diagnosis (single, consensus, etc.): consensus of 2
Info provided during test interpretation: clinical - blinded to serum S-100B; other tests - blinded
185Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Strobel 2007b (Continued)
Target condition and reference
standard(s)
Histology/cytology/imaging/FU
Histological detail (n, %): no details (20, 16.1%). Histopathologist: NR
FNAC (n, %): no details (21, 16.9%)
Follow-up (n, %): MRI, PET-CT follow-up, clinical follow-up (124, 100%, 18 D+ and 61 D-
had status confirmed by PET-CT or clinical FU; 4 D- had MRI to confirm absence of mets and
10/53 D+)
FU schedule: NR
FU duration: minimum 6 months (range 6 to 18 months in all patients)
Reference blinding: N/A
#
Target condition
Data: per pt
Definition: any (incl brain, subcut); Prevalence: 53/124 = 43%
Metastases: documented only for FNs; 7 patients with metastases were missed by PET-CT without
a dedicated CT readout, including in the lungs (4), iliac LNs (1), or gluteal subcutaneous tissue (1)
and the psoas muscle (1)
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 3; chemotherapy before PET-CT
Comparative
Notes Other result: text describes detection of brain metastases on initial PET-CT; lesion confirmed by
MRI 3 days later
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Unclear
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Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Unclear
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
Unclear
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e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
van den Brekel 1998
Study characteristics
Patient sampling Design: non-comparative; retrospective (prospective database NR)
Country:Netherlands
Data collection: Jan 1989 to May 1995
Inclusion criteria: HNMM with CT before neck dissection, including therapeutic and elective (i.
e. negative on palpation). Also included primary and recurrent
Patient characteristics and set-
ting
Presentation: mixed (interval between treatment of primary and neck dissection ranged from 0 to
8.8 years (mean 21 months))
Number patients: 26
Number primary lesions: 26
Number LNBs/metastases: NR
Stage of disease: stage III (palpable LN) 18, 69%; stageI I and II 8, 31%
Mean age: 54.5 years; Range: 55 to 83 years
Male: 18 (69%)
Primary lesion site: scalp 6, 23%; temporal 3, 12%; ear 4, 15%; anterior face 4, 15%; neck 1, 4%;
shoulder 1, 4%; upper limb 1, 4%; nasal mucosa 1, 4%; unknown primary 5, 19%
Breslow/Clark: BT 0.8 to 22 mm
Ulceration: NR
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Other: NR
Index tests CT: CE
Machine: NR
Scan coverage: neck
Contrast: IV bolus plus drip infusion of iodine contrast
CT parameters: NR; 5 mm for 24 pts; 2 mm for 2 pts (both FN)
Breath hold: NR
Threshold: presence of necrosis or axial diameter > 10 or > 11 mm
#
Number observers: 2
Qualification (experience): NR; co-authors (NR)
Diagnosis (single, consensus, etc.): unclear
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histology (LND)
Histological detail (n, %): no details (26, 100%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): N/A (0)
FU schedule: N/A
Reference blinding: CT scored blinded to histopathological outcome; NR for record review
#
Target condition
Data: per pt
Definition: nodal (neck); Prevalence: 21/26 = 81%
Flow and timing Index to histology interval: 4 weeks
Index to FU interval: N/A
Exclusions: n = 0
Comparative
Notes Other result: both FNs on CT were with 8-mm CT slice thickness
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low High
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
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of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
van Rijk 2006
Study characteristics
Patient sampling Design: within-person comparison; retrospective (prospective database NR)
Country:Netherlands
Data collection: Nov 2000 to Dec 2004
Inclusion criteria: SLNB candidates; cutaneous MM BT > 1 mm or Clark ≥ level IV
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 107
Number primary lesions: 107
Number LNBs/metastases: NR; 37 with metastases in 42 LNBs
Stage of disease: NR
Mean age: 50 years;Median age: NR; Range: 15 to 52 years
Male: 57 (53%)
Primary lesion site: HN 6, 6%; trunk 43, 40%; arm 24, 22%; leg 34, 32%
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Breslow/Clark:median BT 2.0 mm (0.6 to 12.5 mm)
Clark level: II 1, 1%; III 37, 35%; IV 55, 51%; V 9, 8%; undeterminable 5, 5%
Ulceration: 32, 30%
Index tests US and US plus FNAC: B-mode linear array
Machine:SiemensElegra (Erlangen,Germany) or aKretzVoluson730Expert (GEMedical Systems,
Zipf, Austria)
Scan coverage: NR
Contrast:N/A
FNAC: US positive (suspicious) underwent FNAC 21- or 22-gauge needle (Figure 1), aspirated
material air dried, methanol fixated and stained (May-Grunwald-Giemsa). FNAC+ underwent
CLND
Threshold:US alone suspicious - length-depth ratio < 2, conversion of a fatty hilum to a hypoechoic
hilum, substantial cortical asymmetry or focal area of low-level echoes in the subcapsular sinus of
the node, and diameter > 5 mm for LN of the neck. US + FNAC - US positive and metastases on
FNAC
#
Number observers: NR
Qualification (experience): NR (NR)
Diagnosis (single, consensus, etc.): NR
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histology (SLNB; CLND)
Histological detail (n, %): CLND not described; SLNB H&E (minimum 6 levels); IHC (S100,
HMB45). Metastases were classified as > 2 mm in diameter or < 2 mm, as 2 mm is the current
spatial resolution of ultrasonography according to Rossi et al (107, 100%). Histopathologist: NR
FNAC (n, %): N/A (22 but not as part of reference standard)
Follow-up (n, %): NR (2/107; 2% (reported only for 2 positive on FNAC))
FU schedule: NR
FU duration: NR
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 37/107 = 35%
Flow and timing Index to histology interval: 1 to several days
Index to FU interval: N/A
Exclusions: n = 0
Comparative
Notes Other result: FU of 2 FNAC positive participants is reported but no further reference to any
recurrences. A breakdown of micro- vs macro-metastases is also reported for those positive on
histology. Of the 12 TPs on ultrasound, 7 (58%) were macro-metastases and 5 (42%) were micro-
metastases; of the 25 FNs on US, 8 (32%) were macro-metastases and 17 (68%) micro-metastases
The single patient who was TP on US & FNAC had macro-metastasis; of the 36 who were FN on
US & FNAC, 14 (39%) were macro-metastases and 22 (61%) were micro-metastases
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Unclear
Unclear Unclear
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Study characteristics
Patient sampling Design: non-comparative; retrospective
Country:Netherlands
Data collection: 2003 to 2013
Inclusion criteria: stage IIIB or IIIC MM with palpable groin metastases; selected for therapeutic
combined groin dissection (CGD)
Patient characteristics and set-
ting
Presentation: mixed (discussion states: “large proportion of our patients were initially treated for
their primary tumour at other hospitals, and sometimes years prior to the current groin dissection”)
Number patients: 70
Number primary lesions: 70
Number LNBs/metastases: NR
Stage of disease: only stage III B & C
Mean age: NR;Median age: 58 years; Range: 24 to 83 years
Male: 35 (50%)
Primary lesion site: leg 58, 83%; trunk 6, 9%; arm 0, 0%; unknown 6, 9%
Breslow/Clark: BT, mm: ≤ 1.00 6 (9%); ≤ 2.00 15 (21%); 2.01 to 4.00 15 (21%); > 4.00 12
(17%); missing/unknown 22 (31%)
Ulceration: yes 11 (16%); missing/unknown 40 (57%)
Other: extracapsular invasion 14 (19%)
Index tests PET-CT: CT (U)
Machine: Gemini II; Philips, Eindhoven, The Netherlands
Scan coverage: WB; not further described
Contrast: none
CT parameters: Kv NR, 40 mAs, 2 to 5 MM
FDG: 180 to 240 MBq
Breath hold: standard acquisition protocols
CT used for: attenuation correction; fused images
Reconstruction: NR
Threshold: FDG uptake (qualitative assessment); indeterminate on PET-CT considered negative
by study authors but have been extracted as both test positive and test negative for this review
#
Number observers: 1
Qualification (experience): nuclear medicine (NR)
Diagnosis (single, consensus, etc.): single
Info provided during test interpretation: clinical - NR; other tests - NR
Target condition and reference
standard(s)
Histology (CGD)
Histological detail (n, %): no details (70, 100%). Histopathologist: originally different patholo-
gists; reports reviewed by single expert pathologist for study purposes
FNAC (n, %): N/A
Follow-up (n, %): NR (not for ref purposes)
FU schedule: NR
FU duration: median 16 months (0 to 71 months)
Reference blinding: NR
#
Target condition
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Data: per pt
Definition: nodal (superficial groin mets only); Prevalence: 59/69 = 86%
Definition: nodal (deep groin mets only); Prevalence: 24/67 = 36%
Flow and timing Index to histology interval: NR
Index to FU interval: NR
Exclusions: n = 4; missing pathology - 1 excluded from superficial LN analysis and 3 from deep
node analysis
Comparative
Notes Other result: 7/10 disease negative had diagnostic resection of a lymph node before lymph node
dissection. PET-CT is likely to have shown inflammation after this resection rather than residual
disease in the groin
Also reports 30-day complications and DFS and OS according to pathology positive/negative iliac
nodal status
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
No
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Unclear
196Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van Wissen 2016 (Continued)
dard?
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Veit-Haibach 2009
Study characteristics
Patient sampling Design: within-person comparison; prospective
Country: Germany
Data collection: NR
Inclusion criteria: any primary MM referred for PET-CT
Excluded if insufficient FU
Patient characteristics and set-
ting
Presentation: primary (any); any primary MM referred for PET-CT
Number patients: 56
Number primary lesions: 56
Number LNBs/metastases: NR
Stage of disease: presentation stage I or II 44, 79%; stage III or IV 12, 21%
Mean age: 62 years;Median age: NR; Range: 23 to 86 years
Male: 27 (48.2%)
Primary lesion site: trunk 26, 46%; upper extremities 10, 18%; lower extremity 18, 32%; HN 2,
4%
Breslow/Clark:NR
Ulceration: NR
Other: NR
Index tests CT: CE; 2-slice
Machine: Biograph Duo PET/CT System (Siemens Molecular Imaging, Hoffman Estates, IL);
integrates a dual-slice CT scanner (Somatom Emotion, Siemens Medical Solutions, Forchheim,
Germany) and a full-ring, BGO-based PET Tomograph (Siemens Molecular Imaging)
Scan coverage: WB; no further detail, just states caudocranial direction
Contrast: dual-phase injection of 140 mL of 300 mmol/mL iodinated contrast agent (90 mL at a
rate of 3 mL/s, and 50 mL at a rate of 1.5 mL/s; dual-phase used to ensure fully diagnostic (portal
venous phase) CT data in the abdomen)
CT parameters: NR
Breath hold: NR
Threshold:nodalmets - lesion size and central necrosis formalignancy; fatty hilumand calcifications
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for benign. For size: short-axis diameter threshold of 1.5 cm for jugulodigastric and pre-carinal LNs
and threshold of 1 cm for all other LNs of the neck, thorax, and abdomen. Distant mets - detection
of soft tissue masses (or focal cutaneous thickening) with contrast enhancement
#
PET-CT: full-ring CT (CE; 2-slice)
Machine: Biograph Duo PET/CT System (Siemens Molecular Imaging, Hoffman Estates, IL);
integrates a dual-slice CT scanner (Somatom Emotion, Siemens Medical Solutions, Forchheim,
Germany) and a full-ring, BGO-based PET tomograph (Siemens Molecular Imaging)
Scan coverage: WB; no further detail, just states caudocranial direction
Contrast: 140 mL of 300 mmol/mL iodinated contrast agent
CT parameters: NR
FDG: 330 to 350 MBq
Breath hold: NR
CT used for: attenuation correction
Reconstruction: reconstructed iteratively (FORE-OSEM, 2 iterations, 8 subsets, 128×128 matrix
with 5-mm gaussian smoothing)
Threshold: nodal mets - increased glucose metabolism and independent of size. Diatant mets -
qualitative + SUV; detection of soft tissue masses (or focal cutaneous thickening) with contrast
enhancement in different body compartments and in conjunction with focally increased glucose
metabolism above the surrounding tissue level on FDG PET/ CT; supported by SUVmax ≥ 1.5
for cutaneous lesions, ≥ 2.5 for other extrahepatic lesions, and ≥ 3.5 for intrahepatic lesions
#
Number observers: 2
Qualification (experience): radiologists and and nuclear medicine specialist for PET-CT (NR)
Diagnosis (single, consensus, etc.): consensus of 2
Info provided during test interpretation: clinical - provided patient-specific clinical background
(first diagnosis of melanoma, postsurgical resection status, location of resection site) but blinded
to clinical exam and histopathology of primary tumour; other tests - blinded to other imaging
procedures
Target condition and reference
standard(s)
Histology/FU
Histological detail (n, %): all patients with suspected metastases on imaging, histopathological
evaluation of at least 1 metastatic site served as the standard of reference for both N-stage and M-
stage during the clinical course. Total of 14 patients had SLNB within 4 weeks of the initial PET-
CT procedure (unclear; 14 with SLNB, 25%). Histopathologist: NR
FNAC (n, %): N/A (0)
Follow-up (n, %): imaging, tumour markers, physical examination (56, 100%)
FU schedule: NR
FU duration:mean 780 days (range 102 to 1390 days); roughly equivalent to 25.6 months (3.3 to
45.7 months)
Reference blinding: N/A
#
Target condition
Data: per pt
Definition: nodal; Prevalence: 13/56 = 23%
Definition: distant; Prevalence: 12/56 = 21% (no breakdown by anatomical site)
Metastases: 12 patients with nodal and/or distant mets reported as detected on initial staging; 4
patients with nodal mets (stage III) and 8 with distant (stage IV). PET-CT correctly classified 6/
12 and CT correctly classified 3/12. A further 6 patients had metastases detected on follow-up for
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a total of 18 patients with any metastases
Of the 8 FNs on PET-CT and 10 FNs on CT alone, 2 were micro-metastases identified by SLNB
Flow and timing Index to histology interval: 4 weeks for SLNB
Index to FU interval: NR
Exclusions: n = 0
Comparative (1) Blinded to other imaging procedures
(2) Same scanner
(3) All referred for PET-CT
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
201Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Veit-Haibach 2009 (Continued)
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Unclear
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
No
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Unclear High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
High
DOMAIN 5: Comparative
1) was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
2) Was the interval between ap-
plication of index tests
Yes
3)Was it predetermined that all
index tests should be given to all
study participants?
Yes
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Low
Voit 2014
Study characteristics
Patient sampling Design: within-person comparison (US vs US + FNAC); unclear (’prospective database’)
Country: Germany
Data collection: July 2001 to Nov 2010
Inclusion criteria: SLNB candidates; BT > 1 mm thickness or Clark IV/V, ulcerated, and/or
regressed
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 1000
Number primary lesions: 1000
Number LNBs/metastases: NR
Stage of disease: NR
Mean age: 59 years;Median age: 62 years; Range: 15 to 94 years
Male: 567 (57%)
Primary lesion site: NR
Breslow/Clark:mean BT 2.58 mm; median BT 1.57 mm. BT < 1 mm 288 29%; 1 to 2 mm 308
31%; 2 to 4mm 231 23%; > 4 mm 173 17%
Clark level: II 32, 3%; III 341, 34%; IV 554, 56%; V 54, 6%, unknown 13, 1%
Ulceration: 242, 24%
Other: regression absent 633, 63%; present 300, 30%, unknown 67, 7%
Index tests US and US + FNAC. B mode & Doppler
Machine: NR
Scan coverage: LNBs; patients first underwent a lymphoscintigraphy, which assists the ultrasono-
graphist to better focus their examination
Contrast:N/A
FNAC:US positive underwent FNAC with 26 gauge needle; smears considered adequate if around
100 cells present. Cyto results reported to the surgeon, who decided whether to proceed with SLNB
or direct to LND
Threshold: malignant on US if total loss of central echoes (LCE) or LN enlarged and balloon
shaped (BS); suspicious if peripheral perfusion present or central echo wandering towards the rim.
NR for FNAC
#
Number observers: 3
Qualification (experience): ultrasonographist (mixed; 1 expert and 2 trained but less expert)
Diagnosis (single, consensus, etc.): unclear; likely single
Info provided during test interpretation: clinical - NR; other tests - LS result available
Target condition and reference
standard(s)
Histology (SLNB or CLND)
Histological detail (n, %): H&E (serial); IHC (S100, HMB45); microanatomical location of
metastases and SN tumour burden were assessed according to Dewar and Rotterdam criteria, re-
spectively (1). Histopathologist: NR
FNAC (n, %): not as reference
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Follow-up (n, %): no details (1000; 100%)
FU schedule: NR
FU duration: mean 56 m; median 53 m; range 1 to 132 m
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 208/1000 = 21%
Flow and timing Index to histology interval: preoperative
Index to FU interval: NR
Exclusions: n = 0
Comparative
Notes Other result: 332 patients underwent FNAC; however authors report as 342 (including 10 US
malignant as FNAC positive even though no FNAC was undertaken)
There were 198 patients (20%) with recurrences and 81 melanoma-related deaths (8%) during this
follow-up (not broken down by index test)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test Ultrasound (pre-SLNB)
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpreted by an
experienced examiner?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
Unclear
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by a dermatopathologist?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Wagner 2012
Study characteristics
Patient sampling Design: non-comparative; retrospective (Prospective database NR)
Country: France
Data collection: Sep 2003 - Sep 2006
Inclusion criteria: SLNB candidates; BT ≥ 4 mm or BT > 1 mm with ulceration
Patient characteristics and set-
ting
Presentation: primary (pre-SLNB)
Number patients: 48
Number primary lesions: 48
Number LNBs/Metastases: NR
Stage of disease: stage IIA 8, 16.7%; stage IIB 19, 39.6%; stage IIC 19, 39.6%; stage NR 2, 4.2%
(both BT > 4 mm)
Mean age: NR;Median age: NR; Range: NR
Male: 25 (52%)
Primary lesion site: NR
Breslow/Clark:mean BT 7.6 mm (±4.5) (range 1.1 to 18 mm)
Ulceration: 19, 39.6%; NR 2, 4.1%
Other: NR
Index tests PET-CT. 2D; CT (NR)
Machine: Discovery ST; General Electric Healthcare, Waukesha, WI, USA)
Scan coverage: WB; not further described
Contrast:NR
CT parameters: 140 kV, 200 mA, 7.5 mm
FDG: 370 MBq (Glucotep Cyclopharma, St Beauzire, France)
Breath hold: normal breathing; “remain rested, to refrain from speaking, and to minimize swal-
lowing”
CT used for: attenuation correction and anatomical correlation
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Reconstruction: iterative OSEM (Ordered Subset Expectation Maximisation) algorithm (3 itera-
tions; 10 subsets)
Threshold: abnormally increased FDG uptake in a lymph node in the drainage territory of the
melanoma
#
Number observers: NR
Qualification (experience): nuclear medicine specialist (high)
Diagnosis (single, consensus, etc.): unclear; ’at least one’
Info provided during test interpretation: clinical - aware of all clinical findings; other tests - NR
Target condition and reference
standard(s)
Histology (SLNB, CLND)
Histological detail (n, %): NR; describes tumoural deposit < 200 Um (n = 4), > 200 Um (n = 5),
and perinodal tumoural deposit (n = 1) (43, 89.6%; 2 CLND only, 1 SLNB + CLND, 40 SLNB
only). Histopathologist: NR
FNAC (n, %): N/A
Follow-up (n, %): FU reported but only for possible distant mets and not nodal
FU schedule: NR
FU duration: minimum 12 months
Reference blinding: NR
#
Target condition
Data: per pt
Definition: nodal mets; Prevalence: 14/43 = 33%
Flow and timing Index to histology interval: before SLNB
Index to FU interval: NR
Exclusions: n = 5; SLNB not performed for technical reasons
Comparative
Notes Other result: result presented for detection of distant mets but only 1 D+ so does not meet sample
size restrictions (2×2 0, 6, 1, 41)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Does the study report results for
participants at the same point
in the clinical pathway and who
would be eligible for imaging in
normal practice?
Yes
Did the study report data on a
per patient rather than per le-
sion basis?
Yes
Low Low
DOMAIN 2: Index Test PET-CT
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the imaging test applied
and interpreted in a clinically
applicable manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpreted by an
experienced examiner?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults based on patient follow-up
interpreted without knowledge
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of the original imaging test re-
sult?
Does the study use the same
definition of disease positive as
the primary review question (i.
e. any mets) OR is it possible
to disaggregate or regroup data
such that data matching the re-
view question can be extracted?
Yes
Was histology or cytology in-
terpretation carried out by an
experienced histopathologist or
by a dermatopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
2D: two-dimensional; 3D: three-dimensional; AJCC: American Joint Committee on Cancer; AWOSEM: attenuation weighted ordered
subsets expectation maximization: BT: Breslow thickness; CE: contrast enhanced; CLND: completion lymphadenectomy; CMM:
cutaneous malignant melanoma; CT: computed tomography; DFS: disease-free survival; DW: diffusion weighted; EDV: end-
diastolic volume; EORTC: European Organisation for Research and Treatment of Cancer; FDG: fluorodeoxyglucose; FFE: fast
field echo; FLAIR: fluid attenuated inversion recovery; FN: false negative; FNAC: fine needle aspiration cytology; FORE: Fourier
rebinned; FP: false positive; FU: follow-up; FWHM: full-width half maximum; H&N: head and neck; HD: high definition; HN:
head and neck; IHC: immunohistochemistry; ITM: in-transit metastases; LN: lymph node; LNB: lymph node biopsy; LND:
lymphadenectomy; MM: malignant melanoma; MRI: magnetic resonance imaging; N/A: not applicable; NR: not reported; OS:
overall survival; OSEM: ordered subsets expectation-maximization; PD: Power Doppler; PET-CT: positron emission tomography-
computed tomography; PI: pulse index; PSV: peak systolic volume; RF: risk factors; SLNB: sentinel lymph node biopsy; SPECT:
single-photon emission computed tomography; SSM: superficial spreading melanoma; SUVmax: maximum standardised uptake
volume; T2STIR: T2-weighted short tau inversion recovery; TNM: tumour node metastasis; TP: true positive; UICC: Union for
International Cancer Control; US: ultrasound; WB: whole body.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbott 2009 Conference abstract
Abdi 1988 Inadequate reference standard
Abella-Columna 2002 Not a primary study
Acland 2000 Wrong index test
Acland 2001 Wrong index test
Agarwal 2008 Not a primary study
Ahmed 2015 Conference abstract
Akcali 2007 Inadequate reference standard
Aldridge 2010 Conference abstract
Aloia 2006 Inadequate sample size; wrong index test; inadequate reference standard
Alvarado 2007 Not a primary study
Angeles 2014 Conference abstract
Ardizzoni 1987 Inadequate sample size; wrong index test
Arrangoiz 2011 Conference abstract
Ashour 2016 Conference abstract
Bafounta 2004 Systematic review
Baker 2011 Conference abstract
Baker 2012 Conference abstract
Baker 2014 Multiple scans reported per participant
Balagula 2012 Wrong index test
Ban 2013 Conference abstract
Barsky 2014 Inadequate reference standard
Bastiaannet 2006 Not test accuracy
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Bastiaannet 2008 Conference abstract
Bastiaannet 2008a Conference abstract
Bastiaannet 2008b Conference abstract
Bastiaannet 2009a Conference abstract
Bastiaannet 2010 Conference abstract
Bastiaannet 2012 Duplicate or related publication
Beasley 2010 Conference abstract
Beasley 2012 Wrong study population
Beitollahi 2013 Conference abstract
Belhocine 2002 Inadequate sample size; wrong index test
Ben Lakhdar 2011 Conference abstract
Bernabo 2015 Conference abstract; wrong index test
Beyeler 2006 Wrong study population
Bhatia 2012 Wrong study population
Bier 2016 Inadequate reference standard
Biersack 1987 Wrong target condition; wrong index test
Bikhchandani 2014 Wrong index test
Binder 1997 Multiple scans reported per participant
Binns 2012 Conference abstract
Blend 1992 Wrong index test
Blessing 1995 Wrong index test
Blum 2000 Multiple scans reported per participant; exclusion on 2×2
Blum 2006 Wrong study population; wrong target condition
Bode 2011 Conference abstract; wrong index test
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Bohelay 2014 Conference abstract
Bohuslavizki 2000 Wrong index test; inadequate reference standard
Boni 1995 Wrong index test; inadequate reference standard
Boni 1996 Not a primary study
Boni 1996a Inadequate sample size
Borrego 2006 Wrong index test
Boy 2011 Conference abstract; wrong index test
Brady 2006 Wrong study population
Breitenbauch 2015 Inadequate sample size; inadequate reference standard
Brenner 1999 Wrong index test
Bronstein 2012 Wrong study population
Brountzos 2003 Multiple scans reported per participant
Buckle 2016 Wrong target condition; wrong index test
Bude 2004 Not a primary study
Buerke 2011 Wrong target population; inadequate reference standard
Buzaid 1993 Inadequate reference standard
Buzaid 1995 Inadequate reference standard; exclusion on 2×2
Bydder 1981 Inadequate reference standard
Cachin 2012 Conference abstract
Catalano 2010 Not a primary study
Catalano 2010a Not a primary study
Catalano 2010b Not a primary study
Catalano 2011 Systematic review
Catalano 2015 Wrong index test
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Chai 2010 Conference abstract
Cho 2005 Inadequate reference standard
Chomyn 1992 Inadequate reference standard
Clark 2006 Wrong index test
Clement 1998 Wrong target condition
Clement 2001 Wrong target condition
Clemente-Ruiz 2012 Wrong target condition; wrong index test
Cobben 2003 Wrong index test
Connell 2003 Not a primary study
Constantinidou 2008 Wrong index test
Cordova 2006 Wrong index test
Cousen 2014 Inadequate reference standard
Crippa 2000 Wrong index test
Curtis 1982 Inadequate sample size; inadequate reference standard
Dalle 2006 Not test accuracy; wrong study population
Damian 1996 Wrong index test
Danielsen 2013 Systematic review
Davidson 2011 Conference abstract
Davis 1991 Inadequate sample size
De Giorgi 2010 Wrong index test
De Rosa 2010 Not test accuracy; inadequate reference standard
DeRose 2010 Conference abstract
Dietlein 1999 Wrong target condition; wrong index test
Diodato 2015 Conference abstract
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Doiron 1981 Wrong index test; inadequate reference standard
Dresel 2003 Wrong study population
Drzezga 2012 Inadequate sample size
Eigtved 2000 Wrong index test
El-Maraghi 2008 Not a primary study; systematic review
Emmett 2012 Not a primary study
Facius 2002 Wrong index test
Fakhry 2009 Inadequate sample size; wrong index test
Falk 2007 Multiple scans reported per participant
Faries 2010 Wrong index test
Ferrandiz 2016 Not test accuracy; inadequate reference standard
Fink 2004 Wrong index test
Finkelstein 2004 Wrong index test
Fletcher 2008 Not a primary study; systematic review
Fogarty 2006 Inadequate reference standard
Fohne 2015 Conference abstract
Friedman 2004 Not a primary study; systematic review
Fuster 2003 Conference abstract
Fuster 2004 Wrong study population
Garbe 2003 Not test accuracy
Gellen 2015 Multiple scans reported per participant
Ghanem 2005 Inadequate reference standard
Giles 2014 Conference abstract; wrong index test
Ginaldi 1981 Inadequate reference standard
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Giovagnorio 2003 Wrong target condition
Gold 2007 Wrong target condition; wrong index test
Grigolato 2011 Conference abstract
Gritters 1993 Wrong index test
Gulec 2003 Inadequate reference standard
Gupta 2012 Conference abstract; inadequate sample size
Haddad 2013 Conference abstract
Haddad 2013a Inadequate sample size
Hall 2013 Not a primary study; systematic review
Harlan 2010 Inadequate sample size
Harris 2005 Wrong index test
Havenga 2003 Wrong index test
Heaston 1983 Inadequate reference standard
Herceg 2012 Conference abstract
Herceg 2013 Conference abstract
Herceg 2014 Conference abstract
Herceg 2015 Conference abstract
Heusner 2011 Inadequate sample size
Hinz 2010 Inadequate sample size
Ho Shon 2008 Not a primary study
Hofmann 2002 Multiple scans reported per participant; inadequate reference standard
Hofmann 2011 Wrong index test
Hoh 1993 Wrong target condition
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Holder 1998 Wrong index test; inadequate reference standard
Holtas 1981 Inadequate reference standard
Horn 2006 Inadequate sample size; wrong index test; inadequate reference standard
Horn 2010 Wrong index test
Hu 2009 Inadequate reference standard
Hughes 2013 Not test accuracy
Hunyadi 2002 Wrong index test; inadequate reference standard
Iscoe 1987 Inadequate sample size
Ismaheel 2016 Inadequate reference standard
Jackson 2014 Not test accuracy
Jadvar 2000 Wrong index test; inadequate reference standard
Jenicke 2001 Wrong index test; inadequate reference standard
Jennings 2009 Not a primary study
Jimenez-Requena 2010 Not a primary study; systematic review
Johnson 1997 Inadequate reference standard; exclusion on 2×2
Jones 2014 Conference abstract
Kader 2016 Wrong study population; wrong index test
Kelly 2013 Not a primary study
Knappe 2000 Wrong study population
Koskivuo 2007 Wrong index test
Krug 2000 Wrong index test; inadequate reference standard
Krug 2008 Systematic review
Krug 2009 Conference abstract; not a primary study
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Krug 2010 Not a primary study
Kuvshinoff 1997 Inadequate reference standard
Lanka 2005 Wrong study population
Laurent 2010 Duplicate or related publication (see Dellestable 2011)
Leon-Ferre 2015 Conference abstract
Lewin 2015 Conference abstract
Liszkay 2010 Conference abstract
Loffler 2003 Inadequate reference standard
Longo 2003 Wrong index test; exclusion on 2×2
Loose 1990 Multiple scans reported per participant
Macfarlane 1998 Wrong index test
Machet 2005 Multiple scans reported per participant
Majchrzak 2013 Inadequate sample size
Mayerhoefer 2012 Wrong study population
McIvor 2014 Wrong index test
McNamara 2005 Conference abstract; wrong index test
Medina-Quiroz 2010 Conference abstract
Mendenhall 2012 Not a primary study
Mercier 2001 Wrong index test
Meyers 2009 Inadequate reference standard
Meyers 2009a Wrong index test
Mijnhout 2001 Systematic review
Mijnhout 2002 Wrong index test
Miner 2011 Conference abstract
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Minn 2011 Not a primary study
Miranda 2004 Inadequate sample size
Miranda 2006 Not a primary study
Mocellin 2007 Not a primary study; systematic review
Moehrle 1999 Wrong study population
Morton 2007 Not a primary study
Mosavi 2013 Inadequate reference standard
Mottaghy 2007 Exclusion on 2×2 data
Mozzillo 2013 Wrong study population; wrong index test
Mruck 1999 Wrong index test
Muller 2006 Not a primary study
Muller-Horvat 2006 Wrong study population
Nazarian 1996 Inadequate reference standard
Nazarian 1998 Wrong study population
Niebling 2013a Conference abstract
Niebling 2013b Wrong index test; duplicate or related publication
Niederkohr 2007 Inadequate reference standard
Novikov 2012 Wrong index test
Oehr 1999 Wrong index test
Ogata 2014 Inadequate sample size
Omlor 1996 Multiple scans reported per participant
Orfaniotis 2012 Multiple scans reported per participant; inadequate reference standard
Ortega-Candil 2016 Not test accuracy; exclusion on 2×2
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Padovano 2013 Conference abstract
Panagiotou 2001 Wrong index test
Pandalai 2011 Inadequate reference standard
Paquet 2000 Wrong index test
Pecegueiro 2005 Wrong index test; inadequate reference standard
Pellacani 2006 Not test accuracy
Peric 2011 Inadequate reference standard
Petersen 2016 Systematic review
Pleiss 2007 Wrong index test; inadequate reference standard
Poduje 2012 Inadequate sample size
Poyraz 2012 Inadequate reference standard
Prakoso 2007 Wrong index test
Prakoso 2011 Inadequate reference standard
Prichard 2002 Systematic review
Punjabi 2006 Not a primary study
Querellou 2010 Multiple scans reported per participant
Querellou 2011 Not a primary study
Ramirez 2015 Conference abstract
Renna 2015 Conference abstract
Rep 2011 Conference abstract; wrong index test
Rinne 1998 Wrong index test
Roarke 2008 Inadequate sample size
Roh 2008 Wrong study population; wrong index test
Rossi 1997 Wrong target condition; inadequate sample size
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Rossi 1999 Conference abstract
Rossi 2000 Duplicate or related publication
Rossi 2003 Exclusion on 2×2 data
Rossi 2008 Not a primary study
Rudolph 2010 Conference abstract
Sadigh 2014 Systematic review
Saiag 2005 Multiple scans reported per participant
Saiag 2010 Conference abstract
Samimi 2010 Wrong study population; wrong target condition
Samples 2012 Conference abstract
Sanli 2010 Conference abstract
Santha 2011 Conference abstract
Sarandi 2008 Not a primary study
Sawyer 2009 Multiple scans reported per participant
Schafer-Hesterberg 2007 Not a primary study
Schafer-Hesterberg 2008 Not a primary study
Schauwecker 2003 Wrong index test
Scheier 2015 Conference abstract
Scheier 2016 Inadequate reference standard
Schmid-Wendtner 2002 Inadequate reference standard
Schmid-Wendtner 2003 Multiple scans reported per participant
Schmid-Wendtner 2004 Inadequate reference standard
Schule 2016 Inadequate reference standard
Schwimmer 2000 Systematic review
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Sergieva 2012 Conference abstract
Serra-Arbeloa 2015 Conference abstract; systematic review
Seshadri 2006 Inadequate sample size; wrong index test
Shah 2015 Conference abstract
Shintani 2008 Inadequate sample size
Sigmund 1985 Wrong study population
Sijan 2010 Wrong study population
Singnurkar 2016 Inadequate reference standard
Smith 2011 Conference abstract
Sofue 2012 Wrong study population
Soler 1997 Wrong index test
Solivetti 2006 Wrong target condition; inadequate reference standard
Solivetti 2012 Not test accuracy
Solivetti 2014 Wrong study population; wrong target condition
Solomon 2004 Wrong study population; wrong target condition; wrong index test
Son 2016 Inadequate sample size
Srivastava 2012 Wrong index test
Starritt 2005 Inadequate sample size
Stas 2002 Wrong index test
Stecco 2016 Wrong study population
Steinert 1998 Wrong index test; inadequate reference standard
Stoffels 2012 Exclusion on 2×2 data
Stoffels 2014 Wrong index test; inadequate reference standard
Stoffels 2016 Conference abstract; wrong target condition
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Stretch 2005 Wrong index test
Stucker 2002 Wrong study population; wrong index test
Subesinghe 2012 Conference abstract
Subesinghe 2013 Wrong study population; multiple scans reported per participant
Supriya 2014 Wrong study population
Swetter 2002 Multiple scans reported per participant
Tejera-Vaquerizo 2007 Wrong index test
Testori 2005 Exclusion on 2×2 data
Thompson 2002 Not a primary study
Thompson 2011 Conference abstract
Tomaszewski 2014 Wrong study population
Tregnaghi 1997 Multiple scans reported per participant
Tyler 2000 Wrong index test
Ulrich 2015 Conference abstract
Uren 1999 Inadequate reference standard
Valdes 2011 Wrong index test
Valk 1996 Not a primary study
Van Akkooi 2012 Conference abstract
Van Akkooi 2013 Conference abstract
Van Akkooi 2014 Conference abstract
Van Akkooi 2015 Conference abstract
Van den Broucke 2010 Conference abstract
Van der Ploeg 2007 Wrong index test
Van der Ploeg 2009a Wrong index test
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Van der Ploeg 2009b Wrong index test
Van der Ploeg 2011 Wrong study population
Vereecken 2005 Wrong index test
Vidal-Sicart 2010 Conference abstract
Voit 1999 Wrong index test; multiple scans reported per participant
Voit 2000 Wrong index test
Voit 2001 Wrong index test
Voit 2005 Conference abstract
Voit 2006 Conference abstract; duplicate or related publication
Voit 2009a Conference abstract; duplicate or related publication
Voit 2009b Conference abstract (overlaps Voit 2014)
Voit 2009c Conference abstract
Voit 2010a Not a primary study
Voit 2010b Not a primary study
Voit 2010c Duplicate or related publication
Voit 2010d Conference abstract; duplicate or related publication
Voit 2011a Conference abstract
Voit 2011b Wrong index test
Voit 2011c Conference abstract
Voit 2013 Conference abstract
Voit 2016 Wrong index test; duplicate or related publication (overlaps Voit 2014)
Von Schulthess 1998 Wrong index test
Wagner 1997 Wrong index test
Wagner 1999 Wrong index test
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Wagner 2001 Wrong index test
Wagner 2005 Wrong index test
Wagner 2009a Conference abstract
Wagner 2009b Conference abstract
Wagner 2011 Wrong index test
Wasif 2013 Conference abstract
Webb 2012 Conference abstract
Weisinger 1998 Conference abstract
Weiss 1995 Wrong index test; not test accuracy
Windorbska 2007 Inadequate reference standard
Winkler 2013 Wrong study population
Wong 2011 Conference abstract
Xing 2010 Conference abstract
Xing 2011 Systematic review
Yancovitz 2007 Inadequate reference standard
Yang 2003 Inadequate reference standard
Zender 2014 Wrong index test
Zimmermann 2000 Wrong index test
Zukauskaite 2013 Inadequate reference standard
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Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Pre-SLNB US vs Histology -
Nodal mets - per patient
11 2604
2 Pre-SLNB US (stringent US
criteria) vs Histology - Nodal
mets - per patient
1 132
3 Pre-SLNB US-FNAC - Nodal
mets - per patient
3 1164
4 Pre-SLNB PET-CT vs Histology
- Nodal mets - all SLNB - per
patient
4 170
5 Pre-SLNB PET-CT vs Histology
- Nodal mets - high risk - per
patient
3 75
6 Pre-SLNB PET-CT vs Histology
- Nodal mets - head and neck
only - per patient
1 20
7 Pre-SLNB PET-CT vs
Histology/FU - Nodal mets -
high risk - per patient
2 76
8 Pre-SLNB PET-CT vs
Histology/FU - Nodal mets
- head and neck only - per
patient
1 22
9 Any metastasis - PET-CT -
PRIMARY - Any stage (per pt)
1 37
10 Any metastasis - PET-CT -
PRIMARY - BT > 4 mm (per
pt)
2 81
11 Any metastasis - CT -
RE-STAGING - Any stage (per
pt)
1 106
12 Any metastasis - PET-CT -
RE-STAGING - Any stage (per
pt)
2 153
13 Any metastasis - PET-CT -
RE-STAGING - Stage IIIb or
less (per pt)
1 76
14 Any metastasis - PET-CT -
RE-STAGING - Stage IIIc to
IV (per pt)
1 30
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15 Any metastasis - CT- MIXED -
All data (per pt)
1 250
16 Any metastasis - PET-CT -
MIXED - All data (per pt)
6 591
17 Any metastasis - PET-CT (plus
CT) - Mixed - Any stage (per
pt)
1 124
18 Any metastasis - PET-CT -
RE-STAGING - Any stage (per
lesion)
1 139
19 Any metastasis - CT- MIXED -
All data (per lesion)
5 1770
20 Any metastasis (incl brain) -
CT (U) - MIXED (per lesion)
1 232
21 Any metastasis (incl brain) -
CT (CE) - MIXED (per lesion)
1 209
22 Any metastasis - MRI -
MIXED - All data (per lesion)
4 1556
23 Any metastasis (excl brain) -
MRI (DW + VIBE) - MIXED
(per lesion)
1 195
24 Any metastasis (incl brain) -
MRI (DW) - MIXED (per
lesion)
1 218
25 Any metastasis (incl brain) -
MRI (DW + VIBE) - MIXED
(per lesion)
1 218
26 Any metastasis (incl brain) -
MRI plus CT - MIXED (per
lesion)
1 116
27 Any metastasis - PET-CT -
MIXED - All data (per lesion)
5 1138
28 Any metastasis (incl brain) -
PET-CT (U) - MIXED (per
lesion)
1 232
29 Any metastasis (direct test
comparisons) - CT - Mixed -
Stage III/IV (per lesion)
3 1430
30 Any metastasis (direct test
comparisons) - MRI - Mixed -
Stage III/IV (per lesion)
3 1439
31 Any metastasis (direct test
comparisons) - PET-CT -
Mixed - Stage III/IV (per
lesion)
2 611
32 Nodal metastasis - US -
PRIMARY (per pt)
2 317
33 Nodal metastasis - CT -
PRIMARY (per pt)
1 56
34 Nodal metastasis - PET-CT -
PRIMARY (per pt)
1 56
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35 Nodal metastasis - US -
RE-STAGING (per pt)
1 460
36 Nodal metastasis - US plus US
(CE) - RE-STAGING (per pt)
1 460
37 Nodal metastasis - US -
MIXED (per pt)
1 79
38 Nodal metastasis - CT -
MIXED (per pt)
2 276
39 Nodal metastasis (superficial
groin) - PET-CT
(indeterminate test positive) -
MIXED (per pt)
1 69
40 Nodal metastasis (superficial
groin) - PET-CT
(indeterminate test negative) -
MIXED (per pt)
1 69
41 Nodal metastasis (deep groin)
- PET-CT (indeterminate test
positive) - MIXED (per pt)
1 67
42 Nodal metastasis (deep groin)
- PET-CT (indeterminate test
negative) - MIXED (per pt)
1 67
43 Nodal metastasis - PET-CT -
MIXED (per pt)
1 250
44 Nodal metastasis - CT -
MIXED - All data (per lesion)
4 629
45 Nodal metastasis - MRI -
MIXED - All data (per lesion)
4 630
46 Nodal metastasis - MRI (DW +
VIBE) - MIXED (per lesion)
1 53
47 Nodal metastasis - PET-CT -
MIXED - All data (per lesion)
4 288
48 Superficial nodal metastasis
- US - Mixed - stage IV (per
LNB)
1 33
49 Superficial nodal metastasis -
CT - Mixed - stage IV (per
LNB)
1 33
50 Superficial nodal metastasis -
MRI - Mixed - stage IV (per
LNB)
1 33
51 Superficial nodal metastasis -
MRI (DW + VIBE) - Mixed -
Stage IV (per lesion)
1 33
52 Superficial nodal metastasis -
PET-CT - Mixed - stage IV
(per LNB)
1 33
53 Distant metastasis - CT -
PRIMARY (per pt)
1 56
54 Distant metastasis - PET-CT -
PRIMARY (per pt)
2 112
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55 Distant metastasis - CT -
MIXED - All data (per pt)
2 501
56 Distant metastasis - PET-CT -
MIXED - All data (per pt)
1 250
57 Distant metastasis - CT -
Mixed - All data (per lesion)
4 920
58 Distant metastasis - MRI -
Mixed - All data (per lesion)
4 926
59 Distant metastasis - PET-CT -
Mixed - All data (per lesion)
4 618
60 Distant metastasis (excl brain) -
MRI (DW + VIBE) - Mixed -
stage III/IV (per lesion)
1 142
61 Distant metastasis (incl brain)
- MRI (DW) - Mixed - stage
III/IV (per lesion)
1 165
62 Distant metastasis (incl brain) -
MRI (DW + VIBE) - Mixed -
stage III/IV (per lesion)
1 165
63 Bone metastasis - CT- MIXED
- All data (per lesion)
3 97
64 Bone metastasis - MRI -
MIXED - All data (per lesion)
3 99
65 Bone metastasis - MRI (DW +
VIBE) - MIXED - All data (per
lesion)
1 35
66 Bone metastasis - PET-CT -
MIXED - All data (per lesion)
4 133
67 Liver metastasis - CT- MIXED
- All data (per lesion)
4 150
68 Liver metastasis - MRI -
MIXED - All data (per lesion)
4 155
69 Liver metastasis - MRI (DW +
VIBE) - Mixed - stage III/IV
(per lesion)
1 27
70 Liver metastasis - PET-CT -
MIXED - All data (per lesion)
4 94
71 Lung metastasis - CT - MIXED
- All data (per lesion)
4 325
72 Lung metastasis - MRI -
MIXED - All data (per lesion)
4 325
73 Lung metastasis - MRI (DW +
VIBE) - Mixed - stage III/IV
(per lesion)
1 45
74 Lung metastasis - PET-CT -
MIXED - All data (per lesion)
4 155
75 Soft tissue metastasis - PET-CT
- MIXED (per lesion)
1 25
76 Local/subcutaneous metastasis
- CT - MIXED (per lesion)
3 139
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77 Local/subcutaneous metastasis
- MRI - MIXED (per lesion)
3 148
78 Local/subcutaneous metastasis
- MRI (DW + VIBE) - MIXED
(per lesion)
1 22
79 Local/subcutaneous metastasis -
PET-CT - MIXED (per lesion)
3 102
80 Brain metastasis - CT- MIXED
- All data (per lesion)
1 20
81 Brain metastasis - MRI (DW) -
MIXED - All data (per lesion)
1 20
82 Brain metastasis - MRI (DW +
VIBE) - MIXED - All data (per
lesion)
1 20
83 Brain metastasis - PET-CT -
MIXED - All data (per lesion)
1 9
93 ’Other’ metastasis - CT - Mixed
- Any stage (per lesion)
1 26
94 ’Other’ metastasis - MRI -
Mixed - Any stage (per lesion)
1 21
95 ’Other’ metastasis - PET-CT -
Mixed - Any stage (per lesion)
1 26
96 ’Other’ metastasis - CT - Mixed
- stage III/IV (per lesion)
2 160
97 ’Other’ metastasis - MRI -
Mixed - stage III/IV (per
lesion)
2 160
98 ’Other’ metastasis - PET-CT
- Mixed - stage III/IV (per
lesion)
1 25
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Test 1. Pre-SLNB US vs Histology - Nodal mets - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 1 Pre-SLNB US vs Histology - Nodal mets - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chai 2012 21 35 43 218 0.33 [ 0.22, 0.46 ] 0.86 [ 0.81, 0.90 ]
Hafner 2004 0 9 23 65 0.0 [ 0.0, 0.15 ] 0.88 [ 0.78, 0.94 ]
Hinz 2011 2 0 6 73 0.25 [ 0.03, 0.65 ] 1.00 [ 0.95, 1.00 ]
Hinz 2013 2 0 10 8 0.17 [ 0.02, 0.48 ] 1.00 [ 0.63, 1.00 ]
Hocevar 2004 10 7 4 36 0.71 [ 0.42, 0.92 ] 0.84 [ 0.69, 0.93 ]
Kunte 2009 2 0 4 19 0.33 [ 0.04, 0.78 ] 1.00 [ 0.82, 1.00 ]
Radzhabova 2009 11 0 0 41 1.00 [ 0.72, 1.00 ] 1.00 [ 0.91, 1.00 ]
Sanki 2009 28 19 97 572 0.22 [ 0.15, 0.31 ] 0.97 [ 0.95, 0.98 ]
Sibon 2007 7 10 27 88 0.21 [ 0.09, 0.38 ] 0.90 [ 0.82, 0.95 ]
van Rijk 2006 12 10 25 60 0.32 [ 0.18, 0.50 ] 0.86 [ 0.75, 0.93 ]
Voit 2014 148 210 60 582 0.71 [ 0.64, 0.77 ] 0.73 [ 0.70, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Pre-SLNB US (stringent US criteria) vs Histology - Nodal mets - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 2 Pre-SLNB US (stringent US criteria) vs Histology - Nodal mets - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Sibon 2007 3 4 32 93 0.09 [ 0.02, 0.23 ] 0.96 [ 0.90, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Pre-SLNB US-FNAC - Nodal mets - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 3 Pre-SLNB US-FNAC - Nodal mets - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hocevar 2004 3 0 11 43 0.21 [ 0.05, 0.51 ] 1.00 [ 0.92, 1.00 ]
van Rijk 2006 1 1 36 69 0.03 [ 0.00, 0.14 ] 0.99 [ 0.92, 1.00 ]
Voit 2014 107 1 101 791 0.51 [ 0.44, 0.58 ] 1.00 [ 0.99, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Pre-SLNB PET-CT vs Histology - Nodal mets - all SLNB - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 4 Pre-SLNB PET-CT vs Histology - Nodal mets - all SLNB - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hinz 2013 0 0 12 8 0.0 [ 0.0, 0.26 ] 1.00 [ 0.63, 1.00 ]
Kell 2007 2 3 7 25 0.22 [ 0.03, 0.60 ] 0.89 [ 0.72, 0.98 ]
Klode 2010 1 0 13 47 0.07 [ 0.00, 0.34 ] 1.00 [ 0.92, 1.00 ]
Singh 2008 2 2 12 36 0.14 [ 0.02, 0.43 ] 0.95 [ 0.82, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Pre-SLNB PET-CT vs Histology - Nodal mets - high risk - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 5 Pre-SLNB PET-CT vs Histology - Nodal mets - high risk - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Maubec 2007 0 1 7 12 0.0 [ 0.0, 0.41 ] 0.92 [ 0.64, 1.00 ]
Singh 2008 2 0 5 5 0.29 [ 0.04, 0.71 ] 1.00 [ 0.48, 1.00 ]
Wagner 2012 6 0 8 29 0.43 [ 0.18, 0.71 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Pre-SLNB PET-CT vs Histology - Nodal mets - head and neck only - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 6 Pre-SLNB PET-CT vs Histology - Nodal mets - head and neck only - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Revel 2010 2 0 8 10 0.20 [ 0.03, 0.56 ] 1.00 [ 0.69, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Pre-SLNB PET-CT vs Histology/FU - Nodal mets - high risk - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 7 Pre-SLNB PET-CT vs Histology/FU - Nodal mets - high risk - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arrangoiz 2012 12 3 17 24 0.41 [ 0.24, 0.61 ] 0.89 [ 0.71, 0.98 ]
Maubec 2007 0 1 8 11 0.0 [ 0.0, 0.37 ] 0.92 [ 0.62, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Pre-SLNB PET-CT vs Histology/FU - Nodal mets - head and neck only - per patient.
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 8 Pre-SLNB PET-CT vs Histology/FU - Nodal mets - head and neck only - per patient
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Revel 2010 2 0 10 10 0.17 [ 0.02, 0.48 ] 1.00 [ 0.69, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Any metastasis - PET-CT - PRIMARY - Any stage (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 9 Any metastasis - PET-CT - PRIMARY - Any stage (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kang 2011 8 11 1 17 0.89 [ 0.52, 1.00 ] 0.61 [ 0.41, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. Any metastasis - PET-CT - PRIMARY - BT > 4 mm (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 10 Any metastasis - PET-CT - PRIMARY - BT > 4 mm (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arrangoiz 2012 15 3 17 21 0.47 [ 0.29, 0.65 ] 0.88 [ 0.68, 0.97 ]
Maubec 2007 3 4 7 11 0.30 [ 0.07, 0.65 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Any metastasis - CT - RE-STAGING - Any stage (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 11 Any metastasis - CT - RE-STAGING - Any stage (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Iagaru 2007 38 3 18 47 0.68 [ 0.54, 0.80 ] 0.94 [ 0.83, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
234Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 12. Any metastasis - PET-CT - RE-STAGING - Any stage (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 12 Any metastasis - PET-CT - RE-STAGING - Any stage (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Iagaru 2007 50 6 6 44 0.89 [ 0.78, 0.96 ] 0.88 [ 0.76, 0.95 ]
Strobel 2007a 38 0 1 8 0.97 [ 0.87, 1.00 ] 1.00 [ 0.63, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Any metastasis - PET-CT - RE-STAGING - Stage IIIb or less (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 13 Any metastasis - PET-CT - RE-STAGING - Stage IIIb or less (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Iagaru 2007 32 4 6 34 0.84 [ 0.69, 0.94 ] 0.89 [ 0.75, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Any metastasis - PET-CT - RE-STAGING - Stage IIIc to IV (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 14 Any metastasis - PET-CT - RE-STAGING - Stage IIIc to IV (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Iagaru 2007 18 2 0 10 1.00 [ 0.81, 1.00 ] 0.83 [ 0.52, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. Any metastasis - CT- MIXED - All data (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 15 Any metastasis - CT- MIXED - All data (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Reinhardt 2006 94 31 22 103 0.81 [ 0.73, 0.88 ] 0.77 [ 0.69, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Any metastasis - PET-CT - MIXED - All data (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 16 Any metastasis - PET-CT - MIXED - All data (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Abbott 2011 5 1 2 26 0.71 [ 0.29, 0.96 ] 0.96 [ 0.81, 1.00 ]
Aukema 2010a 23 4 0 19 1.00 [ 0.85, 1.00 ] 0.83 [ 0.61, 0.95 ]
Aukema 2010b 26 1 4 39 0.87 [ 0.69, 0.96 ] 0.98 [ 0.87, 1.00 ]
Cachin 2014 34 8 5 20 0.87 [ 0.73, 0.96 ] 0.71 [ 0.51, 0.87 ]
Reinhardt 2006 112 3 4 131 0.97 [ 0.91, 0.99 ] 0.98 [ 0.94, 1.00 ]
Strobel 2007b 45 3 8 68 0.85 [ 0.72, 0.93 ] 0.96 [ 0.88, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. Any metastasis - PET-CT (plus CT) - Mixed - Any stage (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 17 Any metastasis - PET-CT (plus CT) - Mixed - Any stage (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Strobel 2007b 52 4 1 67 0.98 [ 0.90, 1.00 ] 0.94 [ 0.86, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. Any metastasis - PET-CT - RE-STAGING - Any stage (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 18 Any metastasis - PET-CT - RE-STAGING - Any stage (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Iagaru 2007 78 8 9 44 0.90 [ 0.81, 0.95 ] 0.85 [ 0.72, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. Any metastasis - CT- MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 19 Any metastasis - CT- MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 53 2 13 40 0.80 [ 0.69, 0.89 ] 0.95 [ 0.84, 0.99 ]
Hausmann 2011 356 186 99 183 0.78 [ 0.74, 0.82 ] 0.50 [ 0.44, 0.55 ]
Jouvet 2014 84 28 11 63 0.88 [ 0.80, 0.94 ] 0.69 [ 0.59, 0.78 ]
Pfannenberg 2007 229 37 68 86 0.77 [ 0.72, 0.82 ] 0.70 [ 0.61, 0.78 ]
Pfluger 2011 129 30 22 51 0.85 [ 0.79, 0.91 ] 0.63 [ 0.52, 0.73 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. Any metastasis (incl brain) - CT (U) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 20 Any metastasis (incl brain) - CT (U) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pfluger 2011 93 39 58 42 0.62 [ 0.53, 0.69 ] 0.52 [ 0.40, 0.63 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. Any metastasis (incl brain) - CT (CE) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 21 Any metastasis (incl brain) - CT (CE) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 103 28 12 66 0.90 [ 0.82, 0.94 ] 0.70 [ 0.60, 0.79 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Any metastasis - MRI - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 22 Any metastasis - MRI - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 58 2 12 45 0.83 [ 0.72, 0.91 ] 0.96 [ 0.85, 0.99 ]
Hausmann 2011 334 60 121 309 0.73 [ 0.69, 0.77 ] 0.84 [ 0.80, 0.87 ]
Jouvet 2014 72 25 33 65 0.69 [ 0.59, 0.77 ] 0.72 [ 0.62, 0.81 ]
Pfannenberg 2007 237 29 60 94 0.80 [ 0.75, 0.84 ] 0.76 [ 0.68, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Any metastasis (excl brain) - MRI (DW + VIBE) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 23 Any metastasis (excl brain) - MRI (DW + VIBE) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 85 12 20 78 0.81 [ 0.72, 0.88 ] 0.87 [ 0.78, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Any metastasis (incl brain) - MRI (DW) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 24 Any metastasis (incl brain) - MRI (DW) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 85 25 40 68 0.68 [ 0.59, 0.76 ] 0.73 [ 0.63, 0.82 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Any metastasis (incl brain) - MRI (DW + VIBE) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 25 Any metastasis (incl brain) - MRI (DW + VIBE) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 105 12 20 81 0.84 [ 0.76, 0.90 ] 0.87 [ 0.79, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. Any metastasis (incl brain) - MRI plus CT - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 26 Any metastasis (incl brain) - MRI plus CT - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 64 2 6 44 0.91 [ 0.82, 0.97 ] 0.96 [ 0.85, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Any metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 27 Any metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 68 42 17 49 0.80 [ 0.70, 0.88 ] 0.54 [ 0.43, 0.64 ]
Dellestable 2011 53 5 19 42 0.74 [ 0.62, 0.83 ] 0.89 [ 0.77, 0.96 ]
Jouvet 2014 83 6 21 81 0.80 [ 0.71, 0.87 ] 0.93 [ 0.86, 0.97 ]
Pfannenberg 2007 269 28 28 95 0.91 [ 0.87, 0.94 ] 0.77 [ 0.69, 0.84 ]
Pfluger 2011 151 6 0 75 1.00 [ 0.98, 1.00 ] 0.93 [ 0.85, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
241Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 28. Any metastasis (incl brain) - PET-CT (U) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 28 Any metastasis (incl brain) - PET-CT (U) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pfluger 2011 146 6 5 75 0.97 [ 0.92, 0.99 ] 0.93 [ 0.85, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Any metastasis (direct test comparisons) - CT - Mixed - Stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 29 Any metastasis (direct test comparisons) - CT - Mixed - Stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 356 183 99 186 0.78 [ 0.74, 0.82 ] 0.50 [ 0.45, 0.56 ]
Jouvet 2014 84 28 11 63 0.88 [ 0.80, 0.94 ] 0.69 [ 0.59, 0.78 ]
Pfannenberg 2007 229 37 68 86 0.77 [ 0.72, 0.82 ] 0.70 [ 0.61, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 30. Any metastasis (direct test comparisons) - MRI - Mixed - Stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 30 Any metastasis (direct test comparisons) - MRI - Mixed - Stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 334 60 121 309 0.73 [ 0.69, 0.77 ] 0.84 [ 0.80, 0.87 ]
Jouvet 2014 72 25 33 65 0.69 [ 0.59, 0.77 ] 0.72 [ 0.62, 0.81 ]
Pfannenberg 2007 237 29 60 94 0.80 [ 0.75, 0.84 ] 0.76 [ 0.68, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 31. Any metastasis (direct test comparisons) - PET-CT - Mixed - Stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 31 Any metastasis (direct test comparisons) - PET-CT - Mixed - Stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 83 6 21 81 0.80 [ 0.71, 0.87 ] 0.93 [ 0.86, 0.97 ]
Pfannenberg 2007 269 28 28 95 0.91 [ 0.87, 0.94 ] 0.77 [ 0.69, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 32. Nodal metastasis - US - PRIMARY (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 32 Nodal metastasis - US - PRIMARY (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hafner 2004 2 9 24 65 0.08 [ 0.01, 0.25 ] 0.88 [ 0.78, 0.94 ]
Prayer 1990 29 6 0 182 1.00 [ 0.88, 1.00 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 33. Nodal metastasis - CT - PRIMARY (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 33 Nodal metastasis - CT - PRIMARY (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Veit-Haibach 2009 3 0 10 43 0.23 [ 0.05, 0.54 ] 1.00 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. Nodal metastasis - PET-CT - PRIMARY (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 34 Nodal metastasis - PET-CT - PRIMARY (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Veit-Haibach 2009 5 0 8 43 0.38 [ 0.14, 0.68 ] 1.00 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 35. Nodal metastasis - US - RE-STAGING (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 35 Nodal metastasis - US - RE-STAGING (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rubaltelli 2011 37 31 0 392 1.00 [ 0.91, 1.00 ] 0.93 [ 0.90, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 36. Nodal metastasis - US plus US (CE) - RE-STAGING (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 36 Nodal metastasis - US plus US (CE) - RE-STAGING (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Rubaltelli 2011 37 2 0 421 1.00 [ 0.91, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 37. Nodal metastasis - US - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 37 Nodal metastasis - US - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Klebl 2003 17 21 0 41 1.00 [ 0.80, 1.00 ] 0.66 [ 0.53, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 38. Nodal metastasis - CT - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 38 Nodal metastasis - CT - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Reinhardt 2006 66 22 12 150 0.85 [ 0.75, 0.92 ] 0.87 [ 0.81, 0.92 ]
van den Brekel 1998 18 0 3 5 0.86 [ 0.64, 0.97 ] 1.00 [ 0.48, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Nodal metastasis (superficial groin) - PET-CT (indeterminate test positive) - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 39 Nodal metastasis (superficial groin) - PET-CT (indeterminate test positive) - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
van Wissen 2016 58 5 1 5 0.98 [ 0.91, 1.00 ] 0.50 [ 0.19, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 40. Nodal metastasis (superficial groin) - PET-CT (indeterminate test negative) - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 40 Nodal metastasis (superficial groin) - PET-CT (indeterminate test negative) - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
van Wissen 2016 57 5 2 5 0.97 [ 0.88, 1.00 ] 0.50 [ 0.19, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 41. Nodal metastasis (deep groin) - PET-CT (indeterminate test positive) - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 41 Nodal metastasis (deep groin) - PET-CT (indeterminate test positive) - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
van Wissen 2016 18 8 6 35 0.75 [ 0.53, 0.90 ] 0.81 [ 0.67, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 42. Nodal metastasis (deep groin) - PET-CT (indeterminate test negative) - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 42 Nodal metastasis (deep groin) - PET-CT (indeterminate test negative) - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
van Wissen 2016 16 4 8 39 0.67 [ 0.45, 0.84 ] 0.91 [ 0.78, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 43. Nodal metastasis - PET-CT - MIXED (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 43 Nodal metastasis - PET-CT - MIXED (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Reinhardt 2006 74 0 4 172 0.95 [ 0.87, 0.99 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 44. Nodal metastasis - CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 44 Nodal metastasis - CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 29 0 2 8 0.94 [ 0.79, 0.99 ] 1.00 [ 0.63, 1.00 ]
Hausmann 2011 166 133 26 54 0.86 [ 0.81, 0.91 ] 0.29 [ 0.22, 0.36 ]
Jouvet 2014 22 11 1 19 0.96 [ 0.78, 1.00 ] 0.63 [ 0.44, 0.80 ]
Pfannenberg 2007 78 13 24 43 0.76 [ 0.67, 0.84 ] 0.77 [ 0.64, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Nodal metastasis - MRI - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 45 Nodal metastasis - MRI - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 28 1 3 8 0.90 [ 0.74, 0.98 ] 0.89 [ 0.52, 1.00 ]
Hausmann 2011 157 43 35 144 0.82 [ 0.76, 0.87 ] 0.77 [ 0.70, 0.83 ]
Jouvet 2014 22 6 1 24 0.96 [ 0.78, 1.00 ] 0.80 [ 0.61, 0.92 ]
Pfannenberg 2007 67 13 35 43 0.66 [ 0.56, 0.75 ] 0.77 [ 0.64, 0.87 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
249Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 46. Nodal metastasis - MRI (DW + VIBE) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 46 Nodal metastasis - MRI (DW + VIBE) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 20 0 3 30 0.87 [ 0.66, 0.97 ] 1.00 [ 0.88, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Nodal metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 47 Nodal metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 17 12 3 7 0.85 [ 0.62, 0.97 ] 0.37 [ 0.16, 0.62 ]
Dellestable 2011 26 0 5 7 0.84 [ 0.66, 0.95 ] 1.00 [ 0.59, 1.00 ]
Jouvet 2014 22 1 1 29 0.96 [ 0.78, 1.00 ] 0.97 [ 0.83, 1.00 ]
Pfannenberg 2007 87 6 15 50 0.85 [ 0.77, 0.92 ] 0.89 [ 0.78, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Superficial nodal metastasis - US - Mixed - stage IV (per LNB).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 48 Superficial nodal metastasis - US - Mixed - stage IV (per LNB)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 0 0 20 1.00 [ 0.75, 1.00 ] 1.00 [ 0.83, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 49. Superficial nodal metastasis - CT - Mixed - stage IV (per LNB).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 49 Superficial nodal metastasis - CT - Mixed - stage IV (per LNB)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 6 0 14 1.00 [ 0.75, 1.00 ] 0.70 [ 0.46, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 50. Superficial nodal metastasis - MRI - Mixed - stage IV (per LNB).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 50 Superficial nodal metastasis - MRI - Mixed - stage IV (per LNB)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 4 0 16 1.00 [ 0.75, 1.00 ] 0.80 [ 0.56, 0.94 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 51. Superficial nodal metastasis - MRI (DW + VIBE) - Mixed - Stage IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 51 Superficial nodal metastasis - MRI (DW + VIBE) - Mixed - Stage IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 1 0 19 1.00 [ 0.75, 1.00 ] 0.95 [ 0.75, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 52. Superficial nodal metastasis - PET-CT - Mixed - stage IV (per LNB).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 52 Superficial nodal metastasis - PET-CT - Mixed - stage IV (per LNB)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 1 0 19 1.00 [ 0.75, 1.00 ] 0.95 [ 0.75, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 53. Distant metastasis - CT - PRIMARY (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 53 Distant metastasis - CT - PRIMARY (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Veit-Haibach 2009 3 3 9 41 0.25 [ 0.05, 0.57 ] 0.93 [ 0.81, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 54. Distant metastasis - PET-CT - PRIMARY (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 54 Distant metastasis - PET-CT - PRIMARY (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arrangoiz 2012 5 3 0 48 1.00 [ 0.48, 1.00 ] 0.94 [ 0.84, 0.99 ]
Veit-Haibach 2009 5 3 7 41 0.42 [ 0.15, 0.72 ] 0.93 [ 0.81, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 55. Distant metastasis - CT - MIXED - All data (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 55 Distant metastasis - CT - MIXED - All data (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bastiaannet 2009 61 11 17 162 0.78 [ 0.67, 0.87 ] 0.94 [ 0.89, 0.97 ]
Reinhardt 2006 62 20 22 146 0.74 [ 0.63, 0.83 ] 0.88 [ 0.82, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 56. Distant metastasis - PET-CT - MIXED - All data (per pt).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 56 Distant metastasis - PET-CT - MIXED - All data (per pt)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Reinhardt 2006 83 4 1 162 0.99 [ 0.94, 1.00 ] 0.98 [ 0.94, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 57. Distant metastasis - CT - Mixed - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 57 Distant metastasis - CT - Mixed - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 24 5 17 34 0.59 [ 0.42, 0.74 ] 0.87 [ 0.73, 0.96 ]
Hausmann 2011 186 53 77 129 0.71 [ 0.65, 0.76 ] 0.71 [ 0.64, 0.77 ]
Jouvet 2014 62 17 10 44 0.86 [ 0.76, 0.93 ] 0.72 [ 0.59, 0.83 ]
Pfannenberg 2007 151 24 44 43 0.77 [ 0.71, 0.83 ] 0.64 [ 0.52, 0.76 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 58. Distant metastasis - MRI - Mixed - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 58 Distant metastasis - MRI - Mixed - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 30 1 9 37 0.77 [ 0.61, 0.89 ] 0.97 [ 0.86, 1.00 ]
Hausmann 2011 177 17 86 165 0.67 [ 0.61, 0.73 ] 0.91 [ 0.85, 0.94 ]
Jouvet 2014 50 19 32 41 0.61 [ 0.50, 0.72 ] 0.68 [ 0.55, 0.80 ]
Pfannenberg 2007 170 16 25 51 0.87 [ 0.82, 0.92 ] 0.76 [ 0.64, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 59. Distant metastasis - PET-CT - Mixed - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 59 Distant metastasis - PET-CT - Mixed - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 51 30 14 42 0.78 [ 0.67, 0.88 ] 0.58 [ 0.46, 0.70 ]
Dellestable 2011 27 5 14 35 0.66 [ 0.49, 0.80 ] 0.88 [ 0.73, 0.96 ]
Jouvet 2014 61 5 20 52 0.75 [ 0.64, 0.84 ] 0.91 [ 0.81, 0.97 ]
Pfannenberg 2007 182 22 13 45 0.93 [ 0.89, 0.96 ] 0.67 [ 0.55, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 60. Distant metastasis (excl brain) - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 60 Distant metastasis (excl brain) - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 65 12 17 48 0.79 [ 0.69, 0.87 ] 0.80 [ 0.68, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 61. Distant metastasis (incl brain) - MRI (DW) - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 61 Distant metastasis (incl brain) - MRI (DW) - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 63 19 39 44 0.62 [ 0.52, 0.71 ] 0.70 [ 0.57, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 62. Distant metastasis (incl brain) - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 62 Distant metastasis (incl brain) - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 85 12 17 51 0.83 [ 0.75, 0.90 ] 0.81 [ 0.69, 0.90 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 63. Bone metastasis - CT- MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 63 Bone metastasis - CT- MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 7 0 7 0 0.50 [ 0.23, 0.77 ] 0.0 [ 0.0, 0.0 ]
Jouvet 2014 10 0 5 18 0.67 [ 0.38, 0.88 ] 1.00 [ 0.81, 1.00 ]
Pfannenberg 2007 22 3 13 12 0.63 [ 0.45, 0.79 ] 0.80 [ 0.52, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 64. Bone metastasis - MRI - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 64 Bone metastasis - MRI - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 13 0 1 0 0.93 [ 0.66, 1.00 ] 0.0 [ 0.0, 0.0 ]
Jouvet 2014 16 10 0 9 1.00 [ 0.79, 1.00 ] 0.47 [ 0.24, 0.71 ]
Pfannenberg 2007 35 4 0 11 1.00 [ 0.90, 1.00 ] 0.73 [ 0.45, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 65. Bone metastasis - MRI (DW + VIBE) - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 65 Bone metastasis - MRI (DW + VIBE) - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 16 5 0 14 1.00 [ 0.79, 1.00 ] 0.74 [ 0.49, 0.91 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 66. Bone metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 66 Bone metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 12 13 2 7 0.86 [ 0.57, 0.98 ] 0.35 [ 0.15, 0.59 ]
Dellestable 2011 10 0 4 0 0.71 [ 0.42, 0.92 ] 0.0 [ 0.0, 0.0 ]
Jouvet 2014 14 1 2 18 0.88 [ 0.62, 0.98 ] 0.95 [ 0.74, 1.00 ]
Pfannenberg 2007 32 3 3 12 0.91 [ 0.77, 0.98 ] 0.80 [ 0.52, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 67. Liver metastasis - CT- MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 67 Liver metastasis - CT- MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 2 0 2 17 0.50 [ 0.07, 0.93 ] 1.00 [ 0.80, 1.00 ]
Hausmann 2011 13 17 20 17 0.39 [ 0.23, 0.58 ] 0.50 [ 0.32, 0.68 ]
Jouvet 2014 10 2 2 13 0.83 [ 0.52, 0.98 ] 0.87 [ 0.60, 0.98 ]
Pfannenberg 2007 28 0 7 0 0.80 [ 0.63, 0.92 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 68. Liver metastasis - MRI - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 68 Liver metastasis - MRI - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 4 0 0 22 1.00 [ 0.40, 1.00 ] 1.00 [ 0.85, 1.00 ]
Hausmann 2011 28 0 5 34 0.85 [ 0.68, 0.95 ] 1.00 [ 0.90, 1.00 ]
Jouvet 2014 11 5 1 10 0.92 [ 0.62, 1.00 ] 0.67 [ 0.38, 0.88 ]
Pfannenberg 2007 35 0 0 0 1.00 [ 0.90, 1.00 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 69. Liver metastasis - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 69 Liver metastasis - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 12 1 0 14 1.00 [ 0.74, 1.00 ] 0.93 [ 0.68, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 70. Liver metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 70 Liver metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 0 2 0 5 0.0 [ 0.0, 0.0 ] 0.71 [ 0.29, 0.96 ]
Dellestable 2011 2 2 2 19 0.50 [ 0.07, 0.93 ] 0.90 [ 0.70, 0.99 ]
Jouvet 2014 12 0 0 15 1.00 [ 0.74, 1.00 ] 1.00 [ 0.78, 1.00 ]
Pfannenberg 2007 33 0 2 0 0.94 [ 0.81, 0.99 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 71. Lung metastasis - CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 71 Lung metastasis - CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 13 0 0 0 1.00 [ 0.75, 1.00 ] 0.0 [ 0.0, 0.0 ]
Hausmann 2011 113 25 32 27 0.78 [ 0.70, 0.84 ] 0.52 [ 0.38, 0.66 ]
Jouvet 2014 29 9 2 5 0.94 [ 0.79, 0.99 ] 0.36 [ 0.13, 0.65 ]
Pfannenberg 2007 51 12 2 5 0.96 [ 0.87, 1.00 ] 0.29 [ 0.10, 0.56 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 72. Lung metastasis - MRI - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 72 Lung metastasis - MRI - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 8 0 5 0 0.62 [ 0.32, 0.86 ] 0.0 [ 0.0, 0.0 ]
Hausmann 2011 68 2 77 50 0.47 [ 0.39, 0.55 ] 0.96 [ 0.87, 1.00 ]
Jouvet 2014 8 1 23 13 0.26 [ 0.12, 0.45 ] 0.93 [ 0.66, 1.00 ]
Pfannenberg 2007 46 4 7 13 0.87 [ 0.75, 0.95 ] 0.76 [ 0.50, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 73. Lung metastasis - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 73 Lung metastasis - MRI (DW + VIBE) - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 16 3 15 11 0.52 [ 0.33, 0.70 ] 0.79 [ 0.49, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 74. Lung metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 74 Lung metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 10 2 0 15 1.00 [ 0.69, 1.00 ] 0.88 [ 0.64, 0.99 ]
Dellestable 2011 4 0 9 0 0.31 [ 0.09, 0.61 ] 0.0 [ 0.0, 0.0 ]
Jouvet 2014 15 0 16 14 0.48 [ 0.30, 0.67 ] 1.00 [ 0.77, 1.00 ]
Pfannenberg 2007 51 11 2 6 0.96 [ 0.87, 1.00 ] 0.35 [ 0.14, 0.62 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 75. Soft tissue metastasis - PET-CT - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 75 Soft tissue metastasis - PET-CT - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 12 3 4 6 0.75 [ 0.48, 0.93 ] 0.67 [ 0.30, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 76. Local/subcutaneous metastasis - CT - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 76 Local/subcutaneous metastasis - CT - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 27 6 6 7 0.82 [ 0.65, 0.93 ] 0.54 [ 0.25, 0.81 ]
Jouvet 2014 0 5 0 8 0.0 [ 0.0, 0.0 ] 0.62 [ 0.32, 0.86 ]
Pfannenberg 2007 38 6 21 15 0.64 [ 0.51, 0.76 ] 0.71 [ 0.48, 0.89 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 77. Local/subcutaneous metastasis - MRI - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 77 Local/subcutaneous metastasis - MRI - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 33 3 0 10 1.00 [ 0.89, 1.00 ] 0.77 [ 0.46, 0.95 ]
Jouvet 2014 7 3 3 9 0.70 [ 0.35, 0.93 ] 0.75 [ 0.43, 0.95 ]
Pfannenberg 2007 46 7 13 14 0.78 [ 0.65, 0.88 ] 0.67 [ 0.43, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 78. Local/subcutaneous metastasis - MRI (DW + VIBE) - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 78 Local/subcutaneous metastasis - MRI (DW + VIBE) - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 9 3 1 9 0.90 [ 0.55, 1.00 ] 0.75 [ 0.43, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
265Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 79. Local/subcutaneous metastasis - PET-CT - MIXED (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 79 Local/subcutaneous metastasis - PET-CT - MIXED (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 6 0 1 0 0.86 [ 0.42, 1.00 ] 0.0 [ 0.0, 0.0 ]
Jouvet 2014 7 3 0 5 1.00 [ 0.59, 1.00 ] 0.63 [ 0.24, 0.91 ]
Pfannenberg 2007 53 7 6 14 0.90 [ 0.79, 0.96 ] 0.67 [ 0.43, 0.85 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 80. Brain metastasis - CT- MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 80 Brain metastasis - CT- MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 19 0 1 0 0.95 [ 0.75, 1.00 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 81. Brain metastasis - MRI (DW) - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 81 Brain metastasis - MRI (DW) - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 13 0 7 0 0.65 [ 0.41, 0.85 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 82. Brain metastasis - MRI (DW + VIBE) - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 82 Brain metastasis - MRI (DW + VIBE) - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jouvet 2014 20 0 0 0 1.00 [ 0.83, 1.00 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 83. Brain metastasis - PET-CT - MIXED - All data (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 83 Brain metastasis - PET-CT - MIXED - All data (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cachin 2014 2 0 7 0 0.22 [ 0.03, 0.60 ] 0.0 [ 0.0, 0.0 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 93. ’Other’ metastasis - CT - Mixed - Any stage (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 93 ’Other’ metastasis - CT - Mixed - Any stage (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 2 4 8 12 0.20 [ 0.03, 0.56 ] 0.75 [ 0.48, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 94. ’Other’ metastasis - MRI - Mixed - Any stage (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 94 ’Other’ metastasis - MRI - Mixed - Any stage (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 5 1 3 12 0.63 [ 0.24, 0.91 ] 0.92 [ 0.64, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 95. ’Other’ metastasis - PET-CT - Mixed - Any stage (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 95 ’Other’ metastasis - PET-CT - Mixed - Any stage (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Dellestable 2011 11 3 1 11 0.92 [ 0.62, 1.00 ] 0.79 [ 0.49, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 96. ’Other’ metastasis - CT - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 96 ’Other’ metastasis - CT - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 33 5 19 78 0.63 [ 0.49, 0.76 ] 0.94 [ 0.86, 0.98 ]
Pfannenberg 2007 12 2 1 10 0.92 [ 0.64, 1.00 ] 0.83 [ 0.52, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 97. ’Other’ metastasis - MRI - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 97 ’Other’ metastasis - MRI - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hausmann 2011 48 12 4 71 0.92 [ 0.81, 0.98 ] 0.86 [ 0.76, 0.92 ]
Pfannenberg 2007 8 1 5 11 0.62 [ 0.32, 0.86 ] 0.92 [ 0.62, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 98. ’Other’ metastasis - PET-CT - Mixed - stage III/IV (per lesion).
Review: Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma
Test: 98 ’Other’ metastasis - PET-CT - Mixed - stage III/IV (per lesion)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pfannenberg 2007 13 1 0 11 1.00 [ 0.75, 1.00 ] 0.92 [ 0.62, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Cross-tabulation of studies by index test, population group, and target condition
Study US US-
FNAC
CT MRI PET-
CT
Popula-
tion
group
Popula-
tion de-
tail
Refer-
ence
stan-
dard
Any
metas-
tases
Distant
metas-
tases
Nodal
metas-
tases
Other
sites
PRIMARY STAGING
Arran-
goiz
2012
- - - - X Primary
(any);
primary
BT > 4
mm
SLNB/
CLND/
Per
patient
Per
patient
Per
patient/
-
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Table 1. Cross-tabulation of studies by index test, population group, and target condition (Continued)
(pre-
SLNB)
FU Pre-
SLNB
Chai
2012
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB/
CLND
± FU
- - Pre-
SLNB
-
Hafner
2004
X - - - (X) Primary
(pre-
SLNB);
primary
Stan-
dard
SLNB
Any
(incl
N+)
SLNB/
CLND
- - Per
patient/
Pre-
SLNB
-
Hinz
2011
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB - - Pre-
SLNB
-
Hinz
2013
X - - - X Primary
(pre-
SLNB)
High
risk (BT
≥
2.0 mm
or other
RF)
SLNB - - Pre-
SLNB
-
Hoce-
var
2004
X X - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB/
CLND
- - Pre-
SLNB
-
Kang
2011
- - - - X Primary
(any)
All stag-
ing (incl
N+)
Histol-
ogy/FU
per pa-
tient
- - -
Kell
2007
X Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB - - Pre-
SLNB
-
Klode
2010
- - - - X Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB - - Pre-
SLNB
-
Kunte
2009
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB - - Pre-
SLNB
-
Maubec
2007
- - - - X Primary
(any);
primary
(pre-
BT > 4
mm
SLNB/
CLND
± FU
Per
patient
- Pre-
SLNB
-
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Table 1. Cross-tabulation of studies by index test, population group, and target condition (Continued)
SLNB)
Prayer
1990
X - - - - Primary
(any)
All stag-
ing (incl
N+)
CLND/
FU
- - Per
patient
-
Radzhabova
2009
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB;
any (incl
N+)
SLNB ±
FU
- - Pre-
SLNB
-
Revel
2010
- - - - X Primary
(pre-
SLNB)
HN
MM
SLNB - - Pre-
SLNB
-
Sanki
2009
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB Pre-
SLNB
Sibon
2007
X - - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB - - Pre-
SLNB
-
Singh
2008
- - - - X Primary
(pre-
SLNB)
Stan-
dard
SLNB/
BT > 4
mm
SLNB - - Pre-
SLNB
-
van
Rijk
2006
X X - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB/
CLND
- - pre-
SLNB
-
Veit-
Haibach
2009
- - X - X Primary
(any)
All stag-
ing (incl
N+)
Histol-
ogy/FU
- Per
patient
Per
patient
-
Voit
2014
X X - - - Primary
(pre-
SLNB)
Stan-
dard
SLNB
SLNB/
CLND
- - Pre-
SLNB
-
Wagner
2012
- - - - X Primary
(pre-
SLNB)
High
risk (BT
≥ 4 mm
or > 1
mm and
ulcer-
ated)
SLNB/
CLND
- - Pre-
SLNB
-
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Table 1. Cross-tabulation of studies by index test, population group, and target condition (Continued)
RE-STAGING
Iagaru
2007
- - X - X Re-
staging
Any re-
staging
Histol-
ogy/FU
Per
patient
/Per le-
sion
- - -
Rubal-
telli
2011
X - - - - Re-
staging
Any FU
and sus-
pi-
cious on
B-mode
US
FNAC/
Histol-
ogy/FU
- - Per
patient
-
Strobel
2007a
- - - - X Re-
staging
High
risk (BT
> 4 mm,
etc.), el-
evated
S100
Histol-
ogy/Cy-
tology/
FU
Per
patient
- - -
MIXED OR UNCLEARLY REPORTED
Abbott
2011
- - - - X Mixed Stage III Histol-
ogy/FU
Per
patient
- - -
Aukema
2010a
- - - (X -
Brain)
X Mixed S100
positive
FNAC/
Histol-
ogy/
Imaging
FU
Per
patient
- - -
Aukema
2010b
- - - (X -
Brain)
X Unclear Node
positive
FNAC/
Histol-
ogy/FU
Per
patient
- - -
Basti-
aannet
2009
- - X - (X) Mixed All node
positive
Histol-
ogy/FU
- Per
patient
- -
Cachin
2014
- - - - X Mixed Stage III Histol-
ogy/
Imag-
ing/FU
Per pa-
tient/Per
lesion
Per
lesion
Per
lesion
Per
lesion
Dellestable
2011
- - X X X Mixed All stag-
ing
Histol-
ogy/FU
Per
lesion
Per
lesion
Per
lesion
Per
lesion
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Table 1. Cross-tabulation of studies by index test, population group, and target condition (Continued)
Haus-
mann
2011
- - X X - Unclear Stage
III/IV
Histol-
ogy/FU
Per
lesion
Per
lesion
Per
lesion
Per
lesion
Jouvet
2014
X - X X X Unclear Stage IV FNAC/
FU
Per
lesion
Per
lesion
Per
lesion
Per
lesion
Klebl
2003
X - - - - Mixed Clark
IV/V in
FU
Histol-
ogy/FU
- - per pa-
tient
-
Pfan-
nen-
berg
2007
- - X X X Mixed Stage
III/IV
Histol-
ogy/
Imag-
ing/FU
Per
lesion
Per
patient
Per
lesion
Per
lesion
Pfluger
2011
- - X - X Mixed All stage
III
Histol-
ogy/FU
Per
patient
- - -
Rein-
hardt
2006
- - X - X Mixed All stag-
ing (incl
N+)
Histol-
ogy/FU
Per
patient
Per
patient
Per
patient
-
Strobel
2007b
- - - - X Unclear High
risk (BT
> 4 mm,
etc.)
Histol-
ogy/Cy-
tology/
FU
Per
patient
- - -
van den
Brekel
1998
X - - Mixed HN
MMand
N+
Histol-
ogy
- - Per
patient
-
van
Wissen
2016
- - - - X Mixed Stage
IIIB/
IIIC pal-
pa-
ble groin
mets
Histol-
ogy
(com-
bined
groin
dissec-
tion)
- - Per
patient
-
BT: Breslow thickness; CLND: complete lymph node dissection; CT: computed tomography; FNAC: fine needle aspiration cytology;
FU: follow-up; HN: head and neck; MM: malignant melanoma; MRI: magnetic resonance imaging; mm: millimetre; N+: node
positive; PET: positron emission tomography; RF: risk factor; SLNB: sentinel lymph node biopsy; US: ultrasound.
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Table 2. Summary results from studies of imaging for primary staging or re-staging
Test Studies Participants (cases) Sensitivity (95% CI), % Specificity (95% CI), %
Comparison of imaging tests before SLNB
Indirect comparison of imaging tests for detection of nodal metastasis (per patient data)
US 11 2614 (542) 35.4 (17.0 to 59.4) 93.9 (86.1 to 97.5)
US-FNAC 3 1164 (259) 18.0 (3.58 to 56.5) 99.8 (99.1 to 99.9)
PET-CT 4 170 (49) 10.2 (4.31 to 22.3) 96.5 (87.1 to 99.1)
Difference P = 0.07 P < 0.001
Direct comparison of imaging tests for detection of nodal metastasis (per patient data)
US 3 1164 (259) 58.7 (36.5 to 77.9) 79.4 (70.0 to 86.4)
US-FNAC 3 1164 (259) 18.0 (3.58 to 56.5) 99.8 (99.1 to 99.9)
Difference -40.7 (-75.0 to -6.50), P = 0.02 +20.4 (+12.2 to +28.6), P < 0.001
Whole body imaging
Imaging for re-staging for the detection of any metastasis (per patient data)
PET-CT 2a 153 (95) 92.6 (85.3 to 96.4) 89.7 (78.8 to 95.3)
CI: confidence interval; CT: computed tomography; FNAC: fine needle aspiration cytology; PET: positron emission tomography;
SLNB: sentinel lymph node biopsy; US: ultrasound.
aWhere there were only two studies, estimates of summary sensitivity and summary specificity were obtained by using univariate fixed-
effect logistic regression models to pool sensitivities and specificities separately.
Table 3. Characteristics of studies conducted in mixed or unclear population groups
Study
Population group
Participant inclu-
sion criteria and re-
ported indications
for imaging
Stage of disease on
presentation
Imaging tests Patients/cases
(prevalence)
[lesions/metastases
(prevalence)]
Average no. metas-
tases per patient
PER PATIENT DATA
Abbott 2011
Mixed - primary or
follow-up
Undergoing FU af-
ter prior SLNB/
CLND for micro-
metastases
or presenting with
Stage:
IIIA 18, 53%
IIIB 10, 29%
IIIC 6, 18%
PET-CT (NR) 34/7 (21%) N/A
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Table 3. Characteristics of studies conducted in mixed or unclear population groups (Continued)
clinically detectable
nodal disease at or
subsequent to initial
diagnosis
Aukema 2010a
Mixed - primary or
re-staging
Asymptomatic
S100 positive. Pre-
viously treated for
locoregional recur-
rence (n = 15) or dis-
tant metastases (n
= 5); or with un-
favourable primary
tumour (n = 6),
primary melanoma
with simultaneous
nodal metastases (n
= 20)
Any (stage NR) PET-CT (U) 46/23 (50%) N/A
Aukema 2010b
Unclear
Pal-
pable and pathol-
ogy proven lymph
node metastases and
no signs of distant
metastases. Imaging
to identify further
‘undetected’ disease
Stage III: 100% PET-CT (U) 70/30 (43%) N/A
Bastiaannet 2009
Mixed - primary or
re-staging
Node positive (clin-
ical or histology/cy-
tology proven) can-
didates for CLND;
imaging to identify
further disease. In-
cludes those with
LN mets diagnosed
at time of primary
diagnosis 39, 15.
5%; LN metastases
identified ≤ 3 years
since primary diag-
nosis 145, 57.8%;
recurrence > 3 years
since primary diag-
nosis 67, 26.7%
Stage III (100%) CT (CE) 251/78 (31%) dis-
tant metastases
N/A
Cachin 2014
Mixed - staging or
re-staging
Any primary MM,
visceral metastases,
or cutaneous metas-
Any; 51% with
metastases
PET-CT (NR) 67/39 (58%)
[176/85 (48%)]
N/A
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Table 3. Characteristics of studies conducted in mixed or unclear population groups (Continued)
tases from unknown
primary
Klebl 2003
Mixed
Clark level IV or V
undergoing FU af-
ter primary surgery.
Reports primary (n
= 8) and imaging
during follow-up (n
= 75)
Any (NR) US 79/17 (22%) nodal N/A
Reinhardt 2006
Mixed - primary, re-
staging, FU, disease
response
All with PET-CT
for primary staging
after sentinel node
biopsy (n = 75);
therapy control af-
ter chemotherapy of
metastatic disease (n
= 42); staging of
clinically suspected
recur-
rent disease (n = 65)
; during follow-up
within 5 years of pri-
mary treatment (n =
68)
Stage I 22, 9%
Stage II 88, 35%
Stage III 108, 43%
Stage IV 32, 13%
CT (CE)
PET-CT (CE)
250/116 (46%) N/A
Strobel 2007b
Unclear
High risk
melanoma (BT > 4
mm, or Clark level
III or IV, or known
resected metastases)
with PET-CT for
depiction or exclu-
sion of metastases
Any (NR) PET-CT (CE) 124/53 (43%) N/A
van denBrekel 1998
Mixed - primary
and recurrence
Head and
neck MM with CT
before neck dissec-
tion, including ther-
apeutic and elective
(negative on palpa-
tion). “Interval be-
tween the treatment
of the primary and
the neck dissection
ranged from 0 to 8.
8 years (mean: 21
months)”
Stage I to II 8, 31%
Stage III 18, 69%
CT (CE) 26/21 (81%) nodal N/A
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Table 3. Characteristics of studies conducted in mixed or unclear population groups (Continued)
van Wissen 2016
Mixed - primary
and recurrence
Stage IIIB or IIIC
MM with palpable
groin metastases; se-
lected for therapeu-
tic combined groin
dissection. Discus-
sion states: “large
propor-
tion of our patients
were initially treated
for their primary tu-
mour at other hospi-
tals, and sometimes
years prior to the
current groin dissec-
tion”
All stage IIIB and C PET-CT (U) 69/59 (superficial
nodes 86%)
67/24 (deep nodes
36%)
N/A
PER LESION DATA
Cachin 2014
Mixed - staging or
re-staging
Any primary
MM, visceralmetas-
tases, or cutaneous
metastases from un-
known primary. Le-
sions with equivocal
focal uptake consid-
ered test positive
Only 1 eligible index
test
Any: 51% with
metastases
CT (NR) 67/39 (58%)
[176/85 (48%)]
1 (85/67)
Dellestable 2011
Mixed - primary or
follow-up
All with PET-CT
regardless of AJCC
stage or indication
for examination
Number of lesions in-
cluded varies per test
Stage I to II: 27.5%
Stage III to IV: 72.
5%
CT (CE)
MRI (DW)
PET-CT
40
[108/66 (61%)]
[117/70 (60%)]
[119/72 (61%)]
2 (72/40)
Hausmann 2011
Unclear
AJCC stage III or IV
with positive SLNB
or suspicious lesions
on ultrasound or X-
ray studies
Number of lesions in-
cluded same per test
Stage III 38%
Stage IV 62%
CT (CE)
MRI (NR)
33
All tests
[824/455 (55%)]
14 (455/33)
Jouvet 2014
Unclear
AJCC stage IV.
Number of lesions in-
cluded varies per test
Stage IV: 100% CT (CE)
MRI (DW)
MRI (DW + ultra-
fast GE)
37 (218 lesions)
[209/115 (55%)]
[218/125 (57%)]
[191/104 excl brain
3 (125/37)
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Table 3. Characteristics of studies conducted in mixed or unclear population groups (Continued)
PET-CT (54%)]
Pfannenberg 2007
Mixed - incl pri-
mary, FU, and NR
Stage III or IV im-
aged before surgery
due to abnormal ra-
diological, clin-
ical, and laboratory
findings, or routine
surveillance in high
risk
Number of lesions in-
cluded same per test
Stage III: 39%
Stage IV: 61%
CT (CE)
MRI (DW + ultra-
fast GE)
PET-CT
64
All tests [420/297
(71%)]
5 (297/64)
Pfluger 2011
Mixed - primary or
follow-up
Melanoma with re-
gional lymph node
metastases;
excluded any lesions
newly arising during
follow-up
Number of lesions in-
cluded same per test
Stage III: 100% CT (CE); CT (U)
PET-CT (CE); (U)
50
All tests
[232/151 (65%)]
3 (151/50)
AJCC: American Joint Cancer Committee; BT: Breslow thickness; CE: contrast enhanced; CLND: complete lymph node dissection;
CT: computed tomography; DW: diffusion weighted; FNAC: fine needle aspiration cytology; FU: follow-up; GE: gradient echo;
HN: head and neck; LN: lymph node; MM: malignant melanoma; MRI: magnetic resonance imaging; mm: millimetre; N+: node
positive; N/A: not applicable; NR: not reported; PET: positron emission tomography; SLNB: sentinel lymph node biopsy; U:
unenhanced; US: ultrasound; VIBE: MRI sequence.
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy ± visual inspection 104
3 Teledermatology 22
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(Continued)
4 Smartphone applications 2
5a Computer-aided diagnosis - dermoscopy-based techniques 42
5b Computer-aided diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection ± Dermoscopy 24
5c Computer-aided diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-aided diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 39
13 Sentinel lymph node biopsy 155
Staging of cSCC
14 Imaging tests review Review dropped; only 1 study identified
15 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Glossary of terms
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Term Definition
Adjuvant therapy or treatment A treatment given after the main treatment for cancer to reduce the risk of recurrence
Adverse event Detrimental change in health occurring in a person receiving the treatment whether or
not it has been caused by the treatment
Axillary In the armpit.
Biopsy Removal of a sample of tissue from the body to assist in diagnosis or inform the choice
of treatment of a disease
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf, which is involved in the control
of cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas,
which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents that inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour
Cervical (lymph nodes) Lymph nodes found in the neck area of the body.
Computed tomography (CT) Imaging technique in which the person lies on a table within an X-ray gantry. The images
are acquired using a spiral (helical) path and banks of detectors, allowing presentation
of the internal organs and blood vessels in different projections including 3D views
Coronal Frontal plane dividing the body into front and back.
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies as
disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies as having
the disease
Histopathology The study of tissue, usually obtained by biopsy or excision, for example under a micro-
scope
Incidence The number of new cases of a disease in a given time period.
Inguinal Lymph nodes in or just above or just below the groin.
Isolated limb perfusion A medical procedure that directly delivers a drug through the bloodstream in a limb to
the site affected by melanoma
Local recurrence Re-growth of a tumour in the area from which it was originally removed
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(Continued)
Locoregional recurrence Re-growth of a tumour in the area fromwhich it was originally removed or in the regional
lymph nodes (usually nearest to the original tumour site)
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that
travels around the body to help fight disease; they are located throughout the body often
in clusters (nodal basins)
Lymph node dissection Surgical removal or 1 or more lymph nodes in the absence of proven involvement with
melanoma
Lymphadenectomy Lymphadenectomy or lymph node dissection is a surgical operation to remove 1 or more
groups of lymph nodes
Lymphoscintigraphy An imaging technique used to identify the lymph drainage basin, determine the number
of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel
node in an unexpected location, and mark the sentinel node over the skin for biopsy. It
requires the injection of a radioisotope into the skin around the biopsy scar and a scan
some hours later to determine to which lymph nodes the tracer has travelled
Lymphovascular invasion Tumour cells that have spread to involve the blood vessels and lymphatic vessels within
the skin
Magnetic resonance imaging (MRI) A type of scan that uses a magnetic field and radio waves to produce images of sections
of the body
Mediastinal and hilar adenopathy Enlargement of the pulmonary lymph nodes.
MEK inhibitors Drugs that inhibit the mitogen-activated protein kinase enzymes, which are often up-
regulated in melanoma
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual
studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream
or the lymphatic system
Micro-metastases Micro-metastases are metastases so small that they can be seen only under a microscope
Mitotic rate Microscopic evaluation of the number of cells actively dividing in a tumour
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age group,
disease, treatment, or other classification, usually expressed as deaths per 100, 1000, 10,
000, or 100,000 people
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(Continued)
Multi-disciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for a patient
Nodal basin Cluster of lymph nodes that filter lymphatic fluid as it travels around the body; clusters
are located under the arm (axilla) and in the groin, neck, chest, and abdomen
Oncology The study of cancers. This term also refers to the medical specialty of cancer care, with
particular reference to the use of radiotherapy or drugs to treat cancer. The medical
specialty is often split into clinical oncology (doctors who use radiotherapy and drug
treatment) and medical oncology (doctors who use drug treatment)
Palpation Feeling with the fingers or hands as part of a clinical examination of the body
Positron emission tomography (PET) A nuclear medicine imaging technique whereby a radioactive glucose (usually 18FDG) is
administered intravenously before a scan is conducted to create an image using colours
to show where the FDG (or other radioactive tracer) has been taken up in the body
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it that might affect the patient’s
prognosis
Radiotherapy The use of radiation, usually high-energy X-rays, to control the growth of cancer cells
RAS-RAF-MEK-ERK signalling pathway A chain of proteins that allow signals from a receptor on the surface of a cell to be sent
to the DNA in the cell nucleus; a mutation in one of the proteins in the pathway is
associated with the development of many cancers
Recurrence Recurrence occurs when new cancer cells are detected following treatment. This can
occur either at the site of the original tumour or at other sites in the body
Relapse Where cancer starts to grow again after treatment.
Sagittal Median plane dividing the body into left and right.
Sensitivity In this context, the term is used to mean the proportion of individuals with a disease
who have that disease correctly identified by the study test
Sentinel lymph node biopsy (SLNB) A radioactive tracer and blue dye are injected into the skin surrounding the primary
lesion and the ’sentinel’ lymph nodes to which the tracer drains are located by imaging
(usually lymphoscintigraphy) and then are removed and examined for nodal metastatic
spread that cannot be detected clinically or on imaging
Signal transduction Occurs when extracellular signalling molecules activate a specific receptor, which then
triggers cellular pathways
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(Continued)
Staging Clinical descriptionof the size and spread of a patient’s tumour, fitting into internationally
agreed categories
Stereotactic radiotherapy A technique for delivering high-dose radiotherapy very accurately to small areas inside
the body, which reduces damage done by radiotherapy to adjacent healthy tissues
Subclinical (disease) Disease that usually is asymptomatic and is not easily observable (e.g. by clinical or
physical examination)
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area
Ultrasound A type of scan in which high-frequency sound waves are used to outline a part of the
body
Appendix 3. Table of acronyms
Acronym Definition
µm micrometre
AK actinic keratosis
ANN artificial neural network
BCC basal cell carcinoma
BD Bowen’s disease
BPC between-person comparison (of tests)
CAD computer-assisted diagnosis
CCS case-control study
CS case series
cSCC cutaneous squamous cell carcinoma
D- disease negative
D+ disease positive
Derm-CAD digital dermoscopy-based computer-assisted diagnosis
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(Continued)
DF dermatofibroma
DRS diffuse reflectance spectroscopy
DRSi diffuse reflectance spectroscopy imaging
Dx diagnosis
EIS electrical impedance spectroscopy
FN false negative
FP false positive
FU follow- up
GP general practitioner
H&E haematoxylin and eosin stain
HFUS high-frequency ultrasound
Hz hertz
KHz kilohertz
K-NN k nearest neighbour
MHz megahertz
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
mm millimetre
MSI multi-spectral imaging
N/A not applicable
NC non-comparative
nm nanometre
NPV negative predictive value
NR not reported
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(Continued)
P prospective
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
se sensitivity
sp specificity
spectro-CAD spectroscopy-based computer-assisted diagnosis
SK seborrhoeic keratosis
SSM superficial spreading melanoma
SVM support vector machine
TN true negative
TS telespectrophotometry system
VI visual inspection
UNREF unreferred population
WPC within-person comparison (of tests)
WPC-algs within-person comparison (of algorithms)
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Appendix 4. Proposed sources of heterogeneity
These may vary between reviews but may include the following.
i. Population characteristics
• AJCC stage of disease
• Sentinel lymph node status (for imaging studies only)
• Clinical nodal status (for imaging studies only)
• Primary tumour site (head and neck, trunk, limb, and other)
ii. Index test characteristics
• Differences in test positivity thresholds (e.g. for SLNB, the tracer threshold for a ’hot’ vs ’cold’ node)
• Other relevant test characteristics as appropriate to the test under consideration
iii. Reference standard characteristics
• Reference standard used (histology, clinical, or imaging-based follow-up; concurrent imaging-based reference standard)
iv. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted, blinded to the reference standard result
• Index test interpreted, blinded to the result of any other index test
• Presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test, with selection dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
Appendix 5. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August Week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
287Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
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69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations August 29, 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
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4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
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56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 2016 August 29
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
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5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
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56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
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108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
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#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
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#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
296Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
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S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
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#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 6. Full text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case-control studies
◦ ’cross-sectional’ test accuracy studies with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
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(Continued)
◦ cSCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
(FNAC)
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging:
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
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(Continued)
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging:
LND of both SLN+ and SLn participants to identify
all diseased nodes
LNDof SLN+ participants and follow-up of SLNpar-
ticipants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography-computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 7. QUADAS interpretation
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions both for
melanoma and for cutaneous squamous cell carcinoma (cSCC)
staging?
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.g.
indeterminate results or where disagreement between evaluators
was observed
Unclear - if not clearly reported
4) For between-person comparative (BPC) studies only (i.e. allo-
cating different tests to different study participants such as ran-
domised controlled trials (RCTs)):
• a) were the same participant selection criteria used for those
allocated to each test?
Yes - if same selection criteria were used for each index test
No - if different selection criteria were used for each index test
Unclear - if selection criteria per test were not described
N/A - if only 1 index test was evaluated or all participants received
all tests
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(Continued)
• b) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
Yes - if adequate randomisation procedures are described
No - if inadequate randomisation procedures are described
Unclear - if the method of allocation to groups is not described
(a description of ‘random’ or ‘randomised’ is insufficient)
N/A - if only 1 index test was evaluated or all participants received
all tests
• c) was the potential for biased allocation between tests
avoided through concealment of allocation before assignment?
Yes - if appropriate methods of allocation concealment are de-
scribed
No - if appropriate methods of allocation concealment are not
described
Unclear - if themethod of allocation concealment is not described
(sufficient detail to allow a definite judgement is required)
N/A - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
v FOR NON-COMPARATIVE (NC) STUDIES
If answers to all of questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk Unclear
v FOR BETWEEN-PERSON COMPARATIVE STUDIES
If answers to all of questions 1) and 2) and 3) and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) or 4) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) or 4) was ‘Unclear’: Risk Unclear
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
For sentinel lymph node biopsy and imaging tests:
1)Does the study report results for participants unselected by stage
of disease or site of primary lesion, i.e. the study does not focus
solely on those with a particular stage of disease such as American
Joint Committee on Cancer (AJCC) stage I or melanoma ≤ 1
mm in thickness?
Yes - if an unrestricted group of participants have been included
No - if a selected group of study participants have been included,
e.g. those with clinical stage I disease or only those with thin
melanoma
Unclear - if insufficient details are provided to determine the
spectrum of included participants
2) Did the study report data on a per patient rather than per lesion
basis?
Yes - if a per patient analysis was reported
No - if a per lesion analysis only was reported
Unclear - if it is not possible to assess whether data are presented
on a per patient or per lesion basis
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For imaging tests only:
3) Does the study focus primarily on participants undergoing pri-
mary staging or those undergoing staging for disease recurrence?
Yes - if at least 80% of study participants are undergoing primary
staging following diagnosis of a primary cutaneous melanoma or
staging of recurrence
No - if less than 80% of study participants are undergoing primary
staging following diagnosis of a cutaneous melanoma or staging
of recurrence
Unclear - if insufficient details are provided to determine the pro-
portion of patients undergoing primary staging vs those undergo-
ing staging of recurrence
Is there concern that the included participants do not match the review question?
If the answer to question 1) or 2) (and 3)) was ‘Yes’: Concern is Low
If the answer to question 1) or 2) (and 3)) was ‘No’: Concern is High
If the answer to question 1) or 2) (and 3)) was ‘Unclear’: Concern is Unclear
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result, or for prospective studies, if index test
is always conducted and interpreted before the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive prespecified?
Yes - if threshold was prespecified (i.e. before analysing study re-
sults)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
For imaging tests only:
3) For studies reporting the accuracy ofmultiple diagnostic thresh-
olds (tumour characteristic or parameter) for the same index test,
was each threshold interpreted without knowledge of the results
of the others?
Yes - if thresholds were selected prospectively and each was inter-
preted by a different reader, or if study implements a retrospective
(or no) cutoff
No - if study uses prospective threshold and report states reported
by same reader
Unclear - if no mention of number of readers for each threshold
or if prespecification of threshold not reported
N/A - multiple diagnostic thresholds not reported for the same
index test
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4) For within-person comparison (WPC) of index tests or testing
strategies (i.e. > 1 index test applied per participant), was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have
introduced bias?
v FOR NC and BPC STUDIES item 3) / 4) to be added
If answers to questions 1) and 2) was ‘Yes’: Risk is Low
If answers to either questions 1) or 2) was ‘No’: Risk is High
If answers to either questions 1) or 2) was ‘Unclear’: Risk is Unclear
v FOR WPC STUDIES
If answers to all questions 1), 2) for any index test and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) for any index test or 3) was
‘No’:
Risk is High
If answers to any one of questions 1) or 2) for any index test or 3) was
‘Unclear’:
Risk is Unclear
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
1) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
This item applies equally to studies using objective and more
subjective approaches to test interpretation. For sentinel lymph
node biopsy (SLNB) studies, this requires description of the tracer
threshold for identification of the SLN and the histological assess-
ment
Yes - if the criteria for diagnosis of the target disorder were reported
in sufficient detail to allow replication
No - if the criteria for diagnosis of the target disorder were not
reported in sufficient detail to allow replication
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided
2) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by an experienced examiner as
defined in the review protocol
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported
in sufficient detail to judge or if examiners described as ’Expert’
with no further detail given
Is there concern that the index test, its conduct, or interpretation differ from the review question?
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If answers to questions 1) and 2) was ‘Yes’: Concern is Low
If answers to questions 1) or 2) was ‘No’: Concern is High
If answers to questions 1) or 2) was ‘Unclear’: Concern is Unclear
REFERENCE STANDARD (3) - RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
a) DISEASE POSITIVE - 1 or more of:
- Histological confirmation of metastases following lymph node
dissection (or SLNB or core biopsy for imaging studies)
- Clinical/radiological follow-up to identify clinically detectable
disease in a mapped nodal basin (SLNB studies)
- Clinical/radiological follow-up to identify any metastases (imag-
ing studies) subsequently confirmed on histology
Yes - if all disease positive participants underwent 1 of the listed
reference standards
No - if a final diagnosis for any disease positive participant was
reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any disease positive participant
b) DISEASE NEGATIVE - 1 or more of:
- Histological confirmation of absence of disease in a mapped
nodal basin following lymph node dissection (or following SLNB
for imaging studies)
- Clinical/radiological follow-up of test negative participants
Yes - if at least 90% of disease negative participants underwent 1
of the listed reference standards
No - if more than 10% of benign diagnoses were reached by
concurrent imaging test
Unclear - if the method of final diagnosis was not reported for
any participant with benign or disease negative diagnosis
2) Were the histology-based reference standard results interpreted
without knowledge of the results of the index test?
Yes - if the histopathologist was described as blinded to the index
test result
No - if the histopathologist was described as having knowledge of
the index test result
Unclear - if blinded histology interpretation was not clearly re-
ported
3) Were the reference standard results based on patient follow-up
interpreted without knowledge of the results of the index test?
Yes - if the clinician or radiologist was described as blinded to the
index test result
No - if the clinician or radiologist was described as having knowl-
edge of the index test result
Unclear - if blinded interpretation was not clearly reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
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REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Does the study use the same definition of disease positive as the
primary review question, or is it possible to fully disaggregate data
such that data matching the review question can be extracted?
Yes - same definition of disease positive used, or patients can be
disaggregated and re-grouped according to review definition
No - some patients cannot be disaggregated
For SLNB review - disease positive includes participants with any
nodal recurrence (not restricted to clinical recurrence in same
nodal basin)
For imaging reviews - participants with nodal vs distant recur-
rences cannot be disaggregated
Unclear - definition of disease positive not clearly reported
For studies of imaging tests:
2)The result of another imaging test (without patient follow-up to
determine later emergence of disease) was not used as a reference
standard
Yes - if imaging-based diagnosis was not used as a reference stan-
dard for any participant
No - if imaging-based diagnosis was used as a reference standard
for any participant
Unclear - if not clearly reported
3) Item on observer experience could be included?
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
If answers to all questions 1), 2) and 3) was ‘Yes’: Concern is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Concern is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Concern is Unclear
***For teledermatology studies only:
If answers to questions 1) and 3) was ‘Yes’: Concern is Low
If answers to questions 1) or 3) was ‘No’: Concern is High
If answers to questions 1) or 3) was ‘Unclear’: Concern is Unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
• a) For index test positive participants, was the interval
between index test and histological reference standard ≤ 1
month?
Yes - if study reports ≤ 1 month between index and histological
reference standard
No - if study reports > 1 month between index and histological
reference standard
Unclear - if study does not report interval between index and
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histological reference standard
• b) If reference standard is clinical or imaging-based follow
up of index test negative participants, was there less than 6
months between application of index test(s) and first follow-up
visit?
Yes - if study reports a follow-up visit within 6 months of appli-
cation of the index test
No - if study reports the first follow-up visit beyond 6 months of
the index test
Unclear - if study does not report timing of follow-up visits
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear - if not clearly reported
4) For WITHIN-PERSON COMPARISON (WPC) of index
tests:
Was the interval between application of index tests ≤ 1 month?
Could the participant flow have introduced bias?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report interval between index tests
v FOR NON-COMPARATIVE and BPC STUDIES
If answers to questions 1) and 2) and 3) was ‘Yes’: Risk is Low
If answers to any one of questions 1) or 2) or 3) was ‘No’: Risk is High
If answers to any one of questions 1) or 2) or 3) was ‘Unclear’: Risk is Unclear
v FOR WITHIN-PERSON COMPARATIVE STUDIES (WPCs)
If answers to all questions 1), 2), 3), and 4) was ‘Yes’: Risk is Low
If answers to any one of questions 1), 2), 3), or 4) was ‘No’: Risk is High
If answers to any one of questions 1), 2), 3), or 4) was ‘Unclear’: Risk is Unclear
Appendix 8. Summary characteristics of studies for pre-SLNB imaging
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Study
Country
Pt/lesion num-
ber
Study design
Outcome:
prevalence
Presentation
Inclusion crite-
ria
Imaging
eligibility
Age, gender,
site, BT, Clark
Index test Threshold
Observers
Reference
Exclusions
Arrangoiz 2012
USA
Patients: 56
Primary
lesions: 56
LNBs/
Metastases: NR
NC
Retro-
spective (medi-
cal record review
not described)
Data: per pt
Nodal mets: 29/
56 = 52%
Primary (pre-
SLNB)
Stage of disease:
all T4 and clin-
ically node neg-
ative and nega-
tive for distant
metastases
Inclusion: node
negative; BT > 4
mm
Mean
age: 67; Median
age:NR;Range:
26 to 89 years
Male: 32 (57%)
Site: trunk 16,
29%; extremities
28, 50%; HN
12, 21%
BT median
6 mm; mean 9
mm; range 4.1 to
40 mm
PET-CT. 2D or
3D; CT (U, he-
lical, low dose)
Scan coverage:
WB; vertex of
the head down to
feet for all pa-
tients
Contrast: U
CT parameters:
Discovery LS -
140 kVp, 90mA;
Siemens Bio-
graph - 130 kVp,
100 mA; 5 mm
18FDG: 15 mCi
(IV)
Breath hold:
normal breath-
ing
CT used for:
attenuation cor-
rection; co-regis-
tered images
Reconstruc-
tion: Discovery
LS -OSEMalgo-
rithm; Siemens
Biograph
- TrueX (itera-
tive reconstruc-
tion) algorithm
SUV of 2.5
Info provided:
NR
No.
observers: NR;
’in-house medi-
cal physicist’
mentioned
Diagnosis: un-
clear
Histology (54,
96% (48 SLNB
and 6 LND))
FNAC (n NR)
FU (n NR): no
details
Histology inter-
val:
NR; states that
6 “proceeded di-
rectly to thera-
peutic lymph
node dissection”
after PET
FU interval:NR
Exclusions: n =
0; N/A
Chai 2012
USA
Patients: 325
Primary
lesions: 325
LNBs/
Metastases: 347
NC
Retrospec-
tive (prospective
database
reported)
Data: per pt
Nodal mets: 64/
317 = 20%
Primary (pre-
SLNB)
Stage of disease:
NR
Inclusion: node
negative,BT > 0.
76 mm or < 0.76
mm with high-
risk features such
as
Mean age: NR;
Median age: 58;
Range: 18 to 86
Male: 189
(58%)
Site:HN34 (10.
5%)
Trunk 129 (39.
7%)
Upper extremity
US. B-mode;
linear array (9 or
12 MHz); US
before LS
Scan cov-
erage: according
to primary MM
site and discre-
tion of attending
surgeon
US
- classed as “ab-
normal,” “suspi-
cious,” or “inde-
terminate
recommending a
short-term
follow-up” were
considered posi-
tive (criteria de-
Histology (325,
100%)
FNAC (6, 1.8%)
FU (NR;
presume 100%)
: NR; FU for
SLNB negatives
is reported but
no description is
given
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ulceration, high
mitotic rate, or
a positive deep
margin
101 (31.1%)
Lower extremity
61 (18.8%)
BT me-
dian (range) 1.78
(0.42 to 14.4)
Clark’s level III
24 (7.4%), IV
275 (84.6%), V
20 (6.2%), un-
known 6 (1.8%)
Contrast: N/A scribed in detail)
Info provided:
NR
No. observers:
NR (NR)
Diagnosis: NR
Histol-
ogy interval:US
performed either
immediately or
several days be-
fore LS
FU interval:NR
Exclusions:
n = 8; 1 draining
basin identified
by LSwas not ex-
amined with US;
plus 7 SLN posi-
tive who did not
get US
Hafner 2004
Switzerland
Patients: 101
Primary
lesions: 101
LNBs/Metas-
tases:105LNBs;
136 SLNs
WPC
Prospective
Data: per pt
Nodal mets: 23/
97 = 24%
Primary (pre-
SLNB)
Stage of disease:
NR; stage IV (ev-
idence of distant
mets) excluded
Inclu-
sion: any cuta-
neous MM with
BT
≥ 1 mm with-
out evidence of
detectable
distant metasta-
sis (includes clin-
ically palpable)
Excluded if < 1
mm
Median age: 55;
Range: 18 to 79
Male: 55 (55%)
Site: limbs 49,
49%, trunk 35,
35%, HN 16,
16%
BT: 1.01 to 2
mm 38; 2.01 to
4 mm 43; > 4.0
mm 19
US. B-mode (5
Mhz); US before
LS
Scan coverage:
regional
lymph nodes of
the groins, ax-
illae, and neck
(abdominal US
also performed)
Contrast: N/A
NR; ’radiologi-
cally suspect’
Info provided:
unclear; clinical
exam by derma-
tologist and US
by radiologist
No.
observers: 1; ra-
diologist (NR)
Diagnosis: sin-
gle
Histology (100;
100%)
FNAC (NR (ab-
stract reports 3
LN mets identi-
fied on physical
exam, 2 of which
were detected by
US)):
FU (n NR): 20
months (8 to 39)
Histology inter-
val: 2 weeks
FU interval: 6
months
Exclusions:
n = 4; 1 sentinel
node was not
found intraoper-
atively; 3 clini-
cally node posi-
tive excluded by
Bham team
Hinz 2013
Germany
Patients: 20
Primary
lesions: 20
LNBs/Metas-
tases:59SLN re-
moved
WPC
Ret-
rospective (ret-
rospective com-
puter-aided
search
of preoperatively
performed stag-
ing procedures)
Primary (pre-
SLNB)
Stage of disease:
NR
Inclusion: high
risk cuta-
neous MM; im-
plies BT ≥ 2.0
mm or RF such
Mean age:
full sample: 55.
2; Median age:
NR; Range: Full
sample: SD 13.3
years
Male: 9 (45%)
. Site: trunk n
= 10 (50%); up-
PET-CT. 2D/
3D NR; CE-CT,
helical. Rein-
hardt 2006 states
helical, dual de-
tector (N/A)
Scan coverage:
WB;
Reinhardt 2006:
PET-CT: NR
Info provided:
NR
No. observers:
unclear; no de-
tails
Diagnosis: un-
clear
US: morphology
Histology (20
(100%))
FNAC (0): his-
tology interval:
NR
FU interval: N/
A
Exclusions: n =
0
309Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Data: per pt
Nodal mets: 12/
20 = 60%
as ulceration or
regression
Excluded if ’fur-
ther risk factors’
or classic sono-
graphic signs of
lymphatic
metastasis
per extremity n
= 3(15%); lower
extremity n = 4
(20%); acral n =
3(15%)
BT: 1.01 to 2
mmn=3 (15%),
2.10 to 4mmn=
9 (45%), > 4mm
n = 8 (40%);
Clark’s level III
n = 1(5%); IV n
= 16(80%); V n
= 3 (15%)
“base of the skull
to the apex of the
lungs, ... from
the shoulders to
upper thighs, ...
from the proxi-
mal femur to the
tip of the toes”
Contrast: Rein-
hardt 2006: iod-
inated oral con-
trast agent (Peri-
trast-
oral-GI; Köhler
Chemie GmbH,
Alsbach,
Germany)
CT parameters:
130 kV, 40 mAs
(Rein-
hardt 2006); 5
mm (Reinhardt
2006)
18FDG: 371 ±
41 MBq (Rein-
hardt 2006)
Breath hold:
limited breath
hold technique
for CT and shal-
lowbreathing for
PET
CT used for:
Reinhardt 2006:
attenuation cor-
rection based on
re-scaling of the
CT image
Recon-
struction: itera-
tive as described
elsewhere (Kina-
han 2003)
US. B-mode (6.
0- to 11.0-MHz
linear trans-
criteria (Solbiati
1988;
Vassalo 1992;
Voit 2010d); sus-
picious LNswere
re-examined
with US after LS
Info
provided: clini-
cal exam/USper-
formed by same
clinician
No. ob-
servers: unclear;
physicians with
broad experience
in dermato-on-
cology (NR)
Diagno-
sis: unclear; ap-
pears as though
single observer
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ducer); US pre-
and post-LS
Scan coverage:
all relevant re-
gional LN basins
depending on lo-
cali-
sation of the pri-
mary melanoma
Contrast: N/A
Hinz 2011
Germany
Patients: 81
Primary
lesions: 81
LNBs/
Metastases:NR;
170 SLNs
NC
Prospective
Data: per pt
Nodal mets: 8/
81 = 10%
Primary
(pre-SLNB) (? 1
secondary nodu-
lar SSM)
Stage of disease:
NR
Inclusion: clini-
cally node nega-
tive,BT≥ 1 mm
or < 1 mm with
risk factors such
as ulceration or
regression
Mean age: 52.
8; Median age:
NR; Range: SD
15.4; node posi-
tive given (36 to
62)
Male: 48
(0.5925%). Site:
HN 2,2.5%;
Trunk 36, 44.
4%; Upper ex-
tremity 14, 17.
2%; Lower ex-
tremity 23, 28.
4%; Acral 6, 7.
4%
MedianBT1.68
mm (0.76 to 6.
00 mm)
Clark’s level: 1
1, 1.4%; 2 26,
35.6%; 3 39, 53.
4%; 4 7, 9.6%
US. B-
mode (linear ar-
ray); Doppler (6.
0 to 11.0 MHz
linear trans-
ducer); US pre-
and post-LS
Scan coverage:
LN areas pre-
dicted by sites of
melanoma
Contrast: N/A
Pos-
itive radiological
findings accord-
ing to published
criteria
Info provided:
NR; likely full
info available
No.
observers: 1 of 4
clinicians trained
in USS imaging;
NR; broad ex-
perience in der-
mato-oncol-
ogy and special
ultrasound skills
(NR)
Diagno-
sis: unclear; ap-
pears as though
single observer
Histology (1)
FNAC (n NR)
FU (N/A): not
stated
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0
Hocevar 2004
Slovenia
Patients: 57
Primary
lesions: 57
LNBs/
Metastases: 61
WPC
Design unclear
Data: per pt
Nodal mets: 14/
57 = 25%
Primary (pre-
SLNB)
Stage of disease:
NR
Inclusion: MM
candidates for
SLNB
Mean age: NR;
Median age:
NR; Range: 1 to
93
Male: 21 (0.
37%). Site: 14,
25% head, 19,
38% trunk, 24,
42% extremity
BT < 1 mm 2,
4%, BT 1 to
2 mm 23, 40%,
BT2.01 to 4mm
20, 35%, BT > 4
US. B-
mode; linear ar-
ray transducer
with small parts
probe (12 and 15
MHz); US be-
fore LS
Scan coverage:
NR
Contrast: N/A
Breath hold: re-
gional lymph
nodes
US + FNAC for
Rounded
appear-
ance of the LN,
Ioss of the hilar
echogenic reflex,
anddeformed ra-
dial nodal vascu-
larity
Info provided:
NR
No. observers:
1; oncological ra-
diologist (NR)
Diagnosis: sin-
Histology
(CLND; SLNB)
FNAC (14/17
US positive un-
derwent FNAC)
FU (n NR): no
details
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0
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mm 12, 21%
Clark’s level un-
known - 2, 4%,
3 23; 42%, 4 26;
44%, 5 6, 10%
those positive on
US
gle
Kell 2007
USA
Patients: 37
Primary
lesions: NR
LNBs/
Metastases: NR
NC
Retrospec-
tive (prospective
database
reported)
Data: per pt
Nodal mets: 9/
37 = 24%
Primary (pre-
SLNB)
Stage of disease:
NR
Inclusion: MM,
BT >
0.75 mm, candi-
dates for SLNB
Mean age: 61.
4 years; Median
age:NR;Range:
NR
Male: NR (0%).
Site: NR
Mean BT: 2.4
mm
PET-CT. 2D/
3D NR; CT (U)
Scan coverage:
base of skull to
feet
Contrast: U
CT parameters:
NR
18FDG: NR
Breath hold:
NR
CT used for:
NR
Reconstruc-
tion: NR
Quantitative for
areas of abnor-
mally increased
18FDG uptake
Info provided:
NR
No. observers:
NR; no details.
Diagnosis: NR
Histology (37,
100%)
FNAC (0):
FU (n NR): no
details
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0; 46 with SLNB
but no PET-CT
could not be in-
cluded
Klode 2010
Germany
Patients: 61
Primary
lesions: NR
LNBs/
Metastases: NR
NC
Retrospective
Data: per pt
Nodal mets: 14/
61 = 23%
Primary (pre-
SLNB)
Stage of disease:
NR (I or II)
Inclusion: pri-
maryMMAJCC
stage I or II (BT
> 1 mm)
Mean age: 58.8;
Median age: 61;
Range: 31 to 82
Male: 36
(0.5901%). Site:
trunk and lower
limbs 26, 42.
6%; upper ex-
tremities 9, 14.
8%; NR for re-
maining 27 le-
sions
BT: mean 2.62
mm, median 2.0
mm, range 1 to 8
mm
PET-CT. 2D/
3D NR; CE-CT
Scan
coverage: cranial
base to mid fe-
mur; additional
views according
to melanoma lo-
calisation
Contrast: io-
dine-containing
contrast agent
CT parameters:
NR
18FDG: 349
mBq
Breath hold:
breath hold in-
structions NR
CT used for:
NR
Reconstruc-
tion: NR
NR; hy-
permetabolic tu-
mour focus
Info provided:
NR
No. observers:
NR; no details
Diagnosis: NR
Histology (61,
100%)
FNAC (N/A)
FU
(61, 100%): me-
dian 38 months,
13 to 55 months
Histology
interval:median
14 days PET to
SLNB
FU interval:NR
Exclusions: n =
0; 60 patients
with SLNB did
not agree to pre-
op PET
Kunte 2009
Germany
Patients: 25
Primary
NC
Prospective
(Prosp database:
N/A)
Primary (pre-
SLNB) (NR).
Stage of disease:
NR
Mean age:
54;Median age:
NR; Range: NR
Male: 15 (60%)
US. B-mode;
linear transducer
(7.5 to 10MHz)
Qualitative pres-
ence of morpho-
logical features
Histology (51%
n = 35)
FNAC (0):
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lesions: 25
LNBs/Metas-
tases: 68 LNBs;
35 SLNs
Data: per pt
Nodal mets: 6/
35 = 17%
Data: per SLN
Nodal mets: 6/
35 = 17%
Inclusion: cuta-
neous
MM SLNB can-
didates; ’mainly’
≥ 1.0 mm BT
or RF (ulcera-
tion or regression
or Clark level IV
and V)
. Site: Limbs 14,
56%;HN2, 8%;
trunk 9 36%
BT: ≤ 1 mm 8,
32%; 1.01 to 2
mm 11, 44%; 2.
01 to 4 mm 5
20%; > 4.0 mm
1, 4%
; US pre- and
post-LS
Scan coverage:
regional
lymphatic basins
Contrast: N/A
Breath hold: re-
gional LN basins
(described)
Info provided:
unclear; may be
same dermatolo-
gists as for clini-
cal exam
No. ob-
servers: 2; der-
matologists (ex-
perienced).
Diagnosis: un-
clear
FU (0): -
Histology inter-
val: < 24 hours
FU interval: N/
A
Exclusions: n =
NR
Maubec 2007
France
Patients: 25
Primary
lesions: 26
LNBs/Metas-
tases:20 from19
pts
NC
Prospective
(Prosp database:
N/A)
Data: per pt
Nodal mets: 7/
20 = 35%; 1 FN
identified on FU
Primary (pre-
SLNB)
Stage of disease:
all
T4; post surgery
AJCC stage IIB
10, 40%;
IIC 4, 16%; IIIA
4, 16%; IIIB 6,
24%; IIIC in 1,
4%
Inclusion:
any MM BT >
4 mm; SLNB
planned if clini-
cally node nega-
tive
Mean age: 60;
Range: 14 to 87
Male: 15 (0.6%)
. Site: trunk 8,
32%; limbs 8;
32%; head and
neck 9, 36%
Mean BT 6.6
mm, range 4.8 to
12.5 mm
PET-CT. 3D;
CT (U)
Scan coverage:
WB; “top of the
head to the mid-
thigh and
included if nec-
essary, the lower
limbs”
Contrast: U
CT parameters:
110 kV; 80 mA;
5 mm
18FDG: 5 MBq/
kg
Breath hold:
normal breath-
ing;
“no breath hold
instructions”
CT used for:
NR; integrated
system
Reconstruc-
tion: iterative al-
gorithm (FORE
and AWOSEM)
Uptake site sus-
picious for ma-
lignancy or not
clearly explained
by a benign eti-
ology (SUV esti-
mated
but does not ap-
pear to formally
contribute to di-
agnosis)
Info provided:
NR
No. observers:
NR; no details.
Diagnosis: NR
Histology (22,
88%; 3 node
positive under-
went CLND; 19
had SLNB; 3 no
surgery)
FNAC (N/A)
FU (25, 100%):
mean 11 months
(2 to 19 months)
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
6; 3 clinically N+
under-
went CLND (all
PET+ and N+);
3 did
not undergo any
surgery
Radzhabova
2009
Russia
Patients: 152
Primary
lesions: NR
LNBs/
Metastases: NR
NC
Design unclear
Data: per pt
Nodal mets: 11/
52=21%; 2FNS
identified on FU
Primary (pre-
SLNB)
Stage of disease:
NR
Inclusion: clini-
cally node neg-
ative MM and
SLNB (based on
Mean age: NR;
Median age:
NR; Range: NR
Male: NR (0%).
Site: NR
NR
US.
B-mode; sectoral
and linear (7 to
10 MHz); pre-
LS
Scan coverage:
NR
Contrast: N/A
High PSV, EDV,
Stuart index, and
PI < 1000. Mets
could not be ex-
cluded if
PSV and PI were
high but EDV =
0, Stuart index
Histology (52,
100%)
FNAC (0):
FU (NR):
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
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US result) Breath hold: N/
A
was undetectable
(PI = pulse in-
dex, PSV = peak
systolic volume,
EDV = end-
diastolic volume,
Stuart index)
Info provided:
NR
No. observers:
NR; no details.
Diagnosis: NR
100; benign on
US did not get
SLNB
Revel 2010
France
Patients: 22
Primary
lesions: 22
LNBs/
Metastases: 21
WPC
Retrospective
Data: per pt
Nodal mets: 10/
20 = 50%; 2 FN
identified on FU
Primary (pre-
SLNB)
Stage of disease:
stage I or II
Inclusion: clini-
cally node neg-
ative HN MM
with pre-SLNB
PET-CT
Excluded if > 1
month between
PET-CT and
SLNB
Mean age: 60.
Range: 18 to 88
Male: 16 (73%)
. Site: scalp 5,
23%; cheek 3,
14%; cervical or
neck
3, 14%; atrial re-
gion (ear, mas-
toid, temples) 6,
27%; palpebral
or periorbital 4,
18%; frontal 1,
5%
BT: 4.5 mm (0.
26 to 10 mm)
PET-CT. 2D/
3D NR
Scan coverage:
WB; vertex to
the toes
Contrast: NR
CT parameters:
Biograph 2: 130
kV, 80 mAs
Biograph 6: 130
kV, 4D
Care Dose; Bio-
graph 2: 5 mm
Biograph 6: 4
mm
18FDG: 5.5
MBq/kg for Bio-
graph 2; 4 MBq/
kg for Biograph
6
True V; Flucis1,
Schering, Cisbio
International
Breath hold: no
breath
hold instructions
reported
CT used for: ap-
pears to be used
for
attenuation cor-
rection; also de-
scribes anatom-
ical localisation
Any hy-
permetabolic fo-
cus more intense
than
the surrounding
background, in-
cluding equivo-
cal foci, com-
pared with
the correspond-
ing anatom-
ical structure on
coupled CT
Info provided:
localisa-
tion of the initial
tumour and the
standard clinical
and radiological
assessment were
known
No. observers:
2; no details.
Diagnosis: con-
sensus of 2
Histology (22,
100%)
FNAC (N/A)
FU (22/22,
100%): mean 17
months (range 1
to 44)ˆ
Histology inter-
val: 12 days
FU interval: NR
Exclusions: n =
2; 2 test fails (no
SN detected)
314Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
on fused images
Reconstruc-
tion: OSEM 3D
Sanki 2009
Australia
Patients: 716
Primary
lesions: NR
LNBs/
Metastases: 871
NC
Design unclear
Data: per pt
Nodal mets:
125/716 = 17%
Primary (pre-
SLNB)
Stage of disease:
NR
In-
clusion: SLNB;
BT > 1 mm or
< 1 mm with ad-
verse histological
features, such as
Clark’s level IV
toV invasion, ul-
ceration, or high
mitotic rate
Mean age: NR;
Median age:
NR; Range: NR
Male: NR (0%).
Site: NR
NR
US.
B-mode US; lin-
ear array trans-
ducer with high-
resolution small-
parts probe 5 to
10 MHz (linear
transducer); 10
to
14 MHz (small
parts probe); LS
before US
Scan coverage:
sites marked by
nuclear
medicine physi-
cian during LS
Contrast: N/A
Breath hold: N/
A
Re-classifi-
cation of original
report as suspi-
cious, or highly
probable, e.g. in-
creased vascular
sig-
nature, rounding
of the normal
ovoid shape of
the nodes, loss
of normal hi-
lar echoes, pres-
ence of focal low-
level subcapsular
space echoes
Info provided:
NR
No. observers:
NR; nuclear
medicine physi-
cian (NR)
Diagnosis: sin-
gle
Histology (716,
100%)
FNAC (0)
FU
(100% (SLNB;
not ref standard
for US)): 13.5
months (mean,
18.4 months)
Histology inter-
val:
SLN performed
within 24 hours
of LS and US
FU interval:NR
Exclusions: n =
0
Sibon 2007
France
Patients: 131
Primary
lesions: 132
LNBs/
Metastases:NR;
189 SLNs
NC
Retrospec-
tive (prospective
database
reported; plus
prospective re-
interpretation of
US images)
Data: per pt
Nodal mets: 35/
133 = 26%
Primary (pre-
SLNB)
Stage of disease:
NR
In-
clusion: SLNB;
BT > 1 mm or
< 1 mm with ad-
verse histological
features, such as
Clark’s level IV
toV invasion, ul-
ceration, or high
mitotic rate
Mean age: 56;
Range: 17 to 92
years
Male: 70 (53.
4%). Site: arms
18, 13.6%, legs
43, 33%; trunk
48, 32%; hands/
feet 10, 8%; HN
18, 14%
Mean BT 2.60 ±
2.91 mm
Clark’s level II 8,
6%; III 30, 23%;
IV 88, 66%, V 7,
5%; unknown 1,
1%
US. B-mode;
linear transducer
(6 to 12 MHz);
US before LS
Scan
coverage: site of
the excised pri-
mary melanoma
scar
and followed the
paths of the lym-
phatic vessels to
the lymph node
area(s)
Contrast: N/A
Breath hold: N/
A
Stringent
criteria: circular/
oval hypoechoic
lymph nodewith
a Solbiati index <
1.5 and no hy-
perechoic hilum;
Non-stringent
criteria included
the presence of 1
or 2 stringent cri-
teria
Info provided:
NR for original
interpretation or
for re-interpreta-
tion
No. observers:
NR; 1 radiolo-
Histology (131,
100%)
FNAC (-):
FU (n NR): no
details
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0;
using stringent
criteria, US de-
tected 1/24 mi-
cro-metastases <
2 mm (as mea-
sured byUS) and
2/
11 macro-metas-
tases ≥ 2 mm
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gist reviewed all
images; radiolo-
gist (high)
Diagnosis: sin-
gle
(both > 5 mm)
Singh 2008
Germany
Patients: 52
Primary
lesions: NR
LNBs/Metas-
tases: 67 LNBs;
111 SLNs
NC
Unclear
Data: per pt
Nodal mets: 14/
52 = 27%
>4mmBT: 7/12
= 58%
≤ 4 mm BT: 7/
40 = 18%
Primary (pre-
SLNB)
Stage of disease:
all I or II
Inclusion: pri-
mary MM un-
dergoing SLNB
(all > 1 mm)
Mean age: 55;
Median age: 61;
Range: 17 to 76
Male:36 (69%).
Site: extremities
23, 44%; trunk
16, 31%; HN
13, 25%
Mean BT 3.46
mm, range 1.0
mm to 12.0 mm
PET-
CT. Helical, CT
(CE, dual detec-
tor)
Scan coverage:
WB;base of skull
to tip of toes in 3
parts
Contrast: Peri-
trast-
oral-GI; Kohler
Chemie GmbH,
Alsbach,
Germany
CT parameters:
130 kV, 40 mAs;
5 mm
18FDG: 370 ±
40 MBq 18FDG
through an ante-
rior cubital vein
Breath hold:
lim-
ited breath hold
for CT and shal-
lowbreathing for
PET
CT used for:
attenuation cor-
rection based on
re-scaling of CT
image; image fu-
sion
Re-
construction: it-
erative (not fur-
ther detailed)
Any focal up-
take more than
background un-
less it was found
to be a false posi-
tive focus (physi-
ological accumu-
lation or brown
fat tissue) in fu-
sion imaging
Info provided:
NR
No. observers:
2; two experi-
enced observers
assessed 18FDG
PET-
CT fusion imag-
ing indepen-
dently; also refers
to team of radi-
ologists and nu-
clear physicians
(experienced)
Diagnosis: con-
sensus
Histology (52,
100%)
FNAC (N/A)
FU (n NR): no
details
Histology inter-
val: PET before
LS before SLNB
FU interval:NR
Exclusions: n =
0;
2 TP both BT≥
4 mm and FPs <
4 mm
van Rijk 2006
Netherlands
Patients: 107
Primary
lesions: 107
WPC
Retrospective
Data: per pt
Nodal mets: 37/
107 = 35%
Primary (pre-
SLNB)
Stage of disease:
NR
In-
Mean age: 50;
Range: 15 to 52
Male: 57 (53%).
Site: HN 6, 6%;
trunk 43, 40%;
US. B-mode lin-
ear array (7.5
MHz; 6 to 12
MHz); US be-
fore LS
Suspicious -
length-depth ra-
tio < 2, conver-
sion of a fatty
hilum to a hy-
Histology (107,
100%)
FNAC (22; not
part of ref stan-
dard)
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LNBs/
Metastases:NR;
37 D+ in 42
LNBs
clusion: SLNB
candidates; cuta-
neous MM BT >
1mmor Clark≥
level IV
arm 24, 22%; leg
34, 32%
median BT 2.0
mm (0.6 to 12.5
mm)
Clark’s level II 1,
1%; III 37, 35%;
IV 55, 51%; V
9, 8%; undeter-
minable 5, 5%
Scan coverage:
NR
Contrast: N/A
Breath hold: N/
A
US + FNAC for
US positive
poechoic hilum,
substantial corti-
cal asymmetry or
a focal area of
low-level echoes
in the subcapsu-
lar sinus of the
node and diam-
eter > 5 mm for
LN of the neck
Info provided:
NR
No. observers:
NR; no details
Diagnosis: NR
FU (2/107; 2%
(reported only
for 2 positive on
FNAC)): NR
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0;
FU
of 2 FNAC pos-
itive participants
is reported but
no further refer-
ence is made to
any recurrences
Voit 2014
Germany
Patients: 1000
Primary
lesions: 1000
LNBs/
Metastases: NR
WPC
Design unclear
Data: per pt
Nodal mets:
208/1000 = 21%
Primary (pre-
SLNB)
Stage of disease:
NR
In-
clusion: SLNB
candidates; BT >
1 mm thickness,
or Clark IV/V,
ulcerated and/or
regressed
Mean age: 59;
Median age: 62;
Range: 15 to 94
Male: 567
(57%) Site: NR
Mean BT 2.58
mm;median BT
1.57 mm BT <
1 mm 288 29%;
1 to 2 mm 308
31%; 2 to 4 mm
231 23%; > 4
mm 173 17%
Clarks II 32 3%;
III 341 34%; IV
554
56%; V 54 6%,
unknown 13 1%
US. B-mode &
Doppler (1 to 18
MHz); LS before
US
Scan coverage:
LNBs; patients
first underwent
a lymphoscintig-
raphy, which as-
sists the ultra-
sonographist to
better focus the
examination
Contrast: NA
US + FNAC for
US positive
Malignant if to-
tal loss of central
echoes (LCE) or
LN enlarged and
balloon shaped
(BS); suspicious
if peripheral per-
fusion present or
central
echo wandering
towards the rim
Info provided:
NR
No. observers:
3; ultrasono-
graphist (mixed;
1 expert and 2
trained but less
expert)
Diagnosis: un-
clear; likely sin-
gle?
Histology
(1000, 100%)
FNAC (332,
33%; authors re-
port
as 342, including
10USmalignant
as FNAC posi-
tive even though
no FNAC was
undertaken):
FU (1000;
100%): mean 56
m;median 53m;
range 1 to 132 m
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0
Wagner 2012
France
Patients: 48
Primary
lesions: 48
LNBs/
Metastases: NR
NC
Retrospective
Data: per pt
Nodal mets: 14/
43 = 33%
Primary (pre-
SLNB)
Stage of disease:
stage IIA 8, 16.
7%; stage IIB 19,
39.6%; stage IIC
19, 39.6%; 2, 4.
2% NR
Inclu-
Mean age: NR;
Median age:
NR; Range: NR
Male: 25 (52%).
Site: NR
Mean
BT 7.6 mm (±4.
5) (range 1.1 to
18 mm)
PET-CT. 2D;
CT (NR)
Scan coverage:
WB; not further
described
Contrast: NR
CT parameters:
140 kV, 200 mA
(attenuation cor-
Abnormally in-
creased 18FDG
uptake
in a lymph node
in the drainage
territory of the
melanoma
Info provided:
aware of all clin-
Histol-
ogy (43, 89.6%;
2 CLND only, 1
SLNB + CLND,
40 SLNB only)
FNAC (N/A)
FU (1): min 12
months
Histology inter-
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sion: SLNB can-
didates; BT ≥ 4
mm or BT > 1
mm with ulcera-
tion
rection
and anatomical
correlation); 7.5
mm
18FDG:
370MBq (Glu-
cotep
Cyclopharma, St
Beauzire,
France)
Breath hold:
normal breath-
ing; “remain
rested, to refrain
from speaking,
and to minimize
swallowing”
CT
used for: attenu-
ation correction
and anatomical
correlation
Recon-
struction: itera-
tive OSEM (Or-
dered Subset Ex-
pectation Max-
imization) algo-
rithm (3 itera-
tions; 10 subsets)
ical findings
No. ob-
servers:NR; nu-
clear medicine
specialist (high)
Diagnosis: un-
clear; ’at least
one’
val: NR
FU interval:NR
Exclusions: n =
5; SLNBnot per-
formed for tech-
nical reasons
+: positive; AJCC: American Joint Cancer Committee; AWOSEM: attenuation weighted ordered subsets expectation maximisation;
BT: Breslow thickness; CE: contrast enhanced; CLND: complete lymph node dissection; CT: computed tomography; 2D: two-
dimensional; 3D: three-dimensional; EDV: end-diastolic volume; 18FDG: 2-deoxy-2-[18F]fluoro-D-glucose; FNAC: fine needle
aspiration cytology; FORE: Fourier rebinning; FU: follow-up; HN: head and neck; LN: lymph node; LNB: lymph node basin; LND:
lymph node dissection; LS: lymphoscintigraphy; mA: measure of tube current; mets: metastases; MM: malignant melanoma; NC:
non-comparative; OSEM: ordered subsets expectation maximisation algorithm; PET: positron emission tomography; PI: pulse index;
PSV: peak systolic volume; prosp: prospective; RF: risk factor; SD: standard deviation; SLN: sentinel lymph node; SLNB: sentinel
lymph node biopsy; SSM: superficial spreading melanoma; SUV: standardised uptake value; U: unenhanced; US: ultrasound; WB:
whole body
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Appendix 9. Characteristics of studies of whole body imaging by population group (primary staging,
re-staging, and mixed or unclear populations)
Study
Country
Pt/lesion num-
bers
Study design
Outcome
Prevalence
Presentation
Inclusion crite-
ria
Imaging
eligibility
Age, gender,
site, BT, Clark
Index test Threshold
Observers
Reference
Exclusions
Other result
PRIMARY STAGING OF DISEASE
Arrangoiz 2012
USA
Patients: 56
Primary
lesions: 56
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
NR)
Data: per pt
Any mets (NR;
scan incl head):
32/56 = 57%
Nodal: 29/56 =
52%
Distant mets : 5/
56 = 9%
Primary (N/A)
Stage of disease:
all T4 and clin-
ically node neg-
ative and nega-
tive for distant
metastases
Inclusion: node
negative; BT > 4
mm
Mean
age: 67; Median
age:NR;Range:
26 to 89
Male: 32 (57.
1428571428571%)
Site: trunk 16,
29%; extremities
28,
50%; head and
neck 12, 21%
BT median
6 mm; mean 9
mm; range 4.1 to
40 mm
PET-CT. 2D or
3D; CT (U, he-
lical, low dose)
Scan coverage:
WB; vertex of
the head down to
feet for all pa-
tients
Contrast: U
CT parameters:
Discovery
LS - 140 kVp,
90 mA; Siemens
Biograph - 130
kVp, 100 mA; 5
mm
FDG: 15 mCi
(IV)
Breath hold:
normal breath-
ing
CT used for:
attenuation cor-
rection; co-regis-
tered images
Reconstruc-
tion: Discovery
LS - OSEM al-
gorithm with 28
subsets and 2 it-
erations
Siemens Bio-
graph - TrueX al-
gorithm with 21
subsets and 2 it-
erations
SUV of 2.5
Info provided:
NR
No.
observers: NR;
’in-house medi-
cal physicist’
mentioned; NR;
’in-house medi-
cal physicist’
mentioned (NR)
Diagnosis: un-
clear
Histology (54,
96% (48 SNB
and 6 LND))
FNAC (NR):
FU (NR): NR
Histology inter-
val:
NR; states that
6 “proceeded di-
rectly to thera-
peutic lymph
node dissection”
after PET
FU interval:NR
Exclusions: n =
0; N/A
Hafner 2004
Switzerland
WPC
Prospective
Primary (N/A).
Stage of disease:
Mean age: NR;
Median age: 55;
US. B-mode (5
Mhz); US before
NR; ’radiologi-
cally suspect’
Histology (100;
100%)
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Patients: 101
Primary
lesions: 101
LNBs/Metas-
tases:105LNBs;
136 SLNs
Data: per pt
Nodal mets: 26/
100 = 26%
NR; stage IV (ev-
idence of distant
mets) excluded
Inclu-
sion: any cuta-
neous MM with
BT
≥ 1 mm with-
out evidence of
detectable
distant metasta-
sis (includes clin-
ically palpable)
Range: 18 to 79
Male: 55 (55%)
Site: limbs 49,
49%, trunk 35,
35%, HN 16,
16%
BT: 1.01 to 2
mm 38; 2.01 to
4 mm 43; > 4.0
mm 19
LS
Scan coverage:
regional
lymph nodes of
the groins, ax-
illae, and neck
(abdominal US
also performed)
Info provided:
unclear
No. observers:
1; radiology resi-
dent (NR)
Diagnosis: sin-
gle (supervision
by senior staff ra-
diologist)
FNAC (NR (ab-
stract reports 3
LN mets identi-
fied on physical
exam, 2 of which
were detected by
US)):
FU (NR): 20
months (8 to 39)
Histology inter-
val: 2 weeks
FU interval: 6
months
Exclusions: n =
1; sentinel node
was not found
intraoperatively
No confirmed
distant mets de-
tected at time of
imaging; 9 pa-
tients with suspi-
cious findings on
imag-
ingwere negative
for progression/
recurrence at 12
months
Kang 2011
S Korea
Patients: 37
Primary
lesions: 37
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
no; medical
record review)
Data: per pt
Any mets (incl
brain): 9/37 =
24%
Primary (N/A)
Stage of disease:
stage 0: 7
(18.9%); stage I:
6 (16.2%); stage
II: 17 (45.9%);
stage III: 6 (16.
2%); stage IV: 1
(2.7%)
Inclu-
sion:newly diag-
nosed cutaneous
MM undergoing
staging work-up
with PET-CT
(any stage, in-
cluding clinically
node positive)
Mean age: 61.
7 years; Median
age:NR;Range:
48.1 to 75.3; ±
13.6 years
Male: 17 (45.
9%)
Site: hand/
foot 23 (62.1%)
, trunk 6 (16.2),
head/neck 4 (10.
8%), extremity 4
(10.8%)
BT < 1.0 mm 8,
22%; ≥ 1 mm
15, 41%;NR14,
38%
PET-CT.
CT (U, 6 slice or
16 slice) (N/A)
Scan
coverage: vertex
of skull to knees;
plus lower limbs
if with lower leg
MM
Contrast: U
CT parameters:
Reveal RT-
HiRez: 130 kV,
95 mA
Discovery
ST: 140 kV, 160
mA; Reveal RT-
HiRez: 2.5 mm
Discovery ST: 3.
SUVmax ≥ 2.2
Info provided:
NR
No.
observers: 2; nu-
clear physicians
(experienced)
Diagnosis: con-
sensus of 2
Histology (6
(16.2%))
FNAC (0)
FU (37 (100%))
: median follow-
up 24.3 ± l l.7
months (range 8
to 55 months)
Histology inter-
val: NR
FU interval: 3
months
Exclusions: n =
0
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75 mm
FDG: 350 to
400 MBq
Breath
hold: NR; ’stan-
dard protocol’
CTused for:un-
clear; combined
PET-CT unit,
mentions identi-
fication
of anatomical lo-
cation on fused
PET-CT image
Reconstruc-
tion: or-
dered subset ex-
pectation-
maximisation
Maubec 2007
France
Patients: 25
Primary
lesions: 26
LNBs/
Metastases: NR
WPC
Prospective
Data: per pt
Any (incl brain):
7/25 = 28%
Primary (N/A).
Stage of disease:
all T4; 3 clini-
cally node posi-
tive
Post surgery:
AJCC stage IIB
10, 40%;
IIC 4, 16%; IIIA
4, 16%; IIIB 6,
24%; IIIC in 1,
4%
Inclusion:
any MM BT >
4 mm; SLNB
planned if clini-
cally node nega-
tive
Mean age: 60;
Range: 14 to 87
Male: 15 (0.6%)
. Site: trunk 8,
32%; limbs 8;
32%; head and
neck 9, 36%
Mean BT 6.6
mm, range 4.8 to
12.5 mm
PET-CT. 3D;
CT (U)
Scan coverage:
WB; “top of the
head to the mid-
thigh and
included if nec-
essary, the lower
limbs”
Contrast: U
CT parameters:
80 mA; 110 kV;
5 mm
FDG: 5MBq/kg
Breath hold:
normal breath-
ing;
“no breath hold
instructions”
CT used for:
NR; integrated
system
Reconstruc-
tion: iterative al-
gorithm (FORE
and AWOSEM)
with 2 iterations,
8 subsets, and
Uptake site sus-
picious for ma-
lignancy or not
clearly explained
by a benign eti-
ology (SUV esti-
mated
but does not ap-
pear to formally
contribute to di-
agnosis)
Info provided:
NR
No. observers:
NR; NR (NR)
Diagnosis: NR
Histology (22,
88%; 3 node
positive under-
went CLND; 19
had SLNB; 3 no
surgery)
FNAC (N/A)
FU (25, 100%):
mean 11 months
(2 to 19 months)
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0; all recruited
pts can be in-
cluded in analy-
sis for any mets.
3 PET +ve for
distant mets (1
orbital, 1 thy-
roid, 1 liver)
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a 5 mm full-
width half max-
imum (FWHM)
Gaussian postfil-
ter
Prayer 1990
Austria
Patients: 217
Primary
lesions: NR
LNBs/
Metastases: NR
WPC
Unclear (Prosp
database: NR)
Data: per pt
Nodal mets: 29/
217 = 13%
Primary
Stage of disease:
NR
Inclusion: pri-
mary MM inves-
tigated either be-
fore or after re-
moval of the pri-
mary melanoma
in postoperative
follow-up
Mean
age: 56; Median
age:NR;Range:
25 to 82
Male: 104 (47.
926267281106%)
Site: HN
42, 19%; arm
61, 28%; shoul-
der 23, 11%; leg
91, 42%
BT < 0.75 mm
25, 12%; 0.75
to 1.5 mm 96,
44%; 1.5 to 3.00
mm 79, 36%; >
3 mm 17, 8%
Clark level
II 936, III 89, IV
33
US.B-mode (7.5
MHz); N/A
Scan coverage:
primary LNs de-
pending on tu-
mour
localisation.Cer-
vical (42); ax-
illary (84); in-
guinal (91)
Contrast: N/A
Suspicious - cir-
cular and
oval masses with
poor echo; longi-
tudinally config-
urated LNs with
echogenic eccen-
tric hilum re-
garded as “en-
larged reactively”
Info provided:
unclear; differ-
ent clinicians for
palpa-
tion (dermatolo-
gist) and for US
(radiologist)
No.
observers: 1; ra-
diologist (NR)
Diagnosis: sin-
gle
Histology (29,
13%)
FNAC (0)
FU (188, 87%):
6 months
Histology inter-
val: NR
FU interval: 2
months
Exclusions: n =
0
There were
no false-negative
sono-
graphic results i.
e. melanoma
metastases did
not occur within
the following 6
months in any
of the patients
classified as hav-
ing no suspect
regional lymph
nodes. The
smallest metasta-
sis detected by
ultrasound was
11 mm in diam-
eter
Veit-Haibach
2009
Germany
Patients: 56
Primary
lesions: 56
LNBs/
Metastases: NR
WPC
Prospective
Data: per pt
Nodal: 13/56 =
23%
Dis-
tant (brain NR):
12/56 = 21%
Primary (N/A)
Stage of disease:
on presentation:
stage I or II 44,
79%; stage III or
IV 12, 21%
Inclusion: any
primary MM re-
ferred for PET-
CT
Excluded if in-
sufficient FU
Mean age: 62
years; Median
age: Range: 23
to 86 years
Male: 27 (48.
2142857142857%)
Site: trunk 26,
46%; upper ex-
tremities 10,
18%; lower ex-
tremity 18, 32%;
HN 2, 4%
CT. CE; two
slice (N/A); NR
Scan coverage:
WB; no further
detail, just states
caudocranial di-
rection
Contrast:
dual phase injec-
tion of 140 mL
of 300 mmol/
mL io-
CT: Lesion size
and
central necrosis
for malignancy;
fatty hilum and
calcifications for
benign. For size:
short-axis diam-
eter threshold of
1.5
cm for jugulodi-
gastric and pre-
Histology (un-
clear; 14 with
SLNB, 25%)
FNAC (0)
FU (56, 100%):
mean 780
days (range 102
to 1390 days);
roughly
equivalent to 25.
6 months (3.3 to
45.7 months)
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NR dinated contrast
agent (90 mL at
a rate of 3 mL/s,
and 50 mL at a
rate of 1.5 mL/s;
dual phase used
to ensure fully
diagnostic (por-
tal venous phase)
CT data in the
abdomen)
CT parameters:
NR; NR
Breath hold:
NR
PET-
CT. full ring-CT
(CE; 2 slice) (N/
A); NR
Scan coverage:
WB; no further
detail, just states
caudocranial di-
rection
Contrast:
140 mL of 300
mmol/mL io-
dinated contrast
agent
CT parameters:
NR; NR
FDG: 330 to
350 MBq
Breath hold:
NR
CT used for:
attenuation cor-
rection
Reconstruc-
tion: re-
constructed iter-
atively (FORE-
OSEM, 2 itera-
tions, 8 subsets,
128×128 matrix
with 5 mm gaus-
sian smoothing)
carinal LNs and
threshold of 1
cm for all other
LNs of the neck,
thorax, and ab-
domen [16]
PET-CT: in-
creased glucose
metabolism and
independent of
their size
Info pro-
vided: provided
patient-specific
clin-
ical background
(first diagnosis of
melanoma, post-
surgical resection
status, location
of the resection
site) but blinded
to clinical exam
and histopathol-
ogy of primary
tumour
No.
observers: 2; ra-
diologists (NR).
Diagnosis: con-
sensus of 2
Histology inter-
val: 4 weeks for
SLNB
FU interval:NR
Exclusions: n =
0
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RE-STAGING OF DISEASE
Iagaru 2007
USA
Patients: 106
Primary
lesions: NR
LNBs/
Metastases: 139
WPC
Retrospective
(Prosp database:
NR)
Data: per pt
Any mets (incl
skin and brain):
56/106 = 53%
(all tests)
Data: per lesion
Any mets (incl
skin and brain):
87/139 = 63%
Re-stag-
ing (all patients
had the study re-
quested for dis-
ease re-staging)
Stage of disease:
NR; 76 stage I to
IIIc and 30 stage
IIIb to IV)
Inclusion: PET-
CT for MM re-
staging
Excluded if NR
ORNR
PET-CT for
MM re-staging
Mean age: 56.8
± 15.9 Median
age: nr; Range:
20 to 87
Male: 68 (64.
1%)
Site: NR
BT at initial di-
agnosis (n = 76)
: mean 3.56 mm,
0.4 to 25 mm; <
1 mm in 6 (8%)
, 1 to 4.0 mm 58
(76%), > 4 mm
12 (16%)
Clark’s level (n
= 70): 3 (4%)
, level II; 13
(19%), level III;
43 (61%), level
IV; 11 (16%),
level V
CT. U, multi-
slice helical (N/
A)
Scan coverage:
WB; top of the
head to the an-
kles
Contrast: N/A
CT parameters:
140 kV, 40 mA;
5 mm
Breath hold: no
breath
hold instructions
reported
PET-CT. 2D;
CT (U, multi-
slice helical) (N/
A)
Scan coverage:
WB ; top of the
head to the an-
kles
Contrast: U
CT parameters:
140 kV, 40 mA,
5 mm
FDG: 15 mCi
Breath hold: no
breath
hold instructions
reported
CT
used for: attenu-
ation correction
and anatomical
localisation
Reconstruc-
tion: OSEM, 2
iterative steps, 28
subsets
CT: NR
PET-CT:
SUVmax ≥ 2.5
Info provided:
NR for original
interpretation or
for re-interpreta-
tion
No. observers:
NR; board-certi-
fied nuclear
medicine physi-
cians and radiol-
ogists (board cer-
tified)
Diagnosis: con-
sensus
Histology (97,
91.5%)
FNAC (N/A)
FU (9, 8.5%):
NR
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0; N/A
Rubaltelli 2011
Italy
Patients: 436
Primary
lesions: NR
WPC
Unclear
Data: per pt
Nodal mets: 13/
436 = 3%
Re-
staging (all un-
dergoingpostop-
erative follow-up
de-
Mean age: 54;
Median age: 58;
Range: 27 to 81
years
Male: Full sam-
US. B-mode; lin-
ear array trans-
ducers (7.5 to 13
MHz)
Scan coverage:
US:
focal hypoechoic
cortical thicken-
ing - a focal area
of cortex at least
Histology (13,
3%)
FNAC (436,
100%)
FU (31/
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LNBs/
Metastases: NR
signed to ensure
the early identifi-
cation of lymph
node metastases)
Stage of disease:
NR
Inclusion: cuta-
neous MM with
US of regional
LNs as part of a
follow-up;
those with ’com-
mon signs of ma-
lignancy’ on B-
mode US were
excluded
ple: 240 (52%)
Site: NR
variable: axillary
lymph nodes for
MM of
the upper limbs,
inguinal lymph
nodes forMMof
the lower limbs,
both axillary and
inguinal lymph
nodes forMMof
the
trunk, and cer-
vical and supra-
clavicular lymph
nodes for MM
of the head and
neck (72 neck,
248 axillary, and
354 inguinal
LNBs were ex-
amined)
Contrast: N/A
US. contrast-en-
hanced US (7.5
to 13 MHz)
Scan coverage:
LNBs identified
on B-mode US
Contrast: sulfur
hexafluoride mi-
crobubbles
(SonoVue,
Bracco)
twice as thick
as the cortex in
the remainder of
the same lymph
node
CE-US:
perfusion defects
corresponding to
the cortical focal
thickening; ho-
mo-
geneous intense
enhancement of
the cortex con-
sidered benign
Info provided:
NR
No. observers: 1
of 3; sonologist
(high)
Diagnosis: sin-
gle
44 FNAC nega-
tive, 70%): 6 to
16 months (me-
dian, 10
months)
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
24; definite signs
of malignancy
on B-mode US
Strobel 2007a
Switzerland
Patients: 47
Primary
lesions: 47
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
NR)
Data: per pt
Any (incl brain):
39/47 = 83%
Re-stag-
ing (all pts fol-
lowed up accord-
ing to updated
Swiss melanoma
guidelines)
Stage of disease:
NR
Inclusion: high
risk
melanoma (BT >
4 mm, or Clark
level III or IV, or
known resected
metastases) and
Mean age: 58.
4 years; Median
age: Range: 20
to 83 years
Male: 20 (42.
5531914893617%)
Site: NR
BT 1.02 mm
to 15 mm; un-
known in 9
PET-CT. 2D
PET, CT (CE,
multi-slice, heli-
cal)
Scan coverage:
head to the knees
with scanning of
the lower legs
for patients with
primary tumours
of the lower ex-
tremities
Contrast:
oral CT contrast
agent given
FDG uptake
clearly greater
than
background and
established mor-
phological CT
criteria; if a fo-
cal FDG-active
lesion was de-
tected, the exact
anatomical local-
isation was de-
termined on the
fused PET-CT
Histology (29,
62%; 20 distant
mets and 9 LN
mets)
FNAC (4, 8.5%)
FU (47, 100%)
: minimum of 6
months (range 6
to 18 months in
all patients
Histology inter-
val:
FU interval: 3
months
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raised S100 (>
0.2 µg/L) un-
dergoing follow-
up after primary
treatment
Excluded
if PET-CT and
S100B measure-
ment > 2 weeks
apart; treatment
initiated be-
tween PET-CT
and
tumour marker
measurement; or
systemic therapy
before the PET-
CT investigation
15 minutes be-
fore injection of
18F-FDG
CT parameters:
140 kV, 40 mAs,
4.25 mm
FDG: 370 to
400 MBq
Breath hold:
CT: breath hold-
ing in the normal
expiratory posi-
tion
CT used for:
attenuation cor-
rection, fused
Reconstruc-
tion: standard it-
erative algorithm
(OSEM)
images. Lesions
with 18F-FDG
uptake in phys-
iological sites or
benign variants,
e.g.
muscles, brown
fatty tissue or
pulmonary infil-
trations, were de-
termined as be-
nign
Info provided:
blinded to serum
S100B
No. observers:
2; nuclear radi-
ology physicians
(experienced)
Diagnosis: con-
sensus of 2
Exclusions: n =
0; N/A
Reports charac-
teristics of those
with elevated
S100 but not
mets detected on
imaging
STAGING IN MIXED OR UNCLEAR POPULATIONS
Abbott 2011
UK
Pa-
tients: 34 (mi-
croscopic group
20; macroscopic
group 14)
Primary
lesions: 34
LNBs/
Metastases: NR
NC
Retrospective
(Prosp. database
used)
Data: per pt
Any (excl brain):
7/34 = 21%
Mixed (primary/
FU)
Stage of disease:
IIIA 18, 53%;
IIIB 10, 29%;
IIIC 6, 18%
Inclusion:
stage III: micro-
metastases
on SLNBor clin-
ically detectable
nodal metastases
on diagnosis or
FU
Mean age: NR;
Median age:mi-
croscopic group:
50; macroscopic
group:
63 Range: mi-
croscopic group:
19 to 74 years
Macro-
scopic group: 48
to 79 years
Male: micro-
scopic group: 14
Macroscopic
group: 6 (Mi-
croscopic group:
70%
Macroscopic
group: 43%%)
Site:HN 1 (3%)
, upper
extremity 3 (9%)
, trunk 20 (59%)
, lower extremity
PET-CT. 2D;
CT (NR)
Scan coverage:
skull base to up-
per thigh
Contrast: NR
CT parameters:
NR; NR
FDG: 400 MBq
Breath hold:
NR
CT used for:
attenuation cor-
rection and le-
sion localisation
Re-
construction: it-
erative technique
using an OSEM
algorithm
Clearly indica-
tive/highly sus-
picious for ma-
lignancy consid-
ered positive
Info provided:
clinical - NR;
other tests - NR
No. ob-
servers:NR; nu-
clear medicine
consultants (ex-
perienced)
Diagnosis: NR
Histology (5,
15%)
FNAC (0)
FU (34, 100%):
micro-
scopic mean 38
months (21 to 54
months); macro-
scopic mean 34
months (15 to 52
months)
Histology inter-
val: NR
FU interval: 3
months
Exclusions: n =
0
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10 (29%)
BT (mean): mi-
croscopic group
2.27 mm (1.2 to
9.7mm); macro-
scopic group 2.
01 mm (1.0 to
13 mm)
Aukema 2010a
Netherlands
Patients: 46
Primary
lesions: NR
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
NR)
Data: per pt
Any (brain NR):
23/46 = 50%
Mixed (im-
aged on recur-
rence or after pri-
mary melanoma
treatment)
Stage of disease:
NR; unfavorable
primary tumour
(n = 6); pri-
mary melanoma
with simultane-
ous nodal metas-
tases (n = 18)
; unknown pri-
mary melanoma
with nodal
metastasis (n = 2)
; locoregional re-
currence (n = 15)
; distant recur-
rence (n = 5)
Inclusion:
raised S100 dur-
ing FU after re-
section of nodal
or distant metas-
tases orwith high
risk primary tu-
mour
Mean age: 59;
Median age: ;
Range: 25 to 93
years
Male: NR (0%)
Site: NR
NR
PET-CT. NR;
CT (U) (N/A)
Scan coverage:
whole body; not
described
Contrast: U
CT parameters:
kV NR; 40 mAs,
5 mm
FDG: 180 to
240 MBq (4.9 to
6.5 mCi)
Breath
hold: No breath
hold instructions
reported
CT used for:
attenuation cor-
rec-
tion; PET fused
to low-dose CT
Reconstruc-
tion: NR
NR; “hyperme-
tabolic lesions”
Info provided:
NR
No.
observers: 3; nu-
clear medicine
physicians (expe-
rienced)
Diagnosis: con-
sensus of 3
Histology (13,
28.3%)
FNAC (0)
FU (33, 71.7%)
: for D nega-
tive only (n =
19): median 12
months (4 to 32
months); NR for
full sample
Histology inter-
val: NR
FU interval
Exclusions: n =
NR
Other result:
“MRI revealed 2
brain metastases
of 2 and 4mm in
1 patient (2%).
This patient also
had other distant
metastases that
were detected by
PET-CT”
Aukema 2010b
Netherlands
Patients: 70
Primary
lesions: 70
LNBs/
Metastases: 73
NC
Prospective
Data: per pt
Any mets: 30/70
= 43%
Unclear (N).
Stage of
disease:
≥ stage IIIb (all
with clinically
palpable nodes)
Inclusion: clini-
cally node posi-
tive with no sign
of distant metas-
Mean age:
58;Median age:
NR; Range: NR
Male: 37 (0.
54%)
Site: upper ex-
tremity 4, 6%;
lower extremity
37, 53%; trunk
19, 27%; head/
PET-CT. 2D ;
CT (U) (N/A)
Scan cover-
age:WB accord-
ing to primary le-
sion site (i.e. IRT
inclusion of cra-
nium or lower
extremities)
Contrast: U
NR; “metaboli-
cally active”
Info provided:
NR
No. observers:
3; nuclear
medicine physi-
cians (NR)
Diagnosis: con-
sensus of 3
Histology (NR;
11 with histol-
ogy or cytology)
FNAC (NR; 11
with histology or
cytology):
FU (59; 84%):
NR;≥ 6 months
Histology inter-
val: N/A
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tases; primary/
re-staging NR
neck 9, 13%; un-
known primary
1, 1%
BT: median 3
mm
CT parameters:
kV NR; 40 mAs,
5 mm
FDG: 180 to
240 MBq
Breath hold: no
breath
hold instructions
reported
CT used for:
attenuation cor-
rec-
tion; PET fused
to low-dose CT
Reconstruc-
tion: PET was
fused with the
low-dose CT af-
ter correction for
attenuation
FU interval:NR
Exclusions: n =
0
Other
result: MRI de-
tected brainmets
in 5 pts, no refer-
ence standard re-
ported
Bastiaannet
2009
Netherlands
Patients: 251
Primary
lesions: 251
LNBs/
Metastases: NR
WPC
Prospective
Data: per pt
Distant mets:
78/251 = 31%
Mixed (primary
(LN mets diag-
nosed at time
of primary di-
agnosis) 39, 15.
5%; recurrence
(LN mets iden-
tified ≤ 3 years
since primary
dx) 145, 57.8%;
recurrence > 3
years since pri-
mary dx 67, 26.
7%)
Stage of disease:
III (100%)
Inclusion: node
positive (clin-
ical or histology/
cytology proven)
candidates for
CLND; imaging
to id further dis-
ease
Mean age: 56.9
years (n = 253)
; Median age:
NR; Range: 19
to 93 years (re-
ported in Bas-
tiannet 2012)
76 (30.3%) <
50 years; 99 (39.
4%) 50 to 65
years; 76 (30.
3%) > 65
Male: 152 (0.
606%)
Site:HN 29, 11.
6%; upper ex-
tremities 26, 10.
4%; trunk 93,
37.0%; lower ex-
tremities 88, 35.
0%; unknown
primary 15, 6.
0%
BT: ≤ 1 mm
32, 12.8%; 1.
0 to 2.0 73,
29.1%; ≥ 2.0
CT. CE, spiral,
multi-slice
Scan cov-
erage: chest, ab-
domen plus neck
for those with
LN in the neck
Contrast: oral
and IV
CT parameters:
NR; NR; ’multi-
slice’
Breath hold: no
breath
hold instructions
reported
NR (presence/
absence of mets)
Info provided:
NR
No. observers:
NR; attend-
ing staff nuclear
medicine physi-
cians (NR)
Diagnosis: NR
Histology (NR)
FNAC (NR)
FU (251, 100%)
: median 13.
7 months; min-
imum 6 months
stated for in-
dex test positive,
NR for index test
negative
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
8; excluded due
to follic-
ular structure (n
= 1), > 13 years
between primary
and lymph nodes
(n = 3), inci-
dence abroad (n
= 1), mu-
cosal melanoma
(n = 2), and pri-
mary melanoma
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129, 51.4%; un-
known primary
15, 5.9%; miss-
ing 2, 0.8%
Clark level: I/
II/III (n = 84;
33.5%), IV/V (n
= 144; 57.4%)
, unknown pri-
mary (n = 15; 5.
9%), missing (n
= 8; 3.2%)
treated as benign
lesion (n = 1)
(1) accuracy of
PET alone, (2)
change in treat-
ment resulting
from PET and/
or CT
Cachin 2014
France
Patients: 87
Primary
lesions: 176
LNBs/Metas-
tases: check en-
try
NC
Prospective
Data: per pt
Any
(incl brain, sub-
cut mets): 39/67
= 58%
Data: per lesion
Any (incl brain):
85/176 = 48%
Nodal: 20/39 =
51%
Distant (incl
brain): 65/137 =
47%
Bone: 14/34 =
41%
Lung: 10/27 =
37%
Soft tissue: 16/
25 = 64%
Skin: 7/9 = 78%
Brain: 7/9=78%
Mixed (states
imaging was for
staging or for re-
staging ).
Stage of disease:
NR; 45 (51%
were diagnosed
with melanoma
mets on study
Inclusion)
Inclusion: prior
history of cuta-
neous or ocu-
lar MM under-
going staging or
restaging includ-
ing: (a) newly di-
agnosed at any
TNM
stage, (b) known
visceral or cuta-
neous MM
metastases with
unknown pri-
mary tumour, or
(c) MM without
metastases (in-
cluded to assess
test specificity)
Mean age: NR;
Median age:
NR; Range: NR
Male: 42 (48.
3%)
Site: NR
Breslow thick-
ness (mm): < 1.
0: 12, 13.8%; 1.
0 to 2.0: 34, 39.
1%; ≥ 2.0, 41,
47.1%
Clark level: I 3,
3.4%; II 2, 2.
3%; III 20, 23.
0%; IV 46, 52.
9%; V 3, 3.4%;
not known 13,
14.9%
PET-CT. NR;
SPECTused in 4
of 8 centres
Scan coverage:
WB (not further
described)
Contrast: NR
CT parameters:
SPECT; N/A
FDG: 3 to 5
MBq/kg
Breath hold:
NR
CT used for:
PET ’correlated’
with CT abnor-
malities
Reconstruc-
tion: iterative in
6 of 8 centres;
filtered backpro-
jection in 2 of 8
centres
PET. Positive if
there was focal
uptake greater
than mediastinal
or liver uptake
that could not
clearly be related
to physiological
processes. Nega-
tive when a nor-
mal distribution
of tracer was ob-
served,
even if the CT
scan showed ab-
normalities.
Bone accumula-
tions were con-
sidered positive
when the uptake
was higher than
in normal bone
marrow. Any in-
stance of equiv-
ocal PET up-
take was consid-
ered positive
Info provided:
NR
No. observers:
NR; nuclear
physician (expe-
rienced)
Diagnosis: sin-
gle
Histology (25;
28.7%)
FNAC (N/A)
FU (87, 100%):
at least 6 months
Histology inter-
val: NR
FU interval:NR
Ex-
clusions: n = 20;
12 did not un-
dergo FDG PET
due to imaging
cancella-
tion; 8 are unac-
counted for (text
describes 75 hav-
ing PET but re-
ports results for
only 67)
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Dellestable 2011
France
Patients: 40
Primary
lesions: 40
LNBs/
Metastases:NR;
72 lesions
WPC
Prospective
Data: per lesion
Any (incl brain):
72/119 = 61%
(CT)
70/117 = 60%
(MRI)
72/119 = 61%
(PET-CT)
Nodal:
31/39 = 79%
(CT)
31/40 = 78%
(MRI)
31/38 = 82%
(PET-CT)
Bone:
14/17 = 82%
(CT)
14/16 = 88%
(MRI)
14/17 = 82%
(PET-CT)
Liver:
4/21 = 19%
(CT)
4/26 = 15%
(MRI)
4/25 = 16%
(PET-CT)
Lung:
13/16 = 81%
(CT)
13/14 = 93%
(MRI)
13/15 = 87%
(PET-CT)
Mixed (both pri-
mary staging and
FU; breakdown
reported but not
legible on pdf )
Stage of disease:
AJCC I to II 11,
27.
5%; AJCC III to
IV 29, 72.5%
Inclusion: PET-
CT for primary
staging
or follow-up of
MM, regardless
of AJCC stage or
indication for ex-
amination
Mean age: 57
years; Median
age: Range: 27
to 85 years
Male: 20 (0.5%)
. Site: NR
BT mean: 3.2
mm, median 2.7
mm, range 0.6 to
11 mm
CT. CT (N/A);
NR
Scan coverage:
skull, neck, tho-
rax, abdomen,
and pelvis
Contrast:
iodised injection
was adminis-
tered by the same
venous route as
for the previous
examinations
CT parameters:
NR; NR
Breath hold: no
breath
hold instructions
reported
MRI. WB, DW,
T2STIR, CE 3D
gradient echo
(N/A); NR
Scan cov-
erage:WB; head
to lower limbs
Contrast:
gadolinium
injection
MRI param-
eters: T2STIR,
T1,
diffusion and 3D
gradient echoT1
after gadolinium
injection; 1.5 T
Breath hold: no
breath
hold instructions
reported
PET-CT. NR;
CT (CE) (N/A);
NR
Scan coverage:
WB; top of the
CT: NR
MRI: NR
PET-CT:
focal uptake; un-
usual location or
visual or quan-
titative intensity
(SUV measure-
ment)
Info provided:
NR
No. observers:
3; NR (NR)
Diagnosis: sin-
gle with consen-
sus if the results
of any modality
disagreed
Histology
(36 lesions, 28%
of 128)
FNAC (0)
FU (72, 56%): >
4 months
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
20 lesions; 4 le-
sions with inde-
terminate refer-
ence and 16 not
picked up by CT
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skull to the feet
Contrast: un-
clear; contrast is
reported for CT;
how-
ever CT compo-
nent of PET-CT
is not clear
CT parameters:
NR; NR
FDG: 5.5 MBq/
kg
Breath hold: no
breath
hold instructions
reported
CT
used for: attenu-
ation correction
and anatomical
registration
Reconstruc-
tion: NR
Hausmann 2011
Germany
Patients: 50 eli-
gible; 33
included
Primary
lesions: 50
LNBs/
Metastases: NR
WPC
Prospective
Data: per lesion
Any mets (excl
brain): 455/824
= 55% (all tests)
Nodal: 192/379
= 51%
Distant: 263/
445 = 59%
Liver: 33/67 =
49%
Lung: 145/197 =
74%
Subcutaneous:
33/46 = 72%
Other (authors’
’Other’ category
plus Adrenal,
Kidney, Muscle
and spleen sites):
51/118 = 43%
Adrenal: 2/5 =
40%
Bone: 1/17 = 6%
Unclear (Pts de-
scribed as having
undergone a pre-
vious assessment
of tumour spread
based on ADO
(German) guide-
lines but staging/
re-staging not
described
Stage of disease:
full sample only:
stage III (19);
stage IV (31)
Inclusion:
AJCC stage III
or IVMM; clini-
cal indication for
imaging was
positive sentinel-
node
biopsy or suspi-
cious lesions on
ultrasound or X-
ray studies
Mean age: full
sample only: 59.
6; Median age:
Range: full sam-
ple only: 26 to 86
Male:
full sample only:
32 (64%)
Site: NR
NR
CT. U +
CE, multi-detec-
tor (N/A)
Scan cov-
erage: skull base
to pelvis; CT and
MR compared
for “neck to the
pelvis” only; sites
imaged included
lungs,
liver, spleen, kid-
neys, adrenal
glands, sub-
cutaneous tissue,
lymph nodes,
mus-
cle, bone mar-
row, and “other”
Contrast: U +
CE
CT parameters:
NR; NR
Breath hold: no
CT: NR (pres-
ence/absence of
mets)
MRI: NR (pres-
ence/absence of
mets)
Info
provided: diag-
nosis/age/sex
No. observers: 4
(2 included); ra-
diologist (high)
Diagnosis: sin-
gle
Histology (NR)
FNAC (0)
FU (33, 100%):
≥ 3 months
Histology inter-
val: N/A
FU inter-
val: minimum 3
months
Exclusions: n =
17; no WB-CT
follow-upunder-
taken.
Results
presented by re-
gion and for less
experienced ob-
servers
3 and 4; also pre-
sented no. Mets
detected by cra-
nial MR but no
2×2 extractable
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Kidney: 2/32 =
6%
Muscle: 22/26 =
85%
Spleen: 4/24 =
17%
breath
hold instructions
reported
MRI. U +
CE; ’standard se-
quences’ (N/A)
Scan coverage:
WB; as above
Contrast: U +
CE
MRI parame-
ters: standard se-
quences with
parallel imaging
techniques; 1.5
T
Breath hold: no
breath
hold instructions
reported
Jouvet 2014
France
Patients: 37
Primary
lesions:
LNBs/
Metastases: 209
lesions (n varies
per test)
WPC
Prospective
Data: per lesion
Any mets (incl
brain):
115/209 = 55%
(CT)
125/218 = 57%
(MRI)
Any mets (excl
brain): 95/186 =
51% (CT)
105/195 = 54%
(MRI)
104/191 = 54%
(PET-CT)
Nodal: 23/53 =
43% (all tests)
Bone:
15/33 = 45%
(CT/MRI)
16/35 = 46%
(PET-CT)
Liver:
12/27 = 44% (all
tests)
Lung:
31/45 = 69% (all
Unclear (NR)
Stage of disease:
stage IV: 37
(100%)
Inclusion:
AJCC stage IV
cutaneous MM
referred
for simultaneous
staging by PET-
CT, CT, superfi-
cial lymph node
US, and MRI
Mean age: NR;
Median age:
NR; Range: NR
Male: NR (0%)
Site: NR
NR
CT. CE; Helical;
16 row (N/A)
Scan
coverage: neck/
chest/ abdomen/
pelvis; “cervico-
thoraco-ab-
domino-pelvic
helicoidal acqui-
sition”; then
skull
Contrast: iodi-
nated IV injec-
tion
CT parameters:
120kV, 250mAs
(neck to pelvis);
140kV, 120mAs
(skull), 1.25 mm
(neck to pelvis),
2.5 mm (skull)
Breath hold: no
breath
hold instructions
reported
MRI. (1) DW
CT and MRI:
NR (presence/
absence of mets)
Info provided:
NR
No.
observers: 1; ra-
diologist (experi-
enced).
Diagnosis: con-
sensus of 2 (all
images interp in-
dependently by 2
ex-
aminers, discor-
dant results re-
solved by con-
sensus)
Histology (0)
FNAC (5, 13.
5%)
FU (32; 86.5%):
> 9 months
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0; N/A
Results are
also presented by
metastatic site.
Provides K val-
ues for inter- and
intra-observer
agreements, but
not the 2×2 ta-
bles for each ob-
server
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tests)
Subcutaneous:
2/15 = 13%
(CT)
10/22 = 45%
(MRI)
7/15 = 47%
(PET-CT)
alone (N/A);
(2) DW, VIBE
- 3D echo gra-
dient CE, T1 -
skull (N/A)
Scan coverage:
WB; top of skull
to feet
Contrast: U
MRI parame-
ters: echo-planar
DW alone; 1.5 T
Breath hold: no
breath
hold instructions
reported
Klebl 2003
Germany
Patients: 83
Primary
lesions: 83
LNBs/
Metastases:NR;
653 LNs exam-
ined
WPC
Prospective
Data: per pt
Nodal mets: 17/
79 = 22%
Mixed (primary
(n = 8), follow-
up (n = 75))
Stage of disease:
NR
Inclusion: MM
Clark level IV
or V undergoing
FU after primary
surgery
Mean age: NR;
Median age:
NR; Range: NR
Male: 46 (55.
421686746988%)
Site: NR
Clark level IV
68, 82%; level V
15, 18%
US. B-mode US;
high resolution
linear array (5 to
10 MHz); N/A
Scan
coverage: cervi-
cal, axillary, and
inguinal LNBs
Contrast: N/A
Suspicious/
indeterminate/
benign based on
diameter, shape,
echogenic-
ity, and vascular-
isation pattern
Info provided:
unclear; could be
same examiner as
for LN palpation
No. observers:
NR; NR (NR)
Diagnosis: NR
Histology (17,
20%)
FNAC (0)
FU
(62, 75%): min-
imum 1 year;
mean time since
primary surgery
2.6 ± 2.3 years
Histology inter-
val: NR
FU interval: 6 to
8 weeks for con-
trol visit, 6 to 12
months for FU
visit
Exclusions: n =
4; 4 were inde-
terminate on fol-
low-up so that
a final diagno-
sis could not be
made
No
Pfannenberg
2007 2007
Germany
Patients: 64
Primary
lesions: 420
LNBs/
Metastases: NR
WPC
Prospective
Data: per lesion
Any metastases
(excl brain): 297/
420 = 71% (all
tests)
Mixed
(pre-surgery; in-
vestigation of ab-
normal findings;
surveillance)
Stage of disease:
Stage III (25,
Mean age: 57.
8 years; Median
age: Range: 23.
3 to 79.1 years
Male: 41 (64.
0625%)
Site: NR
CT. CT (CE, 16
row multi-slice)
(NA); N/A
Scan coverage:
base of the skull
to the lower legs
Contrast: Ultra-
CT: based
on morphologi-
cal charac-
teristics and en-
hancement pat-
tern; region-spe-
cific nodal size
Histology (65
(15%))
FNAC (N/A)
FU (267 (64%)
lesions by imag-
ing follow-
up, 88 (21%)
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Nodal: 102/158
= 65% (CT)
Dis-
tant (excl brain):
195/262 = 74%
(all tests)
Bone: 35/50 =
70% (all tests)
Liver: 35/37 =
95% (all tests)
Lung: 59/80 =
74% (all tests)
Local: 53/70 =
76% (all tests)
Other viscera:
13/25 = 52% (all
tests)
39%); Stage IV
(39, 61%)
Inclusion: stage
III or IV cuta-
neous MM un-
dergoing imag-
ing for exclusion
of widespread
disease and con-
firmation of lo-
cal disease before
surgical resection
(n = 9); charac-
terisation of ab-
normal radiolog-
ical,
clinical and lab-
oratory findings
(n = 48); routine
melanoma
surveil-
lance in high risk
patients (n = 7)
Mean BT: 2.69
mm (0.6 to 12
mm)
vist 370, Scher-
ing GmbH,
Berlin, Ger-
many, plus 1000
mL Manni-
tol 2% as a nega-
tive oral contrast
agent before CT
CT parameters:
120 kV, 120 to
160 mAs; 5 mm
(axial, with an
increment of 5
mm) and 3 mm
(coronal with an
increment of 2
mm)
Breath
hold: CT: pa-
tients were asked
to stop breath-
ing in normal ex-
piration during
the contrast-en-
hanced CT scans
for optimal co-
registration
MRI. CE;multi-
ple phased-array;
axial and coronal
(NA); N/A
Scan coverage:
head to toe
Contrast: yes
PET-CT.
3D; CT (CE, 16
row multi-slice)
(NA); N/A
Scan coverage:
base of the skull
to the lower legs
Contrast: Ultra-
v-
ist 370, Schering
GmbH, Berlin,
Germany, plus
criteria based on
measurement of
the small axis di-
ameter
MRI: based on
morpho-
logical character-
istics and en-
hancement pat-
tern;
detected lymph
nodes smaller
than 10 mm but
with brighter sig-
nal on T1 se-
quences, due to
the
paramagnetic ef-
fect of melanin,
also were rated as
suspicious
PET: any focal
tracer uptake ex-
ceeding
normal regional
tracer accumula-
tion was assessed
as amalignant le-
sion. Le-
sions rated ma-
lignant or proba-
bly malignant
were considered
to be malignant
Info provided:
aware of the clin-
ical status
No. observers:
6; 2 dermato-on-
cologists; 2 radi-
ologists (2 spe-
cialists in nuclear
medicine, 2 CT
radiologists, and
2 MRI radiolo-
gists)
lesions by clin-
ical follow-up):
mean 252.5 days
(range, 99 to 474
days)
Histology inter-
val: NR
FU interval: ev-
ery 3 months
Exclusions: n =
36; no wbMRI
(n = 25; due
to metallic im-
plants or claus-
trophobia (5 pa-
tients), refuse of
a second whole
body examina-
tion on the same
day (17 patients)
or abortion of
the examination
(3 patients); no
evidence of tu-
mour spread (3
patients) or lack
of follow-up data
for lesion charac-
terisation (8 pa-
tients)
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1000mLmanni-
tol 2% as a nega-
tive oral contrast
agent before CT
CT parameters:
120 kV, 120 to
160 mAs, 5 mm
(axial, with an
increment of 5
mm) and 3 mm
(coronal with an
increment of 2
mm)
FDG: 370 MBq
F-FDG IV 55 to
65 minutes be-
fore scanning
Breath
hold: CT: pa-
tients were asked
to stop breath-
ing in normal ex-
piration during
the contrast-en-
hanced CT scans
for optimal co-
registration
CT used for:
attenuation cor-
rected and co-
registered
Re-
construction: it-
eratively re-
constructed us-
ing commercial
software (eSoft;
Siemens., Erlan-
gen, Germany)
Diagnosis: con-
sensus of 2 or 4
Pfluger 2011
Germany
Patients: 50
Primary
lesions: NR
LNBs/
Metastases:NR;
232 lesions
WPC
Retrospective
(Prosp database:
NR)
Data: per lesion
Any (incl brain)
: 151/232 = 65%
(CT)
Mixed (PET-
CT was done for
primary staging
and for follow-
up)
Stage of disease:
NR
Inclusion: MM
with regional LN
Mean age:
57;Median age:
Range: 29 to 85
years
Male: 36 (72%)
Site: NR
NR
CT. (1) CE, dual
slice, helical (N/
A); NR (2) U,
dual slice, helical
(N/A); NR
Scan cov-
erage:WB; from
the skull includ-
ing the legs
CT - abnormal
soft tissue masses
and/or enlarged
LNs (diameter >
1.0 cm) plus de-
gree of contrast
enhancement for
CE CT only
PET alone - non-
Histology (41,
17.7%)
FNAC (0)
FU
(191, 82.3%): ≥
6 months; no
further detail
Histology inter-
val: NR
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metas-
tases (NR if clin-
ically detectable
or micro-metas-
tases) undergo-
ing PET-CT ei-
ther for primary
staging or during
follow-up. Only
included lesions
considered ma-
lignant by at least
1 of the 3modal-
ities
(NECT, CECT,
18F-FDG PET)
Con-
trast: 120mL (2.
5 mL/s) of io-
dine-containing
contrastmedium
CT
parameters: 120
kV, 145 mAs, 2.
5 mm
Breath
hold: CT expi-
ration protocols
for shallow free
breathing during
the emission
scan
PET-CT
(1) 3D; CT (CE,
dual slice, heli-
cal) (N/A); NR
(2) 3D- CT (U,
dual slice, heli-
cal) (N/A); NR
Scan cov-
erage:WB; from
the skull includ-
ing the legs
Con-
trast: 120mL (2.
5 mL/s) of io-
dine-containing
contrastmedium
CT
parameters: 120
kV, 145 mAs, 2.
5 mm
FDG: 200 MBq
Breath
hold: CT expi-
ration protocols
for shallow free
breathing during
the emission
scan
CTused for:un-
clear; reports side
physiologically
increased uptake
of
FDG with SU-
Vmax > 2.5. For
lesions with dis-
crepant findings
on both modal-
ities, the finding
of the modality
with the higher
diagnostic confi-
dence score was
accepted. If re-
sults from both
modalities were
discrepant
and had the same
diagnostic confi-
dence score
value, the lesion
was judged posi-
tive
Info provided:
knowledge of
clinical data
No. observers:
2; NR (experi-
enced)
Diagnosis: con-
sensus
FU interval:NR
n = NR; ** In
cases of new tu-
mour le-
sions during the
follow-
up period, these
lesions were not
included in the
study. The rea-
son given for not
including these
lesions was the
fact that non-de-
tectable
lesions in CT or
18F-FDG PET
cannot be dis-
tinguished from
non-existent le-
sions in the case
of a newly
detected tumour
lesion during fol-
low-up
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by side PET-CT
display with spa-
tially synchro-
nised images
Recon-
struction: NR;
PET and CT in-
terpreted side by
side with spa-
tially synchro-
nised images to
ensure that the
identical lesion
was assessed in
both modalities
Reinhardt 2006
Germany
Patients: 250
Primary
lesions: 250
LNBs/
Metastases:NR;
670 lesions iden-
tified
WPC
Retrospective
(Prosp database:
NR)
Data: per pt
Any (excl brain):
116/250 = 46%
Nodal mets: 78/
250 = 31%
Distant
mets (excl brain)
: 84/250 = 34%
Mixed (pri-
mary staging af-
ter sentinel node
biopsy (n = 75)
; therapy control
after chemother-
apy of metastatic
disease (n = 42)
, staging of clin-
ically suspected
recurrent disease
(n = 65), during
follow-up within
5 years of pri-
mary treatment
(n = 68)
Stage of disease:
initial pathol-
ogy: stage I 22,
9%; stage II 88,
35%; stage III
108, 43%; stage
IV 32, 13%
Inclusion: cuta-
neous MM re-
ferred for PET-
CT
Excluded if in-
ad-
equate reference
standard (no his-
tology or FU < 1
Mean age:
58;Median age:
Range: ±16
Male: 145
(58%)
Site: NR
Tumor depth: ≤
1.0 mm 29,
12%; 1.01 to 2.0
mm 68, 27%; 2.
01 to 4.0mm66,
26%; > 4.0 mm
64, 26%
CT. CE, heli-
cal, dual detector
(N/A); N/A
Scan coverage:
WB;base of skull
to tip of toes in 3
parts
Contrast: Peri-
trast-
oral-GI; Kohler
Chemie GmbH,
Alsbach,
Germany
CT parameters:
130 kV, 40 mAs,
5 mm
Breath hold:
lim-
ited breath hold
for CT and shal-
lowbreathing for
PET
PET-CT.
CT (CE), heli-
cal, dual detector
(N/A); N/A
Scan coverage:
WB;base of skull
to tip of toes in 3
parts
Contrast: Peri-
trast-
NR for any test;
states only that
accuracy was as-
sessed according
to accord-
ing to the cur-
rent AJCC stag-
ing classification
Info provided:
routine clini-
cal fashion; same
clinical informa-
tion about each
patient
No. observers:
NR; NR; con-
sensus by each
of 2 experienced
investigators (ex-
perienced)
Diagnosis: con-
sensus (of 2?)
Histology (100,
40% for N-stag-
ing (including
15 with SLNB)
20, 8% for M-
staging)
FNAC (N/A)
FU (250, 100%)
: NR; ≥ 1 year
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
0
Reports data for
differentiation
by metastatic
sites
(M1A to M1C)
and for detec-
tion of visceral
and non-visceral
mets. Gives Se/
Sp by population
group but preva-
lence per group
not given to al-
low 2×2 to be in-
cluded
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year) oral-GI; Kohler
Chemie GmbH,
Alsbach,
Germany
CT parameters:
130 kV, 40 mAs,
5 mm
FDG: 371
± 40 MBq FDG
through an ante-
rior cubital vein
Breath hold:
lim-
ited breath hold
for CT and shal-
lowbreathing for
PET
CT used for:
attenuation cor-
rection based on
re-scaling of the
CT image
Re-
construction: it-
eratively recon-
structed with at-
tenu-
ation correction
on the basis of
a re-scaling of
the CT image
as described else-
where (Kinahan
2003)
Strobel 2007b
Switzerland
Patients: 124
Primary
lesions: NR
LNBs/
Metastases: NR
NC
Prospective
Data: per pt
Any (incl brain):
53/124 = 43%
Un-
clear (NR; PET-
CT for depiction
or exclusion of
metastases)
Stage of disease:
NR
Inclusion: high
risk
melanoma (BT >
4 mm, or Clark
level III or IV, or
known resected
metastases) and
Mean age: 54.
4 years; Median
age: Range: 15
to 82 years
Male: 59 (47.
5806451612903%)
Site: NR
NR
PET-CT.
CT (CE, multi-
slice, helical) (N/
A); NR
Scan coverage:
head to the knees
with scanning of
the lower legs
for patients with
primary tumours
of the lower ex-
tremities
Contrast:
oral CT contrast
Mets present if
detected by 1 or
both read-
ers. FDG uptake
clearly greater
than back-
ground; if a fo-
cal FDG-active
lesion was de-
tected, the exact
anatomical local-
isation was de-
termined on the
Histology (20,
16.1%)
FNAC (21, 16.
9%)
FU (124, 100%,
18D+ and 61D-
had status con-
firmed by PET-
CT or clinical
FU, 4 D- had
MRI to confirm
absence of mets
and 10/53 D+)
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raised S100 (>
0.2 µg/L) un-
dergoing follow-
up after primary
treatment
Excluded if
systemic therapy
before the PET-
CT investigation
agent given
15 minutes be-
fore injection of
18F-FDG
CT parameters:
140 kV, 40 mAs,
4.25 mm
FDG: 350 to
400 MBq
Breath hold:
CT: breath hold-
ing in the normal
expiratory posi-
tion
CT used for:
attenuation cor-
rection, fused
Reconstruc-
tion: standard it-
erative algorithm
(OSEM)
fused PET-CT
images. Lesions
with 18F-FDG
uptake in phys-
iological sites or
benign variants,
e.g. mus-
cles, brown fatty
tissue or pul-
monary infiltra-
tions, were deter-
mined as benign.
Semi-quatitative
analysis of FDG
uptake in terms
of SUVmax also
conducted
Info provided:
blinded to serum
S100B
No. observers:
2; nuclear radi-
ology physicians
(experienced (13
years and7 years)
)
Diagnosis: con-
sensus of 2
: minimum of 6
months (range 6
to 18 months in
all patients
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
3; chemotherapy
before PET-CT
van den Brekel
1998
Netherlands
Patients: 26
Primary
lesions: 26
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
NR)
Data: per pt
Nodal (neck):
21/26 = 81%
Mixed (NR; but
interval between
treatment of the
primary and
neck dissection
ranged from 0 to
8.8 years (mean
21 months))
Stage of disease:
stage III (pal-
pable LN) 18,
69%; stage I and
II 8, 31%
Inclusion: HN
MM with CT
before neck dis-
section, includ-
ing therapeu-
tic and elective
(negative on pal-
Mean age: 54.
5 years; Median
age: Range: 55
to 83 years
Male: 18 (0.
692307692307692%)
Site: scalp 6,
23%; temporal
3, 12%; ear 4,
15%; anterior
face 4, 15%;
neck 1, 4%;
shoulder 1,
4%; upper
limb 1, 4%;
nasal mucosa 1,
4%; unknown
primary 5, 19%
BT0.8mmto22
mm
CT. CE (N/A);
NR
Scan coverage:
neck
Contrast: IVbo-
lus plus drip in-
fusion of iodine
contrast
CT parameters:
NR; 5mm for 24
pts; 2 mm for 2
pts (both FN)
Breath hold:
NR
Presence
of necrosis or ax-
ial diameter > 10
or > 11 mm
Info provided:
NR
No. observers:
2; NR; co-au-
thors (NR)
Diagnosis: un-
clear
Histology (26,
100%)
FNAC (0)
FU (0): N/A
Histology inter-
val: 4 weeks
FU interval: N/
A
Exclusions: n =
0
Both FN on CT
used 8 mm CT
thickness
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pation). Also in-
cluded primary
and recurrence
vanWissen 2016
Netherlands
Patients: 70
Primary
lesions: 70
LNBs/
Metastases: NR
NC
Retrospective
(Prosp database:
no)
Data: per pt
Nodal (superfi-
cial groin mets
only): 59/69 =
86%
Nodal (deep
groin mets only)
: 24/67 = 36%
Mixed
(NR. Discussion
states “large pro-
portion of our
patients were ini-
tially treated for
their primary tu-
mour at other
hospitals, and
sometimes years
prior to the cur-
rent groin dissec-
tion”)
Stage of disease:
only stage III B
& C
Inclusion: stage
IIIB or IIICMM
with palpable
groin metastases;
selected for ther-
apeutic CGD
Mean age: NR;
Median age: 58;
Range: 24 to 83
Male: 35 (0.5%)
Site: leg
58, 83%; trunk
6, 9%; arm 0,
0%; unknown 6,
9%
BT mm: ≤ 1.
00 6 (9%); ≤
2.00 15 (21%)
; 2.01 to 4.00
15 (21%); > 4.00
12 (17%); miss-
ing/unknown 22
(31%)
PET-CT. CT
(U) (NA)
Scan coverage:
WB; not further
described
Contrast: none
CT parameters:
Kv NR; 40 mAs,
2 to 5 mm
FDG: 180 to
240 MBq
Breath hold:
standard acquisi-
tion protocols
CT used for: at-
tenuation
correction; fused
images
Reconstruc-
tion: NR
FDG up-
take (qualitative
assessment)
Info provided:
NR
No. observers:
1; nuclear
medicine (nr)
Diagnosis: sin-
gle
Histology (70,
100%)
FNAC (NA)
FU (not for ref
purposes): me-
dian 16 months
(0 to 71 months)
Histology inter-
val: NR
FU interval:NR
Exclusions: n =
1; missing
pathology
7/10 disease neg-
ative had a diag-
nos-
tic resection of a
lymph node be-
fore lymph node
dissection poten-
tially leading to
FPs
+ - positive; AJCC: American Joint Cancer Committee; AWOSEM: attenuation weighted ordered subsets expectation maximisa-
tion; BT: Breslow thickness; CE: contrast enhanced; CLND: complete lymph node dissection; CT: computed tomography; 2D:
two-dimensional; 3D: three-dimensional; DW: diffusion weighted; EDV: end-diastolic volume; 18FDG: 2-deoxy-2-[18F]fluoro-D-
glucose; FNAC: fine needle aspiration cytology; FORE: Fourier rebinning; FU: follow-up; GE: gradient echo; HN: head and neck;
LN: lymph node; LNB: lymph node basin; LND: lymph node dissection; LS: lymphoscintigraphy; mA: measure of tube current;
mets: metastases; MM: malignant melanoma; MRI: magnetic resonance imaging; NC: non-comparative; OSEM: ordered subsets
expectation maximisation algorithm; PET: positron emission tomography; PI: pulse index; PSV: peak systolic volume; prosp: RF: risk
factor; SD: standard deviation; SLN: sentinel lymph node; SLNB: sentinel lymph node biopsy; SSM: superficial spreading melanoma;
SUV: standardised uptake value; SUVmax: maximum standardised uptake value; U: unenhanced; US: ultrasound; WB: whole body
Appendix 10. Descriptive synthesis of all included studies of whole body imaging
Study design and setting
Twelve of the 24 studies (50%) were prospective case series (Aukema 2010b; Bastiaannet 2009; Cachin 2014; Dellestable 2011; Hafner
2004; Hausmann 2011; Jouvet 2014; Klebl 2003; Maubec 2007; Pfannenberg 2007; Strobel 2007b; Veit-Haibach 2009), ten (40%)
were retrospective in design (Abbott 2011; Arrangoiz 2012; Aukema 2010a; Iagaru 2007; Kang 2011; Pfluger 2011; Reinhardt 2006;
Strobel 2007a; van den Brekel 1998; van Wissen 2016), and in two, the direction of the design was not clear (Prayer 1990; Rubaltelli
2011). All studies were conducted in Europe apart from two US-based studies - Arrangoiz 2012; Iagaru 2007 - and one conducted in
South Korea (Kang 2011).
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Participants
Primary staging. Of the six studies conducted in participants undergoing primary staging, two included any participant following
diagnosis of melanoma (Kang 2011; Veit-Haibach 2009); two excluded those with distant metastases on diagnosis (Hafner 2004;
Maubec 2007) (Maubec 2007 was restricted to those with melanomas at least 4 mm in thickness); one included clinically node positive
participants but did not report exclusion of those with distant metastases (Prayer 1990); and one included only clinically node negative
participants with melanomas of at least 4 mm Breslow thickness (Arrangoiz 2012). Three studies also reported data for pre-SLNB
imaging (Arrangoiz 2012; Hafner 2004; Maubec 2007), two of which reported subgroup data for clinically node negative participants
who underwent SLNB (Hafner 2004; Maubec 2007). All six studies reported accuracy data on a per patient basis; no per lesion data
were identified.
A total of 492 participants were included with sample sizes ranging from 25 in Maubec 2007 to 217 in Prayer 1990. When reported (n
= 5), the ages of included participants ranged from 18 years in Hafner 2004 to 89 years in Arrangoiz 2012. The mean age of included
participants was reported in five studies (the median of reported means was 61 years, range 56 to 67 years) and median age in one study
(median 55 years in Hafner 2004). Fifty-two per cent of included participants were male. The percentage of participants with head
and neck melanoma ranged from 4% in Veit-Haibach 2009 to 36% in Maubec 2007 (median 15%) and melanoma of the extremities,
including the hands or feet where documented, from 32% in Maubec 2007 to 73% in Kang 2011 (median 50%).
Re-staging.Of the three studies conducted in participants undergoing re-staging of disease, one included any participant having imaging
for re-staging purposes (Iagaru 2007); and two included clinically node negative participants either undergoing ultrasound of the
regional lymph nodes as part of a follow-up program, as in Rubaltelli 2011, or with raised S100 during follow-up, as in Strobel 2007a.
A total of 589 participants were included with sample sizes of 47 in Strobel 2007a, 106 in Iagaru 2007, and 460 in Rubaltelli 2011.
The ages of included participants ranged from 20 years to 87 years. The median of reported mean ages was 55 years. Fifty-three per
cent of included participants were male. The site of the primary melanoma was not reported in any study. All three studies reported
accuracy data on a per patient basis, and one study also reported data per lesion (139 lesions identified in 30 participants; Iagaru 2007).
Mixed or unclear. The 15 studies conducted in mixed or not clearly described population groups are described in Table 3 according to
the reported indication for imaging and participant stage of disease on recruitment.
Two studies clearly included participants at any stage of disease (Dellestable 2011; Reinhardt 2006). In Dellestable 2011, 27% of
participants had stage I or II melanoma and 73% had stage III or IV disease; imaging was undertaken for primary staging or follow-up.
In Reinhardt 2006, 44% of participants had stage I or II melanoma and the remaining participants had stage III or IV disease. Imaging
was undertaken for primary staging after SLNB (30%); therapy control after chemotherapy of metastatic disease (17%), staging of
clinically suspected recurrent disease (26%), and imaging during follow-up within five years of primary treatment (27%). Insufficient
data were available from this study to allow 2×2 contingency tables to be estimated for each subgroup of participants, despite author
contact.
Stage of disease on recruitment was not reported in four studies, and these were judged to have included ‘any’ stage of disease (Aukema
2010a; Cachin 2014; Klebl 2003; Strobel 2007b). Aukema 2010a included asymptomatic patients with raised S100 either judged to be
high risk after primary melanoma treatment (56%) or undergoing follow-up after surgical treatment of regional (33%) or distant (11%)
metastases. Cachin 2014 described imaging for staging or for re-staging but did not give a breakdown of the number of participants
in each group. Klebl 2003 restricted inclusion to those with Clark level IV or V melanomas, with 10% of participants having primary
staging and 90% undergoing follow-up, and Strobel 2007b included those with melanomas at least 4 mm in thickness, Clark level III
or IV, or known resected metastases, further reporting only that imaging was used for depiction or exclusion of metastases.
The remaining nine studies in mixed or not clearly described population groups included only participants with stage III disease (Abbott
2011; Aukema 2010b; Bastiaannet 2009; Pfluger 2011; van den Brekel 1998; van Wissen 2016), stage IV disease (Jouvet 2014), or
both (Hausmann 2011; Pfannenberg 2007) (Table 3). In the two studies including participants with stage III and IV melanoma, the
percentage with stage III disease was 38% in Hausmann 2011 and 39% in Pfannenberg 2007. Four studies in mixed population groups
included those having primary staging or follow-up but did not report the number of participants with each indication for imaging
(Abbott 2011; Pfluger 2011; van den Brekel 1998; van Wissen 2016). Bastiaannet 2009 included those with nodal disease identified at
the time of primary diagnosis (15%), or with recurrence up to three years from diagnosis (58%) or more than three years since primary
diagnosis (27%). In Pfannenberg 2007, imaging was undertaken to exclude widespread disease and before surgical resection (14%);
to characterise abnormal radiological, clinical, and laboratory findings (75%); or as part of routine surveillance in high-risk patients
(11%). The remaining three studies did not clearly describe the indication for imaging and were conducted in patients with palpable
and pathology proven lymph node metastases and no signs of distant metastases (Aukema 2010b); participants with positive sentinel
node biopsy or suspicious lesions on ultrasound or X-ray studies (Hausmann 2011); or patients with stage IV melanoma (Jouvet 2014).
A total of 1265 participants were included in the 15 studies with sample sizes ranging from 26 in van den Brekel 1998 to 251 in
Bastiaannet 2009. When reported (n = 10), the ages of included participants ranged from 15 years in Strobel 2007b to 93 years in
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Aukema 2010a. The mean age of included participants was reported in nine studies (the median of reported means was 57 years, range
54 to 59 years) and median age in two studies (Abbott 2011 reporting a median age of 50 for those with microscopic disease and
63 for those with macroscopic disease; and van Wissen 2016 reporting a median age of 58 years). Forty-eight per cent of included
participants were male. The site of the primary melanoma was reported in only five of the 16 studies (Abbott 2011; Aukema 2010b;
Bastiaannet 2009; van den Brekel 1998; van Wissen 2016), one of which included only head and neck melanoma (van den Brekel
1998), and one of which included only those undergoing combined groin dissection for melanomas of the trunk (17%) or extremities
(83%) (van Wissen 2016). Excluding van den Brekel 1998 and van Wissen 2016, the percentage of participants with head and neck
melanoma ranged from 3% in Abbott 2011 to 13% in Aukema 2010b, and melanoma of the extremities, including the hands or feet
where documented from 38% in Abbott 2011 to 59% in Aukema 2010b.
Index tests
Sixteen studies contributed data for a single index test (Abbott 2011; Arrangoiz 2012; Aukema 2010a; Aukema 2010b; Bastiaannet
2009; Cachin 2014; Hafner 2004; Kang 2011; Klebl 2003; Maubec 2007; Prayer 1990; Rubaltelli 2011; Strobel 2007a; Strobel 2007b;
van den Brekel 1998; van Wissen 2016), and eight compared the accuracy of one or more index tests (Dellestable 2011; Hausmann
2011; Iagaru 2007; Jouvet 2014; Pfannenberg 2007; Pfluger 2011; Reinhardt 2006; Veit-Haibach 2009) (Table 1). Two studies also
provided data for PET alone (ineligible index test) (Bastiaannet 2009; Hafner 2004), and two reported data for MRI of the brain in all
patients but 2×2 contingency table data could not be included because of small patient or lesion numbers (Aukema 2010a; Aukema
2010b). However, available information on MRI of the brain has been separately summarised as an additional result.
Ultrasound. Five studies evaluated ultrasound as a staging tool (Hafner 2004; Jouvet 2014; Klebl 2003; Prayer 1990; Rubaltelli 2011).
All studies employed B-mode ultrasound, three at single frequencies of 5 MHz (Hafner 2004), 7.5 MHz (Prayer 1990), and 12.5 MHz
(Jouvet 2014), and two using variable frequencies of 5 to 10 MHz (Klebl 2003), and 7.5 to 13 MHz (Rubaltelli 2011). One study
of ultrasound used in potential SLNB candidates performed ultrasound before lymphoscintigraphy. Lymph node basins were imaged
according to the site of the primary melanoma in all studies. The criteria for the detection of nodal metastases were described in all
studies apart from Hafner 2004 (Appendix 9). Ultrasound was performed by radiologists (Hafner 2004; Jouvet 2014; Prayer 1990),
was performed by a sonologist (Rubaltelli 2011), or was not reported (Klebl 2003).
CT. Ten studies evaluated CT - unenhanced (Iagaru 2007), contrast enhanced (Bastiaannet 2009; Dellestable 2011; Jouvet 2014;
Pfannenberg 2007; Pfluger 2011;Reinhardt 2006; van denBrekel 1998;Veit-Haibach 2009), or both (Hausmann 2011).CTparameters
(tube current (mA), tube voltage (kV), and slice thickness (mm)) were not reported in four studies (Bastiaannet 2009; Dellestable 2011;
Hausmann 2011; Veit-Haibach 2009), and ranged from 40 mA in Iagaru 2007 and Reinhardt 2006; to 250 mA in Jouvet 2014; 120
kV in Jouvet 2014, Pfannenberg 2007, and Pfluger 2011; to 140 kV in Iagaru 2007, with slice thicknesses from 1.25 mm in Jouvet
2014 to 5 mm in Iagaru 2007, Pfannenberg 2007, Reinhardt 2006, and van den Brekel 1998 (reported per study in Appendix 9).
Scan coverage included the skull (Dellestable 2011; Iagaru 2007; Jouvet 2014; Pfluger 2011), or specifically excluded the skull (
Bastiaannet 2009; Hausmann 2011; Pfannenberg 2007; Reinhardt 2006), and it extended to the abdominal or pelvic area (Bastiaannet
2009; Dellestable 2011; Jouvet 2014; Pfluger 2011), or it also included the lower limbs (Iagaru 2007; Pfannenberg 2007; Pfluger 2011;
Reinhardt 2006). van den Brekel 1998 imaged the neck area only, and Veit-Haibach 2009 did not clearly document the scan coverage,
describing whole body imaging in a caudocranial direction. The criteria for the detection of metastases were not reported in six studies
(Bastiaannet 2009; Dellestable 2011; Hausmann 2011; Iagaru 2007; Jouvet 2014; Reinhardt 2006). Four studies reported the use of
morphological characteristics (Pfannenberg 2007; van den Brekel 1998), soft tissue masses (Pfluger 2011; Veit-Haibach 2009), contrast
enhancement (Pfannenberg 2007; Pfluger 2011; Veit-Haibach 2009), and nodal size criteria (Pfannenberg 2007; Pfluger 2011; van
den Brekel 1998).
Test interpretation was provided by radiologists (Hausmann 2011; Jouvet 2014; Veit-Haibach 2009), nuclear medicine physicians
(Bastiaannet 2009), or both (Iagaru 2007), or by dermato-oncologists and radiologists (Pfannenberg 2007). Four studies did not report
observer qualifications (Dellestable 2011; Pfluger 2011; Reinhardt 2006; van den Brekel 1998). Half of studies reported providing test
interpreters with clinical information including the diagnosis, age, and sex of the patient (Hausmann 2011), clinical status (Pfannenberg
2007), clinical data (Pfluger 2011), routine clinical information (Reinhardt 2006), or patient-specific clinical background (Veit-Haibach
2009). All studies apart from two - Iagaru 2007 and van den Brekel 1998 - reported blinding to the results of other imaging tests.
MRI. Four studies evaluated 1.5 T MRI using a variety of different sequences before and after gadolinium contrast enhancement
(Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007), including diffusion weighting (Dellestable 2011; Jouvet 2014),
as well as ultrafast gradient echo (described as VIBE in the study reports) sequences (Jouvet 2014; Pfannenberg 2007). Scan coverage
in three studies was from the head to the feet (Jouvet 2014; Pfannenberg 2007; Laurent 2010), and from the neck to the pelvis only
in Hausmann 2011. Two studies did not report the criteria used to assess the presence of metastases (Hausmann 2011; Jouvet 2014);
one reported a qualitative assessment of signal intensity (Dellestable 2011), and one reported use of morphological characteristics,
342Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
enhancement pattern, and lymph node size and signal (Pfannenberg 2007). Four studies reported test interpretation by radiologists
(Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007). Two studies reported providing test interpreters with clinical
information including the diagnosis, age, and sex of the patient (Hausmann 2011), or clinical status (Pfannenberg 2007). All studies
reported blinding to the results of other imaging tests.
PET-CT. Seventeen studies examined the use of PET-CT for staging purposes, combining PET with unenhanced CT (Arrangoiz 2012;
Aukema 2010a; Aukema 2010b; Dellestable 2011; Iagaru 2007; Kang 2011; Maubec 2007; van Wissen 2016), contrast enhanced CT
(Jouvet 2014; Pfannenberg 2007; Reinhardt 2006; Strobel 2007a; Strobel 2007b; Veit-Haibach 2009), or evaluating both (Pfluger
2011). Two studies did not report whether or not the CT component was contrast enhanced (Abbott 2011; Cachin 2014). CT was
clearly described as used for attenuation correction (Arrangoiz 2012; Aukema 2010a; Aukema 2010b; Pfannenberg 2007; Reinhardt
2006; Strobel 2007a; Strobel 2007b; van Wissen 2016; Veit-Haibach 2009), or for anatomical localisation (Cachin 2014; Kang 2011),
or for both (Abbott 2011; Dellestable 2011; Iagaru 2007), or it was not clearly described (Jouvet 2014; Maubec 2007; Pfluger 2011).
Where reported (n = 8), studies employed 2D PET (Abbott 2011; Aukema 2010b; Iagaru 2007; Strobel 2007a), 3D PET (Maubec
2007; Pfannenberg 2007; Pfluger 2011), or either 2D or 3D PET (Arrangoiz 2012). CT parameters were not reported in four studies
(Abbott 2011; Cachin 2014; Dellestable 2011; Veit-Haibach 2009). In 14 studies, parameters ranged from 40 mA - Aukema 2010a;
Aukema 2010b; Iagaru 2007; Reinhardt 2006; Strobel 2007a; Strobel 2007b; vanWissen 2016 - to 160 mA - Kang 2011; Pfannenberg
2007, or from 110 kV - Maubec 2007 - to 140 kV - Arrangoiz 2012; Iagaru 2007; Jouvet 2014; Kang 2011; Strobel 2007a; Strobel
2007b - and slice thickness from 2.5 mm - Kang 2011; Pfluger 2011 - to 6.5 mm - Jouvet 2014 - and are reported in Appendix 9.
Scan coverage included the skull (Arrangoiz 2012; Dellestable 2011; Iagaru 2007; Kang 2011; Maubec 2007; Pfluger 2011; Strobel
2007a; Strobel 2007b), or specifically excluded the skull (Abbott 2011; Jouvet 2014; Pfannenberg 2007; Reinhardt 2006), and it
extended to the upper thigh (Abbott 2011), or to the lower limbs (Arrangoiz 2012; Dellestable 2011; Iagaru 2007; Jouvet 2014; Kang
2011; Maubec 2007; Pfannenberg 2007; Pfluger 2011; Reinhardt 2006; Strobel 2007a; Strobel 2007b). Five studies did not clearly
document the scan coverage, describing whole body imaging (Aukema 2010a; Cachin 2014; van Wissen 2016), imaging according to
the primary lesion site (Aukema 2010b), or imaging in a caudocranial direction (Veit-Haibach 2009).
The criteria for the detection of metastases were not reported in three studies (Abbott 2011; Jouvet 2014; Reinhardt 2006), or they
were described as the presence of metabolically active lesions with no further detail in two (Aukema 2010a; Aukema 2010b). Six studies
reported assessment of focal FDG uptake relative to background (Cachin 2014; Strobel 2007a), as supported by SUVmax assessment
(Dellestable 2011; Maubec 2007; Pfannenberg 2007; Pfluger 2011; Strobel 2007b; van Wissen 2016; Veit-Haibach 2009). Three
studies reported the use of SUVmax alone (≥ 2.2 in Kang 2011 and ≥ 2.5 in Arrangoiz 2012 and Iagaru 2007).
Test interpretation was provided by nuclear medicine physicians alone (Abbott 2011; Arrangoiz 2012; Aukema 2010a; Aukema 2010b;
Cachin 2014; Jouvet 2014; Kang 2011; Strobel 2007a; Strobel 2007b; van Wissen 2016), or teamed with radiologists (Iagaru 2007;
Veit-Haibach 2009), or by dermato-oncologists and radiologists (Pfannenberg 2007). Four studies did not report observer qualifications
(Dellestable 2011; Maubec 2007; Pfluger 2011; Reinhardt 2006). Four studies reported providing test interpreters with some form of
clinical patient information (Pfannenberg 2007; Pfluger 2011; Reinhardt 2006; Veit-Haibach 2009). Seven studies reported blinding
to the results of other imaging tests (Dellestable 2011; Jouvet 2014; Pfannenberg 2007; Reinhardt 2006; Strobel 2007a; Strobel 2007b;
Veit-Haibach 2009).
Reference standards
Four of the 24 studies (17%) evaluated the accuracy of imaging in comparison to histology alone, using samples from SLNB or CLND
(Hafner 2004; Maubec 2007), or from neck (van den Brekel 1998), or from groin (van Wissen 2016) dissection, and in two studies,
the reference standard combined histology based on CLND or SLNB with follow-up to determine any false negative results on imaging
(Arrangoiz 2012; Prayer 1990). The remaining studies used a combination of histology or follow-up (Abbott 2011; Bastiaannet 2009;
Cachin 2014; Dellestable 2011; Hausmann 2011; Iagaru 2007; Kang 2011; Klebl 2003; Pfannenberg 2007; Pfluger 2011; Reinhardt
2006; Veit-Haibach 2009), FNAC or follow-up (Jouvet 2014), or histology, FNAC, or follow-up as a reference standard (Aukema
2010a; Aukema 2010b; Rubaltelli 2011; Strobel 2007a; Strobel 2007b).
Across the 20 studies reporting some form of follow-up, two did not report the length of follow-up, but more than 90% of included
participants had a histological reference standard reported (Arrangoiz 2012; Iagaru 2007). Eighteen studies reported or required
minimum follow-up periods of at least three months (n = 11) or reported the mean or median follow-up with a range that was at least
three months (n = 7). Minimum follow-up was between three and six months (Aukema 2010a; Dellestable 2011; Hausmann 2011;
Pfannenberg 2007; Veit-Haibach 2009), from six months to a year (Aukema 2010b; Bastiaannet 2009; Cachin 2014; Jouvet 2014;
Kang 2011; Pfluger 2011; Prayer 1990; Rubaltelli 2011; Strobel 2007a; Strobel 2007b), or one year or longer (Abbott 2011; Klebl
2003; Reinhardt 2006). Where reported, median follow-up times ranged from 10 months in Rubaltelli 2011 to 24.3 months in Kang
2011, and mean follow-up from 8.3 months to 34 months (Abbott 2011).
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Follow-up schedules were documented in eight studies (Abbott 2011; Hausmann 2011; Kang 2011; Klebl 2003; Pfannenberg 2007;
Prayer 1990; Reinhardt 2006; Strobel 2007a). Tests used during follow-up were mentioned in 16 studies (Abbott 2011; Aukema 2010a;
Aukema 2010b; Bastiaannet 2009; Cachin 2014; Dellestable 2011; Hausmann 2011; Jouvet 2014; Kang 2011; Pfannenberg 2007;
Pfluger 2011; Reinhardt 2006; Rubaltelli 2011; Strobel 2007a; Strobel 2007b; Veit-Haibach 2009), although the detail provided varied
considerably, for example from ‘clinical or radiological follow-up’ in Dellestable 2011 to ‘physical examination, blood tests, ultrasound
studies, X-rays, and CT scans of the body from the neck to the pelvis (WB-CT) as well as an MRI of the head (MRI-CR)’ in Hausmann
2011 (Appendix 9).
Exclusions
Ten studies reported the exclusion of between 1 and 36 study participants (Bastiaannet 2009; Cachin 2014; Hausmann 2011; Klebl
2003; Pfannenberg 2007; Rubaltelli 2011; Strobel 2007b; van Wissen 2016), or lesions (Dellestable 2011). Pfluger 2011 further
reported that new lesions detected during the follow-up period were not included as false negative on imaging on the basis that they
may have been newly emergent lesions.
Appendix 11. Sensitivities and specificities of imaging tests from studies reporting data for more
than one target condition
Test
Study
Popula-
tion
group
No. pa-
tients/
cases a
[Le-
sions/
cases]
Imaging
detail
Sensitivity [95% CI] % TP/Diseased Specificity [95% CI] % TN/Non-Diseased
Any metastasis Nodal
metas-
tasis
Distant metastasis Any metastasis Nodal
metas-
tasis
Distant metastasis
Includ-
ing
brain
Exclud-
ing
brain
Includ-
ing
brain
Exclud-
ing
brain
Includ-
ing
brain
Exclud-
ing
brain
Includ-
ing
brain
Exclud-
ing
brain
CT
Veit-
Haibach
2009
Primary
Per pa-
tient
data
56
CT
(CE)
Not as-
sessed
Not as-
sessed
23
[5 to 54]
3/13
Not as-
sessed
Brain
NR
25
[5 to 57]
3/12
Not as-
sessed
Not as-
sessed
100
[92 to
100]
43/43
Not as-
sessed
Brain
NR
93
[81 to
99]
41/46
Rein-
hardt
2006
Mixed
Per pa-
tient
CT
(CE)
81
[73 to
88]
94/116
Not as-
sessed
85
[75 to
92]
66/78
74
[63 to
83]
62/84
Not as-
sessed
77
[69 to
84]
103/
134
Not as-
sessed
87
[81 to
92]
150/
172
88
[82 to
92]
146/
166
Not as-
sessed
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data
250/
116
Dellestable
2011
Mixed
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sion data
40 [118
/ 72]
CT
(CE)
80
[69 to
89]
53/66
Not as-
sessed
94
[79 to
99]
29/31
59
[42 to
74]
24/41
Not as-
sessed
95
[84 to
99]
40/42
Not as-
sessed
100
[63 to
100]
8/8
87
[73 to
96]
34/39
Not as-
sessed
Haus-
mann
2011
Unclear
Per le-
sion data
33 [824
/455]
CT
(CE)
Not as-
sessed
78
[74 to
82]
356/455
86
[81 to
91]
166 /
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Not as-
sessed
71
[65 to
76]
186/263
Not as-
sessed
50
[44 to
55]
183/369
29
[22 to
36]
54/187
Not as-
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71
[64 to
77]
129/182
Jouvet
2014
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Per le-
sion data
37 [218
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CT
(CE)
90
[82 to
94]
103/115
88
[80 to
94]
84/95
96
[78 to
100]
22/23
88
[80 to
94]
81/92
86
[76 to
93]
62/72
70
[60 to
79]
66/94
69
[59 to
78]
63/91
63
[44 to
80]
19/30
73
[61 to
84]
47/63
72
[59 to
83]
44/61
Pfan-
nenberg
2007
Mixed
Per le-
sion data
64 [420/
297]
CT
(CE)
Not as-
sessed
77
[72 to
82]
229/297
76
[67 to
84]
78/102
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77
[71 to
83]
151/195
Not as-
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70
[61 to
78]
86/123
77
[64 to
87]
43/56
Not as-
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64
[52 to
76]
43/67
MRI
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2011
Mixed
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40 [118
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MRI
(DW)
83
[72 to
91]
58/70
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28/31
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45/47
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8/9
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mann
2011
Unclear
Per le-
sion data
33 [824
/ 455 ]
MRI
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37 [218
/ 125 ]
MRI
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76]
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71]
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81]
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80]
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90]
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90]
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87]
65/82
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93]
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100]
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81
[69 to
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[68 to
89]
48/60
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2007
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Per le-
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64 [420/
297 ]
MRI
(DW+
VIBE)
Not as-
sessed
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[75 to
84]
237/297
66
[56 to
75]
67/102
Not as-
sessed
87
[82 to
92]
170/195
Not as-
sessed
76
[68 to
84]
94/123
77
[64 to
87]
43/56
Not as-
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76
[64 to
86]
51/67
PET-CT
Arran-
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56/32
CT
(NR)
47
[29 to
65]
15/32
Not as-
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Not as-
sessed
100
[48 to
100]
5/0
Not as-
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88
[68 to
97]
21/24
Not as-
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Not as-
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[84 to
99]
48/51
Not as-
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Rein-
hardt
2006
Mixed
Per pa-
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data
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116
CT
(CE)
97
[91 to
99]
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Not as-
sessed
95
[87 to
99]
74/78
99
[94 to
100]
83/84
Not as-
sessed
98
[94 to
100]
131/
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Not as-
sessed
100
[98 to
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98
[94 to
99]
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Not as-
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Veit-
Haibach
2009
CT
(CE)
38
[14 to
68]
Brain
NR
42
100
[92 to
100]
Brain
NR
93
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41/44
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2014
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Per le-
sion data
87 [176
/ 85]
CT
(NR)
80
[70 to
88]
68/85
Not as-
sessed
85
[62 to
97]
17/20
78
[67 to
88]
51/65
Not as-
sessed
54
[43 to
64]
49/91
Not as-
sessed
37
[16 to
62]
7/19
58
[46 to
70]
42/72
Not as-
sessed
Dellestable
2011
Mixed
Per le-
sion data
40 [118
/ 72]
CT
(CE)
74
[62 to
83]
53/72
Not as-
sessed
84
[66 to
95]
26/31
66
[49 to
80]
27/45
Not as-
sessed
89
[77 to
96]
42/47
Not as-
sessed
100
[59 to
100]
7/7
88
[73 to
96]
35/40
Not as-
sessed
Jouvet
2014
Unclear
Per le-
sion data
37 [218
/ 125]
CT
(CE)
Not as-
sessed
80
[71 to
87]
83/104
96
[78 to
100]
22/23
PET-
CT did
not
cover
skull
75
[64 to
84]
61/81
Not as-
sessed
93
[86 to
97]
81/87
97
[83 to
100]
29/30
PET-
CT did
not
cover
skull
91
[81 to
97]
52/57
Pfan-
nenberg
2007
Mixed
Per le-
sion data
64 [420/
297]
CT
(CE)
Not as-
sessed
91
[87 to
94]
269/297
85
[77 to
92]
87/102
PET-
CT did
not
cover
skull
93
[89 to
96]
182/195
Not as-
sessed
77
[69 to
84]
95/123
89
[78 to
96]
50/56
PET-
CT did
not
cover
skull
67
[55 to
78]
45/67
a studies with per patient data denoted in bold type
CE: contrast enhanced; CT: computed tomography; DW: diffusion weighted; GE: gradient echo;MRI: magnetic resonance imaging;
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Appendix 12. Findings from studies conducted in mixed or not clearly reported populations
Sensitivities and specificities from studies evaluating more than one target condition (any metastasis, nodal metastasis or distant
metastasis) are tabulated in Appendix 11. Summary estimates of sensitivities and specificities are presented in Appendix 13.
Results: detection of any metastases
Eleven studies reported accuracy data for the detection of any metastasis in mixed study populations (Abbott 2011; Aukema 2010a;
Aukema 2010b; Cachin 2014; Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007; Pfluger 2011; Reinhardt 2006;
Strobel 2007b) (Table 1).
Forest plots of study data are provided in Figure 10 (per patient) and Figure 11 (per lesion). Summary estimates for indirect and direct
comparisons of tests are presented in Appendix 13 and ROC plots of direct comparisons between tests in Figure 12, Figure 13, and
Figure 14 (per lesion data only).
Figure 10. Forest plot of tests for the detection of any metastases (mixed populations - per patient data).
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Figure 11. Forest plot of tests for the detection of any metastases (mixed populations - per lesion data).
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Figure 12. ROC plot of direct comparisons between CT and MRI for the detection of any metastases in
mixed population group studies (per lesion data).
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Figure 13. ROC plot of direct comparisons between CT and PET-CT for the detection of any metastases in
mixed population group studies (per lesion data).
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Figure 14. ROC plot of direct comparisons between MRI and PET-CT for the detection of any metastases in
mixed population group studies (per lesion data).
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Per patient data
Six studies reported per patient data for a total of 553 study participants and 268 cases of metastases (Abbott 2011; Aukema 2010a;
Aukema 2010b Cachin 2014; Reinhardt 2006; Strobel 2007b) (Figure 10); prevalence ranged from 21% in Abbott 2011) to 58% in
Cachin 2014.
CT. CT was evaluated in one study of 250 participants with mixed indications for imaging, including over 40% with stage I or II
disease on presentation (Reinhardt 2006); scan coverage did not include the skull in this study. Observed sensitivity was 81% (95%
CI 73, 88%) and specificity 77% (95% CI 69, 84%) (250 participants; 166 cases).
MRI. No per patient data for MRI were identified.
PET-CT. Six studies provided per patient data for PET-CT for the detection of any metastasis (Abbott 2011; Aukema 2010a; Aukema
2010b Cachin 2014; Reinhardt 2006; Strobel 2007b). The sensitivity of PET-CT ranged from 71% (95% CI 29% to 96%) in Abbott
2011 to 100% (95% CI 85% to 100%) in Aukema 2010a and specificity from 71% (95% CI 41% to 87%) in Cachin 2014 to 98%
(95% CI 94% to 100%) in Reinhardt 2006.
Summary sensitivity from the six studies was 91.1% (95% CI 83.6% to 95.3%) and specificity 93.8% (95% CI 85.1% to 97.6%) (591
patients, 268 cases) (Appendix 13; Table A).
Observed sensitivity in Strobel 2007b increased from 85% (95% CI 72% to 93%) to 98% (95% CI 90% to 100%) (seven additional
metastases detected) when PET-CT interpretation was combined with a separate dedicated CT interpretation, with one additional
false positive result (specificities 96% and 94%, respectively).
Reinhardt 2006 provided a direct comparison of the accuracy of contrast enhanced CT with PET-CT, which found PET-CT to be
significantly more sensitive (97%, 95% CI 91% to 99%) and specific (98%, 95% CI 94% to 100%) in comparison to CT alone
(increases of 16% and 22%, respectively).
Per lesion data
Six studies reported per lesion data for a total of 311 study participants, 1989 lesions, and 1185 confirmed metastases (Cachin 2014;
Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007; Pfluger 2011) (Figure 11). The prevalence of metastases on a
lesion basis ranged from 48% in Cachin 2014 to 71% in Pfannenberg 2007. The average number of confirmed metastatic lesions per
study participant ranged from 1 in Cachin 2014 to 14 in Hausmann 2011, with a median of 3.
CT. Five studies presented data for contrast enhanced CT for the detection of any metastases (Dellestable 2011; Hausmann 2011;
Jouvet 2014; Pfannenberg 2007; Pfluger 2011). Sensitivity ranged from 77% (95% CI 72% to 82%) in Pfannenberg 2007 to 88%
(95% CI 80% to 94%) in Jouvet 2014, and specificity from 50% (95% CI 44% to 55%) in Hausmann 2011 to 95% (95% CI 84%
to 99%) in Dellestable 2011.
Summary sensitivity from the five studies was 81.3% (95% CI 76.8% to 85.1%) and specificity 71.2% (95% CI 53.9% to 83.9%)
(1770 lesions, 1064 metastases) (Appendix 13; Table B).
A single study providing a direct comparison of the accuracy of contrast enhanced CT with unenhanced CT found contrast enhanced
CT to be significantly more sensitive (85%, 95% CI 79% to 85%) compared to unenhanced CT (62%, 95% CI 53% to 69%), with a
smaller decrease (11%) in specificity for unenhanced CT (52%, 95% CI 40% to 63%) (232 lesions, 151 confirmed metastases) (Figure
11) (Pfluger 2011).
MRI. Four studies presented data for MRI for the detection of any metastases (Dellestable 2011; Hausmann 2011; Jouvet 2014;
Pfannenberg 2007). Sensitivity ranged from 69% (95% CI 59% to 77%) in Jouvet 2014 to 83% (95% CI 72% to 91%) in Dellestable
2011, and specificity from 72% (95% CI 62% to 81%) in Jouvet 2014 to 96% (95% CI 85% to 99%) in Dellestable 2011.
Summary sensitivity from the four studies was 76.4% (95% CI 70.6% to 81.4%) and specificity 83.0% (95% CI 71.9% to 90.3%)
(1556 lesions, 927 metastases) (Appendix 13; Table B). Sensitivity and specificity in Jouvet 2014 were both increased (by 13% and
15%, respectively) with the addition of ultrafast gradient echo (VIBE) sequences to the MRI protocol.
PET-CT. Five studies evaluated PET-CT for the detection of any metastasis (Cachin 2014; Dellestable 2011; Jouvet 2014; Pfluger
2011; Pfannenberg 2007). Sensitivity ranged from 74% (95% CI 62% to 83%) in Dellestable 2011 to 100% (95% CI 98% to 100%)
in Pfluger 2011, and specificity from 54% (95% CI 43% to 64%) in Cachin 2014 to 93% (95% CI 86% to 97%) in Jouvet 2014.
Summary sensitivity from the five studies was 90.7% (95% CI 69.0% to 97.7%) and specificity 84.5% (95% CI 69.7% to 92.9%)
(1138 lesions, 709 metastases) (Appendix 13; Table B).
Pfluger 2011 showed only marginal differences in accuracy between PET-CT using contrast enhanced CT versus unenhanced CT;
sensitivity for unenhanced PET-CT (97%, 95% CI 92% to 99%) compared to enhanced PET-CT (100%, 95% CI 98% to 100%)
(232 lesions; 151 confirmed metastases).
Comparisons between tests.The statistical model comparing the three sets of pooled estimates showed no statistically significant differences
in sensitivity (P = 0.17) or specificity (P = 0.29) between tests (Appendix 13; Table B).
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Three of the studies provided a direct comparison of CT, MRI, and PET-CT (Dellestable 2011; Jouvet 2014; Pfannenberg 2007),
Hausmann 2011 compared CT andMRI, and Pfluger 2011 compared CT and PET-CT. The direct comparisons between tests in these
studies are plotted ROC space in Figure 12, Figure 13, and Figure 14. None of the differences in sensitivity and specificity between
tests reached statistical significance (Appendix 13; Table C).
Results: detection of nodal metastases
Ten studies reported accuracy data for the detection of nodal metastases (Cachin 2014; Dellestable 2011; Hausmann 2011; Jouvet
2014; Klebl 2003; Pfannenberg 2007; Reinhardt 2006; Rubaltelli 2011; van den Brekel 1998; van Wissen 2016).
Forest plots of study data are provided in Figure 15 (per patient) and Figure 16 (per lesion).
Figure 15. Forest plot of tests for the detection of nodal metastases (mixed populations - per patient data).
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Figure 16. Forest plot of tests for the detection of nodal metastases (mixed populations - per lesion data).
Per patient data
Four studies reported per patient data for a total of 355 study participants and 175 cases of nodal metastases (Klebl 2003; Reinhardt
2006; Van den Brekel 1998; van Wissen 2016) (Figure 15); the prevalence of nodal metastases ranged from 22% in Klebl 2003 to 86%
in van Wissen 2016.
Ultrasound.One study evaluated ultrasound for nodal metastases in participants with Clark level IV or V melanoma following primary
treatment (n = 8) or during follow-up (n = 75) (Klebl 2003). All 17 participants with nodal metastases were identified on ultrasound
(sensitivity 100%, 95% CI 80% to 100%) with 21 false positives (specificity 66%, 95% CI 53% to 78%); 11 of the 17 true positive
results were also detected on palpation, with a total of 12 false positive results (Klebl 2003).
CT.CTwas evaluated for the detection of nodal metastases in two studies. In Reinhardt 2006, 78 of the 166 participants with confirmed
metastatic disease had nodal metastases (prevalence 78/250; 31%). Sensitivity was 85% (95% CI 75% to 92%) and specificity 87%
(95% CI 81% to 92%). Similarly high sensitivity was reported in a high prevalence study of CT before therapeutic or elective dissection
of the lymph nodes of the neck in participants with head and neck melanoma (86%, 95% CI 64% to 97%), with specificity of 100%
(95% CI 48% to 100%) (26 participants; 21 cases of nodal metastases) (van den Brekel 1998).
MRI. No per patient data were identified for MRI in this patient group.
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PET-CT. PET-CT was evaluated for the detection of nodal metastases in two studies. In a direct comparison with CT alone, PET-CT
was more sensitive (95%, 95% CI 87% to 99%) than CT alone but with overlapping confidence intervals, and was significantly more
specific (100%, 95% CI 98% to 100%) (250 participants; 78 cases of nodal metastases) (Reinhardt 2006).
van Wissen 2016 evaluated the use of PET-CT in 69 participants scheduled for combined superficial and deep groin dissection due to
palpable groin metastases. Results showed that although PET-CT was highly sensitive for the detection of superficial groin metastases
(98%, 95% CI 91% to 100%) (59 cases), six participants with deep groin metastases were missed by PET-CT even when indeterminate
PET-CT results were considered test positive (sensitivity 75%, 95% CI 53% to 90%) (24 cases). Specificity was 81% (95% CI 76%
to 92%), with eight false positive results.
Per lesion data
Per lesion data were reported in five studies for a total of 241 study participants, 669 lesions, and 338 confirmed metastases(Cachin
2014; Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007) (Figure 16). The prevalence of metastases on a lesion basis
ranged from 43% in Hausmann 2011 to 78% in Dellestable 2011. Summary estimates for indirect and direct comparisons of tests are
presented in Appendix 13, and ROC plots of direct comparisons between tests in Figure 17, Figure 18, and Figure 19 (per lesion data
only).
356Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 17. ROC plot of direct comparisons between CT and MRI for the detection of nodal metastases in
mixed population group studies (per lesion data).
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Figure 18. ROC plot of direct comparisons between CT and PET-CT for the detection of nodal metastases
in mixed population group studies (per lesion data).
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Figure 19. ROC plot of direct comparisons between MRI and PET-CT for the detection of nodal metastases
in mixed population group studies (per lesion data).
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CT. Four studies evaluated contrast enhanced CT for the detection of nodal metastasis (Dellestable 2011; Hausmann 2011; Jouvet
2014; Pfannenberg 2007). Sensitivity ranged from 76% (95% CI 67% to 84%) in Pfannenberg 2007 to 96% (95% CI 78% to 100%)
in Jouvet 2014, and specificity from 29% (95% CI 22% to 36%) in Hausmann 2011 to 100% (95% CI 63% to 100%) in Dellestable
2011.
Summary sensitivity from the four studies was 87.2% (95% CI 76.5% to 93.4%) and specificity 69.2% (95% CI 34.6% to 90.5%)
(629 lesions, 348 metastases) (Appendix 13; Table B).
MRI. The same four studies consideredMRI for the detection of nodalmetastasis using a number of differentMRI protocols (Dellestable
2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007). Sensitivity ranged from 66% (95% CI 56% to 75%) in Pfannenberg 2007
to 96% (95% CI 78% to 100%) in Jouvet 2014, and specificity from 77% (95% CI 64% to 87%) in Pfannenberg 2007 to 77% (95%
CI 70% to 83%) in Hausmann 2011 to 89% (95% CI 52% to 100%) in Dellestable 2011. Summary sensitivity from the four studies
was 83.9% (95% CI 68.9% to 92.5%) and specificity 78.1% (95% CI 72.1% to 83.1%) (630 lesions, 348 metastases) (Appendix 13;
Table B).
The direct comparison of diffusion weighted MRI compared with diffusion weighted plus VIBE sequences in Jouvet 2014 found the
addition of VIBE to be less sensitive but more specific, but with small lesion numbers (53 nodal lesions and 23 malignancies), the
differences were not statistically significant.
PET-CT. Four studies evaluated PET-CT for the detection of nodal metastasis (Cachin 2014; Dellestable 2011; Jouvet 2014;
Pfannenberg 2007). Sensitivities ranged from 84% (95% CI 66% to 95%) in Dellestable 2011 to 96% (95% CI 83% to 100%) in
Jouvet 2014, and specificities from 37% (95% CI 16% to 62%) in Cachin 2014 to 100% (95% CI 59% to 100%) in Dellestable 2011.
Summary sensitivity from the four studies was 86.4% (95% CI 80.5% to 90.7%) and specificity 89.1% (95% CI 53.1% to 98.3%)
(288 lesions, 176 metastases) (Appendix 13; Table B).
Comparison between tests.The statistical model comparing the three sets of pooled estimates showed no statistically significant differences
in sensitivity (P = 0.22) or specificity (P = 0.89) between tests (Appendix 13; Table B).
Three studies in mixed population groups provided a direct comparison of CT, MRI, and PET-CT (Dellestable 2011; Jouvet 2014;
Pfannenberg 2007); Hausmann 2011 also compared CT and MRI. Three studies included the same total numbers of nodal lesions
and metastases per test, while the number detected per test varied for Dellestable 2011. ROC plots show direct comparisons between
tests in Figure 17, Figure 18, and Figure 19 (per lesion data only). No statistically significant differences in sensitivity were observed in
any of the direct comparisons, but the specificity of PET-CT (92.5%, 95% CI 85.0% to 96.4%) was significantly higher than both
MRI (by 13.5%, 95% CI 3.73% to 23.3%; P = 0.007) and CT alone (by 18.0%, 95% CI 7.69% to 28.3%; P = 0.001) (Appendix 13;
Table C).
Results: detection of distant metastases
Nine studies considered the detection of distant metastases (Arrangoiz 2012; Bastiaannet 2009; Cachin 2014; Dellestable 2011;
Hausmann 2011; Jouvet 2014; Pfannenberg 2007; Reinhardt 2006; Veit-Haibach 2009).
Forest plots of study data are provided in Figure 20 (per patient) and Figure 21 (per lesion).
Figure 20. Forest plot of tests for the detection of distant metastases (mixed populations - per patient data
only).
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Figure 21. Forest plot of tests for the detection of distant metastases (per lesion data).
Per patient data
Two studies reported per patient data for a total of 501 study participants and 162 cases of distant metastases (Bastiaannet 2009;
Reinhardt 2006) (Figure 20); the prevalence of nodal metastases was 31% (Bastiaannet 2009) and 34% (Reinhardt 2006).
CT. Reinhardt 2006 reported sensitivity of 74% (95% CI 63% to 83%) and specificity of 88% (95% CI 84% to 99%) in participants
at any stage of disease and with mixed indications for imaging (250 participants; 84 cases of distant metastases). Bastiaannet 2009
included participants with palpable, confirmed lymph node metastases who were considered candidates for regional lymph node
dissection. Sensitivity was 78% (95% CI 67% to 87%) and specificity 94% (95% CI 89% to 97%) (251 participants; 78 cases of
distant metastases).
MRI. No per patient data were identified for MRI in this patient group.
PET-CT. Reinhardt 2006 reported a direct comparison of CT with PET-CT (Figure 20). Both sensitivity and specificity increased
significantly with PET-CT (sensitivity 99%, 95% CI 94% to 100% and specificity 98%, 95% CI 94% to 99%).
Per lesion data
Per lesion data were reported in five studies for a total of 501 study participants, 1090 lesions, and 666 confirmed metastases (Cachin
2014; Dellestable 2011; Hausmann 2011; Jouvet 2014; Pfannenberg 2007) (Figure 21). The prevalence of distant metastases on a
lesion basis ranged from 47% in Cachin 2014 to 74% in Pfannenberg 2007.
CT. Four studies evaluated contrast enhanced CT for the detection of distant metastasis (Dellestable 2011; Hausmann 2011; Jouvet
2014; Pfannenberg 2007). Sensitivity ranged from 59% (95% CI 42% to 74%) in Dellestable 2011 to 86% (95% CI 76% to 93%)
in Jouvet 2014, and specificity from 64% (95% CI 52% to 76%) in Pfannenberg 2007 to 87% (95% CI 73% to 96%) in Dellestable
2011 (Figure 21).
Summary sensitivity from the four studies was 73.4% (95% CI 63.6% to 81.3%) and specificity 71.9% (95% CI 64.3% to 78.5%)
(920 lesions, 571 metastases) (Appendix 13; Table B).
MRI. The same four studies considered MRI for the detection of distant metastasis (Dellestable 2011; Hausmann 2011; Jouvet 2014;
Pfannenberg 2007). Sensitivity ranged from61% (95%CI 50% to 72%) in Jouvet 2014, to 87% (95%CI 82% to 92%) in Pfannenberg
2007, and specificity from 68% (95% CI 64% to 87%) in Jouvet 2014 to 97% (95% CI 70% to 83%) in Dellestable 2011 (Figure
21).
Summary sensitivity from the four studies was 74.5% (95% CI 62.1% to 83.9%) and specificity 85.8% (95% CI 70.4% to 93.9%)
(926 lesions, 579 metastases) (Appendix 13; Table B).
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The low sensitivity and specificity observed in Jouvet 2014 were improved to 79% (95% CI 69% to 87%) and 80% (95% CI 68% to
89%) with the addition of VIBE sequences but with overlapping confidence intervals.
PET-CT. Four studies evaluated PET-CT for the detection of nodal metastasis (Cachin 2014; Dellestable 2011; Jouvet 2014;
Pfannenberg 2007). Sensitivities ranged from 66% (95% CI 49% to 80%) in Dellestable 2011 to 93% (95% CI 89% to 96%) in
Pfannenberg 2007, and specificities from 58% (95% CI 46% to 70%) in Cachin 2014 to 91% (95% CI 81% to 97%) in Jouvet 2014
(Figure 21).
Summary sensitivity from the four studies was 81.0% (95% CI 67.5% to 90.0%) and specificity 78.5% (95% CI 61.0% to 89.5%)
(618 lesions, 382 metastases) (Appendix 13; Table B).
Comparison between tests.The statistical model comparing the three sets of pooled estimates showed no statistically significant differences
in sensitivity (P = 0.22) or specificity (P = 0.89) between tests (Appendix 13; Table B).
Three studies in mixed population groups provided a direct comparison of CT, MRI, and PET-CT (Dellestable 2011; Jouvet 2014;
Pfannenberg 2007); Hausmann 2011 also compared CT and MRI. Two studies included the same total numbers of lesions and
metastases per test (Hausmann 2011; Pfannenberg 2007), and two included only those lesions detected by each test so that the number
of lesions varied per test (Dellestable 2011; Jouvet 2014). The direct comparisons between tests in these studies are plotted as ROC
space in Figure 22, Figure 23, and Figure 24. No statistically significant differences in sensitivity were observed in any of the direct
comparisons, but the specificity of MRI (85.8%, 95% CI 70.4% to 93.9%) was significantly higher than CT (by 13.9%, 95% CI
0.43% to 27.3%; P = 0.043) (Appendix 13; Table C).
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Figure 22. ROC plot of direct comparisons between CT and MRI for the detection of distant metastases in
mixed population group studies (per lesion data).
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Figure 23. ROC plot of direct comparisons between CT and PET-CT for the detection of distant
metastases in mixed population group studies (per lesion data).
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Figure 24. ROC plot of direct comparisons between MRI and PET-CT for the detection of distant
metastases in mixed population group studies (per lesion data).
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Results: detection of distant metastases by metastatic site
Four studies conducted in mixed or not clearly described population groups reported per lesion data according tometastatic site (Cachin
2014; Dellestable 2011; Jouvet 2014; Pfannenberg 2007). Appendix 14 presents sensitivities and specificities for all metastatic sites
according to test for ease of comparison of accuracy across different sites. Sensitivity and specificity were not estimated for sites with
fewer than five malignant or benign lesions. Forest plots of study data for each test by metastatic site are presented in Figure 25, Figure
26, Figure 27, and Figure 28. Summary estimates for indirect and direct comparisons of tests are presented in Appendix 13.
Figure 25. Forest plot of tests for the detection of bone metastasis in mixed population groups (per lesion
data).
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Figure 26. Forest plot of tests for the detection of lung metastasis in mixed population groups (per lesion
data).
Figure 27. Forest plot of tests for the detection of liver metastasis in mixed population groups (per lesion
data).
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Figure 28. Forest plot of tests: 75 soft tissue metastasis - PET-CT - MIXED (per lesion), 76
local/subcutaneous metastasis - CT - MIXED (per lesion), 77 local/subcutaneous metastasis - MRI - MIXED
(per lesion), 78 local/subcutaneous metastasis - MRI (DW + VIBE) - MIXED (per lesion), 79 local/subcutaneous
metastasis - PET-CT - MIXED (per lesion).
Bone metastases
For the detection of metastases in the bone, CT performed the poorest in terms of sensitivity, which ranged from 50% (95% CI 23%
to 77%) in Dellestable 2011 to 67% (95% CI 38% to 88%) in Jouvet 2014 in three studies, compared to 93% (95% CI 66% to
100%) in Dellestable 2011 to 100% in Jouvet 2014 and Pfannenberg 2007 for MRI, and 71% (95% CI 42% to 92%) in Dellestable
2011 to 91% (95% CI 77% to 98%) in Pfannenberg 2007 for PET-CT (Figure 25).
Data could be pooled for CT and PET-CT for two studies with more than five metastases and more than five benign lesions (Jouvet
2014; Pfannenberg 2007). For PET-CT (85 lesions and 51 metastases), summary sensitivity was 90.2% (95% CI 78.5% to 95.9%)
and specificity 88.2% (95% CI 72.5% to 95.5%) (Appendix 13). Summary sensitivity for CT was 26.2% lower (P = 0.001) at 64.0%
(95% CI 49.9% to 76.0%) and specificity non-significantly higher at 94.0% (95% CI 49.5% to 99.6%), (P = 0.56).
Lung metastases
For the detection of lung metastases (four studies), CT performed the best in terms of sensitivity, which ranged from 78% (95% CI
27% to 84%) in Hausmann 2011 to 100% (95% CI 75% to 100%) in Dellestable 2011 compared to 47% (95% CI 39% to 55%) in
Hausmann 2011 to 87% (95% CI 75% to 95%) in Pfannenberg 2007 for MRI and 31% (95% CI 09% to 61%) in Dellestable 2011
to 100% (95% CI 69% to 100%) in Cachin 2014 for PET-CT (Figure 26). For those studies with more than five disease negative
lesions identified, specificities were consistently poor for CT compared to MRI or PET-CT.
Data were pooled for CT and for MRI for three studies with more than five metastases and more than five benign lesions (Jouvet
2014; Pfannenberg 2007). For CT (312 lesions and 229 metastases), summary sensitivity was 90.6% (95% CI 75.7% to 96.8%) and
specificity 43.8% (29.5% to 59.1%) (Appendix 13). Summary sensitivity for MRI was 34.9% lower (P = 0.054) at 55.7% (95% CI
24.0% to 83.4%) and specificity significantly higher at 91.3% (95% CI 77.3% to 97.0%) (P < 0.001).
Liver metastases
For liver metastases, only three studies included more than five metastatic lesions to allow comparison of sensitivities (Hausmann
2011; Jouvet 2014; Pfannenberg 2007). Both MRI - Hausmann 2011; Jouvet 2014; Pfannenberg 2007 - and PET-CT - Jouvet 2014;
Pfannenberg 2007 - had higher sensitivities compared to CT, but differences were significant only for Hausmann 2011 due to small
numbers (Figure 27).
Three studies included more than five benign lesions to allow comparison of specificities. Specificities were 90% or more for CT, MRI,
and PET-CT in Dellestable 2011, but the number of benign lesions detected by each test varied from 17 (for CT) to 22 (for MRI).
Hausmann 2011 reported specificity to be higher for MRI (100%) compared to CT (50%), but specificities were consistently high for
CT, MRI, and PET-CT (87% to 100%) in Jouvet 2014.
No statistical pooling could be undertaken for this target condition.
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Local or subcutaneous metastases and soft tissue metastases
The detection of local or subcutaneous metastases was reported in three studies. Overall PET-CT appeared more sensitive than MRI
(sensitivities 90% - Pfannenberg 2007 - and 100% - Jouvet 2014 - compared to 70% and 78% for MRI, respectively) and MRI more
sensitive in comparison to CT (sensitivities 78% - Pfannenberg 2007 - and 100% - Hausmann 2011 - compared to CT (sensitivities
64% - Pfannenberg 2007 - and 82% - Hausmann 2011), but lesion numbers were small and confidence intervals overlapping. No clear
differences in specificities were observed (Figure 28).
Brain metastases
Only two studies included sufficient numbers of imaging abnormalities of the brain to allow sensitivity to be estimated for CT and
MRI (Jouvet 2014), and for PET-CT (Cachin 2014). The lowest sensitivity was observed for diffusion weighted MRI (65%, 95% CI
41% to 85%); however the addition of VIBE sequences increased sensitivity to 100% (95% CI 83% to 100%) (23 lesions identified,
20 confirmed metastases). In comparison, the sensitivity of CT was 95% (95% CI 75% to 100%).
In Cachin 2014, the sensitivity of PET-CT for detection of brain metastases was 22% (95% CI 3% to 60%) (nine lesions identified,
seven confirmed metastases).
Three additional studies conducted in mixed or unclear populations reported some data on the detection of brain metastases, but
numbers were insufficient to include 2×2 contingency tables. In Strobel 2007b, a single confirmed brain metastasis was described as
detected on PET-CT. Two studies evaluated whole body PET-CT in combination with MRI of the brain (Aukema 2010a; Aukema
2010b). In Aukema 2010a, MRI detected two confirmed brain metastases in one patient, and in Aukema 2010b, five confirmed brain
metastases were detected - four in patients with multiple metastases detected by PET-CT and one solitary brain metastasis. Neither
study reported the detection of any benign imaging abnormalities.
Appendix 13. Summary estimates of sensitivities and specificities from mixed or unclear population
studies
Table A Summary estimates for tests evaluated in mixed study populations, per patient data
Test
Target condition
Studies Participants (cases) Sensitivity (95% CI) % Specificity (95% CI) %
Any metastasis
PET-CT 6 591 (268) 91.1 (83.6 to 95.3) 93.8 (85.1 to 97.6)
Table B Indirect comparison of imaging tests from mixed study populations, per lesion data
Test
Target condition
Studies Participants (cases) Sensitivity (95% CI) % Specificity (95% CI) %
Detection of any metastasis
CT 5 1770 (1064) 81.3 (76.8 to 85.1) 71.2 (53.9 to 83.9)
MRI 4 1556 (927) 76.4 (70.6 to 81.4) 83.0 (71.9 to 90.3)
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PET-CT 5 1138 (709) 90.7 (69.0 to 97.7) 84.5 (69.7 to 92.9)
Difference (P value) 0.17 0.29
Detection of nodal metastasis
CT 4 629 (348) 87.2 (76.5 to 93.4) 69.2 (34.6 to 90.5)
MRI 4 630 (348) 83.9 (68.9 to 92.5) 78.1 (72.1 to 83.1)
PET-CT 4 288 (176) 86.4 (80.5 to 90.7) 89.1 (53.1 to 98.3)
Difference (P value) 0.22 0.89
Detection of distant metastasis
CT 4 920 (571) 73.4 (63.6 to 81.3) 71.9 (64.3 to 78.5)
MRI 4 926 (579) 74.5 (62.1 to 83.9) 85.8 (70.4 to 93.9)
PET-CT 4 618 (382) 81.0 (67.5 to 90.0) 78.5 (61.0 to 89.5)
Difference (P value) 0.58 0.21
Table C Direct comparisons of imaging tests from mixed study populations, per lesion data
Test
Target condition
Studies Participants (cases) Sensitivity (95% CI) % Specificity (95% CI) %
Detection of any metastasis
CT 4 1538 (913) 79.6 (76.0 to 82.8) 73.8 (51.5 to 88.2)
MRI 4 1556 (927) 76.4 (70.6 to 81.4) 83.0 (71.9 to 90.3)
Difference % (95% CI), P value 3.19 (-3.25 to 9.64),
P = 0.33
-9.21 (-30.1 to 11.7),
P = 0.39
Detection of any metastasis
PET-CT 4 962 (624) 93.2 (63.9 to 99.1) 88.8 (80.6 to 93.8)
CT 4 946 (609) 82.3 (76.6 to 86.9) 75.8 (58.9 to 87.2)
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Difference % (95% CI), P value 10.9 (-3.08 to 24.8),
P = 0.13
13.0 (-2.66 to 28.7),
P = 0.10
Detection of any metastasis
PET-CT 3 730 (473) 83.1 (65.3 to 92.8) 87.3 (76.7 to 93.5)
MRI 3 732 (472) 77.4 (70.6 to 82.9) 83.1 (72.9 to 90.0)
Difference % (95% CI), P value 5.79 (-4.67 to 16.3),
P = 0.28
4.20 (-11.6 to 20.0),
P = 0.60
Detection of nodal metastasis
CT 4 629 (348) 87.2 (76.5 to 93.4) 69.2 (34.6 to 90.5)
MRI 4 630 (348) 83.7 (68.8 to 92.3) 77.7 (72.4 to 82.1)
Difference % (95% CI), P value 3.41 (-10.8 to 17.6),
P = 0.64
-8.45 (-39.7 to 22.8),
P = 0.60
Detection of nodal metastasis
PET-CT 3 249 (156) 86.5 (80.2 to 91.1) 92.5 (85.0 to 96.4)
CT 3 250 (156) 89.0 (71.9 to 96.2) 74.5 (64.7 to 82.3)
Difference % (95% CI), P value -2.44 (-14.9 to 10.0),
P = 0.70
18.0 (7.69 to 28.3),
P = 0.001
Detection of nodal metastasis
PET-CT 3 249 (156) 86.5 (80.2 to 91.1) 92.5 (85.0 to 96.4)
MRI 3 251 (156) 86.1 (63.1 to 95.7) 78.9 (69.6 to 86.0)
Difference % (95% CI), P value 0.48 (-15.8 to 16.8),
P = 0.95
13.5 (3.73 to 23.3),
P = 0.007
Detection of distant metastasis
CT 4 920 (571) 73.4 (63.6 to 81.3) 72.0 (64.3 to 78.5)
MRI 4 926 (579) 74.5 (62.1 to 83.9) 85.8 (70.4 to 93.9)
Difference % (95% CI), P value -1.10 (-15.2 to 13.0),
P = 0.88
-13.9 (-27.3 to -0.43),
P = 0.043
Detection of distant metastasis
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PET-CT 3 481 (317) 81.8 (63.1 to 92.2) 83.5 (68.0 to 92.3)
CT 3 475 (308) 76.0 (62.6 to 85.7) 74.2 (61.9 to 83.6)
Difference % (95% CI), P value 5.77 (-12.7 to 24.2),
P = 0.54
9.35 (-6.85 to 25.5),
P = 0.26
Detection of distant metastasis
PET-CT 3 481 (317) 81.8 (63.1 to 92.2) 83.5 (68.0 to 92.3)
MRI 3 481 (316) 77.0 (61.7 to 87.4) 83.8 (59.8 to 94.8)
Difference % (95% CI), P value 4.78 (-14.6 to 24.1),
P = 0.63
-0.33 (-21.1 to 20.4),
P = 0.98
Table D Direct comparisons of tests by metastatic site
Test Studies Participants (cases) Sensitivity (95% CI) % Specificity (95% CI) %
Detection of bone metastasis
PET-CT 2 85 (51) 90.2(78.5 to 95.9) 88.2 (72.5 to 95.5)
CT 2 83 (50) 64.0 (49.9 to 76.0) 94.0 (49.5 to 99.6)
Difference % (95% CI), P value 26.2 (10.6 to 41.8), P=.001 -5.73(-24.8 to 13.3), P=0.56
Detection of lung metastasis
CT 3 312 (229) 90.6 (75.7 to 96.8) 43.8 (29.5 to 59.1)
MRI 3 312 (229) 55.7 (24.0 to 83.4) 91.3 (77.3 to 97.0)
Difference % (95% CI), P value 34.9 (-0.61 to 70.4 ), P=0.054 -47.5 (-65.2 to -29.8), P<0.001
Detection of local or subcutaneous metastasis
CT 2 126 (92) 71.8 (57.6 to.82.7 ) 64.7 (47.6 to 78.7)
MRI 2 126 (92) 96.2 (31.1 to 99.9) 70.6 (53.4 to 83.3)
Difference % (95% CI), P value -24.4 (-43.9 to -4.86), P=0.01 -5.88 (-28.1 to 16.3), P=0.60
Detection of local or subcutaneous metastasis
372Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
PET-CT 2 95 (66) 90.9 (81.2 to 95.9) 65.5 (46.9 to 80.3)
MRI 2 102 (69) 76.8 (65.4 to 85.2) 69.7 (52.3 to 82.9)
Difference % (95% CI), P value 14.1 (1.96 to 26.2), P=0.02 -4.18 (-27.5 to 19.2), P=0.73
Detection of local or subcutaneous metastasis
MRI 3 148 (102) 89.7 (53.7-98.5) 71.7 (57.2-82.8)
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bFourteen ‘other metastatic sites described’, all assumed (by us) to be malignant adrenal (4), heart (2), spleen (2), peritoneal carcinosis
(2), breast (1), pleura (1), vagina (1), and small intestine (1)
cother visceral metastases such as bowel or peritoneal lesion (Pfannenberg 2007).
dBrain metastases excluded from comparison of accuracy; reports 15 patients with cerebral metastases, “exclusively diagnosed by
wbMRI” (Pfannenberg 2007).
CE: contrast enhanced; CI: confidence interval; CT: computed tomography; Dis: diseased group; DW: diffusion weighted; excl:
excluding;GE: gradient echo; incl: including;MRI:magnetic resonance imaging;NoDis: non-diseased group;NR: not reported; PET:
positron emission tomography; Se: sensitivity; Sp: specificity; TN: true negative; TP: true positive; U: unenhanced; US: ultrasound;
WB: whole body
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We set out to separately review the evidence for ultrasound, CT, MRI, and PET-CT for staging of melanoma, and to bring the reviews
together in a Cochrane Overview review; however, as our main focus is on the comparative accuracy of different imaging tests, the
reviews were brought together into a single review.
A new primary objective was added: to determine the diagnostic accuracy of ultrasound or PET-CT for detection of nodal metastases
before SLNB in adults with confirmed cutaneous invasive melanoma.
A new secondary objective was added: to determine the diagnostic accuracy of ultrasound, CT, MRI, or PET-CT for detection of
any metastasis in the staging of disease in mixed or not clearly described populations of adults with cutaneous invasive melanoma.
According to the protocol, the effect of mixed or not clearly reported populations was to be considered as a subgroup analysis.
We clarified that the primary objectives refer to adults with melanoma.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review; studies available
only as conference abstracts do not allow a comprehensive assessment of study methods or methodological quality.
Sources of heterogeneity could not be formally investigated because of lack of data.
We allowed the inclusion of up to 10% of participants having non-cutaneous melanoma.
We excluded studies of PET alone as the technology is now considered obsolete, instead including only those that examined PET
combined with CT.
Studies reporting multiple applications of the same test in more than 10% of study participants were excluded because of anticipated
effects on test accuracy (multiple tests increasing the chance ofmetastases being detected), thereby increasing test sensitivity and reducing
specificity.
Reference standard inclusion criteria were amended to allow malignancy to be confirmed by imaging follow-up (growth or regression
of suspicious lesion on imaging) and to recognise that histology may be available for index negative (e.g. SLNB may be conducted in
all those with ultrasound regardless of positive or negative). The minimum follow-up required was also dropped from six months to
three months in accordance with the minimum required in diagnosis reviews.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists’ Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology), but because of the volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, we tailored the QUADAS-2 tool according to the review topic. In terms of analysis, we did not restrict analysis
to per patient data due to lack of data.
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